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ABSTRACT. Development of a Breast Cancer Specific Patients Concerns 
Inventory (PCI). By A. Kanatas. 
Introduction 
Treating breast cancer is based on a combination of therapies: surgery, radiotherapy, 
chemotherapy, as well as hormonal and biological agents. The full impact of the disease and 
its treatment at a human level is often underestimated, and the benefits of holistic cancer care 
are increasingly recognised. Furthermore, patients often face a frightening and uncertain 
journey that presents a variety of needs. Moreover, recovery is not necessarily the end-point 
of the cancer experience. The many complexities and challenges in the identification of 
patient issues along this journey can lead to unmet needs. This can be particularly difficult in 
the confines of a busy clinic, where time constraints, together with an over-reliance on verbal 
communication, can pose significant barriers to effective consultations. 
A novel tool, known as the patient concerns inventory (PCI), has been successfully 
developed and introduced for use in patients with head and neck cancer. In this setting, it has 
helped to formulate an individualized record of patient concerns, needs, and priorities, 
thereby structuring outpatient consultations, and promoting and facilitating a 
multidisciplinary approach. This study aimed to develop and assess a PCI specific to breast 
cancer and to evaluate its impact on patient care; that is, to provide a “proof of concept” for a 
breast cancer PCI. 
Methods 
This was a four-phase study, as follows. (1) Item generation through a literature review, 
input from clinicians (n = 10), four patient focus groups (n = 24), and national breast cancer 
charities (n = 3). (2) A survey of breast cancer patients (n = 200) for cross-sectional 
validation, to compare the PCI with an established quality of life tool and to look at the 
relative frequency of items and any associations. (3) A pilot, before and after study, 
assessing the PCI in a clinical setting with breast cancer patients (n = 53). (4) Semi-
structured interviews with a breast surgeon (n = 1) and specialist nurses (n = 2) who used the 
PCI during clinics, to identify the perceived benefits of using the PCI. 
Results 
In total 277 patients responded and participated in this work. The literature review identified 
164 items; following input from clinicians, focus groups, and national charities, 56 items 
remained. The cross sectional study (phase 2; n=200, 80 % response rate) revealed that 
patients wanted to discuss the following: breast sensitivity or pain (46 %), fatigue (46 %), 
hot flushes (44 %), sleep (34 %); breast appearance (30 %), unable to control weight (28 %), 
mastectomy appearance (19 %), overall physical appearance (17 %); fear of recurrence (62 
%), fear of cancer spreading (39 %), fear about the future (32 %), or one or more of these (72 
%); ‘mood’ (15 %),  ‘anxiety’ (21 %), ‘depression’ (17 %), or one or more of these (35 %); 
Phase 3 found that the PCI resulted in a focused consultation and no increase in consultation 
time. All the patients from phase 3 wanted to see a breast surgeon. Phase 4 revealed that 
clinicians involved with the PCI supported its use, and stated several advantages. In its final 
format, the breast cancer specific PCI had 57 items over several domains, with 16 referral 
options.  
Conclusions 
The PCI could identify issues that patients would like to discuss in the breast oncology 
clinic. The routine use of the PCI in follow-up clinics could ultimately improve care for 
women with breast cancer; however, the clinical environment continues to make it difficult 
to screen for issues related to intimacy, relationship, and sex.  
Further research is essential to evaluate the breast cancer specific PCI. A larger patient 
cohort, a longitudinal approach, qualitative input, and a link to possible interventions, would 
each improve our understanding of the issues faced by breast cancer patients. 
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PREFACE: Thesis Overview 
 
The chapters in this thesis present a stepwise sequence of the process necessary for the 
development of the breast cancer specific patient concerns inventory (PCI). The hypothesis 
was that ‘using a specifically developed PCI in clinical practice will help to identify patient 
concerns, improve consultations between professionals and patients, and help inform 
pathways for patients to follow so that their concerns are addressed.’ Specific objectives 
identified from this, were: (1) to develop a PCI specific to breast cancer; (2) To pilot the use 
of the developed PCI; and (3) to gain feedback on the merit of the PCI from members of the 
multidisciplinary team. The following provides an overview of the contents of this thesis. 
Chapter 1 reviews the treatment of breast cancer and its effects on patients’ health-related  
quality-of-life. 
Chapter 2 looks at the assessment of need in breast cancer patients and the potential role of 
a breast cancer specific PCI in this context. 
Chapter 3 presents the methodology used in all of the phases in this thesis to ensure 
reproducibility.  
Chapter 4 identifies the issues assessed by the current, validated outcome instruments, used 
with breast cancer patients. Data from this review forms the basis of the PCI development. 
Chapters 5 and 6 present the progression of the item generation process, together with their 
further reduction into a preliminary PCI. Also, the roles of focus groups and National breast 
cancer charities are outlined. 
Chapter 7 details and assesses the results of a cross-sectional survey of breast cancer 
patients within two National Health Service hospitals. At this stage, a relatively stable form 
of the PCI was produced that was considered suitable for clinical introduction.  
Chapter 8 reviews a pilot study -before and after study- evaluating the introduction of the 
PCI in a consultant breast surgeon’s clinic. 
Chapter 9 is an evaluation of the PCI from the breast cancer specialist and the breast cancer 
nurses 
Chapter 10 concludes on the scope and potential use of the PCI. Future directions for this 
research are considered. 
Chapter 11 outlines all the publications that were produced during this thesis, as well as 
both the poster and oral presentations made at National and International meetings. 
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 CHAPTER 1. Breast Cancer – An Overview of Treatment and its Effect on Health 
Related Quality of Life (HRQOL) 
 
Breast cancer is the third most common cause of cancer death in the UK, accounting for 7% 
of all cases. In 2010, there were 49,564 women and 397 men in the UK diagnosed with 
invasive breast cancer [Office for National statistics (2012), Northern Ireland Registry 
(2012), Welsh Cancer Intelligence and Surveillance (2012)]. It is known that women 
previously treated with curative intent can develop local recurrence or metastases many 
years after their original treatment, making this a significant issue worthy of investigation 
(NICE, 2009). In addition, a small proportion of women are diagnosed with advanced 
disease where the tumour has spread exensively within the breast or to other organs (NICE, 
2009). However, before we move on to consider the minutiae of this thesis, it is important to 
place it in context. Here, a brief overview of the current breast cancer research is presented. 
This includes a review of the risk factors as well as the diagnostic and treatment options. 
Ultimately, we consider the increasing survival rates and the impact this is likely to have on 
future health needs.  
 
Risk factors 
 
Age related factors: 
After gender, the strongest risk factor for breast cancer is age: the older a woman, the higher 
her risk. Additionally, early age at menarche has been consistently associated with an 
increased risk of breast cancer, with an estimated 22% decrease in risk associated with a 
five-year delay (Koprowski et al, 1999). Conversely, the younger a woman is when she 
begins childbearing, the lower the risk of breast cancer (Collaborative group on hormonal 
factors and breast-feeding, 2002). Indeed, childbearing in general reduces the risk of breast 
cancer; the higher the number of full-term pregnancies, the greater the protection 
(Collaborative group on hormonal factors and breast-feeding, 2002). Women who have been 
through the menopause have a lower risk of breast cancer than pre-menopausal women of 
the same age and childbearing pattern (Collaborative group on hormonal factors in breast 
cancer and hormonal replacement therapy).  
Breastfeeding: 
Women in developed countries are at increased risk of breast cancer when compared with 
women from less developed countries. We know that women who breastfeed reduce their 
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risk of breast cancer compared with women who do not. Furthermore, the longer a woman 
breastfeeds, the greater the protection: the risk is reduced by 4% for every 12 months of 
breastfeeding (Collaborative group on hormonal factors and breast-feeding, 2002). A large 
part of the variation between developed and developing countries is thought to be explained 
by the fact that women in developed countries tend to have fewer children on average and a 
limited duration of breastfeeding [ (Collaborative group on hormonal factors and breast 
feeding  (2002), Collaborative group on hormonal factors and breast feeding (2002)].  
Hormonal factors: 
Higher levels of endogenous hormones have long been hypothesized to increase breast 
cancer risk. Studies show that post-menopausal women with the highest levels of oestrogen 
and testosterone have two to three times the risk of women with the lowest levels (Key et al, 
2002). However, the link between these hormones and pre-menopausal breast cancer risk is 
less clear (Eliassen et al, 2006). A relationship has been found between high insulin levels 
and breast cancer, which might explain the 20% increased risk of breast cancer for women 
with diabetes shown in a recent meta-analysis (Larsson et al, 2007).  
The use of oral contraceptives (OCs) increases the risk of breast cancer in current and recent 
users, but there is no significant excess risk ten or more years after stopping use 
(Collaborative group on hormonal factors in breast cancer, 1996). Cancers diagnosed in 
women who have used OCs also tend to be less clinically advanced than those detected in 
women who have never used them (Collaborative group on hormonal factors in breast 
cancer, 1996). Indeed, in 2010 only 1% of breast cancers in women in the UK were linked to 
OCs (Parkin DM, 2011). Use of hormone replacement therapy (HRT) on the other hand, is 
associated with a 66% increased risk of breast cancer, compared to non-users (Parkin DM, 
2011).    
Previous breast cancer and benign breast disease: 
Benign breast disease is a generic term describing all non-malignant breast conditions, some 
of which carry an increased risk for breast cancer while others do not. Women with 
proliferative breast disease without atypia have a two-fold increased risk, whilst those with 
atypical hyperplasia have a more than four-fold increased risk (Hartmann et al, 2005). 
Women are also more likely to develop breast cancer in the same breast as a benign breast 
lesion than in the opposite breast (Hartmann et al, 2005). Overall, women with a previous in 
situ tumour have double the risk of invasive breast cancer compared to the general 
population, and it is higher in the same breast than in the other breast (Robinson et al, 2008). 
Further, a previous diagnosis of breast cancer raises the risk of developing a second primary 
breast cancer (Rubino et al, 2010). 
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The role of inheritance: 
There is growing evidence that the most important determinant is inheritance (Boyd et al, 
2002). A woman with one affected first-degree relative (mother or sister) has approximately 
double the risk of breast cancer of a woman with no family history of the disease; if two (or 
more) relatives are affected, her risk increases further (Familial breast cancer, 2001). Small 
proportions of women have a particularly strong family history of breast cancer and are at 
very high risk. Mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, are 
present in the majority of families with four or more affected members (Peto et al, 1999). 
Intermediate-penetrance gene variants that confer a two-to-three-fold increase in risk have 
been found in other genes, such as CHEK2, ATM, BRIP1, and PALB2. Some low-penetrance 
gene variants have also been identified, but are beyond the scope of this thesis (Turnbull et 
al, 2008).  
Weight: 
Overweight and obesity, as measured by a high body mass index (BMI; BMI= weight in Kg 
divided by height in meters squared), moderately increases the risk of post-menopausal 
breast cancer and is one of the few modifiable risk factors for breast cancer. Compared to 
lean women (BMI 22.5-24.9), overweight post-menopausal women (BMI 25-29.9) have a 
10-20% increased risk of breast cancer, while obese post-menopausal women (BMI > 30) 
have a 30% increase in risk. Women with a BMI under 22.5 have a 15% reduction in risk 
compared to women with a BMI of 22.5-24.9 [Reeves et al (2007), Parkin et al (2011)]). It is 
also interesting to note that women with dense breasts have an almost five times higher risk 
of breast cancer than those with less dense breasts (McCormack et al, 2006). Menopausal 
status, weight, and number of children, each affect breast density, meaning that there several 
confounders that confuse whether or not breast density represents an independent risk factor. 
Other Lifestyle factors: 
A study published in December 2011 estimated that over 3% of breast cancers in the UK 
were linked to inadequate levels of physical activity (less than 150 minutes of moderate 
physical activity per week) (Parkin DM, 2011). Furthermore, estimations at the same time 
suggested that more than 6% of breast cancers in women in the UK were linked to alcohol 
consumption (Parkin DM, 2001). In spite of extensive research, findings are generally 
inconsistent and inconclusive on the effects of dietary factors on breast cancer risk. A meta-
analysis of 45 studies (Boyd et al, 2003) reported that higher total fat intake increased breast 
cancer risk by 13%. Other risk factors include for breast cancer include shift work (Megdal 
et al, 2005), in-utero exposure to higher levels of oestrogen (Xue et al, 2007), and ionising 
radiation (John et al, 2007). 
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Breast cancer Symptoms and diagnosis 
 
Breast cancer rarely causes symptoms in its early stages (Pintz C, 2011). The symptoms of 
breast cancer include (Dixon et al, 1995):  
• A lump in the breast  
• A change in the size or shape of the breast  
• Dimpling of the skin or thickening in the breast tissue  
• A nipple that turns in on itself (i.e., that becomes inverted)  
• A rash (like eczema) on the nipple  
• Discharge from the nipple  
• A swelling or a lump in the armpit 
Women aged 50–70 years receive invitations every three years to attend screening through 
the NHS Breast Screening Programme (NHSBSP, 2002). Women over the age of 70 years 
are encouraged to continue to attend every three years although they are not routinely 
invited. However, there is evidence that breast self-examination does not reduce either 
morbidity or mortality in breast cancer (Thomas et al, 2002). Optimal assessments of breast 
abnormalities are by a combination of clinical examination, imaging, and sampling of the 
lesion for cytological/histological assessment. These three investigations collectively 
comprise the ‘triple assessment’ (Morris et al, 2001) and form the cornerstone of diagnosis.  
 
Breast cancer treatment, reconstructive surgery, and long term implications 
 
The available treatments include surgery, chemotherapy, radiotherapy, biological and 
hormonal agents, or a combination of the above. These are tailored to both the disease stage 
at presentation as well as the patient’s needs and preferences. Here we consider the available 
options, together with the indications and contraindications. 
Surgery is the mainstay of treatment for ductal carcinoma in situ (DCIS) and invasive breast 
cancer, and is typically the first treatment option (NICE, 2009). However, early diagnosis 
may allow for conservation surgery with local excision, rather than mastectomy. Although 
approximately 60–80% of newly diagnosed cancers are amenable to breast conservation 
surgery, only around 23% of breast cancer patients diagnosed through screening ubdergo 
mastectomy. In most cases, this is due to tumour size (relative to breast size), tumour 
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multicentricity, inability to achieve negative surgical margins after multiple resections, prior 
radiation to the chest wall or breast, other contraindications, or patient preference (Senkus, 
2013). Indeed, breast conserving surgery is contraindicated in specific cases, including: 
patients where the ratio of the size of the tumour to the size of the breast would not result in 
acceptable cosmesis; where there is multifocal disease; and, where local radiotherapy is 
contraindicated. Several trials have compared mastectomy and breast conservation surgery, 
concluding that conservative surgery plus local radiotherapy is appropriate, provided the 
margins of the resected specimen are tumour-free, and acceptable cosmesis is possible 
[Curran et al (1998),Veronesi et al (2001), Veronesi et al (2002), Fisher et al (2002), Holli et 
al (2001), Fisher et al (2001)] 
The most significant prognostic indicator for patients with invasive breast cancer is 
metastatic spread to axillary lymph nodes. Guidelines from the Association of Breast 
Surgery (2009) recommend obtaining histological lymph node status for all operable 
invasive breast cancers. Others prognostic indicators include tumour size, hormone receptor 
status, and the patient’s menopausal status [Veronesi et al (1993), Chetty et al (2000)]. The 
recommended practice from NICE (2009) advocates that minimal surgery, rather than lymph 
node clearance, be performed to stage the axilla in patients meeting the following criteria: 
those with early invasive breast cancer; no evidence of lymph node involvement on 
ultrasound; and, those with negative ultrasound-guided needle biopsy. Sentinel lymph node 
biopsy (SLNB) is the preferred technique (NICE, 2009). These results typically guide 
systemic adjuvant therapy. 
Adjuvant therapy continues to play an important role in the management of breast cancer 
[EBCTCG (2000), Malmstrom et al (2003) and include chemotherapy, hormonal therapy, 
trastuzumab (Herceptin®), radiation therapy, or, a combination thereof. Clinical trials have 
demonstrated that adjuvant chemotherapy reduces the risk of recurrence (EBCTCG, 2005). 
However, not all women with breast cancer need adjuvant therapy; patients at higher risk of 
cancer recurrence are more likely to benefit. In addition to a woman’s age and menopausal 
status, several prognostic factors help to determine the risk of recurrence [Goldhirsch et al 
(2005), Lonning PE (2007)]. These include the cancer stage, grade and its proliferative 
capacity, as well as hormone receptors and HER2 status.  
Several studies support preoperative chemotherapy for women with operable breast cancer 
(Wolmark et al, 2001). Results from non-randomized studies have shown that chemotherapy 
administered before surgery resulted in high rates of clinical response (50-80%) but low rates 
of pathologic complete response (<5%) [Van der Hage et al (2001), Fisher et al (1998), 
Mauri et al (2005)]. These studies concluded that reducing tumour size with chemotherapy 
allowed for breast-conserving surgery. Unfortunately, not all patients are suitable for 
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chemotherapy or surgery, and the management of metastatic breast cancer is often guided by 
a patient’s symptoms. Usually an oncologist, with input from the palliative care team, 
delivers therapy. In some cases, surgery may be limited to the control of local disease 
(Association of Breast Surgery, 2009).Oncoplastic breast reconstruction techniques are 
increasingly becoming the standard of care in breast cancer management. This may result in 
a significant improvement in the overall health related quality of life (HRQOL). The recently 
completed National Mastectomy and Breast Reconstruction Audit (NMBRA) involving more 
than 18,000 women examined a wide range of clinical and patient-reported outcomes 
(Jeevan, 2011). This national audit was commissioned to answer several questions related to 
the provision of breast reconstruction services across England and Wales. First, to assess if 
women undergoing mastectomy had sufficient information to make an informed decision 
about breast reconstruction, and if they were happy with that decision. Secondly, to evaluate 
the outcomes following mastectomy with or without reconstruction. This audit found that 
compared to 2006, more women  with breast cancer in England underwent immediate 
reconstruction at the time of their mastectomy; one in five for 2011, compared to one in nine 
for 2006 (Jeevan, 2011). This audit also concluded that there was variation in the provision 
of care and that there were potential unmet needs as a result of the available reconstructive 
options. The decision making process was scrutinized during the audit. Specifically, 
concerns were raised about how the offer of immediate reconstruction was communicated to 
patients, as the proportion of women accepting an offer varied regionally from 17 to 62 per 
cent. The audit also noted that the demand for breast cancer surgery had increased over the 
last decade, which corresponded with the increase in the disease’s incidence (Jeevan, 2011). 
This increase in patient numbers will contribute to increase pressures on already stretched 
clinical services, and potentially increase the amount of unmet need. The current BAPRAS 
guidance (British Association of Plastic Reconstructive and Aesthetic Surgeons, 2012) 
advocates that in the absence of significant contraindications, immediate or delayed breast 
reconstruction should be offered to all suitable patients requiring mastectomy. The positive 
physical and psychological effects of breast reconstruction have been highlighted in the 
NMBRA. The audit also outlined specific information needs necessary for a successful 
outcome. A PCI tool that could identify unmet need has the potential to improve outcomes 
following surgery. 
The diagnosis and treatment of breast cancer is a life-changing event that necessitates a 
systematic approach. The aims of long-term follow up include the detection of early local 
recurrence, or contralateral breast cancer, the identification of therapy-related complications, 
and the provision of support and information to facilitate a return to normal life [2013 
European society for medical oncology guidelines (ESMO); (Senkus, 2013)]. These may be 
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ambitious goals in a busy outpatient with pressures on resources and time, or that lack 
training and expertise within the clinical team. With increasing clinical demands, an 
instrument that can identify patient needs has clear advantages.  
The ESMO guidance emphasises the psychological needs of patients with a history of breast 
cancer. Such women often have increased levels of anxiety and depression following their 
initial treatment (Senkus, 2013). Fatigue and depression are often present in the months 
following adjuvant treatment such as radiotherapy and chemotherapy (Allemani, 2013). 
Indeed, many other common needs may be overlooked, remained undetected, or be 
unaddressed in long term survivors, and include social, family and intimacy issues (Senkus, 
2013). If we aim to ensure a return to the pre-morbid quality of life that these women 
enjoyed, then as clinicians we must develop and implement mechanisms that support a 
holistic approach to breast cancer management. 
 
 
Breast Cancer and Health Related Quality of Life 
 
Health-related quality of life (HRQOL) and patient-reported outcome measurement 
(PROMS) 
High quality cancer care aims to improve a range of patient outcomes, including survival 
and health related quality of life (HRQOL), representing the patient’s physical, 
psychological, and social response to the disease and therapy (WHOQOL, 1998). It includes 
measures of physical symptoms (pain, fatigue, vomiting), physical functioning (e.g. 
mobility, self-care), emotional functioning (anxiety, depression, stress) and social and 
family functioning. It is a patient-subjective measure capturing important information that 
cannot be achieved by traditional objective measures, such as tumour response or survival. 
More recently, the Food and Drug Administration (USA) introduced the umbrella terms 
patient-reported outcomes (PROs) or patient-reported outcome measurements (PROMs) as 
to encompass any measures obtained directly from the patient, which include areas of 
HRQOL, as well as broader concepts such as patient satisfaction with care.  
Over the last three decades, HRQOL has become a significant outcome measure for cancer 
patients in clinical trials. In this setting, patient-reported HRQOL data is commonly 
required alongside biomedical outcomes such as progression-free survival, and overall 
survival to assess the value of a given therapeutic intervention. Patient-reported HRQOL 
has also been found to predict treatment response and survival in a number of advanced 
solid cancers (Efficace et al, 2006). More recently, PROMs are increasingly being used by 
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the National Health Service (NHS) as quality indicators when assessing service delivery and 
treatment outcomes (incl. health economic outcomes) (DoH, 2007). 
HROL and PROMS in clinical practice 
The routine care of individual patients in oncology clinics requires a regular measurement of 
symptoms, functioning, and HRQOL, both before and during treatment. This plays an 
important role in informing clinicians of patient concerns, and in supporting treatment 
decisions. However, there is a growing need to study the potential role of HRQOL 
measurement in routine clinical practice with the aim of improving patient care through 
better detection of problems, better control and monitoring of symptoms, and enhanced 
communication and shared decision-making. There are a number of assessment tools 
currently being used by various health and social care professionals (Kanatas et al, 2009) but 
these tools do not yet cover all the domains required for a holistic assessment. Furthermore, a 
lack of co-ordination between health and social care often prevents the effective sharing of 
patient information. This results in patients having repeated assessments on their care 
pathway, repeatedly providing the same information to different professionals. 
Health Related Quality of life and Breast Oncology                    
The health-related QOL (HRQOL) assessment is now regarded as a key component of 
clinical oncology trials (Versmessen et al, 2012). Radiotherapy for breast cancer tends to be 
stressful and may increase fatigue, skin irritation, and breast pain during the first year 
(Prescott et al, 2007). Attendance at daily radiotherapy treatments for up to six weeks may 
also have an impact on the patient's QOL, although it is hoped that use of the 
hypofractionated schedule can reduce this burden by shortening the overall treatment time. 
There are a number of studies looking at the use of HRQOL in oncology practice. They 
showed benefit for patients including better symptom control and wellbeing [Velikova et al 
(2004), Valderas et al (2008)].  
Sprangers (Sprangers MAG, 2002) considered that HRQOL can be measured reliably and 
validly, to help clinicians gain insights into a patient’s perspective of their disease and 
treatment. However, patients may change their perspectives during the course of their 
disease, referred to as a ‘response shift,’ which in standardized questionnaires may result in 
patients reporting a stable QOL over time, while concurrently exhibiting deteriorating 
clinical health [Schwartz et al (1999), Sprangers et al (1999)]. 
Seen from the patient’s perspective, a diagnosis of breast cancer may have multiple 
implications: it may be viewed as a sudden, unexpected threat to life; it may cause acute 
hospitalisation; it usually involves surgery with the removal of either a breast or part of a 
breast; it creates a need for medical decisions; it may necessitate additional treatments; and, 
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it may give rise to associated symptoms and other practical problems. These and many other 
factors can cause an acute and severe disruption to the patient’s daily life (Hewitt et al, 
2004). HRQOL data is used in two ways in the interpretation of randomised clinical trials 
(Groenvold et al, 2010). First, the researchers simply use this information in the 
interpretation of their results. If, for example, the available research data show no difference 
in survival between two treatments but the HRQOL data shows a clear advantage, then 
researchers may conclude that this is a potential argument in favour of treatment. Second, the 
availability of HRQOL data can provide patients with improved information when making 
treatment decisions, via access to more patient-orientated insights into the results. The use of 
HRQOL data may convey information about the consequences of treatment that would 
otherwise be unavailable, and therefore provide a better basis for decision-making by the 
patient.  
HRQOL is now considered an important endpoint in clinical cancer trials. It has been shown 
that assessing QOL in cancer patients could contribute to improved treatment, and that it 
could even be used as a prognostic factor, in much the same way that medical factors are 
used [Montazeri et al (1996), Montazeri et al (2003). Above all, studies of QOL can further 
indicate the directions needed for more efficient treatment of cancer patients. Among the 
QOL studies in cancer patients, breast cancer has received most attention for several reasons. 
First, the number of women with breast cancer is increasing: each year over 1.1 million 
women worldwide are diagnosed with breast cancer, and 410,000 die from the disease 
(Montazeri A, 2008). Second, the early detection and treatment of breast cancer have 
improved, with cancer survivors now living longer. Third, breast cancer affects a woman's 
identity. In addition, it is believed that females play important roles as partners, wives, and 
mothers within any family; when a woman develops breast cancer, all members of the family 
are affected, making breast cancer a disease of the whole family. The overall consequence of 
this myriad of factors, is that QOL is becoming an increasingly important research topic; 
particularly due to increased longevity and the psychosocial impact of the loss of a breast. 
Although other reasons could be added, it is crucial to recognize that with continuing 
advances in medical practice, studying the impact on QOL is highly relevant for any cancer, 
regardless of anatomical site or gender.  
A descriptive analysis of the 230 papers published between 1990 and 2000, (Mandelblatt et 
al, 2004) on non-biomedical outcomes in breast cancer patients (QOL, preference, 
satisfaction and economics), found that the most frequently reported outcomes were: 
HRQOL (54%), followed by economic analyses (38%), and patient satisfaction (14%); with 
only 9% measuring patient preference (Mandelblatt et al, 2004).  Over the past ten years, 
much clinical effort has been expended looking at improving the treatment of breast cancer 
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and survival from it; the question is now: to what extent have studies of quality of life in 
breast cancer patients added to the extensive knowledge base, or contributed to improved 
outcomes in breast cancer care? Whilst this is very difficult to answer, it is possible to try to 
investigate the contribution of QOL studies to breast cancer care as a whole. There are 
several useful review papers on QOL in breast cancer patients but most published papers 
have either provided an overview or have been systematic literature searches with much 
focused objectives (Montazeri A, 2008).  
Evidence is accumulating that the multifaceted sequelae of breast cancer do not cease with 
the conclusion of treatment. Two recent reports make clear that the period after completion 
of active treatment brings its own set of unique, and in some cases, still poorly understood 
challenges (Hewitt et al (2005). Many breast cancer survivors experience persistent physical 
symptoms related to cancer and its treatment, including: fatigue [Barton-Burke M 
(2006),Lawrence et al (2004), Bower et al (2006), pain or abnormal sensations in the arm or 
breast (Erickson et al 2001), hormone-related symptoms [Ganz et al (1998), Ganz et al 
(2002), Carpenter et al (1999) and sexual dysfunction [Ganz et al (2002), Kornblith et al 
(2003)]. The prevalence of these long-term physical symptoms is not trivial: for as many as a 
third of breast cancer survivors, fatigue may continue to be problematic five to seven years 
into survivorship (Bower et al, 2006); equally, a third of long-term survivors suffer post-
surgical pain and troublesome physical sensations (e.g., numbness, paresthesia) in the arm, 
breast or chest wall (Kornblith et al, 2003). Hormone-related symptoms including vasomotor 
symptoms (hot flashes, sweats, palpitations), urinary incontinence, vaginal dryness, and 
cognitive and mood changes are common in breast cancer survivors too (Carpenter et al, 
1999), and occur at higher rates than in age-matched healthy peers (Ganz et al, 1998). 
Furthermore, approximately 20–30% of breast cancer survivors experience sexual problems 
including general sexual disruption, decreased frequency of intercourse, and difficulties 
reaching orgasm that can persist 20 years post-treatment (Kornblith et al, 2003). These 
physical symptoms can inhibit psychosocial adaptation, disrupt the ability to perform normal 
life roles, and decrease the HRQOL for years after the conclusion of primary treatment 
[Carpenter et al (1999), Ronson et al (2002), McWayne et al (2005)]. Persistent physical 
symptoms also serve as a continuous reminder of cancer, and result in significant 
psychological morbidity including anxiety, depression, problematic levels of fear of 
recurrence [Deimling et al (2002), Holzner et al (2001)], and symptoms of post-traumatic 
stress disorder for up to 20 years after treatment (Kornblith et al, 2003).  
Specific support for the protective role of physical activity comes from a growing number of 
intervention studies investigating the effect of physical activity during and after cancer 
treatment on symptom and physical domains of the HRQOL. Indeed, several recent reviews 
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on the impact of physical activity in cancer survivors, both on- and off-treatment, show that 
physical activity can have positive effects on: physical symptoms such as fatigue, pain, 
cognition, sleep, fitness, body composition; biological changes such as immune functioning; 
and, on psychosocial measures including depression, anxiety, self-esteem, and multiple 
aspects of QOL, including the HRQOL [Irwin et al (2004), Schwartz AL (2004), Oldervoll et 
al (2004), McTiernan A (2004), Pinto et al (2005), Schmitz et al (2005), McNeely et al 
(2006)]. 
 
Mortality and Survival related to breast cancer 
 
Breast cancer was the most common cause of death from cancer in women until 1998; since 
then there have been more deaths from lung cancer in women (Lavelle et al, 2007). By 2010, 
breast cancer was therefore the second most common cause of cancer death among women, 
accounting for around 15% of all female deaths from cancer (ONS, 2010). Between 2005 
and 2009, 85% of women in England survived longer than five years after a diagnosis of 
invasive breast cancer (Stapelkamp et al, 2011). The National Institute for Health and 
Clinical Excellence (NICE) guidelines on the use of trastuzumab estimate that approximately 
40-50% of women presenting with early or localised breast cancer, will eventually develop 
metastatic breast cancer (NICE, 2006). Data from the West Midlands Cancer Intelligence 
Unit indicates that about 5% of women and men diagnosed with breast cancer between 1992 
and 1994 had metastases at the time of their primary diagnosis. In addition a further 35% of 
all those with a primary diagnosis went on to develop metastases in the 10 years following 
diagnosis (SBCTF, 2007).   
Overall, patients with breast cancer therefore survive much longer today, compared with 
twenty years ago. Indeed, the number of cancer survivors in the UK population has been 
increasing each year (Maddams et al, 2009), largely because of advances in diagnosis and 
treatment. Maddams et al (Maddams et al, 2012) used data from the National Cancer 
Registry to estimate cancer prevalence in the UK for 2009. In that study, projections were 
made to 2040; they revealed that by 2040, nearly three-quarters of all breast cancer survivors 
will be 65 and over, representing an increase from 59% today to 73% in 2040 (Maddams et 
al, 2012). This research also projected the increases in breast cancer among over 65-year-old 
patients to be almost double those in younger patients (Maddams et al, 2012). It can 
therefore be concluded that the population needs will be increased accordingly, with a 
significant change in the demands placed on the National Health Service (NHS). As part of a 
holistic approach to care there is an emerging need to be able to identify potential issues and 
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to manage them efficiently. The identification of issues, and patient needs related to breast 
cancer diagnosis and treatment may be as challenging as their management. The current 
research projections for population change must be taken into account in the allocation of 
future resources. Plans need to be made now, to ensure that the varied and increasing needs 
of cancer survivors can be met in the future. By proactively managing need, we may be able 
to reduce how this increasing burden affects the NHS. 
Therefore, as survival rates are increasing and therapeutic options are becoming more 
diverse, there is a growing need for a tool that can identify the needs of this evolving 
situation. Only then, we will be able to improve the quality of life of patients with breast 
cancer, and be able to allocate our resources according to both disease and social 
determinants. 
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 CHAPTER 2. An Assessment of Need in Breast Cancer Patients and the Role of 
a Breast Cancer Specific Patient Concerns Inventory (PCI) 
 
This part of the thesis provides a short overview of the needs of breast cancer patients. In 
particular, it addresses the physical and psychological needs relevant to its diagnosis and 
treatment. A review is made of the current UK guidance for breast cancer care, together with 
the various tools used to assess need. Ultimately, the chapter concludes on the requirements 
of effective needs assessments. 
 
What guidance exists in the UK? 
 
In an attempt to meet the ever increasing needs of the breast cancer population, the National 
Institute of Clinical Excellence (NICE) published updated guidance on ‘Improving outcomes 
in breast cancer’ in 2002 (NICE, 2002). Following this, a process was put in place in 
England to monitor the progress made toward implementing the recommended changes in 
service organisation and delivery. Since breast services were the first to utilize 
multidisciplinary teams (MDTs) breast cancer MDTs were the first to be reviewed in 2001, 
and again in the 2004-2007 review round (BCCOM, 2007).  
The 2002 NICE guidance required that each MDT had two core members in all the key 
disciplines (BCCOM, 2007). These included a designated consultant breast surgeon, a 
designated breast care nurse, a designated imaging consultant, a designated histopathologist, 
a consultant oncologist and an MDT co-ordinator. Of the 174 breast cancer MDTs that were 
included 88% achieved full core team membership by the 2004-2007 peer review round, 
although only half of the teams met the NICE 2002 requirement. The overall compliance 
against all measures outlined in the 2002 guidance was around 77%, with 5% of teams 
having compliance levels under 50% (BCCOM, 2007). A review period limited to a 
maximum of three years was presented in the NICE 2002 guidance (NICE, 2002) but 40% of 
cancer networks did not consent to this requirement (BCCOM, 2007). However, in spite of 
only 69% of teams allocating a key worker, there was high compliance with patient 
experience measures, such as patient surveys, in most breast cancer teams (SBCT, 2007). 
MDTs bring together staff with the necessary knowledge, skills, and experience to ensure 
high quality diagnosis, treatment, and post-treatment support. Effective MDTs ensure good 
communication between primary, secondary and tertiary care and are thus in a position to 
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address most patient needs that arise. Compliance with these guidelines moves us closer to a 
situation where the holistic needs of breast cancer patients are achievable. 
 
The role of primary care 
 
Often the Primary care setting may be the first point of contact for patients with physical, 
social, and psychological problems associated with breast cancer treatment. It is estimated 
that an average practice of 10,000 patients will have around 23 registered patients who 
consult their GP with breast cancer each year (Birmingham research unit, Annual prevalence 
report, 2007). Unfortunately, the level and quality of treatment vary across the country, 
according to the patient’s age and socioeconomic status [Coleman et al (2001), Coleman et al 
(2001), Macleod et al (2000)]. Physical access to services also remains inequitable, with 7% 
of the population of England and Wales living over 50 km from their local radiotherapy 
centre. This variation in treatment access can result in differences in clinical need between 
breast cancer patients and creates the search for a better way that will ensure patient 
satisfaction through the recognition and the effective management of disease specific issues. 
It is a challenge to promote a follow-up regimen that maintains patient confidence and takes 
into account the issues of patients who may be living with a potentially life threatening 
condition. However, focusing on the active identification of issues in both primary care and 
the community, using a validated tool to improve teamwork and a holistic approach, could 
go a long way to managing these needs [de Bock et al (2004), Grunfeld et al (1996).  
 
What is need? 
 
The National Health Service (NHS) was created from the ideal that good quality healthcare 
should be available to all. Three principles (NHS, 2012) have guided the development of the 
NHS: that it meet the needs of everyone; that it be free at the point of delivery; and, that it be 
based on clinical need, not the ability to pay. The first point in particular is difficult to define 
however, due to the inherent complexity of the concept of 'need' (Asadi-Lari et al, 2003). 
'Need' as a natural right in the pursuit of happiness, was introduced in the ancient Greek 
civilisation by Aristotle in the Nicomachean Ethics (Melden AI, 1957). Today, the Medical 
Research Council considers need to exist when a patient's functioning falls below a 
minimum specified level, and where there is a remediable cause (Stevens et al, 1998). 
Buchan et al have defined health service needs in economic terms, as 'those for whom an 
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intervention produces a benefit at reasonable risk and acceptable cost' (Buchan et al, 1990). 
However, a more holistic approach has been proposed by Maslow (Maslow AH, 1968), 
where needs are hierarchically organized into five levels (Figure 1). Here, basic needs are at 
the bottom of the hierarchy, and the need for self-actualisation is at the top. This theory 
argues that individuals will be motivated to meet higher need levels only when lower order 
needs are satisfied.  
 
 
Figure 1 Maslow's Hierarchy of Needs 
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Assessing multidimensional need in Breast cancer 
 
Need assessment in oncology necessitates the inclusion of a direct and comprehensive 
assessment of the multidimensional impact of cancer on the lives of patients and should 
address important domains of physical, functional, emotional, social, spiritual, and practical 
needs [Ferrell et al (1997), Bonevski et al (2000), Soothill et al (2001)]. A better 
understanding of patient needs can help clinicians and nurses to focus their care on those that 
are most relevant [Holmes et al (1997), Wen et al (2004)]. In 2008 Schmid-Büchi et al., 
divided the needs of women with breast cancer into four key categories: physical and 
treatment-related needs; psychological needs; social needs; and, informational and support 
needs (Schmid-Büchi et al, 2008). 
Physical factors 
Breast cancer patients typically have a range of needs that have to be met in order to 
establish a positive patient-doctor relationship (Davis et al, 2004). Prevalent among these are 
physical and treatment related needs, where several studies have described fatigue and lack 
of energy during treatment among both long term survivors and cancer patients [Haberkorn 
et al (2013), Schultz et al (2005), as well as symptoms such as impaired arm/shoulder 
movements and lymphoedema (Raupach et al, 2002). It has also been found that menopausal 
women with a history of breast cancer treatment tend to report a higher frequency of 
menopausal symptoms [Schultz et al (2005), Ayers et al (2013). Given that the incidence of 
breast cancer increases with a woman's age - a 60-year-old woman has a higher risk of being 
diagnosed with breast cancer in the next 10 years than a 40-year-old woman - a significant 
number of patients with breast cancer will potentially be at an age close to / or at menopause. 
This adds an extra dimension to their care needs. Indeed, such women also report additional 
physical complaints, including: impaired sexual functioning, sleep disturbance, reduced 
libido, hot flashes, reduced concentration, and a reduced interest in sex (Hodgkinson et al, 
2007). These complaints frequently give rise to problems related to body image and a 
perceived loss of femininity (Davis et al, 2004). Many women with a history of treatment for 
breast cancer can have physical symptoms that can be somewhat overwhelming with a 
negative influence in their quality of life. 
Psychological factors 
From a psychosocial perspective, patients report body image problems, together with the loss 
of a sense of attractiveness, femininity and sexuality (Schultz et al, 2005). Research suggests 
that these challenges to the self-image and general well-being of the patient are such that 
significant psychiatric morbidity can result (Wen et al, 2004), with women tending to suffer 
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from anxiety, stress and depression, than is often related to the fear of either spread or 
recurrence of the cancer (Hodgkinson et al, 2007). Empirical studies focusing on the social 
and psychological needs of breast cancer patients, such as that by Hodgkinson et al 
(Hodgkinson ,2007), have concluded that breast cancer patients experience depression due to 
the fear of their cancer returning. Additionally, more than half of long-term survivors 
indicate that they were unhappy with the way things had turned out for them (Schultz et al, 
2005), with anxious and depressed women perceiving significantly more unmet needs 
(Hodgkinson et al, 2007).   
In order to combat the emotional demands of breast cancer, one of the most commonly 
expressed needs is the need to retain a sense of control over their life. Maslow et al (Maslow 
AH, 1968) suggest that this sense of control can be achieved for most patients, by improving 
the patient doctor relationship: offering a higher level of involvement in treatment-related 
decisions, and by facilitating the discussion of expectations about the course of their 
treatment. According to Hodgkinson et al (Hodgkinson et al, 2007), there is a significant 
correlation between the number of unmet needs among breast cancer patients and their level 
of anxiety and depression. The effect of breast cancer on the patient’s psychological well-
being has been clearly documented. Other effects that include their social functioning need 
to be taken into account at the review outpatient clinic. 
Social factors 
Hanson Frost et al (Hanson-Frost et al, 2000) identified that women newly diagnosed with 
breast cancer felt that their function in society was more severely impaired. The majority of 
these patients expressed a need for empathic listening and for emotional support, which was 
usually provided by their partner and family. However, the extent to which their family 
provides these emotional needs varies considerably; Schultz et al (Schultz et al, 2004) for 
example revealed that, although 50 per cent of women experienced an improvement in their 
family relationships, 30 per cent experienced a deterioration in their relationships. The study 
by Hanson Frost et al (Hanson-Frost et al, 2000) however, suggests that there is no 
significant difference in either the psychosocial measures, or the marital or sexual 
relationships, between women with stable breast cancer and the newly diagnosed. The effect 
of disease on social functioning may be profound. In order for a patient to be able to reach 
the pre-disease levels of function in society, simple interventions such as identifying and 
addressing the informational needs may be all that is required. 
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Informational Needs 
Finally, breast cancer patients have a wide range of informational needs. Lobb et al (2001) 
report that as many as 80 per cent of breast cancer patients interviewed in their study wanted 
access to as much information as possible, with just 16 per cent of respondents stating that 
they wanted limited information. Specifically, the information requested included: details 
about treatment; possible side effects; life expectancy; the risk that other family members 
might develop breast cancer; things which they could do to help themselves; and, remission 
(Opatt et al, 2007). This was expanded upon by Hunter et al (2004) through semi-structured 
interviews, who found that the majority of breast cancer patients wanted information to help 
them cope effectively with treatment side effects and to manage their illness. In addition, 
patients wanted to know what “was considered normal" in both psychological and physical 
terms.  
It is important to note, however, that many of the patients expressed a clear preference for 
how they wanted this information communicated to them. Opatt et al (2007) report that a 
large proportion of women want their cancer specialist to first ask them whether or not they 
wanted specific information. Decision making is also important to patients; Hanson Frost et 
al (2000) report that 53 per cent of women in their survey wanted to collaborate in the 
decision making process about their treatment, while 23 per cent wanted to be the sole 
decision maker, and 23 per cent wanted the decision to be made by the doctor.  
There are other factors needing consideration too. Katz et al (Katz et al, 2005) suggest that 
the desire for information also extended to a desire to learn about complementary therapies 
and support groups. In addition, women that have had to overcome barriers when obtaining 
health information tend to have significantly lower psychosocial well-being, and a lower 
perception of their health competence (Arora et al, 2002). It is therefore arguable that there is 
an unmet need for easily accessible additional information, particularly in relation to support 
groups and complementary therapies [Hodgkinson et al (2007), Lobb et al (2004)]. 
Difficulties in obtaining the required information often has clear negative effects (Lobb et al, 
2001), making the accessible provision of information a key factor for the patient. 
 
Maslow and need assessment in oncology 
 
Attainment of basic needs, as detailed above, are simply steps along the path to self-
actualisation according to the Maslow model of clinical need (Maslow AH, 1968) (Figure 1). 
If a need is identified, action is recognised as desirable by clinicians: inaction will result in 
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dissatisfaction and a persistence of the need. A need assessment should directly measure the 
divergence between a patient’s experiences and expectations (Bonevski et al, 2000).  
Cancer survivorship is an ongoing challenge, for both patients and their relatives; they do not 
return to a pre-cancer-diagnosis state of functioning, and retain specific and unique needs 
(Hodkinson et al 2007). According to Maslow for example (Maslow AH, 1968), breast 
cancer patients have high needs for safety and security: the needs to find safe circumstances, 
stability, protection and to regain a more predictable life. However, there is considerable 
individual variability in the reaction of breast cancer patients to their illness and treatment; 
we do not understand why some women present with supportive care needs, why others have 
no specific needs at all, and why some have unsatisfied needs. Identifying patients with 
unsatisfied needs at an early stage of their treatment provides the opportunity to address 
these needs and enhance the quality of care [Bonevski et al (2000), Boberg EW (2003)]. 
Unsatisfied need and symptom burden have a significant impact on a patients’ well-being 
during both treatment and their long-term adjustment (Holmes et al, 1997).  
 
Unmet needs and Health related Quality of Life 
 
Two conceptually different morbidity outcomes, unmet needs and health-related quality of 
life (HRQOL), are used to identify cancer patients in need of clinical attention. Hansen et al 
(Hansen et al, 2012) have confirmed that patient-perceived unmet needs during cancer 
rehabilitation are associated with decreased quality of life (QOL), advocating the use of 
questions to identify unmet clinical needs in patients. This is confirmed elsewhere in the 
literature, which has found that cancer patients experience significantly more psychological, 
interpersonal, health policy and system difficulties and other problems of living [Hansen et 
al (2012), Welch-McCaffrey et al (1989)]. It is possible to measure psychological adaptation 
to breast cancer by assessing quality of life, satisfaction with care, and needs; however, the 
needs assessment differs from the other constructs in that it directly identifies patients with 
higher levels of need, and suggests specific interventions for them [Bonevski et al (2000), 
Foot et al (1995), Park et al (2012)]. Evaluating a patient’s psychological needs is important 
if we are to offer timely, effective interventions. Furthermore, Caucasian cancer patients 
report more unmet psychological needs [Lam et al (2011), Harrison et al (2009)], and require 
more psychological support. 
Interventions based on specific unmet needs, could also result in less depression, and 
enhanced QOL among breast cancer survivors (Park et al, 2012). The same study concluded 
that needs diminish with advancing duration of survival; most needs are seen in survivors of 
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less than one year, followed by survivors of one to three years, with the least needs in long-
term survivors (over five years since surgery) (Park et al, 2012). It is difficult to know if this 
is because over the five years patients are seen in an outpatient clinic and their needs are 
gradually identified or it is because the patients come to terms with the issues and put up 
with functional or emotional disability. Consequently, earlier psychosocial interventions that 
aim to meet unmet needs, may improve the overall QOL of breast cancer patients. 
 
The doctor-patient relationship and areas of conflict 
 
Recognition of the importance of specific aspects of the doctor-patient relationship  in breast 
cancer is evidenced in NICE guidance. The statement “Members of the breast care team - 
particularly those providing direct clinical care - should have special training in 
communication and counselling skills,” emphasises a new role for the clinician. Clinical care 
is important but this should be provided as part of a holistic approach that is delivered 
appropriately at different stages of the cancer journey. 
 
Failing to address core patient needs often results in conflict in the doctor patient 
relationship. However, empirical research suggests that the extent to which the needs of 
breast cancer patients are met by their doctors varies considerably. A review of the literature 
reveals that the most significant area of conflict surrounds the decisions that are made about 
treatment. In a study conducted by Fagerlin et al (Fagerlin et al, 2006), 50 per cent of 
surgeons who were surveyed reported conflict with patients over decisions about different 
options for surgical treatment. However, the findings suggest that clinical experience affects 
individual perceptions of the nature of the conflict, with high volume surgeons being more 
likely to experience conflict. This higher incidence of conflict may be because such surgeons 
are more likely to favour breast-conserving surgery (BCS), whereas patients tend to prefer 
complete mastectomy due to concerns about cancer recurrence.  
Lobb et al (2001) who conducted a series of interviews with doctors and breast cancer 
patients expand upon these ideas. They conclude that much of the conflict concerning 
treatment options can be traced to the failure of doctors to provide patients with relevant 
information about their treatment options. This results in many patients obtaining 
information about breast surgery options from the popular media, and from family and 
friends, which may not provide a balanced view of the benefits and risks of different 
treatment options in their specific cases. Wen and Gustafson (2004) support this, finding that 
just 50 % of women undergoing treatment were aware that both BCS and mastectomy 
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resulted in equal survival rates. After a breast cancer diagnosis the patient is faced with a 
plethora of life changing decisions. Often the decision favouring a mastectomy is based on 
society perceptions since often it is seen as a way to "take it all out as quickly as possible." 
These perceptions can lead women to prefer mastectomy even when their surgeons don’t, 
resulting in conflict that could be easily avoided by better discussion of the options available. 
Breast cancer patients may also have cause to complain about the failure of doctors to 
empathise with the experience of their patients. In particular, almost 60 per cent of breast 
cancer patients surveyed by Opatt et al (Opatt et al, 2007) felt that their doctors did not 
attempt to ask them about their emotional needs, or to address their anxieties about 
treatment. One patient who was interviewed in this study stated that she often felt that her 
doctor was impatient when dealing with her queries about treatment, and made her feel that 
her questions were not warranted. This is supported by Siminoff et al (Siminoff et al, 2000) 
who argues that the presence of specific characteristics in the patient-doctor relationship are 
more likely to reduce conflict. In particular, those breast cancer patients with a higher level 
of participation, and who spoke more when interacting with their doctor, were typically more 
knowledgeable about their cancer and consequently experienced higher levels of satisfaction. 
In contrast, those patients who asked more questions of their doctor were less likely to 
experience satisfaction – this has been attributed to the fact that many of these women had 
conducted independent research prior to the visit and therefore had higher expectations of 
their doctor that were not met. Interestingly, the results of the research suggest that those 
doctors who used more affective utterances (specifically, phrases which focused on the 
emotions of their patients) were more likely to have satisfied patients.  
The patient-doctor interaction may have a direct bearing, not only on patient satisfaction, but 
also on the patient’s sense of regret. In their study, Siminoff et al (Siminoff et al, 2000) 
indicated that patients who spoke more were significantly less likely to feel conflicted or 
regretful about their decisions. It is clear, therefore, that the avoidance of patient-doctor 
conflict is dependent on the extent to which doctors are capable of meeting both the 
information and psychosocial needs of their patients. 
 
Resolving conflict and meeting needs in the doctor patient relationship 
 
Most studies in this area suggest that conflict in the doctor-patient relationship can be 
resolved if doctors display greater empathy, thereby establishing shared understanding with 
their patients. Halpern (2007) defines this as exhibiting ‘engaged curiosity’ about the 
emotional state of their patient, arguing that this can be achieved if physicians become more 
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self-aware and more adept at recognising their own emotions, and the sources of any 
negative feelings. Lobb et al (2001) expand on this, and argue that doctors need to listen 
deliberately for the emotional concerns that patients may have, and which may be obscured 
by their concrete clinical demands. Indeed, many clinicians tend to focus their attention on 
the clinical facts presented by patients, rather than on the emotional meanings that often 
underpin their words. 
Aside from the importance of engaging in empathetic communication with patients, Wen and 
Gustafson (2004) also argue that physicians need to be careful to ensure that their patients 
are regularly updated on their available treatment options at all stages of their relationship. It 
is also essential for doctors to have a detailed discussion with their patient when the 
diagnosis is made in order to establish what information needs the patient has, and to 
determine the extent to which the patient wants to collaborate in the decision making 
process. Although research suggests that the majority of patients want to take an active role 
in decision-making, this is not true of all patients. Recognising the individual characteristics 
and specific requirements of patients is an important step towards reducing conflict in the 
patient-doctor relationship (Siminoff et al, 2000).  
Hanson Frost et al (2000) expand upon this theme, suggesting that all clinicians should be 
provided with tools to make them capable of improving informed decision making, even 
within practice settings where it is possible for patients to gain access to several clinicians. 
An example of one such tool is a decision board, where it is possible for patients to 
understand the range of treatment choices available for the local therapy of breast cancer. 
The results of a randomised trial conducted by Hanson Frost et al (2000) revealed that the 
use of the decision board was associated with significantly lower levels of decisional conflict 
between the patient and the doctor, with a higher level of patient knowledge and satisfaction. 
The use of the board also meant that patients were significantly more likely to opt for BCS 
when compared to those patients who did not use the board. Although there are fundamental 
differences, a breast cancer specific patient concerns inventory (PCI) may result in similarly 
reduced levels of conflict by providing a patient 'platform' that quantifies the specific issues 
occurring along the cancer journey.  
 
Clinician communication skills and patient experience 
 
The quality of the patient-doctor interaction, rather than the frequency and length of 
consultation appears to have the greatest effect on patient reported outcomes (PROs) (Tan et 
al, 2011). Although one might expect a positive outcome, such as a reduction in treatment 
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related symptoms, this is not necessarily the case. Tan et al (2011) report that as patients 
discussed and sought information from their physicians at baseline, about their cancer 
treatment, quality of life, and other cancer-related issues, there was a tendency for patients to 
report a greater number of cancer-related issues the following year. Elsewhere, the collection 
of health-related quality of life data from patients has led to a better subsequent quality of 
life and emotional functioning (Velikova et al, 2004). In a study by Detmar et al (2002), the 
use of patient-reported quality of life assessments during consultations, led to a greater 
percentage of patients identifying moderate to severe problems in various health domains. 
Conversely, Stark et al (2004) observed that anxiety could be exacerbated through medical 
discussions. Unidentified concerns during review appointments can build up and develop 
into significant problems later on, long after the cancer treatment has ended. Patient 
satisfaction with the consultation depends on their perception of a given doctor’s 
interpersonal and clinical skills. The persistent failure of the clinician to recognise issues 
may affect the patients' confidence levels towards the treating team, and to the treatment 
options offered. 
We know from both the literature, and clinical experience that good communication skills 
are crucial in the clinical care of women with breast cancer [Fallowfield et al (1999), 
Maguire et al (1999)]. However, it appears that the relationship of a patient’s experience to a 
clinician’s communication skills is much more complex. Patients with cancer want a 
relationship with their doctors [Jefford et al (2002), McWilliam et al (2000), Butow et al 
(2002); this relationship is a dynamic process that can be affected by the clinician’s 
communication skills. Communication skills can be enhanced by training but in doing so, 
may not always improve patient experience (Fallowfield et al, 1999). It appears that patients 
primarily want information to maintain hope and trust throughout the cancer journey 
[Hulsman et al (2002), Leyden et al (2000)]. A central feature of effective therapeutic 
relationships is mutual communication: a non-judgmental, inclusive orientation towards the 
other person [Hack et al (2005), Feldman-Steward et al (2005), Kreps G (1998), Roter DL 
(2000). Good quality oncologist-patient communication should serve as an information 
exchange platform that takes into account the relational needs of patients (Hack et al, 2005). 
Early research into cancer communication and the patient-doctor relationship, described 
patterns of information exchange with a clear dominance of talk by clinicians [Kaplan et al 
(1989), Siminoff et al (2006), Butow et al (1997), Nussbaum et al (2003). Effective patient-
centred communication is dependent on both the clinician’s expressed recognition of the 
patient’s needs, as well as the communication of complex medical information (Step et al, 
2009). In the context of communication between the head and neck cancer patient and 
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clinician, a head and neck cancer Patient Concerns Inventory has been developed (Rogers et 
al, 2009). 
 
The Patient Concerns Inventory (PCI) 
Patient symptom checklists are tools that may aid the early identification of symptoms that if 
they remained unidentified they may place patients at risk and may affect their health related 
quality of life (Mitchell AJ, 2007). The PCI concept, initially developed by Professor Rogers 
(Rogers et al, 2009) at the Merseyside Head and Neck cancer centre in partnership with the 
evidence based practice unit of Edge Hill University, started as a checklist for use with head 
and neck cancer patients. The PCI was developed due to the inherent limitations of existing 
HRQOL questionnaires: the number of domains and items, their wording, and the scoring 
systems used, as well as their limited ability to inform clinical consultations.  
The use of the PCI in Head and neck cancer 
In head and neck cancer the use of a PCI (Rogers et al, 2009) helps to focus consultations 
onto patient need, and to promote multidisciplinary care. The purpose of the head and neck 
PCI is to identify concerns that patients would like to discuss during their consultation, 
covering a range of issues including: hearing, intimacy, fatigue, finance/benefits, 
percutaneous endoscopic gastrostomy (PEG) tubes, relationships, regret, support for family, 
and wound healing. A 28-week pilot study that ran from August 2007 with 123 patients 
using a touch-screen computer looked at this in more detail (Rogers et al, 2009). In this 
short questionnaire, in which the median time to complete was eight minutes, patients most 
frequently selected the following concerns: fear of recurrence (37 %), dental health/teeth 
(27 %), chewing (24 %), pain in the head/neck (20 %), fatigue/tiredness (19 %), saliva (18 
%), and swallowing (18 %). The two multidisciplinary team members patients most 
commonly wished to see were also identified as the dentist (19 %) and the speech and 
language therapist (10 %). The vast majority felt the PCI made a difference (quite a bit/very 
much) to their consultation, as it made it ‘a bit more personal,’ ‘reminds them of the points 
they want discussed,’ and ‘allows the consultation to get straight to the point’. Although the 
PCI raised many disparate issues, it did not noticeably prolong the consultation.  
The rationale for a breast cancer specific PCI 
Since the merit of a PCI has been demonstrated in Head and Neck Cancer, it is important to 
explore the incorporation of this reliable and valid PRO tool [(Kanatas et al (2012), Flexen 
et al (2012), Rogers et al (2012), Ghazali et al (2013), Kanatas et al (2013)] in the 
management of other cancers. In patients with breast cancer for example, PRO tools exist, 
but even the best instruments do not address all of the important surgery-specific and 
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psychometric issues relevant to oncologic breast surgery patients (Jacobsen et al, 2005)). 
Issues like fatigue, anxiety, body image, sexuality, and upper-body limitations are some of 
the lingering factors that have a strong impact on the health related quality of life (HRQOL) 
following breast cancer diagnosis and treatment. While many women with early-stage breast 
cancer return to good levels of health, others struggle to regain their pre-cancer quality of life 
(QOL).  
In breast cancer, there are several surgical and drug therapies available, each with similar 
survival rates, but different side effects that affect the HRQOL. Hence, an effective PCI 
instrument should support a patient tailored approach to identifying needs. A PCI is different 
to the current HRQOL questionnaires; it is designed with a practical intent, to be used in 
clinical practice to screen patients for concerns, before that information is used directly to 
inform communication and patient care. It does not generate a score that allows 
measurement and monitoring of issues over time. HRQOL questionnaires are designed as 
outcome measures that compare different groups of patients. Although there have been many 
studies using them in clinical practice, they are not specifically designed for clinical practice.  
The National Comprehensive Cancer Network recommends a simple screening tool referred 
to as the distress thermometer (DT) (Mitchell AJ, 2007) which allows screening of large 
numbers of patients without the need for complex scoring. Such tools are available for 
holistic assessment but are neither specific to breast cancer, nor to the potential range of 
items reflected in the head and neck PCI. Although PCIs have been shown to be of clinical 
value in head and neck cancer patients, the value of such tools in breast cancer patients is 
not currently known. Hence, this current study seeks to develop a PCI for breast cancer 
patients and to undertake a preliminary evaluation of that PCI in a routine outpatient clinic. 
PCI and the patient-doctor relationship 
The implementation of successful symptom management relies on the appropriate exchange 
of information between a physician and patient. Patient self-efficacy during this interaction is 
a key component in the perceived ability of a patient to obtain medical information and 
attention regarding their chief medical concerns from their physicians (Maly et al, 2004). It 
has been suggested that vulnerable patient populations might receive suboptimal care due to 
a decreased sense of control over the health care process, and that this results in less 
confidence in their ability to get physicians to attend to their health concerns [Woodward et 
al (1987), Greene et al (1986). The PCI may play a role in empowering patients from this 
group, and may help to uncover disease or treatment-related symptoms that were previously 
unreported; thereby potentially enhancing a patient’s QOL. The use of a PCI in breast cancer 
clinics could therefore increase patient self-efficacy within the patient–doctor encounter, 
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resulting in faster resolution of their symptoms. Regardless of who initiates the information 
exchange, it remains the doctor’s awareness of common symptoms that provides the 
opportunity to discuss treatment options and ultimately treat them.   
Recently, studies have emerged in breast cancer patients investigating whether differences in 
patient-doctor communication could impact on the prevalence and/or resolution of breast 
cancer related symptoms (Maly et al, 2010). Depression was highlighted to be the most 
common symptom reported by patients (66%), yet physicians were the least aware of it 
(26.3%); this is probably because doctors tend to focus on the details of cancer treatment 
during patient visits, and may overlook psychiatric symptoms (Maly et al, 2010). In addition, 
physicians may feel less well-equipped to deal with psychiatric issues than with medical 
problems [Valente et al (1994), Maguire P (1985).  A breast specific PCI may be in a 
position to identify patients with depression and in need of more extensive evaluation and 
specific management. 
Another area that is worthy of specific note in the patient-doctor interaction, is pain; a 
common symptom among breast cancer patients. It is documented in the literature that 
younger age and the presence of co-morbidity tends to be inversely associated with pain 
[Badger et al (2001), Boyar et al (2006). Further, a lack of information on pain management 
has been identified as a significant barrier against pain control among minority groups 
(Cleeland et al, 1997). Reluctance to report pain might lead to reduced physician awareness 
of the symptom, and therefore inadequate pain assessment and management. There are well 
documented differences in the communication between doctors and patients from ethnic 
minorities [Johnson et al (2004), Cooper et al (2003). These differences of care may 
contribute to disparities in health. A breast cancer specific PCI could play an important role 
in identifying patients with pain in low income and ethnic minority groups by an 
improvement in the quality of the patient-clinician interaction. 
Pressures of time in routine outpatient clinics encourage a more tightly controlled doctor-
centred consultation with less attention paid to the social and psychological aspects of a 
patient’s illness (Howie et al, 1992). Potentially, the use of a breast cancer specific PCI will 
encourage a participative style in a clearly defined format that could reduce the time spent on 
consultations by identifying areas for attention more rapidly. Overall, this tool specifically 
targets the patient-clinician consultation, helping the clinician to identify themes that they 
may otherwise miss but in addition can help women feel listened to. 
The PCI at key stages in a breast cancer patient’s journey 
Limited evidence suggests that patients are often unhappy with the care received at key 
transition periods in their care, particularly between the end of treatment and long-term 
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survivorship [Ganz et al (2004), Cox et al (2003), Gotay et al (1998)]. Patients in this group 
may, for example, feel let down after eagerly anticipating the end of their primary treatment, 
and may have specific concerns such as fear of recurrence (FOR) as well as sexual function 
and fertility [Gotay et al (1998), Northhouse et al (1981), Hodgkinson et al (2003), Hewitt et 
al (2007), Kim et al (2006), Connell et al (2006)]. The use of breast specific, or general 
HRQOL tools is a common method for recording the post-treatment sequelae, with several 
studies reporting that the most common concerns are psychological and social [Ganz et al 
(2002), Gotay et al (1998)]. However, HRQOL tools were developed to assess newly 
diagnosed patients and those receiving treatment; hence they may lack the ability to identify 
issues specific to long-term survivorship. In addition, when using HRQOL tools, it can be 
unclear to clinicians whether a specific item is a problem for which patients need help, as 
they are only required to select a score or to rate the presence and severity of an item (Armes 
et al, 2009); there is no need to qualify what have been recorded. Another aspect of breast 
cancer care that HRQOL tools have not been specifically designed for is the assessment of 
long-term hormonal treatment and its side effects. It has been reported that the use of 
hormonal therapy in patients is a significant predictor of unmet needs (Armes et al, 2009). 
The published literature also suggests that there is an association between FOR and 
psychological distress, with reduced QOL scores [Sneeuw et al (1992), Humphris et al 
(2008)]; for example, Armes et al (Armes et al, 2009) have reported that FOR is a significant 
predictor of unmet need, and that 30% to 50% of breast cancer survivors have unmet needs . 
Furthermore, cognitive behavioural therapy has been employed effectively to help patients 
with the negative effect posed by the threat of recurrence (Humphris et al, 2008). A breast 
cancer specific PCI may therefore be an important first step in the systematic assessment of 
patient need at key stages along the cancer journey. Furthermore, the breast cancer specific 
PCI may be better suited to capturing the concerns of these patient groups than HRQOL 
tools, allowing greater scope for clinicians to offer education and support. 
 
What a needs assessment tool should be 
 
In summary, we have seen that need is a difficult concept to define, and that breast cancer 
patients are a unique group with very specific needs. Moreover, it has been demonstrated 
that the tools currently used to assess need in breast cancer are insufficient in several key 
areas. Therefore, a new approach is needed, and learning from our positive experiences in 
head and neck cancer, a breast cancer specific PCI may be a more suitable and effective tool 
with which we can move forward.  
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A need assessment tool should be able to assess the gap between normative and perceived 
need (Carr et al, 1976). Here, normative need refers to what expert opinion based on 
research, defines as need; and, perceived need is defined as what people think their needs 
are, or feel their needs to be. Breast cancer specific supportive care needs assessment tools 
do exist, and have been used in patients [Skrutkowski et al (2011), Halkett et al (2007), 
Rapport et al (2006), Can et al (2004), McTavish et al (1995). However, methodological 
weaknesses during their development limit their general applicability, including small 
sample sizes, specific patient groups, and specific aspects such as positive adjustment 
following breast cancer (Boot et al, 2010). Also most of these have tended to focus on the 
identification of informational needs, and do not include aspects that seek to identify 
depression or FOR. In contrast, a PCI tool that is based on the experiences in head and neck 
cancer, allows for the ability to raise a variety of concerns and to direct the patient for 
appropriate care.   
The breast cancer specific PCI should be a tool that can be used effectively in a busy clinical 
practice in order to identify patient concerns efficiently. In addition, it should act as a 
communication tool between clinicians and patients that can at least mitigate aspects such as 
a clinician’s poor communication skills, or a patient’s reluctance to voice their concerns. 
Finally, the tool must be easy to use so that it could be completed in primary care or online at 
home. These factors would ensure that the patient has a greater role in the management of 
their disease, as well as ensuring the maximum benefit for community based services. These 
aspects should be taken into consideration during the development of a breast specific PCI. 
The next stage was the development of the PCI for breast cancer patients. The first 
consideration was the development of a suitable methodology, and this is presented in the 
next chapter.  
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CHAPTER 3. Methods Overview: Hypothesis and Study Design—a Four Phase 
“Proof of Concept” Study 
 
This chapter aims to provide a summary of the methodology used throughout the thesis. 
First, the thesis objective and experimental hypothesis are stated with an overview of the 
thesis. Following this, the four-phase study design undertaken to generate the PCI is 
outlined. In this chapter, the various phases of the thesis, with the methodology used 
throughout, are outlined in detail. At the end of the chapter, the statistical analyses, together 
with the relevant ethical considerations used throughout the thesis, are presented. 
 
Hypothesis and Specific objective 
Hypothesis: Using a specifically developed PCI in clinical practice will help to identify 
patient concerns, improve consultations between professionals and patients, and help inform 
pathways for patients to follow so that their concerns are addressed. 
Specific objective: To develop a PCI specific to breast cancer 
 
Basic Study Format: A Four Phase Prospective Study 
In order to help the reader, the four phases of this work are summarised below: 
Phase 1: Identification of primary patient concerns 
 
 
Step 1. Literature review and item generation (chapters 4 and 5) 
Step 2. Input from clinicians (chapter 6) 
Step 3. Input from patient focus groups (chapter 6) 
Step 4. Input from national bodies (chapter 6) 
Phase 2: A cross-sectional survey of breast cancer patients (chapter 7) 
Phase 3: A before and after study introducing the breast PCI into a clinic. (chapter 8) 
Phase 4: Interviews with Clinicians and specialist nurses (chapter 9) 
 
Inclusion Criteria 
Adult patients (over 18-years) with a history of either diagnosis or treatment for breast 
cancer were included (For non-English speakers, interpreters were provided in the clinic in 
line with current NHS practice) 
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Study Design 
 
An observational study using quantitative and qualitative methods was undertaken. Phases 1 
and 2 involved the development of a PCI tool that was suitable for use with breast cancer 
patients, and the measures supporting the face and content validity of the items. Phase 3 
assessed the feasibility of the PCI through a before and after study. Phase 4 sought to gain 
the opinions of the professionals who used the PCI tool, and included interviews with the 
consultant that used the PCI, and two specialist nurses. Here follows a detailed summary of 
these phases; detailed information can be found by referring to the methods sections of the 
relevant chapters (Chapters 4—9). 
 
Phase 1. The generation of breast-specific PCI items in four steps: 
Step 1.  
A structured literature review of HRQOL questionnaires specific to breast cancer was 
undertaken and a tabulated summary of the items raised in the measures constructed. 
Step 2.  
A sample of clinical specialists (n=10) were consented (Appendix 2A) and interviewed at 
breast oncology clinics in Leeds. They were asked a series of questions designed to identify 
common problems faced by breast cancer patients. This questionnaire (Appendix 2B) was 
based on the experiences of the principal investigator. 
Step 3.  
Patient recruitment for the focus groups occurred as follows: identification of eligible 
patients; approaching patients in clinic and providing preliminary information; provision of 
an information pack (Appendices 2C, 2D, and 2E); and, receiving informed consent.  
Step 4.  
Several national bodies were contacted, the background of the PCI was explained and they 
were asked to comment on the draft PCI arising from step 3. These included: The Heaven 
Foundation, Breast Cancer Campaign, and Yorkshire Cancer Research. 
Phase 1 outcome measures 
The outcome of this phase was the PCI tool, highlighting the most relevant concerns patients 
might wish to raise in outpatient clinics. 
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Phase 1 Analysis 
The literature review generated a list of items that directly effected HRQOL, which 
facilitated item selection for the formation of a core PCI. Relevant phrases and expressions 
were obtained from the items discussed by the focus groups, followed by an initial 
qualitative reduction of the identified sentences, in which inappropriate, ambiguous, or 
redundant expressions, were excluded. To make them suitable for use in a questionnaire, 
some statements needed to be reworded.  
 
Phase 2. A cross-sectional survey of breast cancer patients receiving treatment in two 
National Health Service Hospitals.  
This aimed to provide an indication of the relative frequency of individual PCI items and to 
compare clinical characteristics with the identified PCI items and established breast cancer 
HRQOL measures (EORTC C30 and BR23) (Appendix 2-F). Patients were identified and 
consented (Appendix 2-H) for participation by clinic staff, from the available clinic lists. 
Patients with a history of breast cancer were included, while those with cancer at other sites 
were excluded. The principal investigator then explained the rationale for the study and 
provided an information pack (Appendices 2-F, 2-G, 2-H, 2-I, and 2-O), and a letter was sent 
to their general practitioner (Appendix 2-J). If they agreed to take part the primary 
investigator collected socio-demographic and treatment data from their clinical files 
(Appendices 2-K, 2-L). 
Phase 2 outcome measures 
The PCI tool was assessed through a specific cross-sectional self-completed questionnaire. 
This allowed analysis of patient and clinical characteristics and their relationship to the PCI.  
Phase 2 Analysis 
A correlation analysis resulted from patients indicating which concerns they wanted to 
discuss during consultations (if they were to have one at that moment in time). There was 
also an opportunity for patients to comment on the PCI content itself and to suggest changes.   
 
Phase 3. A before and after study that introduced the breast PCI into a clinic.  
The aim was to evaluate the items raised in the consultation with a specific clinician, before 
and after the implementation of the PCI generated through phases 1 and 2. Patients were 
identified and consented for participation by clinic staff from the available clinic lists. The 
principal investigator then explained the rationale for the study and provided an information 
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pack. The outcome measures were compared between two different cohorts:  
1. Cohort 1 - Patients attending clinic prior to the introduction of the PCI (the ‘no PCI 
cohort’; n=25) 
2. Cohort 2 - Patients attending clinic after the introduction of the PCI (the ‘PCI 
cohort’; n=25) 
Study Measures 
1. A consultation questionnaire (Stewart el al, 1999 and 2001) was used to ask patients 
to consider their consultation. This involved nine questions, each with four options.  
2. The PCI was used. 
Phase 3 outcome measures 
The outcomes that were recorded included: duration of consultations; items discussed in the 
consultation; any onward referrals made; and, patient satisfaction questionnaire scores. 
Phase 3 analysis  
A framework approach (Ritchie J, 1994) was used to analyse the transcribed recordings, and 
to chart the problems experienced by patients in answering each question. Based on the 
identified needs and suggestions from the interviews, modifications were applied to the 
questionnaire pack. Themes were identified and coded into discrete categories relating to the 
concern items, the healthcare professionals, and the type of clinical action or decision made 
during the consultation. Outcomes were classified as medical (e.g., treatment related) or non-
medical (e.g., lifestyle advice). A second independent and skilled qualitative researcher 
assessed the transcripts and compared the conclusions. Statistical analysis was performed as 
detailed in the relevant section below. 
 
Phase 4. Semi-structured interviews with the clinician and the specialist nurses that used the 
PCI in the before and after study. 
Interviews took place in a breast cancer clinic with one oncologist, and two breast cancer 
specialist nurses. These members of the MDT were chosen pragmatically, given availability, 
as well as the need to record, transcribe, and analyse the interviews. The interviews were 
audio-recorded, and the perceived advantages and disadvantages of the PCI from the 
perspective of those MDT members were analysed. 
Phase 4 outcome measures  
The advantages or disadvantages of a PCI breast cancer specific tool as perceived by the 
clinical team using that tool. 
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Statistical Analysis 
 
Data management: 
Completed PCI results were entered into SPSS (Version 19.0). Data from the paper 
questionnaires was entered manually. Data analysis was carried out by the principal 
investigator with DL, who was a supervisor for the thesis and the statistician of the research 
team. 
Audio transcripts: 
Qualitative data was audio-recorded with a Tascam DR-40 (TEAC UK Ltd., Watford, UK) 
recorder. Consultations were recorded in their entirety and were saved in MP3 format; they 
were transcribed verbatim. All identifiable information was removed and anonymous 
identity codes were used to assure that the identity of participants was not revealed, thereby 
maintaining confidentiality.  
Reliability and Validity: 
Both the interview and focus group transcripts were independently assessed and discussed by 
the principal investigator with an experienced member of the supervising team (BR). The 
themes and sub-themes were identified in this discussion through consensus. This provided a 
degree of reliability. Validity was assured by ensuring lines of inquiry verified the accuracy 
and consistency of the responses. 
Power: 
Sample size justification for the qualitative elements of the study was between 8-10 patients 
per each focus group (Morse et al, 1994), in keeping with recommended practice. 
The aim was that the total number of patients was 200 responders for the phase 2 cross-
sectional survey. These figures were based on a literature review and retrospective audit 
of the experience obtained during the development of the head and neck PCI. 
Phase 3 statistical analysis: 
The Mann-Whitney test was used to compare Cohort 1 (no PCI) and Cohort 2 (with PCI) for 
distribution of responses to ordinal questions from the consultation questionnaire, and in the 
distribution of tumour staging and year of most recent diagnosis. Age was compared 
between cohorts using the two-sample t-test, whilst Fisher’s exact test compared other 
characteristics. The chi-squared test compared responses to question 5 of the consultation 
questionnaire, which was non-ordinal. 
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Ethical considerations 
 
This study was approved by the Leeds Central Research Ethics Committee and the Research 
and Development department of the Leeds Teaching Hospitals (REC: 11/YH/0245 and REC: 
12/YH/0215). 
All demographic and medical data collected in this study was anonymised and stored 
confidentially. Patients were given study ID numbers and no reference to personally 
identifiable information was made. Electronic data was stored on password protected, 
firewalled University computers. Hard copies of the data were stored in locked filing 
cabinets in research offices at St James’s University Hospital. Only members of the research 
team had access to the anonymised data file. 
 
Indemnity arrangements  
 
Indemnity arrangements were place in the Department of Breast Oncology conforming 
to the requirements of the University of Liverpool and the Leeds Teaching 
Hospitals NHS Trust.  
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CHAPTER 4. Patient Reported Outcomes in Breast Oncology - A Review of 
Validated Outcome Instruments (Step 1 of Phase 1) 
 
This chapter reviews the validated Patient Reported Outcome (PRO) tools that are currently 
in use, as the first step of the item identification process. This is essential for both practical 
purposes, and the need to include the methodology. The tools’ contents are analysed in 
chapter 5, and items are subsequently identified and assessed for potential inclusion in the 
breast cancer specific PCI. 
Abstract 
Background 
Patient-reported outcome measures (PROMs) offer the potential to improve the quality 
clinical care delivery. They may be used to assess levels of need in specific population 
groups and over time they can provide evidence of the outcomes for research and quality 
assurance. Reliable and valid PRO measures exist for use in breast cancer patients, but even 
the best instruments do not address important issues such as fatigue, anxiety, body image, 
sexuality, and upper-body limitations. 
Aims and Objectives 
This review aimed to identify PRO instruments relevant to the treatment of breast cancer, 
and to summarise instruments with evidence of validation in the breast cancer population. 
Data sources 
The following databases were examined: Medline, Ebase (Excerpta Medica), HAPI (Health 
and Psychosocial Instruments), Science Citation Index ⁄ Social Sciences Citation Index, Ovid 
Evidence Based Medicine databases, and PsychINFO 
Study eligibility criteria 
The selection process considered the following: studies where a principal tool was evaluated; 
studies that were evaluating several tools concurrently; clinical tool application with 
sufficient reporting of methodological issues; patient-reported instruments; any published 
evidence of measurement reliability, validity, or responsiveness; tools specifically developed 
using breast cancer patients; and, English language publications. 
Results 
In total, 323 papers were identified that described quality of life measures. Following the 
identification process, 15 instruments satisfied our inclusion criteria. These included the 
EORTC QOL –C30 (European Organization for Research and Treatment of Cancer Quality 
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of Life Questionnaire) with the QLQ-BR23 module (Breast Cancer Module), FACT-B 
(Functional Assessment of Cancer Therapy—Breast Cancer), and SLDS-BC (The 
Satisfaction with Life Domains Scale for Breast Cancer), as well as the BIBCQ (Body Image 
after Breast Cancer Questionnaire), the HIBS (Hopwood Body Image Scale), and PBIS 
(Polivy Body Image Scale). The MBROS (Michigan Breast Reconstruction Outcomes 
Study) Satisfaction and Body Image Questionnaires respectively, the BREAST-Q and the 
BCTOS (Breast Cancer Treatment Outcome Scale) were also included.  The chemotherapy 
questionnaires the BCQ and the Breast Cancer Prevention Trial Symptom Checklist that 
related to the use of Tamoxifen. Other questionnaires were the FACT –ES and the MAS. 
Limitations 
Limitations were evident in most instruments. Current HRQOL tools lack the ability to 
capture all expected side effects of breast cancer treatment. Internal consistency estimates of 
reliability were adequate for research purposes in some tools, but the internal consistency 
were incompletely reported. 
Recommendations 
(1) To use validated instruments tailored for a particular clinical practice.  
(2) To develop comprehensive surgical outcome measurements, requiring both 
objective and subjective measures.  
(3) A scale incorporating both cancer-related QOL generalizability and breast cancer 
issue specificity as a compromise between the first two competing recommendations. 
 
 
Introduction 
 
The evolving nature of therapeutic interventions and their integration into the care of cancer 
patients have transformed the cancer journey. The disease now has many of the features of a 
chronic disease, as improved survival has led to a long-term focus on palliation [Rowland et 
al (2001), Velikova et al (2004)]. This change has brought about a new and growing demand 
upon cancer clinicians to identify and monitor the complex adverse effects of cancer 
treatment, and to include these in decision-making.  
The term health related quality of life (HRQOL) in patients with a history of breast 
cancer represents their physical, psychological, and social response to the disease and its 
treatment. HRQOL assessments include measures of physical symptoms (pain, fatigue, 
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vomiting), physical functioning (e.g. mobility, self-care), emotional functioning (anxiety, 
depression, stress) and social and family functioning (Absolom et al, 2011).  
More recently, the term Patient-reported outcomes (PROs) or Patient-reported 
Outcome Measurement (PROMs) was introduced by regulatory authorities (Department of 
Health; DoH, 2007), as a term designed to encompass any measure obtained directly from 
the patient including, not only aspects of the HRQOL, but also broader concepts such as 
patient satisfaction with care. Patient-reported HRQOL has also been found to predict 
response to treatment and survival in a number of advanced solid cancers [(Rogers SN 
(2010), Efficace et al (2006)]. More recently, PROMs have started to be used as quality 
indicators when assessing service delivery and the outcomes of different interventions in the 
National Health Service in the United Kingdom (DoH, 2007). Several tools have been used 
for the measurement of patient reported outcomes in patients with previous history of breast 
cancer (Chen et al, 2010). These tools may be used in clinical practice before treatment, 
during treatment or at different times following the completion of treatment. In addition, 
any member of the treating oncology team can deliver them in order to monitor closely the 
patients’ care. 
Reliable and valid PRO measures exist for use in breast cancer patients, but even the best 
instruments do not address all the important issues salient to breast cancer treatment 
(Jacobsen et al, 2005). Lingering factors strongly affect HRQOL following breast cancer 
diagnosis and treatment, including issues such as fatigue, anxiety, body image, sexuality, 
and upper-body limitations. Chen et al (2010) performed a systematic literature review to 
identify existing breast surgery specific PRO measures, and to assess their development and 
validation criteria; significant shortcomings were reported in terms of formal development 
and psychometric evaluation. A recent systematic review conducted by Pusic et al (Pusic et 
al, 2009) found that only seven out of 223 PRO measures used in studies of breast surgery 
had psychometric evidence to support their use in the breast cancer population. The reviews 
from Chen et al (2010) and Pusic et al (2009) are limited to breast cancer surgery-specific 
instruments.   
 
The aim of this review was to address the following aspects: 
1. Identify PRO instruments that are relevant to the treatment of breast cancer (surgery, 
chemotherapy, and radiotherapy) 
2. Review the instruments with evidence of validation in the breast cancer population 
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Materials and Methods 
 
The topic ‘‘quality of life measurement following treatment for breast cancer’’ was explored. 
A search strategy was devised using the following key terms: ‘breast oncology’, ‘breast 
surgery’, ‘lumpectomy’, ‘breast conservation’, ‘breast conserving surgery’, ‘breast 
chemotherapy’, ‘breast radiotherapy’, ‘mastectomy’, ‘breast reconstruction’, ‘patient 
reported outcomes’, ‘questionnaires’, ‘quality of life’, ‘validated instruments’ and ‘patient 
satisfaction’. The following databases were examined independently by the primary 
investigator and verified by another member of the research team: Medline, Ebase (Excerpta 
Medica), HAPI (Health and Psychosocial Instruments), Science Citation Index ⁄ Social 
Sciences Citation Index, Ovid Evidence Based Medicine databases, and PsychINFO. Taking 
into account the time and resource limitations during a research degree, only manuscripts 
written in English were included. There was no time limit for the search. All instruments 
included in the review were identified as PRO measures measuring breast-related quality of 
life and ⁄or satisfaction that had undergone development and validation with breast oncology 
patients. This was ensured because subsequent phases of this work the items included from 
the validated instruments would be closely examined to identify issues that could potentially 
affect inclusion in the breast cancer specific PCI. The minimum standard of appraisal of the 
psychometric and operational performance of the instruments involved looking for evidence 
of validity, reliability, and responsiveness criteria (Table 1, appendix 1). Validity is defined 
as an assessment of the extent to which it measures what it purports to measure; reliability is 
defined as the extent to which the instrument is free from random error; and, responsiveness 
is defined as he ability of the instrument to detect changes over time. Rather than setting a 
standard value for inclusion, the processes of development of the instruments were examined 
for evidence that their validity had been assessed. Similarly, evidence that the reliability of 
an instrument had been assessed was sought, rather than setting a cut-off value for the 
reliability coefficient (not always reported). The primary investigator obtained all data from 
the papers (tables 2 and 3), which were independently assessed by an experience member of 
the research team using the modified proforma described by Smith et al. (2005). The final 
short-listing of promising PROMs to formulate recommendations was based on these 
assessments and on discussion between reviewers. The evidence regarding validity, 
reliability, and responsiveness are presented in table 2. 
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In summary: 
Selection by study design 
 Studies where a principal  tool is being evaluated; 
 Any studies that were evaluating several tools concurrently; 
 Clinical application of tools with sufficient reporting of methodological issues. 
Specific inclusion criteria for disease-specific instruments 
 The instrument was patient-reported; 
 Any published evidence of measurement reliability, validity or responsiveness 
 Tools specifically developed with breast cancer patients 
 English language publications 
 
Results  
 
In total, 323 papers were identified that described quality of life measures. All articles were 
retrieved in full. Once the non-English manuscripts and editorials were excluded, 267 
relevant papers indicated in their abstract and methods that they used quality of life 
instruments. Following a close examination, 196 studies included quality of life tools to 
describe and compare patient groups, but did not describe aspects that would specifically 
support the validity, reliability, and responsiveness of the tools. A further 56 papers were 
subsequently identified and excluded. Although these stated that the PRO that they employed 
was validated and reliable, it was not possible to obtain specific details (such as the patient 
groups and their characteristics) that would satisfy the inclusion criteria. Some of the PRO 
tools in these 56 papers were later found to be validated through specific evidence of 
reliability and validity in the remaining 15 papers comprising this review.  
The identification process highlighted 15 instruments (Tables 2 and 3, Appendix 1) that 
satisfied the inclusion criteria. These were described from the following authors:  Pusic et al 
(2009), Levine et al (1988), Fallowfield et al (1999), Feather et al (1988), Sprangers et al 
(1996), Aaronson et al (1993), Brady et al (1997), Baxter et al (2006), Polivy J (1977), 
Hopwood et al (2001), Stanton et al (2001), Alderman et al (2000), Wilkins et al (2000), 
Spagnola et al (2003), and Ganz et al (1995). The summary of the paper identification 
process is presented in Figure 2. 
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Figure 2 Search results included in the review 
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Organization for Research and Treatment of Cancer Quality of Life Questionnaire)  
(Aaronson et al, 1993) with the QLQ-BR23 module (Breast Cancer Module) (Sprangers et 
al, 1996); FACT-B (Functional Assessment of Cancer Therapy—Breast Cancer) (Brady et 
al, 1997); and, SLDS-BC (The Satisfaction with Life Domains Scale for Breast Cancer) 
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EORTC QLQ-BR23 and QOL-C30 
This module was developed by the EORTC consisting of 23 items and covering symptoms 
as well as side effects related to different treatment modalities, body image, sexuality, and 
future perspective (Sprangers et al, 1996). The assessment comprises of five domains: body 
image, sexuality, arm symptoms, breast symptoms, and side effects of systemic therapy 
(Perry et al, 2007). The subscale measuring body image includes only four items and does 
not measure a multidimensional construct of body image (Baxter et al, 2006). According to 
Sprangers et al (Sprangers et al, 1996), the QLQ-BR23 can therefore not be recommended as 
a freestanding instrument for assessing the QOL of breast cancer patients, but rather should 
be administered in conjunction with the core instrument – the QLQ-C30. The QLQ-C30 was 
developed as a cancer-specific quality of life questionnaire. It has 30 items that form five 
functional scales, a global quality of life scale, three symptom scales, five single-item 
symptom measures, and one financial impact question (Baxter et al, 2006). The assessment 
comprises nine domains: physical, role, cognitive, emotional, social, fatigue, pain, nausea, 
and vomiting (Perry et al, 2007). Extensive psychometric analysis was conducted and 
showed adequate reliability, clinical and cross-cultural validity, and sensitivity to change 
over time (Chen et al, 2010). 
The Functional Assessment of Cancer Therapy – Breast Cancer (FACT B)  
The FACT- B is a 44-item questionnaire designed to measure multidimensional quality of 
life in patients with breast cancer (Chen et al, 2010).The assessment comprises six domains: 
physical well-being, social/family well-being, relationship with doctor, emotional well-
being, functional well-being, and additional concerns (Perry et al, 2007). In its third version, 
the FACT-B incorporates the FACT-General (FACT-G) with five subscales: physical, 
functional, social/family and emotional well-being and satisfaction with doctors (Burckhardt 
et al, 2005). It includes the Breast Cancer Subscale (BCS), which complements the general 
scale with items specific to QOL in breast cancer (Brady et al, 1997). Brady et al (1997) 
conclude that FACT-B is reliable, relates to similar measures in an expected pattern, and 
performs as predicted in relation to change in clinical status over time. The FACT-B was 
created with an emphasis on patients' values and brevity. It is written at the sixth-grade 
reading level, takes approximately 10 minutes to complete. Its psychometric properties, 
brevity, and relevance to patients' values make its suitable for use in both research and 
clinical settings. The instrument was validated and underwent extensive psychometric 
analysis. Significant sensitivity to change in performance status and quality of life was 
demonstrated in two validation samples totalling 342 patients. Internal consistency reliability 
was high (Cronbach’s alpha 0.90). Evidence supported test-retest reliability, as well as 
convergent, divergent, and known group validity.  
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The Satisfaction with Life Domains Scale for Breast Cancer (SLDS-BC) 
The Satisfaction with Life Domains Scale for Breast Cancer (SLDS-BC) is a reliable and 
valid scale that aims to assess QOL throughout the various phases of patient care (Spagnola 
et al, 2003). In comparison to the FACT-B, it offers a more user-friendly format that can 
assess QOL across the continuum of breast cancer care in the clinical setting.  
 
Body image related questionnaires included the BIBCQ (Body Image after Breast Cancer 
Questionnaire) (Baxter et al, 2006), the HIBS (Hopwood Body Image Scale) (Hopwood et 
al, 2001), and PBIS (Polivy Body Image Scale) (Polivy J, 1977).  
The Body Image after Breast Cancer Questionnaire (BIBCQ) 
The Body Image after Breast Cancer Questionnaire (BIBCQ) was designed specifically to 
measure the long-term impact of breast cancer on body image in a multidimensional fashion. 
It is a 53-item questionnaire with six optional items specific to women with two breasts, and 
two optional items specific to women missing one or both breasts. The BIBCQ is easy to 
complete, requiring less than 10 minutes, and is acceptable to the relevant patient population 
(Baxter et al, 2006). Results from studies developed in Toronto, Canada by Baxter et al 
(2006) indicate that the BIBCQ is quantifiable and has been shown to be reliable, having 
minimal measurement error due to item sampling (internal consistency) and adequate 
reproducibility in stable populations (test-retest reliability. However, validation of the 
BIBCQ will be an ongoing process and further testing is required. The authors suggest that 
the use of the BIBCQ should be considered in the evaluation of various forms of treatment of 
breast cancer, when a substantial impact on body image is expected. 
 Hopwood Body Image Scale (HBIS) 
HBIS is a 10-item questionnaire developed in conjunction with the EORTC to assess body 
image changes in patients with cancer (Hopwood et al, 2001). It was designed for use as a 
module, with the methodology not relying on a particular theoretical model, and there being 
no consensus on the definition of body image disturbance. Instead, the authors took a 
patient-focused approach to form the basis of the development of cancer-specific QOL scales 
(Hopewood et al, 2001). From pilot testing to final revision, the instrument underwent 
psychometric testing using data sets from seven treatment trials and clinical studies. It 
showed adequate reliability, clinical validity, discriminant reliability, and consistency of 
scores between different breast cancer treatment centres. Although considered 
psychometrically robust, the setting of a threshold is problematic as there are no agreed 
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diagnostic criteria for body image disturbance or standardized interview assessments 
(Hopwood et al, 2001).   
Polivy Body Image Scale (PBIS) 
PBIS is a self-concept scale developed in 1977, and is designed to measure perceptions of 
the self in relation to other people (Reaby et al, 1994). It is a 13-item questionnaire, which 
measures the psychological effects of mastectomy on breast cancer patients. It covers three 
domains: body image, self-concept, and feelings of satisfaction with intimate relationships. 
Several studies have demonstrated internal consistency (Reaby et al, 1994).  
 
Breast Reconstruction-specific Questionnaires including the breast conserving treatment and 
radiotherapy questionnaires: we have identified the MBROS (Michigan Breast 
Reconstruction Outcomes Study) Satisfaction and Body Image Questionnaires respectively 
[Alderman et al (2000), Wilkins et al (2000), the BREAST-Q (Pusic et al (2009) and the 
BCTOS (Breast Cancer Treatment Outcome Scale) (Pusic et al, 2009). 
Michigan Breast Reconstruction Outcomes Study (MBROS) Satisfaction Questionnaire 
This is a 7-item instrument, which assesses patient satisfaction after breast reconstruction. 
Alderman et al (Alderman et al, 2000) used this instrument a postoperative questionnaire 
measuring General Satisfaction and Aesthetic Satisfaction with reconstruction among 
women undergoing first-time mastectomy reconstructions with expander/implant, pedicle 
transverse rectus abdominis muscle (TRAM) flap, and free TRAM flap techniques. Using a 
five-point Likert scale, item responses were scored ranging from very satisfied to very 
dissatisfied. Items were generated by an expert panel without patient interviews, and formal 
item reduction was not performed.  
MBROS Body Image Questionnaire 
This is a 9-item questionnaire developed to evaluate patient perceptions of physical 
appearance after breast reconstruction. An expert panel generated items without patient 
interviews, and formal item reduction was not performed. However, Cronbach’s alpha was 
measured to be at 0.89, indicating adequate internal consistency for the single construct of 
body image. The psychometric battery of instruments used in the Michigan Breast 
Reconstruction Outcome Study (Body Image) included two previously published, health-
related quality of life surveys: the Medical Outcome Study Short Form-36 (SF-36) and 
FACT-B (Wilkins et al, 2000).  
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BREAST-Q 
The Breast-Q is a new PRO questionnaire designed to measure satisfaction and surgery-
related quality of life in patients undergoing mastectomy with or without reconstruction. The 
development of the Breast-Q follows PRO measurement guidelines and criteria: Phase 1 – 
Conceptual Framework Formation; Phase 1-B – Item Generation, Preliminary Scale 
Formation, and Pretesting; Phase 2 – Field Testing, Final Scale Generation, and 
Psychometric Evaluation, using the Rasch Measurement Psychometric Analysis to guide 
scale construction (Pusic et al, 2009). Cronbach’s alphas for the scales ranged from 0.81 to 
0.98. Its test-retest reliability as measured by the intraclass correlation coefficient, ranged 
from 0.85 to 0.98 (Chen et al, 2010), suggesting the stability of scale (Pusic et al, 2009).  
Breast Cancer Treatment Outcome Scale (BCTOS) 
The BCTOS has been developed to assess patients’ perceptions of cosmetic and functional 
outcomes of treatments for breast cancer (Stanton et al, 2001). Aesthetic and functional 
outcome seems to be closely related to QOL. A significant limitation is that it does not apply 
to women with bilateral disease. 
 
As far as chemotherapy questionnaires the BCQ, which is related specifically to 
chemotherapy only (Levine et al, 1998) has been included and the Breast Cancer Prevention 
Trial Symptom Checklist that related to the use of Tamoxifen. Other questionnaires that may 
be included are the FACT –ES, which is relevant to endocrine issues (Fallowfield et al, 
1999), and the MAS, a 10-page questionnaire with significant practical problems in clinical 
practice (Feather et al, 1988).  
Breast Cancer Chemotherapy Questionnaire (BCQ) 
This is an outcome measure used in clinical trials of adjuvant chemotherapy in women with 
stage II breast cancer (Levine et al, 1988). The BCQ consists of 30 questions that focus on 
loss of attractiveness, fatigue, physical symptoms, inconvenience, emotional distress, and 
feelings of hope and support from others. The direct evaluation of the BCQ with its 
comparison with the Spitzer, Karnofsky, and Rand instruments revealed that the BCQ 
correlated more strongly with global ratings of both physical and emotional function in 
patients and physicians, than the other instruments. The BCQ is a valid and responsive 
method of assessing treatment-related morbidity in patients receiving adjuvant chemotherapy 
for stage II breast cancer (Levine et al, 1988). 
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Functional Assessment of Cancer Therapy – Endocrine System (FACT-ES) 
The FACT-ES is an 18-item self-administered questionnaire, usually administered with the 
FACT-B, focusing on endocrine concerns experienced during breast cancer treatment.  
Mastectomy Attitude Scale (MAS) 
This 33-item scale was designed to assess the attitudes and expectations of post-mastectomy 
breast cancer patients regarding adjustment to mastectomy (Feather et al, 1988). 
Breast Cancer Prevention Trial Symptom Checklist (BCPT) 
The BCPT [Ganz et al (1995), Day et al (1999)] is a 43-item self-administered questionnaire 
designed to examine the physical and psychological symptoms associated with the 
menopause and Tamoxifen usage. This questionnaire seeks to identify eight symptoms (hot 
flashes, nausea, bladder control, vaginal problems, musculoskeletal pain, cognitive problems, 
weight problems, and arm problems). 
 
Discussion 
 
 In order to appreciate fully the impact of breast surgery in oncology, data from well-
validated disease specific PRO instruments is essential. There is a need to determine which 
therapies are safe to use alongside conventional treatments and whether they are effective in 
alleviating treatment side effects and improving wellbeing. Such information would be 
useful for both local commissioners and breast cancer survivors wishing to make an 
informed choice about the provision and use of available therapies. Understanding the effect 
of breast cancer treatment on a patient's QOL has been a central clinical and research 
question (Perry et al, 2007). There are conflicting reports in the health care literature 
regarding the psychological effects of mastectomy (Reaby et al, 1994). For instance, 
traditional surgical outcomes centred on morbidity and mortality remain imperative, but are 
no longer sufficient on their own (Pusic et al, 2007) due to the high degree of individual 
variation in women’s’ adjustment to the disfigurement produced by mastectomy (Reaby et 
al, 1994). Therefore, is perhaps unavoidable that there is a propensity to use patient ad hoc 
questionnaires that have not been formally tested to ask questions of patients (Pusic et al, 
2007). Consequently, in terms of reliability, validity and reproducibility, the results obtained 
from breast cancer studies may be compromised if increasing numbers of informally 
developed PRO questionnaires continue to be used (Chen et al, 2010). Psychometric 
qualities that may be examined in the evaluation of an instrument include acceptability, 
validity, reliability (including internal consistency and test—re-test reliability and 
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responsiveness [Fitzpatrick et al (2006), Stanton et al (2005)]. Questionnaire responsiveness 
in this study was defined as the ability of a scale to detect significant change over time, 
assessed by comparing scores before and after an intervention of known efficacy based on 
various methods including t-tests, effect sizes, standardised response means, or 
responsiveness statistics. The information available on questionnaire responsiveness in this 
study was scarce. 
Like the QLQ-BR23, the FACT-B was designed for use in breast cancer patients at a 
range of disease stages, and undergoing different treatments (Sprangers et al, 1996). The 
EORTC QLQ-BR23 and the FACT-B are two well-developed instruments that have been 
extensively tested among breast cancer patients. However, these measures are nevertheless 
disease-specific rather than surgery specific, and their ability to detect changes brought about 
by surgical intervention is less. Furthermore, questions measuring HRQOL, body image, 
sexual functioning, or satisfaction with appearance are not well represented. In comparison 
to the QLQ-BR23, the FACT-B is shorter, covering fewer symptoms and treatment-related 
side effects (Sprangers et al, 1996). Although the questionnaires have been translated and 
validated in a number of languages, the breast cancer-specific questionnaires have not yet 
been validated cross-culturally. However, during their study, Sprangers et al (Sprangers et al, 
1996) were able to obtain a degree of cross-cultural validity as evidenced by the similarity of 
the results across three samples in Spanish, Dutch, and American subjects; this further 
suggests the suitability of the QLQ-BR23 for use in international cancer clinical trials. In the 
literature, the BIBCQ and HBIS are considered as two of the best-developed measures (Chen 
et al, 2010). Never the less, the following limitations are notable: (1) failure to address fully, 
surgery-specific issues, particularly related to breast conserving surgery; and, (2) measures 
were largely developed without the aid of newer psychometric methods that enhance the 
questionnaire’s ability to measure individual patient outcomes. Baxter et al (2006) are 
concerned about cross-cultural validation of the measure, which they recommend as 
necessary for use in different populations. Hence, further item generation and validation if 
the measure is observed as sensitive to change. The HBIS was developed along pragmatic 
guidelines thereby theoretical underpinnings are desirable in the construction of core QOL 
measures. Moreover, it leans more towards an affective-cognitive-behavioural model of 
body image disturbance. Thereby patients and health professionals generate items; this could 
result in several kinds of framework bases, for example using a cognitive-behavioural 
paradigm or subject-objective perception of body image disturbance.   
On the other hand, the PBIS may actually address important issues, but has undergone a less 
rigorous development and psychometric evaluation. Reaby et al (1994) raised a similar view 
suggesting that the state of medical progress has a perceptional impact affecting test results 
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between certain periods. Surgical techniques in mastectomy have improved dramatically 
compared to the 1970’s (Reaby et al, 1994) when the PBIS was designed and used, which 
was a time when surgery could potentially cause more psychological and emotional 
repercussions. Therefore, some aspects of the hypothetical framework involved in the 
questionnaire design may no longer be relevant. For example, Reaby et al (1994) 
hypothesized that the control group would exhibit more positive self-perceptions, and that 
such a hypothesis would have been only remotely conceivable decades before.  
Some of the instruments reviewed, such as the BCPT, are in need of further development. 
Limitations include that it lacks the ability to capture all expected side effects of breast 
cancer treatment, such as fatigue and breast-specific pain. Internal consistency estimates of 
reliability are adequate for research purposes, although the internal consistency estimates 
were somewhat lower for the nausea and weight problems scales, which might require 
further refinement (Stanton et al, 2005). 
Both of the MBROS questionnaires (satisfaction and body Image) have addressed specific, 
important issues, but have undergone less rigorous development and psychometric 
evaluation. The major limitation of the MBROS questionnaires is the possibility of 
confounding bias inherent in the use of a prospective cohort design rather than a randomized 
controlled trial (Reaby et al, 1994). Furthermore, outcomes of reconstruction may be affected 
by an almost infinite variety of confounding variables, encompassing a wide range of patient, 
surgeon, and study site characteristics; no matter how well designed, a cohort study cannot 
control for all of these factors (Wilkins et al, 2000). Alderman et al (2006) however, contend 
they have controlled certain variables, which was a significant or nearly significant 
difference across the group. Nevertheless, they acknowledge the presence of other 
unsuspected independent variables that may impact upon patient satisfaction. Psychometric 
characteristics were available in detail for the BCQ and the Breast-Q outcome measures 
(Table 2, Appendix 1). The BREAST-Q was developed using a newer psychometric 
method called the Rasch Measurement Psychometric Analysis, which is considered pivotal 
in creating new instruments that are more clinically meaningful and psychometrically sound 
(Chen et al, 2005). However, during use of the questionnaire, Pusic et al (Pusic et al, 2009) 
note that the BREAST-Q has limitations. According to them, the validity and reliability of 
the BREAST-Q needs further validation and additional procedure-specific scales to establish 
their psychometric properties. Furthermore, the BREAST-Q is not considered valid for 
patient groups that were not represented in the development i.e., the North American 
population. Patient perceptions of outcomes in breast surgery are not independent of their 
cultural environment (Pusic et al, 2009).  
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Concluding remarks 
 
 This review provides a categorical distinction over which PRO measures, whether 
freestanding or for use in conjunction with a core instrument, are appropriate for a specific 
study objective. It is clear from the literature that many authors have not only stressed the 
importance of addressing surgery-specific issues, but have recommended the incorporation 
of newer psychometric methods to extend their clinical utility. Reflecting on how the 
original literature was presented, there were limitations to some of the discussions of the 
limitations with specific PRO test measures. This review has delivered additional scientific 
literature – enabling further discernment towards better tool selection or appropriateness, by 
highlighting not only the strengths and characteristics found in certain PRO measures, but 
also some of their weaknesses. Other than concerns encompassing psychometric validation, 
it is also evident that cross-cultural variations pose significant challenges that are unknown 
until the actual selection of the study setting has begun. Moreover, this weakness is evident 
in many of the PRO measures reviewed, particularly in those of body image and breast 
reconstruction. Therefore, suggestions for future directions can be made around three key 
points: 
(1) To use validated instruments tailored for a particular clinical practice (Ganz et al, 1995).  
(2) To develop a comprehensive measurement of surgical outcomes, requiring the 
combination of both objective and subjective measures (Burckhardt et al, 2005).  
(3) A scale incorporating both generalizability in cancer-related QOL and specificity in 
breast cancer issues, as a compromise between these two competing considerations (Brady et 
al, 1997). 
This review was undertaken to identify validated PRO measures, which in turn would help to 
identify the issues relevant to patients during their cancer journey. The issues derived from 
this chapter are presented and analysed in the next chapter. This review also aimed to 
identify and select a validated PRO measure that would be suitable for use with the breast 
cancer PCI in the cross-sectional study of phase 2, and that would help to validate the breast 
cancer PCI. The EORTC C30 with the BR23 module was selected for this purpose since this 
tool has been validated in breast cancer patients and has been successfully adapted by many 
clinicians and researchers worldwide. This therefore allows the data from this work to be 
compared with the many other studies that have used the EORTC. In addition, the practical 
aspects of using two tools together provided valuable experience in the use of both 
instruments when screening for patient issues in breast-cancer outpatient clinics. In the next 
chapter, the validated PRO items obtained, are presented in detail.   
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CHAPTER 5. Item Generation for the Breast Cancer Specific Patient Concerns 
Inventory (PCI) (Step 1 of Phase 1) 
 
Several validated patient-reported outcome (PRO) tools were identified in chapter 4 through 
an extensive literature review. In this chapter, we progress from identification to content 
analysis of each of the tools, in order to identify suitable items for inclusion in the breast 
cancer specific patient concerns inventory (PCI). Details of the item reduction process are 
provided as part of the first step in Phase 1 of this work. 
 
Introduction 
 
There are several Health- Related-Quality of life (HRQOL) instruments available (Kanatas et 
al, 2012) in the breast cancer literature. This is a reflection of the notion that over 60% of 
survivors had their overall health affected by the diagnosis and treatment of breast cancer 
(Schultz et al, 2005). The physical effects of a breast cancer diagnosis and treatment have 
been described extensively [Girgis et al (2000), Hanson Frost et al (2000), and Raupach et al 
(2002)]. Hot flashes, night sweats, impaired sexual function, sleep disturbance and impaired 
ability to concentrate, are all features that commonly present after treatment of breast cancer 
[McPhail et al (2000), Hunter et al (2004)]. Anxiety, distress, depression, and fear of cancer 
recurrence are additional issues encountered in this group of patients [Kanatas et al (2012), 
Schultz et al (2005), Hanson Frost et al (2000), Hoskins et al (1997), Hodgkinson et al 
(2007)]. The information needs of women with breast cancer, as well as their effect on 
treatment decisions, are important features in the cancer journey that need to be taken into 
consideration if we are to ensure holistic care (Marlow et al, 2003). Indeed, at least 80% of 
breast cancer patients wanted as much information as possible, with only 16% wanting 
limited information in one study (Lobb et al, 2001). Taking these factors into account, this 
part of the thesis aimed to identify the concerns common to patients with a history of either 
diagnosis or treatment for breast cancer. In addition, we seek to categorise those concerns 
into subgroups, in order to assist the development of the breast cancer specific PCI. 
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Methodology 
 
The process used to identify the PRO questionnaires used is detailed in the methods section 
of Chapter 4 (page 54—55). The details of the item identification and reduction process now 
follow. All PRO measures cited in the papers were assessed for evidence regarding their 
development and validation criteria. PRO measures without evidence of any development or 
validation process were excluded. The items were then arranged in subgroups as they 
appeared in the literature, with the identification of 164 items. The next step in the item 
generation was to review the concerns with the view to limiting the total number used in the 
final PCI; 164 concerns is a significant number for a patient to consider. As a result, they 
may either lose interest, or feel that the PCI is not worth their time, if presented with such a 
number of questions. Also, some of the items within the different questionnaires were 
worded similarly, and could be removed without loss of content. Although it was important 
to reduce the total number of items, it was still necessary to include every concern identified 
within the initial list of 164. Therefore, in this second stage of item generation, items were 
revised and grouped together with similar items. This way, the total number of items was 
decreased to 51. The process of removing and revising the items in the PCI is outlined in 
Figure 3. 
 
Figure 3 The process of removing and revising items in the PCI 
 
The subgroups identified in the literature are included in Table 4 (Appendix 1). It was 
evident from the literature review that all of the validated tools contained specific items that 
are often grouped under one heading. For example: the body image specific tool (Hopewood 
et al, 2001) included only items relating to body image; Sprangers et al (1996) included 
Items were grouped 
that covered the same 
concern. 
Constant pain
Pain interrupting work
Pain during activity 
Pain using stairs 
Pain
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global quality of life domains as well as physical functioning and health-related domains; 
Baxter et al (2006) included sexual functioning as well as psychological state and emotional 
well-being related domains; and, Brady et al (1997) included social functioning and family 
related domains. As a result, the items derived from the various validated tools were grouped 
under these subheadings in the PCI. All other items, which were either non-specific 
information data, or which could not be accommodated in to one of the above groups, were 
organised under ‘general information’ in the first breast cancer PCI list. The number of 
specific items per subgroup is given in Table 5 (Appendix 1).  
The final list of 51 concerns identified after the literature review and revision process, appear 
in Table 6 (Appendix 1). The second part of the PCI, listing the professionals that patients 
would like to consult with, was based on the following two factors: (1) the available 
Multidisciplinary Team members (MDT) for breast cancer; and, (2) the list available in the 
Head and Neck PCI (Table 6, Appendix 1). 
 
Results 
 
The items are presented below in six domains: (1) Global Quality of Life; (2) Body Image; 
(3) Physical Functioning and Health; (4) Psychological State and Emotional Well-Being; (5) 
Sexual Functioning; and, (6) Social Functioning and Family. 
 
1. Global Quality of life domains 
During the past week, were you limited in doing either your work or other daily activity? 
(Sprangers et al, 1996)  
During the past week, were you limited in pursuing your hobbies or other leisure time 
activities? (Sprangers et al, 1996) 
During the past week, did pain interfere with your daily activities? (Sprangers et al, 
1996)  
During the past week, have you had difficulty in concentrating on things, like reading a 
newspaper or watching television? (Sprangers et al, 1996) 
During the past week, have you had difficulty remembering things? (Sprangers et al, 
1996)  
How would you rate your overall quality of life during the past week? (Sprangers et al, 
1996) 
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During the past week, has your physical condition or treatment caused you financial 
difficulties? (Sprangers et al, 1996)  
During the past week, did you feel ill or unwell? (Sprangers et al, 1996) 
I am content with the quality of my life right now. (Brady et al, 1997)  
Would like to know more information about breast cancer? (Faether et al, 1988)  
 
2. Body image –related domains 
During the past week, have you lost any hair? (Sprangers et al, 1996) 
During the past week, have you felt physically less attractive as a result of your disease 
or treatment? (Sprangers et al, 1996)  
During the past week, have you been feeling less feminine as a result of your disease or 
treatment? (Sprangers et al, 1996)  
During the past week, did you find it difficult to look at yourself naked? (Sprangers et al, 
1996)  
During the past week, have you been dissatisfied with your body? (Sprangers et al, 1996)  
I avoid looking at my scars from breast surgery. (Baxter et al, 2006)  
I am satisfied with the shape of my body. (Baxter et al, 2006)  
I feel less feminine since cancer. (Baxter et al, 2006) 
I like my body. (Baxter et al, 2006)  
I feel comfortable about the way I look when exercise. (Baxter et al, 2006)  
I would feel comfortable changing in a public change-room. (Baxter et al, 2006)  
I feel my body has been invaded. (Baxter et al, 2006)  
I am satisfied with the appearance of my arm. (Baxter et al, 2006)  
I am satisfied with the appearance of my hips. (Baxter et al, 2006)  
I am satisfied with the shape of my buttocks. (Baxter et al, 2006) 
I feel comfortable looking at my mastectomy. (Baxter et al, 2006)  
I am happy with the position of my nipple. (Baxter et al, 2006)  
I feel satisfied with the size of my breast. (Baxter et al, 2006)  
I feel comfortable when other see my breast. (Baxter et al, 2006)  
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The appearance of my breasts could disturb others. (Baxter et al, 2006)  
I feel that people are looking at my breasts. (Baxter et al, 2006)  
How satisfied are you with the way your breast looks? (Polivy J, 1997)  
Have you been feeling self-conscious about your appearance? (Hopwood et al, 2001)  
Have you felt less physically attractive as a result of your disease or treatment? 
(Hopwood et al, 2001)  
Have you been dissatisfied with your appearance when dressed? (Hopwood et al, 2001)  
Did you find it difficult to look at your self naked? (Hopwood et al, 2001)  
Did you avoid people because of the way you felt about your appearance? (Hopwood et 
al, 2001)  
Have you been feeling the treatment has left your body less whole? (Hopwood et al, 
2001) 
Have you been dissatisfied with your body? (Hopwood et al, 2001)  
Have you been dissatisfied with the appearance of your scar? (Hopwood et al, 2001)  
Is there a difference between the treated and untreated areas in terms of Breast size? 
(Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of breast texture 
(hardening)? (Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of nipple 
appearance? (Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of breast shape? 
(Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of breast elevation? 
(Stanton et al, 2005) 
Is there a difference between the treated and untreated areas in terms of scar tissue? 
(Stanton et al, 2005)  
I am self-conscious about the way I dress. (Brady et al, 1997)  
I am bothered by hair loss. (Brady et al, 1997)  
How satisfied or dissatisfied have you been with how you look in the mirror clothed? 
(Pusic et al, 2009)  
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How satisfied or dissatisfied have you been with the shape of your reconstructed breasts 
when you are wearing a bra? (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how normal you feel in your clothes? 
(Pusic et al, 2009)  
How satisfied or dissatisfied have you been with the size of your reconstructed breasts? 
(Pusic et al, 2009)  
How satisfied or dissatisfied have you been with being able to wear clothing that is more 
fitted? (Pusic et al, 2009) 
How satisfied or dissatisfied have you been with how your breasts are lined up in 
relation to each other? (Pusic et al, 2009) 
How satisfied or dissatisfied have you been with how comfortably your bras fit? (Pusic 
et al, 2009) 
How satisfied or dissatisfied have you been with the softness of your reconstructed 
breasts? (Pusic et al, 2009) 
How satisfied or dissatisfied have you been with how equal in size your breasts are to 
each other? (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how natural your reconstructed breast 
looks? (Pusic et al, 2009) 
How satisfied or dissatisfied have you been with how natural your reconstructed breast 
sits/hangs? (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how your reconstructed breast feels to 
touch? (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how much your reconstructed breast 
feels like a natural part of your body? (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how closely matched your breasts are to 
each other? (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how your reconstructed breast look 
now compared to before you had any surgery? (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how you look in the mirror unclothed? 
(Pusic et al, 2009) 
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3. Physical Functioning and health-related domains 
During the past week, were you short of breath? (Sprangers et al, 1996)  
During the past week, did you need to rest? (Sprangers et al, 1996)  
During the past week, did you have trouble sleeping? (Sprangers et al, 1996)  
During the past week, did you feel week? (Sprangers et al, 1996)  
During the past week, have you had pain? (Sprangers et al, 1996)  
During the past week, have you lacked appetite? (Sprangers et al, 1996)   
During the past week, have you felt nauseated? (Sprangers et al, 1996)  
During the past week, have you vomited? (Sprangers et al, 1996)  
During the past week, have you felt constipated? (Sprangers et al, 1996)  
During the past week, have you had diarrhoea? (Sprangers et al, 1996)  
During the past week, were you tired? (Sprangers et al, 1996)  
Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag 
or a suitcase? (Sprangers et al, 1996)  
Do you have any trouble taking a long walk? (Sprangers et al, 1996) 
Do you have any trouble taking a short walk outside of the house? (Sprangers et al, 
1996)  
Do you have to stay in bed or a chair for most of the day? (Sprangers et al, 1996)  
Do you need help with eating, dressing, washing yourself or using the toilet? (Sprangers 
et al, 1996) 
During the past week, did you have a dry mouth? (Sprangers et al, 1996)  
During the past week, did food and drink taste different than usual? (Sprangers et al, 
1996)  
During the past week, were your eyes painful, irritated, or watery? (Sprangers et al, 
1996)  
During the past week, did you have hot flushes? (Sprangers et al, 1996)  
During the past week, did you have any pain in your arm or shoulder? (Sprangers et al, 
1996)  
During the past week, did you have a swollen arm or hand? (Sprangers et al, 1996)  
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During the past week, was it difficult to raise your arm or to move it sideways? 
(Sprangers et al, 1996)   
During the past week, have you had any pain in the area of your affected breast? 
(Sprangers et al, 1996)  
During the past week, was the area of your affected breast swollen? (Sprangers et al, 
1996)  
During the past week, was the area of your affected breast oversensitive? (Sprangers et 
al, 1996)  
During the past week, have you had skin problems on or in the area of your affected 
breast? (Sprangers et al, 1996) 
I have a lack of energy. (Brady et al, 1997)  
I have nausea. (Brady et al, 1997)  
Because of my physical condition, I have trouble meeting the needs of my family. 
(Brady et al, 1997)  
I have pain. (Brady eta al, 1997)  
I am bothered by side effects of treatment. (Brady et al, 1997)  
I feel ill. (Brady et al, 1997)  
I am forced to spend time in bed. (Brady et al, 1997)  
Skin dryness is a problem from me. (Baxter et al, 1988)  
I can use my arm normally. (Baxter et al, 1988)  
I try to hide my body. (Baxter et al, 1988)  
I am sleepy during the day. (Baxter et al, 1988)  
I am happy with my level of energy. (Baxter et al, 1988)  
Is there a difference between the treated and untreated areas in terms of shoulder 
movement? (Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of breast pain? 
(Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of ability to lift 
objects? (Stanton et al, 2005)  
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Is there a difference between the treated and untreated areas in terms of breast 
tenderness? (Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of shoulder 
stiffness? (Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of breast 
sensitivity? (Stanton et al, 2005)  
Would like to know more information about personal hygiene/clothing/exercise? 
(Feather et al, 1988)  
Would like to know more information about nutrition / weight control? (Feather et al, 
1988)  
Would like to know more information about prosthesis /clothing? (Feather et al, 1988) 
One or both of my arms are swollen or tender. (Brady et al, 1997)  
 
4. Psychological state and emotional well-being-related domains 
During the past week, did you feel tense? (Sprangers et al, 1996)  
During the past week, did you worry? (Sprangers et al, 1996) 
During the past week, did you feel irritable? (Sprangers et al, 1996)  
During the past week, did you feel depressed? (Sprangers et al, 1996)  
During the past week if you lost any hair, were you upset by the loss of your hair? 
(Sprangers et al, 1996)  
I feel sad (Brady et al, 1997)  
I am proud of how I am coping with my illness. (Brady et al, 1997)  
I am losing hope in the fight against my illness. (Brady et al, 1997)  
I feel nervous. (Brady et al, 1997) 
I worry about dying. (Brady et al, 1997)  
I worry that my condition will get worse. (Brady et al, 1997)  
I feel there is a time bomb inside me. (Baxter et al, 2006)  
I feel prone to cancer. (Baxter et al, 2006)  
I feel my body has let me down. (Baxter et al, 2006)  
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I feel part of me must remain hidden. (Baxter et al, 2006) 
I am afraid of touching the scars from breast surgery. (Baxter et al, 2006)  
I feel that something is taking over my body. (Baxter et al, 2006)  
I worry that the cancer is spreading. (Baxter et al, 2006)  
I worry about my body. (Baxter et al, 2006)  
I worry about minor aches and pains. (Baxter et al, 2006)  
I feel people can tell me my breasts are not normal. (Baxter et al, 2006)  
I worry about my prosthesis or padding slipping. (Baxter et al, 2006)  
I worry about the risk of cancer in other family members. (Brady et al, 1997)  
I worry about the effect of stress on my illness. (Brady et al, 1997) 
I am bothered by a change in weight. (Brady et al, 1997)  
5. Sexual Functioning 
During the past four weeks to what extent were you interested in sex? (Sprangers et al, 
1996)  
During the past four weeks to what extent were you sexually active? (Sprangers et al, 
1996) 
Have you been sexually active during the past year? (Brady et al, 1996)  
I feel sexually attractive when I am nude. (Baxter et al, 2006) 
I would keep my chest covered during sexual intimacy. (Baxter et al, 2006)  
My breast is painful to touch. (Baxter et al, 2006)  
Would like to know more information about sexual issues? (Feather et al, 1988) 
I am satisfied with my sex life. (Wilkins et al, 2000)  
 
6. Social Functioning/ Family-related domains 
During the past week, has your condition or medical treatment interfered with your 
family? (Sprangers et al, 1996)  
During the past week, has your physical condition or medical treatment interfered with 
your social activities? (Sprangers et al, 1996)  
I am able to work. (Brady et al, 1997)  
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My work is fulfilling. (Brady et al, 1997) 
I am able to enjoy life. (Brady et al, 1997) 
I have accepted my illness. (Brady et al, 1997)  
I am sleeping well. (Brady et al, 1997)  
I am enjoying the things I usually do for fun. (Brady et al, 1997)  
I feel distant from my friends. (Brady et al, 1997)  
I get emotional support from my family. (Brady et al, 1997)  
I get support from my friends and neighbours. (Brady et al, 1997)  
My family has accepted my illness. (Brady et al, 1997)  
Family communication about my illness is poor. (Brady et al, 1997) 
I feel close to my partner. (Brady et al, 1997)  
My body stops me from doing things I want to do. (Baxter et al, 2006)  
Is there a difference between the treated and untreated areas in terms of fit of clothing? 
(Stanton et al, 2005) 
Is there a difference between the treated and untreated areas in terms of fit of bra? 
(Stanton et al, 2005) 
Would you like to know more information about social support? (Feather et al, 1988)  
 
Conclusions and further development 
 
In this chapter the issues faced by breast cancer patients, that form the basis of the breast 
cancer specific PCI, have been presented. The next stage in the PCI development involved 
presenting the list of concerns (Table 6, Appendix 1) to breast cancer surgeons, oncologists, 
consultants, specialist nurses and other health care professionals at Leeds Teaching 
Hospitals, UK (Step 2 of Phase 1). A presentation was given explaining the concept of the 
PCI, along with the list of PCI items. That list was scrutinised by attendees, and additions or 
deletions were discussed, along with the appropriateness of the item terminology. The 
subsequent list was presented to focus groups (Step 3 of Phase 1) and then to several national 
bodies (Step 4 of Phase 1), who were each asked to comment and further refine the PCI. 
Steps 2, 3, and 4 of phase 1 are discussed in the next chapter. 
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CHAPTER 6. Further Development of the Breast Cancer Specific Patient 
Concerns Inventory (PCI)—Study Phase 1, Steps 2, 3, and 4: Input from 
Clinicians, Patient Focus Groups, and National Bodies 
 
This chapter covers Steps 2, 3, and 4 of phase 1, and has been divided into three parts: input 
from clinicians (step 2), patient focus groups (step 3), and national bodies (step 4). The first 
part includes a summary of the input from clinicians. The second part provides an 
explanation of the use of focus groups in the development of the instrument. The third part 
provides specific information of the input from National bodies related to breast cancer and 
the utilisation of their experience in the identification of specific patient issues. 
 
Phase 1—Step 2: Input from clinicians in the development of the PCI 
 
Once a list of issues was constructed, it was taken to the breast cancer clinic and given to the 
clinicians involved in the treatment of patients with breast cancer. At that initial stage of 
development it was essential, to ensure that there was a need / desire for such instrument to 
be developed.  Another aim was to ensure, that there were not any obvious practical issues 
that may be a hindrance to the long term use of this tool. Ultimately the use of such a tool is 
dependent on the perceived long term clinical and practical benefits by the clinicians. The 
advantage of this approach was that clinicians could provide some input on the relative 
frequency of the issues presented as well as being able to provide content information. Based 
on the experience form the development of the head and neck PCI a pragmatic sample of 10 
clinicians were included. The clinicians were chosen based on their clinical interest and 
clinical experience. Four consultants were chosen from the Leeds Teaching Hospitals that 
were involved in the management of breast cancer patients and three surgical registrars (2 
final year and one on his fourth year of training). Three specialist nurses with a minimum of 
ten years experience in the management of patients with breast cancer were included in this 
step. All clinicians that were asked agreed to participate initially. All clinicians were 
recruited from the Multidisciplinary Team.  
Consent was obtained (Appendix 2-A) 
For this part of the work, the initial aim was to use a series of questions (Appendix 2-B) that 
were developed based on the experience from the head and neck PCI, and a Likert like scale 
in order to assess every issue presented. The aim was for every interview to be recorded. 
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Results 
This approach proved unrealistic in a busy NHS clinic and the input was more general than 
specific. One consultant agreed to be recorded in his clinic. All interviews were less than 
twenty minutes in duration. Reason for the clinician poor response was mainly the limited 
clinical time and the extensive workload. However the clinicians verified the relevance of 
these items in addition to the verification that list of issues was comprehensive and included 
items that they frequently encounter in an outpatient clinic. No items were added or 
removed.  
 
Discussion 
This part of the work provided clinician input for the development of the tool based largely 
on clinical experience. There are limitations in the methodology of this step. Clinicians can 
be reluctant to have their consultation recorded and this has been the experience from the 
literature using audio recordings of consultations (Tattersall et al, 2002). Also other practical 
issues were that the primary investigator is not a breast surgeon. Those proposed recordings 
were at the start of this work and there was minimal familiarisation of the primary 
investigator and the clinical team. The overall outcome from this step although helpful was 
not optimal. A common issue such as ‘hot flushes’ was somewhat missed and was not 
included until much further in the development of this tool. One of the reasons may have 
been that in a busy clinic the focus may be on the presence or absence of cancer recurrence  
rather than in issues that may not be immediately life threatening.  
 
 
Phase 1—Step 3: The role of Focus groups in the development of the PCI 
 
Focus groups are a frequently used group interview format that capitalises on the natural 
communication between research participants, in order to generate data (Kitzinger et al, 
1994). Initially, focus groups were used as a marketing strategy and were designed to assess 
the desirability of a product, and to test responses to the way it was positioned prior to 
entering the market (Buchanan DR, 1992).These groups have also been used within the 
communication industry, to explore the effects of films and television programmes (Merton 
et al, 1956). However, focus groups can also be used to explore the patient experience in 
health services and identify consensus, in addition to providing a basic research tool that can 
contribute to the development of knowledge or theories [Patton MQ (1990), Beaudin et al 
(1996)].  
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The focus group approach has several distinct advantages in the healthcare setting. One of its 
most significant advantages is that it has the capacity to encourage an open conversation 
about embarrassing subjects. Other advantages include: it does not discriminate against 
people who cannot read or write; it can encourage participation from those who are reluctant 
to be interviewed on their own; and, passive participants may engage in the conversation 
generated by other group members [Kitzinger J (1995), Murray et al (1994), Denning et al 
(1993), O'Brien K (1993), Fardy et al (1994)]. However, for this strategy to produce these 
advantages, the group members must be carefully chosen. Groups that work well tend to be 
those that are drawn together specifically for the project, such as those including people with 
the same disease (Kitzinger J, 1994). It is widely accepted that involving patients in research 
design, results in more relevant research questions, higher levels of participation, improved 
study design, and better interpretation of the findings [Chalmers I (1995), DoH (2005). The 
literature varies on the optimal size of a focus group. Whilst larger groups may generate 
more ideas, participants can become competitive or even aggressive. Conversely, in smaller 
groups participants can be tactful, constrained, passive, and tense, although they may not 
necessarily generate fewer ideas (Tang et al, 1995).  
A patient concerns inventory (PCI) has been developed in the head and neck cancer setting 
that aims to identify unmet patient needs, and promote multidisciplinary care (Rogers et al, 
2009). The PCI contains a list of 45 head and neck cancer specific concerns that patients may 
wish to discuss during their consultation. The items are designed to cover emotional, social, 
and physical factors, and include: anxiety, cancer treatment, chewing, and fear of the cancer 
coming back, mood, pain, and relationships. It also contains a list of eight professionals to 
which the patient may wish to be referred. The head and neck PCI was piloted in 2007, using 
123 participants (Rogers et al, 2009). Patients that were involved stated that they believed it 
made the consultation ‘a bit more personal’, ‘reminded them of the points they wanted 
discussed’, and ‘allowed the consultation to get straight to the point’ (Rogers et al, 2009).  
The aim of this work has been to develop a practical tool, referred to as the breast cancer 
specific patient concerns inventory (PCI) that can be used in the health care setting, and that 
is modelled on the head and neck PCI. The early development phase of the breast cancer 
specific tool involved an exploratory observational study, using quantitative and qualitative 
methods to support the face and content validity of the items. A central aspect of this work 
was to be able to identify the issues faced by patients, with a history of either diagnosed or 
treated breast cancer, during the transition period from a patient with breast cancer to a 
survivor. The use of focus groups in this work allowed for the identification of key issues, 
and obtained patient and carer perspectives on the usefulness of the PCI, as well as giving an 
'empirical' indication of the frequency and importance of each item produced. 
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Materials and Methods 
Four focus groups were arranged for breast cancer patients, and carers, at one of Leeds 
Teaching Hospitals. For practical purposes, two of the focus groups were arranged with 
patients from Leeds General Infirmary and two with patients from Pinderfields Hospital in 
Wakefield. The research ethics committee imposed several restrictions on the principal 
investigator. All patients had to be approached by the treating clinical team. Because of 
recruitment and attendance difficulties and practicalities, no attempt was made to match the 
groups for clinical or other characteristics. Ideally, all patients should be matched with 
respect to disease stage, age, type of treatment, and ethnicity. All patients were adults with a 
history of diagnosis or treatment of breast cancer. Forty patients consented to participate in 
the focus groups and twenty-four participated in the meetings. Study information packs were 
provided (Appendices 2-C, 2-D, and 2-E). The details of the method are presented in Chapter 
3. 
The discussions were audio-recorded, and stored in keeping with General Medical Council 
guidance (GMC, 2011). The recorded interviews were anonymised and a professional 
medical transcription company transcribed the recorded interviews. The transcribed 
interviews and recordings were kept in a secure storage facility within the hospital.  
Patients were asked to add to, or remove items from, a draft PCI list generated by a literature 
review (step 1 phase 1) (Table 6, Appendix 1) and by asking clinicians managing patients 
with breast cancer (step 2 phase 1). The focus group was also asked to comment on the 
appropriateness of the terminology used within the PCI. The first focus group used the draft 
PCI as their starting point, the second focus group started with the revised draft, and so on 
until the suggested alterations were minimal. Each focus group was also asked about which 
health professionals a patient might want to see at various steps of their cancer journey. The 
principal investigator moderated the focus groups with the assistance of a specialist nurse 
who had additionally been tasked to ensure patient welfare.  
Four focus groups were held between July and October 2011. Each focus group was 
instructed that the purpose of the discussion was to build consensus. The interviews took 
between 52 and 90 minutes, and after each session, the researchers (principal investigator 
and specialist nurse) recorded their immediate impressions.  
Data Analysis 
This study followed previously described quality standards for qualitative research (Miles et 
al, 1994). The two investigators read and discussed focus group audiotape transcriptions 
following every meeting. This allowed for formal review of the transcripts and the 
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identification of themes. Content analysis was used to identify key themes and sub-themes 
raised by the focus groups (Miles et al, 1994). A degree of reliability was afforded to the 
analysis through independent reading of the focus group transcripts by two members of the 
supervisory team. These independent readings were followed by further discussion and 
agreement of the themes and sub-themes until agreement was reached. Validity was assured 
during the focus groups by ensuring lines of inquiry verified the accuracy and consistency of 
the responses. After transcribing the interviews, phrases and expressions were obtained for 
each of the assessed items. An initial qualitative reduction of the identified sentences 
followed, in which expressions considered inappropriate, ambiguous, or redundant were 
excluded. Some of the expressions included were slightly reworded to make them suitable 
for use as statements in an initial questionnaire. 
In order to ensure comprehensibility of the research, supervisory meetings took place on a 
regular basis; these supervisory meetings also ensured the continuous evaluation of the 
research process by the research supervisors. 
 
Results 
Twenty-four women took part in the focus group meetings; 16 from Wakefield and 8 from 
the Leeds area. The women were aged between 41 and 78 years. All had received surgical 
treatment for their breast cancer, with or without radiotherapy and chemotherapy, within the 
last three years. Seventeen were taking endocrine therapy at the time of the focus groups. 
The PCI tool following input from the focus group can be seen in Table 7 (Appendix 1). 
The subgroups that were identified from the literature review (step 1 of Phase 1) and were 
presented in chapter 4 were used as the basis of structuring the items during the focus 
groups: 
 
1. General information 
2. Body Image 
3. Physical Functioning and health 
4. Psychological state and emotional well-being 
5. Sexual Functioning 
6. Social Functioning/ Family 
7. Global Quality of Life 
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1. General information 
A woman who has breast cancer may have no problems until she finds a lump in her 
breast. The diagnosis of breast cancer is a life-changing event, and the need for 
information about all aspect of the disease may suddenly become overwhelming. 
That was the case in the focus groups, with quotes such as: 
'Well, things like ... you do get short of breath, which is very tiring. Also 
chemotherapy makes you tired. The very confusing issue, I found, was the number of 
choices that you have if you want to have breast reconstruction. There are so many 
different brand types and replacements, you know, the plastic ones, the patent ones.  
And you have to have a spare one.  Every single thing that previously you knew 
nothing about, it’s a whole new world I didn’t think I would ever need to go into....' 
(Focus group 3) 
 
'When you are first diagnosed with cancer you want to know as much as possible, I 
did anyway. But initially during the first week or so, I don’t know, my brain couldn’t 
take any more.  There is so much information out there and you don’t know what 
applies to you and your family, what is best for you.  So many treatments you read 
about on the internet.  And there are a lot of good stories there but they can also be 
confusing I think.' (Focus group 3) 
 
2. Body Image related domains 
Body image is how someone views them self physically; it is one's view of one's 
appearance. The treatment of breast cancer, especially through surgery and 
chemotherapy, can cause body image alterations. Bodily changes may result in a 
profound psychological stress that can require long-term adjustment. Quotes from 
the patients included the following: 
 
'I can’t say I was pleased with my scar.  I didn’t look at it for months, in fact it still 
feels very obvious today, you know, so many years later.' (Focus group 3) 
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'After the third treatment I noticed that in the morning there were hairs on my pillow 
and that was so strange... ' (Focus group 4) 
 
3. Physical Functioning and health related domains 
The physical effects of breast cancer diagnosis and treatment have been extensively 
reported in the literature. Several aspects are almost universal in the management of 
breast cancer, such as effects on appetite and energy levels, as well as hot flushes, 
pain and nausea. The patients in these focus groups raised additional concerns: 
 
'I think mainly the fluid in my arm or the operation site' (focus group 1) 
 
'I guess I also lost my appetite.  I had this odd taste in my mouth, like metal, for 
weeks and weeks and weeks, and although they told me I’d put on weight, to me it 
was going the other way, I was losing weight.  I saw a dietician and I was told that I 
may have to be admitted to hospital to help with my feeding, but luckily I didn’t have 
to.' (Focus group 1) 
 
'I had problems with the chemotherapy, hair loss of course.  I had – my mouth felt 
different, my skin felt different - I had very dry skin.  I always felt very tired, in fact I 
still feel tired a year or so later.  But, on the other hand... I’m happy to say I’m 
cancer free.' (Focus group 1) 
 
'I thought my memory wasn’t very good during the treatment. It felt like I was always 
preoccupied, I was quite forgetful.' (Focus group 3) 
 
'Well, I don’t think, I had any pain after the operation, in fact when they drain the 
fluid from my arm now I don’t feel anything at all. It’s like that side is all numb. I 
had a stiff shoulder, but I think I’ve got better over time.' (Focus group 3) 
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Of the more commonly addressed concerns, sickness and pain received particular 
attention: 
 
'The sickness was terrible. And I felt sick and I was drained physically and 
emotionally.’ (Focus group 3) 
 
'I had a lot of problems with sickness. In fact, after the first lot of chemotherapy I 
thought I’d die. I was sick continuously 24 hours, couldn’t hold anything down, 
couldn’t hold any water down. And it wasn’t just the sickness...I felt physically ill all 
the time, some days not wanting to get out of bed! And the worst thing was that when 
I was going through that I felt like it was never gonna get better... and that was very 
scary.’ (Focus group 3) 
 
'I still get some pain in my arm, but I’ve come to terms with it now and I don’t think 
of it too much during the day.' (Focus group 1) 
 
 
4. Psychological state and emotional well-being related domains 
The psychological changes in patients with breast cancer may start from the time of 
diagnosis and remain through remission. Women with breast cancer often feel 
diverse physical concerns, as well as emotional problems such as distress, anxiety, 
and depression. Some of these concerns were raised in the groups interviewed: 
 
'When I was told, I was shocked initially, you know, people with cancer die, it’s not 
something that … your brain goes numb for a bit, or that’s what happened to me 
anyway.' (Focus group 3) 
 
'Then, a few days later he told me that it was cancer. I was absolutely devastated. In 
fact both of us were. We kept it between us, we have two children, but we didn’t say 
anything to them.' (Focus group 3) 
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'We put our life on hold and didn’t know what it was, what treatment I am going to 
have. And you don’t – you feel like you are going to die and, you know, all the fear is 
there. And well perhaps I had that for a long time.' 
'Well, it was difficult to come to terms with all this, I was blaming myself for a while, 
I thought it was down to my smoking and drinking alcohol. That made me feel upset 
for a while. Also, people look at you differently when you tell them you have cancer, 
you know, my family was upset and my friends didn’t come to see me as often as they 
used to.  Some of them did, to be fair, but it wasn’t the same, you know, they were 
quiet, upset?, they didn’t know what to say.  They felt sorry for me and that was the 
hardest part.' (Focus group 3) 
 
'The first year or so I was quite upset, I was much less tolerable, I think.  I hope I’m 
much better now.' (Focus group 3) 
 
5. Sexual Functioning 
During this work it appeared that the women participating in the groups agreed with 
the items included on 'intimacy', 'Relationships' and 'sex' but did not discuss these 
extensively. It may be that such issues were embarrassing, or viewed as personal. 
For the items relating to sexual functioning there were no comments from the 
patients. The facilitator asked about these items if they should be included in the list 
and the patients will only agree, without any other input. 
 
 
6. Social Functioning/ Family-related domains 
The effect of breast cancer diagnosis and treatment on both family and social 
functioning is well documented. Women in the groups gave their own perspective: 
 
'But certainly in the first year or so you worry, this cancer, when you are told you 
have cancer, you worry, you want to know how extensive that is. It can be very 
stressful sometimes because you expect to be out of work but you don’t know how 
long for, or if you will ever be able to go back at all...and if money is tight then other 
problems can crop up as well. That was a big source of stress for me.’ (Focus group 
2) 
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For the second part of the breast-specific PCI, patients were asked to indicate the 
people that they would specifically like to talk to, either at clinic or after referral. It 
was identified that further explanation was essential as to the roles of the specialists 
that could be involved in the management of patients with breast cancer: 
 
'I think if there was an explanation or perhaps give us an idea of what these people 
do, it might be easier to know who can help with what problems.  For instance, what 
is radiation – what’s the difference between medical and radiation oncologist?  And 
what is the difference between the surgeon who operated on me and a plastic 
surgeon, aren’t they the same?' (Focus group 3) 
 
Discussion 
This study supports other findings on this topic, suggesting that breast cancer survivors are at 
risk for developing medical and psychosocial issues from their cancer and its treatment 
[McCabe et al (2008), Hurria et al (2003), Partridge et al (2003)]. The face-to-face 
involvement of patients and the facilitator ensured that the conversation remained on track, 
and encouraged participants to engage, without any one individual dominating the meeting. 
Additionally, every participant was observed by the facilitator, and was aware that the 
process was audio taped. Although this helped people to participate, the focus groups were 
thought to be an artificial environment, and this may have influenced the research outcomes. 
For example, people were grouped into a meeting room where they might behave differently 
to an attendance in an outpatient clinic, thereby affecting the quality of research results.  
It was also clear from the relatively poor response to the items relating to sexual function, 
that focus groups are not very effective at dealing with such sensitive issues. A minimum of 
10-12 participants from similar backgrounds were sought for each focus group  [Miles et al 
(1994), Krueger et al (2000)], and it was found that smaller groups were more manageable. 
Patients from similar backgrounds were selected to improve the quality of the data obtained, 
because different cultures may find different topics more appropriate than others may, and 
may not discuss them as thoroughly; as a result it was notable that ethnic minorities were 
under-represented in our study. Similar findings have been presented elsewhere (Miles et al, 
1994). This may be due to the lack of interpreters, or because breast cancer and related 
concerns may be taboo subjects in certain cultures; it could also be due to the catchment area 
of the hospitals from which the patients were recruited. This is a common problem in 
research of this type (Jack et al, 2009). Lack of participation was not limited to minority 
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groups, and it was observed that some participants did not contribute much to the 
discussions. Lack of participation can imply agreement, but in the absence of a clear 
response, it may also mean that they disagree and do not want to say so. Every effort was 
made by the facilitators to ensure that all participants were involved in the conversations. 
There are several specific limitations to this study; the small number of participants is one. In 
a study of this type and size, there is also the possibility of self-selection to participate. A 
purposive sampling approach has been proposed to eliminate this problem [Mays et al 
(1995), Ashbury JE (1995)]; however, taking into account the purpose of this work, this 
approach was considered neither possible nor practical. Another limitation is that the patients 
who participated may not be representative of all breast cancer survivors, particularly those 
who were active survivor volunteers or were engaged in other support groups or research 
with a similar methodology. We tried to minimise volunteer bias by recruiting directly from 
the breast-cancer outpatient clinic but the sample was not designed to be statistically 
representative, and hence it cannot be concluded that the findings reflect the general breast 
cancer population. Other selection bias may include workers or those with family 
commitments that could not participate or who dropped out .This bias was minimised by 
ensuring that the recruited patients were not taking part in other studies, and that they had not 
previously been involved in focus group research. Another limitation is that the women 
willing to participate in the research were more educated about health research than average. 
The ethnic minorities were under-represented in the focus groups. This may be seen as a lost 
opportunity since a PCI type tool may be especially useful to such groups that traditionally 
have consultation difficulties (Epstein, 2005). This needs to be addressed with further 
longitudinal work in a comprehensive before-after study.  Finally, only seven of the women 
were less than sixty-five, meaning that we may not have a balanced view of all women with 
breast cancer across the age spectrum. 
In effect, there were no new items added to the list of issues from the step 1 of phase 1. The 
focus groups input was to make the items more understandable with the inclusion of 
explanations next to items in the PCI. Also, the role of the clinicians in the second part of the 
PCI has been explained and included in subsequent versions. 
 
Phase 1—Step 4: The role of National bodies in the development of the breast cancer 
specific Patient Concerns Inventory (PCI) 
Introduction  
Increasingly, there is a drive for cancer care to move from hospitals to community facilities 
(Kessler et al, 2002). In this context, breast cancer may be managed as a chronic illness with 
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an emphasis placed on meeting the needs of people living with cancer through social support 
networks (Davison et al, 2000). The interaction between cancer patients is key to this, and 
can be considered an indication of good quality care (Lipscomb et al, 2002). Although 
support groups have traditionally been face-to-face, web-based support has recently been 
gaining popularity [Gray et al (1997), Winzelberg et al (2003), Mayer et al (1996), Wienberg 
et al (1996), Sharf et al (1997), Klemm et al (1999), Gustafson et al (2001), Lieberman et al 
(2003)]. Patients in support groups can spend time with people who understand their 
experience, and play an important role regardless of whether face-to-face or online.  
Reported benefits of support group involvement include emotional, informational, and 
practical support benefits (Bjorneklett et al, 2013). Björneklett et al (2013) for example, 
further reported that support intervention resulted in improved cognitive function, body 
image, future perspective, and fatigue in patients with breast cancer. Benefits of emotional 
support include connecting with other breast cancer survivors, feeling understood, providing 
hope, as well as sharing experiences, including healing laughter [Lieberman et al (2003), 
Kim et al (2012)]. There is additional evidence that over 28% of internet users have visited 
an online support group at least once (Eysenbach et al, 2004), and that millions of people 
visit online peer-to-peer discussion groups daily [Griffiths et al (2009), Pinheiro et al 
(2008)]. Spiegel et al (Spiegel et al, 1981) provided evidence that a support group 
intervention for patients with metastatic cancer resulted in significant psychological benefit. 
In view of the large number of patients that are now part of support groups, it can be 
concluded that such groups are in a position to provide valuable input in the identification of 
common concerns faced by patients with a history of diagnosis and treatment for breast 
cancer. This chapter describes how national bodies and support groups were identified, in 
order to receive input into a patient concerns inventory (PCI) list that had earlier been 
designed through literature review (step 1 phase 1), the general input from clinicians (step 2 
phase 1) and focus groups (step 3 phase 1) (Table 7, Appendix 1). 
Materials and methods 
The web-based resource ‘Just Giving’ (http://www.justgiving.com) was used to source 
potential groups. In total, 40 UK National bodies were identified with some degree of 
involvement in the management of patients with a history of breast cancer. The principal 
investigator accessed their contact details, and they were initially contacted via telephone. 
Six groups agreed to receive relevant material with a view to providing input to the 
development of the tool: The Haven Foundation; Breast Cancer Campaign; Breast Cancer 
Care; Breakthrough Breast Cancer;  The Lavender Trust at Breast Cancer Car'; and, 
‘Macmillan Cancer Support’. An information pack was sent to each of these that included 
the PCI (Table 7, Appendix 1), a brief information leaflet (Appendix 2-M), and a self-
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addressed envelope. Essentially, there were asked to comment on the suitability of the items, 
if there were items that were missing and any practical aspects about the use of such a tool in 
their interaction with patients. 
Results 
Of the six National bodies approached, two ultimately agreed to provide input for the 
development of the PCI, 'The Haven Foundation’, and 'Breast Cancer Campaign'. Reasons 
for not participating included: excessive workload of the charity staff; that the work was not 
directly relevant to the specific organisation; and, that they were not qualified enough to be 
able to comment on aspects of research. Several groups stated that they do not offer advice 
and support directly to breast cancer patients, because they feel that other charities such 
as Breast Cancer Care and Macmillan Cancer Support do so as part of their specific 
remit. 
The Haven Foundation suggested the inclusion of 'hot flushes' and 'complementary therapy'. 
The 'Breast Cancer Campaign' provided useful feedback, including agreement with the 
suggested items and that such a list may potentially be of significant benefit to women with 
breast cancer. The PCI was further developed as a result of this input (Table 8, Appendix 1).  
Discussion 
Although the participation rate for this part of the study was significantly lower than 
expected, there are possible explanations. For example, the creation of the National Cancer 
Research Institute has fuelled an intense need to influence both national research expenditure 
and health-care policy (Glass et al, 2002). The economic models of both national research 
bodies and breast cancer charities often demands increased media communication as a tool to 
leverage funding (Hayes et al, 2007). Such an approach may leave no time for the 
development of relatively small-scale interventions, and may partly explain the low 
participation rate for this part of the study. However, input from 'The Haven Foundation' 
appeared relevant, and contributed positively in the development of the PCI.  
 It possible that the approach used was not appropriate-the initial contact with telephone- 
and a formal letter to each National body followed by a telephone conversation may have 
produced better results. 
The next part of the study involved a cross-sectional survey of patients with breast 
cancer, the aim of which was to further refine the breast cancer specific PCI before 
rolling it out in the breast cancer outpatient clinic.  
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CHAPTER 7. A Cross-Sectional Survey of Breast Cancer Patients Receiving 
Treatment from Multiple Consultants at Two Hospitals. 
 
In this chapter, two aspects of the study are considered. The first is the implementation of the 
breast cancer specific Patient Concerns Inventory (PCI) through a cross-sectional study is 
presented. This is followed by a consideration of the members of the breast cancer 
multidisciplinary team (MDT) that patients wished to see during their consultations . 
Information from the Breast cancer specific PCI was analysed in relation to personal, 
clinical, and Health-Related Quality-of-Life (HRQOL) data as part of the process of its 
validation and development. The results from this cross-sectional study are divided as 
follows: (A) Issues patients would like to discuss at review consultations in Breast Cancer 
clinics — a cross-sectional survey; (B) Fear of recurrence (FOR) — a cross sectional study 
using the breast cancer specific PCI; and (C) The breast cancer specific PCI as a means to 
assist the identification of body image concerns in routine follow up clinics. 
 
Aims 
 
The aim of this cross-sectional study was to gain an understanding of the relative frequency 
of the individual PCI items, to assess the need for further item inclusion, and to compare 
clinical characteristics with the PCI items and an established, validated HRQOL measure 
(EORTC C30 with the BR23 module). 
 
Materials and methods 
 
The development of the breast cancer specific PCI took place over several stages. The initial 
item generation was from a comprehensive literature review, before input was gained from 
clinical specialists, patients, and carers. This led to a preliminary PCI (Appendix 2-N) that 
was then used in a cross-sectional survey of breast cancer patients, following the completion 
of their initial treatment. In this study we indicate the relative frequency of individual PCI 
items and compare PCI  item selection with clinical characteristics such as age, stage, 
treatment, time since treatment, and established breast cancer HRQOL measures [EORTC 
C30 (European Organisation for Research and Treatment of Cancer) with BR23] . A 
convenience sample of 249 patients with a history of diagnosis and treatment for breast 
cancer agreed to take part in the study between February and July 2012. Based on a 
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literature review, and the experience obtained during the development of the head and neck 
PCI, we estimated that at least 200 patients were needed for meaningful results. Patient 
recruitment took place in the clinic by the clinical team in charge of care. Patients that 
expressed an interest to be included in the study were given a study information pack. The 
information pack contained details about the study (Appendicies 2-F and 2-G), together with 
the preliminary PCI tool (Appendix 2-O), as well as a consent form (Appendix 2-H) and a 
reply slip (Appendix 2-I). A letter was sent to general practitioners (Appendix 2-J).  Patients 
selected for inclusion also gave consent for the principal investigator to collect demographic, 
social, and treatment related data from their clinical files (Appendices 2-K and 2-L). The 
patients that took part in this cross-sectional survey completed the PCI type tool and the 
EORTC C30 with the BR23 module at their home and sent these with a SAE to the principal 
investigator several days later. 
Ethical considerations 
The Leeds Central Ethics Committee (Appendix 4) approved this study. 
Data analysis 
 SPSS Statistics version 19 was used for the statistical analysis. Response rates between 
patient subgroups were compared by either Fisher’s exact test or the chi-squared test. 
Subgroup comparison in the full distribution of PCI items was performed using with the 
Mann-Whitney or Kruskall-Wallis test, as appropriate. Spearman’s correlation was used to 
assess the significance of the number of PCI items with age, and for assessing the strength 
and significance of the association between the number of PCI items and the summary scores 
from the EORTC QLQ-C30 and the breast cancer module QLQ-BR23. The internal validity 
of the test was assessed using Cronbach’s alpha for individual PCI domains, and for the test 
as a whole. Alpha values between 0.70–0.95 (Staquet et al, 1988) represented internal 
consistency. 
Reliability / Validity /Rigour 
This cross-sectional study aided the validation of the PCI type tool. The information packs 
were given after completion of the clinic appointment for the patients to take away with 
them. All patients had the same explanation of the study by the principal investigator. 
Results 
 
Sample description: 
Survey responses were obtained from 80% (200) of the 249 patients. Depending on the 
stratification of data, response varied from 65% to 100% (Table 9, Appendix 1). The 
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response was lower among patients aged 70 and over, those with tumours that are more 
advanced, those with primary local disease, and those having anti-oestrogen therapy. The 
response rate was higher if the patient had undergone either radiotherapy or reconstructive 
surgery. The median (inter-quartile range) age of responders was 59 (52-68) years. Other 
patient characteristics are shown in Table 9 (Appendix 1).  
Most recent diagnosis was stated as 2009/2010 for 54% (108), 2011/2012 for 31% (61), 
unknown for 16% (31). Extent of disease was detailed as follows: 51% (101) primary local, 
2% (3) local recurrent, 5% (9) metastatic and 4% (8) living with cancer. Treatment was 
detailed as follows: 47% (93) on chemotherapy, 63% (126) radiotherapy, 47% (93) wide 
local excision or lumpectomy, 44% (88) mastectomy, 13% (25) reconstructive surgery, and 
41% (82) anti-oestrogen therapy. Responders were from two hospital sites, 57% (113) Leeds 
and 32% (64) Wakefield. It was possible to derive the IMD1 (IMD = Index of Multiple 
Deprivation: A measure of multiple deprivation at the small area level made up of seven 
domains) deprivation statistics for most, with 17% (30/178) living in an area described as 
one of the 20% most deprived in the country. Examination of the scores obtained from the 
EORTC C30 with the BR23 module (Figure 4) revealed similar patient scoring to that 
reported in other studies in the literature [Hamidou et al (2011), Cohen et al (2012), Moro-
Valdezate et al (2013)] 
 Not at all A little Quite a 
bit 
Very 
much 
Cases 
E1 Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase? 
29% (57) 39% (78) 18% (36) 14% (27) 198 
E2 Do you have any trouble taking a long walk? 43% (86) 34% (67) 13% (25) 10% (20) 198 
E3 Do you have any trouble taking a short walk outside 
of the house? 
84% 
(165) 
7% (13) 5% (10) 4% (8) 196 
E4 Do you need to stay in bed or a chair during the 
day? 
73% 
(144) 
18% (35) 7% (13) 3% (5) 197 
E5 Do you need help with eating, dressing, washing 
yourself or using the toilet? 
91% 
(181) 
8% (15) 2% (3) - 199 
E6 Were you limited in doing either your work or other 
daily activities? 
55% 
(108) 
26% (51) 14% (28) 5% (10) 197 
E7 Were you limited in pursuing your hobbies or other 
leisure time activities? 
53% 
(105) 
29% (57) 12% (24) 6% (12) 198 
E8 Were you short of breath? 66% 
(131) 
27% (54) 5% (9) 3% (6) 200 
E9 Have you had pain? 34% (68) 43% (86) 15% (30) 7% (14) 198 
E10 Did you need to rest? 35% (69) 42% (84) 18% (35) 5% (10) 198 
E11 Have you had trouble sleeping? 35% (70) 32% (64) 19% (38) 14% (28) 200 
E12 Have you felt weak? 46% (92) 36% (71) 14% (27) 5% (10) 200 
E13 Have you lacked appetite? 79% 
(157) 
11% (22) 8% (15) 3% (6) 200 
E14 Have you felt nauseated? 78% 
(155) 
14% (27) 8% (16) 1% (2) 200 
E15 Have you vomited? 95% 
(189) 
3% (6) 2% (4) 0.5% (1) 200 
E16 Have you been constipated? 67% 
(134) 
22% (43) 9% (18) 3% (5) 200 
                                                          
Figure 4: Individual question responses from the EORTC C30 and the BR23 module 
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E17 Have you had diarrhoea? 83% 
(161) 
10% (20) 5% (9) 2% (3) 193 
E18 Were you tired? 19% (38) 51% (99) 23% (45) 7% (14) 196 
E19 Did pain interfere with your daily activities? 60% 
(117) 
24% (46) 11% (21) 6% (11) 195 
E20 Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 
56% 
(110) 
28% (55) 13% (25) 3% (6) 196 
E21 Did you feel tense? 40% (78) 42% (82) 15% (30) 3% (6) 196 
E22 Did you worry? 25% (49) 44% (85) 24% (47) 7% (13) 194 
E23 Did you feel irritable? 44% (85) 33% (65) 19% (37) 4% (8) 195 
E24 Did you feel depressed? 49% (93) 32% (61) 15% (28) 5% (9) 191 
E25 Have you had difficulty remembering things? 43% (83) 37% (71) 12% (24) 8% (16) 194 
E26 Has your physical condition or medical treatment 
interfered with your family life? 
53% 
(103) 
29% (56) 13% (25) 5% (10) 194 
E27 Has your physical condition or medical treatment 
interfered with your social activities? 
54% 
(105) 
29% (56) 12% (24) 5% (9) 194 
E28 Has your physical condition or medical treatment 
caused you financial difficulties? 
54% 
(105) 
29% 956) 12% (24) 5% (9) 194 
 
 
1 
Very poor 
2 3 4 5 6 7 
Excellent 
Cases 
E29 How would you rate your 
overall health during the past 
week? 
0.5% (1) 
5% 
(10) 
10% 
(19) 
19% 
(36) 
35% 
(69) 
24% 
(46) 
7% (14) 195 
E30 How would you rate your 
overall quality of life during 
the past week? 
2% (3) 4% (7) 
11% 
(22) 
16% 
(32) 
27% 
(52) 
29% 
(57) 
12% (23) 196 
         
 Not at all A little Quite a 
bit 
Very 
much 
Cases 
BR1 Did you have a dry mouth? 60% 
(119) 
24% (48) 12% (23) 4% (7) 197 
BR2 Did food and drink taste different than usual? 77% 
(152) 
14% (28) 5% (10) 4% (7) 197 
BR3 Were your eyes painful, irritated or watery? 66% 
(130) 
21% (42) 7% (13) 6% (11) 196 
BR4 Have you lost any hair? 76% 
(148) 
15% (30) 2% (3) 7% (14) 195 
BR5 Answer this question only if you had any hair loss: 
Were you upset by the loss of your hair? 
17% (7) 32% (13) 27% (11) 24% (10) 41 
BR6 Did you feel ill or unwell? 64% 
(119) 
23% (43) 9% (17) 4% (8) 187 
BR7 Did you have hot flushes? 30% (57) 31% (60) 22% (42) 18% (34) 193 
BR8 Did you have headaches? 59% 
(113) 
31% (60) 7% (14) 3% (6) 193 
BR9 Have you felt physically less attractive as a result of 
your disease or treatment? 
38% (74) 34% (67) 14% (27) 14% (27) 195 
BR10 Have you been feeling less feminine as a result of 
your disease or treatment? 
45% (87) 31% (60) 14% (27) 10% (20) 194 
BR11 Did you find it difficult to look at yourself naked? 47% (92) 28% (55) 14% (27) 10% (20) 194 
BR12 Have you been dissatisfied with your body? 37% (72) 37% (72) 16% (31) 9% (18) 193 
BR13 Were you worried about your health in the future? 12% (24) 36% (70) 26% (51) 26% (50) 195 
BR14 To what extent were you interested in sex? 51% (90) 37% (65) 11% (20) 1% (2) 177 
BR15 To what extent were you sexually active?(with or 
without intercourse) 
57% (99) 35% (60) 8% (13) 1% (2) 174 
BR16 Answer this question only if you have been sexually 
active: To what extent was sex enjoyable for you?  
9% (6) 38% (26) 40% (27) 13% (9) 68 
BR17 Did you have any pain in your arm or shoulder? 41% (80) 37% (73) 16% (31) 6% (12) 196 
BR18 Did you have a swollen arm or hand? 74% 
(145) 
17% (34) 5% (9) 4% (8) 196 
BR19 Was it difficult to raise your arm or to move it 
sideways? 
64% 
(126) 
25% (49) 7% (14) 4% (7) 196 
BR20 Have you had any pain in the area of your affected 
breast? 
35% (68) 46% (91) 14% (27) 6% (11) 197 
BR21 Was the area of your affected breast swollen? 71% 
(137) 
21% (40) 5% (10) 4% (7) 194 
BR22 Was the area of your affected breast oversensitive? 45% (88) 38% (74) 14% (27) 3% (6) 195 
BR23 Have you had skin problems on or in the area of 
your affected breast (e.g., itchy, dry, flaky)? 
61% 
(121) 
27% (54) 9% (17) 3% (5) 197 
Figure 4 Individual question responses from the EORTC C30 and the BR23 module 
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PCI domain 
Number of 
items 
Cronbach's 
alpha 
Range of Cronbach's alpha with (n-1) 
items - i.e. if one item deleted 
Physical functioning & 
health related 
20 0.775 0.760 - 0.775 
Psychological state & 
emotional well-being 
10 0.709 0.673 - 0.716 
Body image-related 9 0.640 0.581 - 0.682 
Social functioning & 
emotional well-being 
8 0.628 0.577 - 0.626 
General information 6 0.237 0.128 - 0.263 
Sexual functioning 3 0.598 0.411 - 0.598 
TOTAL 56 0.897 0.893 - 0.898 
Figure 5 PCI domains and Cronbach’s alpha 
 
Cronbach’s alpha values are presented in figure 5 for the individual domains, and for the test 
as a whole. Overall, the test demonstrated internal validity. However, only two of the 6 
domains demonstrated alpha values above 0.7. 
(A) Issues patients would like to discuss at review consultations in Breast Cancer clinics  
The PCI items selected by patients are shown ranked by order of frequency in Figure 6. The 
most frequent items were: fear of cancer coming back (62%, 124), breast sensitivity/pain 
(46%, 92), fatigue or tiredness- low energy levels overall (46%, 92), hot flushes (44%, 87), 
fear of cancer spreading (39%, 78), sleeping (34%, 67), fear about the future (32%, 63) and 
breast appearance (30%, 59). The members of the MDT that were the most frequently 
selected were: the breast care nurse (46%, 92), the medical oncologist (28%, 55) and the 
psychologist (20%, 40). It is noteworthy that 72% (143) wanted to discuss ‘fear’, either of 
cancer coming back, spreading, or about the future in general. Psychological factors were 
also prominent; within the psychological state and emotional well-being section of the PCI 
as a whole, 84% (167) wanted to discuss one or more items (median 2; IQR 1-3). 
Specifically, significant numbers wanted to discuss the following: 15% (30) ‘mood’; 21% 
(41) ‘anxiety’; 17% (33) ‘depression’; and, 35% (70) selecting one or more of these. A 
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psychologist consultation was requested by 20% (40) of patients who selected a median of 4 
(IQR 3-6) items from this section.  
In all, 1952 PCI items were selected, with the following breakdown: 42% (816) for physical 
function and health; 24% (472) for psychological state and emotional well-being; 16% (313) 
for body image; 7% (142) for general information; 7% (138) for social functioning and 
family; and, 4% (71) for sexual functioning. In addition, the ‘other’ box on the PCI form was 
ticked by 7% (14) of patients with comments including: problems with clothing, skin itching, 
side effects from the anti-oestrogen treatment, complementary therapies, job and 
employment issues, and concerns about the possibility of breast cancer inheritance to close 
family members. The items that were presented by the patients in the 'other' box did not lead 
to changes to the PCI. Items were selected from six, five, four, three, two, one and zero PCI 
domains, by 12 % (23), 18 % (36), 22 % (44), 20 % (40), 16 % (32), 10 % (19) and 3 % (6), 
respectively.  
Variation by personal and clinical features was analysed with regard to the number of items 
ticked within PCI domains and by the total number of PCI items and the total number of 
health professionals selected (Table 10, Appendix 1). Younger patients selected more PCI 
items overall, and more specifically concerning sexual function, psychological state, well-
being and social functioning or family related domains. Other significant associations 
(P<0.01) indicated body-image related items, which were more relevant for patients having 
had chemotherapy, mastectomy or reconstructive surgery. Those on anti-oestrogen therapy 
selected fewer general information items, while those with wide local excisions selected 
fewer body-image related items. More PCI items were selected overall for mastectomy 
patients, and those that had reconstructive surgery selected more health professionals. With 
regard to health professional staff domains, the only significant correlation (P < 0.001) was 
between reconstructive surgery and the number of treatment-related professionals selected. 
Here, 100 % (25/25) versus 82 % (138/168) selected at least one from the list of seven 
professionals, 40 % (10/25) versus 22 % (37/168) selected at least three, and 24 % (6/25) 
versus 4 % (7/168) selected at least five.  
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Figure 6 The PCI items selected by the 200 responders in the cross-sectional survey 
 
 
 
A summary of the more notable correlations (P<0.001) between the number of PCI items or 
staff selected with the summary scores from the EORTC tools (QLQ-C30 and QLQ-BR23), 
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is shown in Table 11 (Appendix 1). These correlations are generally quite weak, as might be 
expected from summary measures, but the associations clinically plausible, and as such help 
support the validity of the data reported on the PCI. 
 
(B) Fear of recurrence (FOR) 
As detailed in section A of this chapter, the PCI items most frequently selected by patients 
were: fear of cancer coming back (62%), breast sensitivity/pain (46%), fatigue/tiredness- low 
energy levels overall (46%), hot flushes (44%), fear of cancer spreading (39%), sleeping 
(34%), fear about the future (32%) and breast appearance (30%). In addition, the members of 
the MDT that were the most frequently selected were the breast care nurse (46%), medical 
oncologist (28%) and psychologist (20%). Nearly three-quarters, wanted to discuss fears, 
either of cancer coming back, spreading, or about the future, and 18% wanted to discuss all 
three fears. For 29% only one fear was selected, with ‘fear of the cancer returning’ being the 
most frequently selected (40/57). There was a significant correlation between the number of 
fears selected, the number of other PCI items selected within each PCI domain, the total 
number of other PCI items selected, and the total number of health professionals selected 
(Table 12, Appendix 1). Those selecting all three fears selected a median (IQR) of 16 (9-21) 
and 5 (3-6), for ‘other items’ and health professions, respectively: more than double the 
median numbers selected by the other patients, and consistently more ‘other items’ within 
each PCI domain.  
The relationship of number of fear items selected with specific PCI items is shown in Table 
13 (Appendix 1) and Figures 7 and 8 (see below). There were associations at P<0.01 for 22 
of the 53 non-fear items, notably for 6 of the 9 items concerning ‘body image’. Associations 
at P<0.001 were found with the following: wanting to discuss hair loss, nausea, sleeping, 
anxiety and relationships; and, wanting to see the medical oncologist, breast care nurse, 
psychologist, and complimentary therapist. The associations with depression and mood were 
notably weaker. The group selecting only one of the ‘fears’ (predominantly the fear of the 
cancer returning) did not appear to differ much from the group selecting ‘no fears at all’ in 
regard to the number of other PCI items selected, the number of health professionals 
selected, or the specific items selected. 
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Figure 7 Percentage of patients (%) selecting professionals by number of fear items  
 
The number of fear items was significantly associated with reconstructive surgery (Table 14, 
Appendix 1; P=0.003) with 88% (22/25) selecting one or more fear items and 40% (10/25) 
selecting all three fear items. A similar trend for selecting more fear items was seen for 
mastectomy patients (P=0.04). There was also a trend (P=0.05) associated with patient age, 
with younger patients - particularly those under 65 years - more likely to want to discuss 
fears. This pattern was seen for both ‘fear of cancer coming back’ and ‘fears about the 
future’ but not for ‘fears about spread’. There was also a non-significant trend (P=0.07) for 
more fears to be selected for diagnoses made in 2009/2010, than for those made more 
recently in 2011/2012. 
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 Figure 8 Percentage of patients (%) selecting items by number of fear items 
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A summary of the correlations between number of PCI Fear items and summary scores from 
the EORTC tools (QLQ-C30 and QLQ-BR23) is shown in Table 15 (Appendix 1). These 
correlations were generally quite weak and largely non-significant apart from the association 
with the ‘future perspective’ summary score from the EORTC BR23 scale (P<0.001). This 
summary score is in effect a single question ‘were you worried about your health in the 
future?’ with four potential responses: ‘not at all’, ‘a little’, ‘quite a bit’, and ‘very much’. 
For patients responding ‘quite a bit’ or ‘very much’ to this question, 89% (90/101) selected 
the desire to discuss one or more PCI fear items, as compared to 74% (45/70) when 
responding ‘a little’ and 33% (8/24) if responding ‘not at all’. In separate tests the 
distribution of responses to this question varied significantly (P<0.001) concerning ‘fear of 
the cancer coming back’, and ‘fears about the future’, but not (P=0.28) concerning ‘fears 
about spread’. Other tests significant at P<0.01 were those comparing EORTC C30 physical 
functioning scores in relation to fear of the cancer coming back, EORTC C30 emotional 
functioning scores, and EORTC BR23 upset by hair loss scores in relation to fears about the 
future.  
 
(C) Body image issues 
Two-thirds (68%, 136) of patients selected one or more of the nine PCI items within the 
Body-image-related domain, with 28% (56) selecting 1 item, 27% (54) selecting  2-3 items 
and 13% (26) selecting 4-8 items (Table 17, Appendix 1) . In descending order of frequency 
the items selected were breast appearance 30%, weight- unable to control weight 28%, 
mastectomy appearance 19%, overall physical appearance 17%, wound healing – scar 
appearance 17%, breast prosthesis/padding 15%, hair loss 14%, arm appearance 13% and 
hair replacement-wig 6%. Those who selected hair replacement-wig were a subset of those 
who selected hair-loss. Nearly half (26/56) of those selecting just one item selected weight.  
There was significant correlation between the number of body image related items selected 
and the number of PCI items selected in other PCI domains, the total number of other PCI 
items selected and the total number of health professionals selected (Table 18, Appendix 1). 
Those selecting four or more body image related items also selected a median (IQR) of 17 
(10-23) other items and there was a clear gradient in the increase in numbers of other items 
across the PCI and in the number of health professionals selected as the number of body 
image related items increased. This is reflected also in the analysis of specific PCI items 
(Table 19, Appendix 1) and there were associations at P < 0.01 for 37 of the 46 non-body 
image related items. Associations existed at P < 0.001 for several items: wanting to discuss 
activity, arm swelling, breast texture, breast sensitivity/pain, indigestion, 
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memory/concentration, nausea, pain in arm or shoulder, sleeping, taste, vomiting, or 
sickness, anger, anxiety, fear of cancer spreading, mood, self-esteem, and fear about the 
future. Associations also existed at P < 0.001 for wanting to see the plastic surgeon, medical 
oncologist, radiation oncologist, breast care nurse, lymphoedema specialist, hair prosthesis 
advisor or breast prosthesis expert, and nurse practitioner.  
The number of body image related items was significantly associated with treatment by 
chemotherapy, wide local excision/lumpectomy, mastectomy and reconstructive surgery 
(Table 20, Appendix 1), with an increase in items related to chemotherapy and mastectomy 
and reconstructive surgery and the absence of wide local excision/lumpectomy. There was 
also a tendency for fewer items to be selected by older patients aged 65 years and over, but 
no notable differences concerning the IMD deprivation measure and time of most recent 
diagnosis. A fuller stratification by treatment combination is shown in Table 21 (Appendix 
1). Correlations between the number of PCI body-image related items and summary scores 
from the EORTC QLQ-C30 and the EORTC breast cancer QLQ-BR23 are summarised in 
Table 22, Appendix 1. These correlations were generally quite weak, the strongest of these 
being with the QLQ-BR23 Body image score and the QLQ BR23 systemic therapy side 
effects score.  
 
 
Discussion  
 
Breast cancer care was the first major cancer to be managed consistently by MDTs, and 
these MDTs were reviewed in the first round of the cancer peer review carried out in 2001 
by the Breast Cancer Clinical Outcome Measures (BCCOM, 2007). A total of 174 breast 
cancer MDTs were included as part of the 2004-2007 peer review round. Of these, 88% had 
a full core team membership in place although only half of the teams met the National 
Institute of Clinical Excellence (NICE 2002) requirement to have two core members in all 
the key disciplines (BCCOM, 2007). Often the Primary care setting may be the first point of 
contact of patients with physical problems associated with the cancer and its treatment, plus 
social and psychological support. It has been estimated that an average practice of 10,000 
patients will have around 23 registered patients who consult their GP about their breast 
cancer each year (Birmingham Research unit, 2007). Identifying patients with unsatisfied 
needs in an early stage of their treatment provides the opportunity to address these needs and 
enhance their quality of care (Bonevski et al, 2000). Unsatisfied needs and patient symptom 
burdens have a significant impact on patient well-being during treatment and on long-term 
adjustment (Holmes et al, 1997). Two conceptually different morbidity outcomes, unmet 
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needs and health-related quality of life, are used to identify cancer patients in need of clinical 
attention. Hansen et al (Hansen et al, 2012) confirmed that patient-perceived unmet needs of 
rehabilitation during the cancer trajectory are associated with decreased quality of life. In 
their study that included breast patients, they supported the use of ‘unmet needs’ questions to 
identify patients in need of clinical attention. According to the literature, the majority of 
cancer patients experience more psychological, interpersonal, health policy and system 
difficulties and other problems of living, than psychiatric symptoms [Cell DF (1987), Welch-
McCaffrey et al (1989)]. Psychological adaptation to breast cancer could be measured in 
many ways including quality of life, satisfaction with care and needs assessment. Needs 
assessment differs from other assessment constructs in that it directly identifies patients with 
higher levels of need and suggests specific interventions for them [Bonevski et al (2000), 
Foot et al (1995), Park et al (2012)]. Therefore, evaluating patients need is important if we 
are to offer timely, effective interventions. 
 
Of the 1952 items endorsed, 816 were related to physical function and care, indicating that 
this was a significant issue following breast cancer treatment. Indeed, the physical problems 
following breast cancer treatment can be overwhelming, and include postsurgical 
complications, skin reactions to radiation therapy, pain, numbness, functional limitations, 
lymphoedema, weight gain, hot flushes, and fatigue (CRUK, 2012).In this study, we 
specifically identified the following: fatigue and tiredness, sleeping and hot flushes, pain in 
the breast/arm, pain in the shoulder/elsewhere, and lymphodema. These seem to be common 
concerns following breast cancer treatment.  
Fatigue, manifested as a global sense of loss of energy, is the most frequently reported 
source of distress associated with breast cancer, regardless of treatment modality 
(Winningham et al, 1994). Fatigue may be a symptom of directly related conditions or the 
result of breast cancer treatment, and includes anaemia, dehydration, chronic pain, 
depression, and sleep problems.  It may also result from muscle mass loss and increased fat 
mass, particularly in those undergoing chemotherapy (Demark-Wahnefried et al, 2001). 
Identification in the review clinic should stimulate appropriate examination and investigation 
if needed, and the clinician can reassure patients and provide practical advice or treatment 
for its management. Furthermore, there is an opportunity to educate and reassure patients and 
families that fatigue is a frequent and expected side effect of breast cancer treatment. 
Encouraging self-care strategies may also provide benefit including exercise programs or 
recommending support groups such as ‘The Haven Foundation’. In selected patients, the 
breast specific PCI may aid the monitoring of issues such as fatigue, and by proxy, aid in the 
evaluation of the menagement strategies. 
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Breast cancer survivors have 10% more sleep problems, and sleep problems that persist, than 
their peers without cancer. Additionally, survivors often develop hot flashes and a worse 
physical condition. For example, up to 90% of young breast cancer survivors experience 
premature menopause due to adjuvant treatment strategies such as chemotherapy, 
antioestrogenic agents, and ovarian ablation. Both therapy-induced hot flashes and 
vasomotor symptoms are common among breast cancer survivors undergoing natural 
menopause (Frieden et al, 2011), and their management can be difficult. Specific 
interventions are necessary to prevent them becoming an unmet need. However, the clinical 
team may lack the expertise in hypnotherapy, complementary and alternative medicine, or 
for pharmacological management that many women demand (Kimmick et al, 2006).  
Lymphoedema was also endorsed, which is consistent with the fact that arm lymphedema 
affects approximately 30% of breast cancer survivors (Paskett, 2007). Some may not have 
troublesome lymphodema. However, it can have devastating consequences, with patients 
experiencing heavy, swollen, and stiff arms, with thickened, rough skin and frequent arm 
infections.  Intervention is esential if it is flagged up as an issue, and will need addressing by 
the clinical team. Courses of regular, intensive physical therapy can help to reduce the 
lymphatic fluid volume in the affected arm.  
Studies have shown that persistent pain after treatment for breast cancer is a common 
problem, ranging between 25% and 60% depending on the definition, measurement, and 
treatment (Andersen et al, 2011). There are several plausible reasons for this variation. 
Indeed, the most likely of these is that it can be difficult to detect pain in the clinic if not 
presented as an issue by the patient, or enquired over by the clinician. Additionally, some 
cases may relate to the need for ongoing treatment to prevent negative outcomes. It is 
therefore possible that the prevalence of persistent pain after breast cancer treatment has 
been underestimated.  
The aromatase inhibitors (anastrazole, exemestane, and letrozole) used as adjuvant hormonal 
treatment in postmenopausal women with hormone-dependent breast cancer, can reduce 
bone mineral density, and increase the incidence of osteoporotic fractures. This could lead to 
pain, decreased physical activity, and declining functional mobility (Baum et al, 2003). A 
chronic pain syndrome following axillary dissection for breast carcinoma, known as post-
mastectomy syndrome, often results from inadequately treated acute pain (Jacobs et al, 
2006). Additionally, there are difficulties in the assessement and management of long term 
pain. Future studies with a tool such as the breast cancer specific PCI can provide repeat 
clinic assessement over time , offering a better overview of the symptoms and nature of pain 
following breast cancer treatment.  
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In this work, the significance of identifying and managing physical symptoms cannot be 
over-emphasized. This is particularly important because these may be the symptoms that 
clinicians are equipped to handle. That is in contrast with issues such as sexuality and 
intimacy that most surgeons are often ill-equipped to address effectively. It is evident that 
achieving the correct balance between rehabilitation and essential cancer surveillance is 
inherently difficulty in a busy National Health Service clinic. The breast cancer specific PCI 
may facilitate early target identification and provide an opportunity for interventions that 
impact both the patient-doctor relationship and the quality of the consultation. 
 
HRQOL tools were developed to assess either newly diagnosed patients or those receiving 
treatment, and may therefore be inherently unable to identify the specific issues of long-term 
survivorship, such as FOR [Gotay et al (1998), Northhouse LL (1981), Hodgkinson et al 
(2003)]. In addition, with health- related- quality of life tools, patients rate the presence and 
severity of an item, and clinicians may be not sure if a specific item is a problem for which 
they need help (Armes et al, 2009). In the literature there are studies that report an 
association between FOR and psychological distress and a reduced quality of life score 
[Scharloo et al (2005), Humphris et al (2008)]. Armes et al (Armes et al, 2009) reported that 
FOR is a significant predictor of unmet needs. 30% to 50% of breast cancer survivors have 
unmet needs (Armes et al, 2009). A breast cancer specific PCI may be an important first step 
in the systematic assessment of patients' needs at different key moments in the cancer 
journey that specifically identifies issues including FOR. Pain is another common symptom 
among breast cancer patients. Lack of information on pain management has been identified 
as a significant barrier for pain control among minorities (Cleeland et al, 1997). Reluctance 
to report pain might lead to less physician awareness of the symptom and inadequate pain 
assessment. A breast cancer specific PCI may play an important role in resolving pain for 
low-income ethnic minority patients by improving the patient clinician interaction. Recently, 
studies have emerged in breast cancer patients investigating whether differences in clinician-
patient communication may have an impact in the prevalence and /or resolution of breast 
cancer related symptoms (Maly et al, 2010). Depression was the most common symptom 
reported by patients (66%), yet physicians were the least aware of it (26.3%) (Maly et al, 
2010). Often, physicians tend to focus on cancer treatment details during patient visits and 
may overlook psychiatric symptoms (Maly et al, 2010). In addition, physicians may feel less 
well equipped to deal with psychiatric issues than with medical problems [Valente et al 
(1994), Maguire P (1985)].A Breast cancer specific PCI may contribute to the resolution of 
depressive symptoms since it is aimed as an intervention targeting the patient-clinician 
consultation. The quality of the interaction between a breast cancer patient and her / his 
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clinician appears to have an effect on the PROs, rather than the frequency and the length of 
the consultation (Tan et al, 2011). One might expect a positive outcome such that of a 
reduction of the treatment related symptoms. However, Tan et al (Tan et al, 2011) reported 
that as patients discussed with and sought information at baseline from their physicians about 
their cancer treatment, quality of life, and other cancer-related issues, there was a tendency 
for patients to report experiencing more cancer-related issues the following year. Literature 
reports several outcomes as a direct consequence of the clinician -patient interaction. For 
example, an experiment revealed that the routine collection of health-related quality of life 
data from patients led to a better subsequent quality of life and emotional functioning 
(Velikova et al, 2004). In a study by Detmar et al (Detmar et al, 2002) the use of patient-
reported quality of life assessments during visits led to a greater percentage of patients 
identifying moderate to severe problems in various health domains. Stark et al (Stark et al, 
2004) observed that anxiety could be exacerbated through medical discussions. We know 
from the literature that good communication skills are crucial for the clinical care of women 
with breast cancer [Fallowfield et al (1999), Maguire P (1999)], but it appears that the 
relationship between patient experience and a clinician’s communication skills is much more 
complex. Patients with cancer want a relationship with their doctors [Jefford et al (2002), 
McWilliam et al (2000), Butow et al (2002)], yet this relationship is a dynamic process and 
can be affected by the clinician’s communication skills. Although these communication 
skills can be enhanced by training, enhanced skills do not always improve a patient’s 
experience (Fallowfield et al, 1999). It appears that patients want information that will help 
them to maintain hope and trust throughout the cancer journey [Hulsman et al (2002), 
Leydon et al (2000)]. Therefore, mutual communication that is non-judgmental and features 
an inclusive orientation towards each other, is considered a central feature of therapeutic 
relationships [Hack et al (2005), Feldman-Stewart et al (2005), Kreps G (1988), Roter DL 
(2000)]. The oncologist-patient communication has been shown to serve as an information 
exchange platform that takes into account the relational needs of patients (Hack et al, 2005). 
Early cancer communication research described patterns of information exchange, revealing 
clear dominance of talk by clinicians [Kaplan et al (1989), Siminoff et al (2006), Butow et al 
(1997), Nussbaum et al (2003)]. Patient-cantered communication is dependent on both the 
clinician’s expressed recognition of the patient’s needs, as well as communication of 
complex medical information (Step et al, 2009). The BC specific PCI may play a vital part 
towards the improvement of the consultation as a process by the provision of specific points 
as well as by acting as an aid memoire for the patients. 
Following the guidance from documents such as ' Improving supportive and palliative care 
for adults with cancer' (NICE, 2004) and ' Improving outcomes in breast cancer' (NICE, 
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2002), clinicians involved in the management of patients with breast cancer recognised the 
need for a holistic approach. The assessment and discussion of patients’ needs for physical, 
psychological, social, spiritual, and financial support are key points in breast cancer care and 
followed locally by our institution. The breast cancer specific PCI offers a role in ensuring 
comprehensive care and could be incorporated into both local and national integrated care. 
There are over 550,000 women living in the UK who have been treated for breast cancer 
(Cancer Research UK; CRUK, 2013). Survivorship after Breast Cancer together with the 
medical and psychological needs of these patients has become increasingly recognised [Ganz 
PA (2004), Ganz PA (2002), and Ganz PA (2008)]. FOR is a common challenge and unmet 
need among cancer survivors (Lebel et al, 2012). Recurrence may be local, regional, distant 
(often lungs, liver, bone marrow) including in the contralateral breast. For some patients, 
emotions that were put aside during cancer treatment come flooding back all at once, and 
they feel overwhelmed with fear. In 9% to 34% of cancer patients, the fear of cancer 
recurrence becomes so overwhelming that it affects quality of life (Custers et al, 2013). 
Patients are cancer survivors but often they are afraid that the cancer may come back and 
that they will have to go through the experience again. In some occasions, this emotion is so 
overpowering that may be one of the driving forces for prophylactic mastectomies. Recently 
in the literature, there is a substantial increase in the number of therapeutic mastectomies for 
breast cancer and an increased rate of contralateral prophylactic mastectomies [Arrington et 
al (2009), Jones et al (2009), McGuire et al (2009)].  
Specific tools designed to identify FOR may not be practical for use in isolation in a busy 
breast-cancer outpatient clinic. A tool that may be able to identify FOR as an issue, as well 
as assessing other core issues that breast cancer patients feel overwhelmed by, may be much 
more practical, useful, and applicable in routine outpatient care. It is with this scope in mind 
that the breast cancer specific PCI has been employed in this study. Here we explore the 
ability of the PCI to identify a group of breast cancer patients in which FOR is a barrier that 
prevents them from making the transition from cancer sufferer to cancer survivors. 
Using the PCI, we identified a sizeable group of patients that reported FOR as an issue 
following their treatment for breast cancer. Of interest was that the patients that selected 
more than on 'fear' had also selected multiple other items. The PCI may identify the patients 
that are in need of extensive support during their cancer journey. The relationship with age 
and FOR that has been reported previously (Lebel et al, 2013) has been confirmed once 
again by this study. Apart from FOR, we confirmed a series of issues that breast cancer 
patients need to overcome in order to escape the shadow of living with a life-threatening 
illness (Table 12, Appendix 1). 
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FOR is a common concern that may become an issue since it may not be possible to identify 
patients based on clinical parameters (Rogers et al, 2010). FOR has been reported elsewhere 
using the PCI in head and neck cancer patients (Ghazali et al, 2012), as have specific 
interventions, such as ‘AFTER’ (the adjustment to the fear, threat or expectation of 
recurrence). The proposed AFTER intervention targets recurrence fears, inappropriate 
checking behaviour, and beliefs about cancer intervention (Humphris et al, 2012). It is of 
interest to note that initial testing of the AFTER intervention showed acceptability, which 
may have applicability for patients who have been treated with cancer at other sites. A study 
that was conducted in women one week after breast cancer surgery indicated that FOR and 
anxiety regarding post-operative treatments accounted for more than 65% of the responses to 
the question "What concerns you most about your new diagnosis?" (Stephens et al, 2008).  
FOR may be more prominent in women with a history of anxiety or depression. Costanzo et 
al (Costanzo et al, 2007) reported that some breast cancer survivors are at risk of sustained 
distress. In that study, participants reported moderate distress that appeared to be associated 
with FOR. Another aspect that must be taken into account in the management of patients 
after diagnosis and treatment of breast cancer is that both patients and their partners may be 
pre-occupied with FOR and that this may remain for years after treatment (Jiwa et al, 2006). 
Hodges et al (Hodges et al, 2005) for example, reported in a meta-analysis that carer FOR is 
higher than that of patients, and suggested that early intervention with the patient and their 
carer could prevent later development of psychological distress in both. Another aspect of 
interest is that there may be significant emotional distress in a small number of husbands. 
Walker (1997) (Walker BL, 1997) concluded that women with breast cancer are best viewed 
as a unit with their spouses; behavioural changes within this unit can affect either member. 
Also FOR may not always be obvious, but instead manifests as a variety of mental health 
problems. 
Radiotherapy is a common modality that is often used in the management of breast cancer. 
FOR has such an impact on HRQOL, that patients are willing to accept the side effects of 
radiation therapy, perhaps in an attempt to alleviate that fear (Hayman et al, 1997). It is 
essential that FOR should be evaluated longitudinally. Simply waiting for FOR to recede 
may not be a viable clinical option for supporting the cancer survivor, as it may simply not 
resolve without proper intervention. 
Once FOR is identified, the management of these patients can be a challenge. Several 
interventions have been reported in the literature. Van den Berg et al (2012) suggested the 
‘Breath Intervention’ in order to facilitate emotional, physical, and social recovery of all 
breast cancer survivors. Another approach (Crane-Okada et al, 2012) includes trained senior 
peer counsellor volunteers, supervised by a skilled clinical team, as an adjunct in addressing 
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psychosocial needs of women after breast cancer surgery. Little attention has been directed 
to the longer-term survivorship phase for older breast cancer survivors who often continue to 
be affected adversely from the late and long-term effects of treatment including FOR (Crane-
Okada et al, 2012). The available feedback indicated that The Mindful Movement Program 
experience yielded positive results and was feasible for a variety of older BCSs (29). Thewes 
et al (2013) explored the relationship between FOR and maladaptive metacognitions. They 
concluded that treatments that focus on altering unhelpful metacognitions might prove a 
useful approach for the treatment of FOR (Thewes et al, 2013). Literature reports suggest 
that mindfulness-based stress reduction (MBSR) reduce FOR and improves physical 
functioning, which reduce self-perceived stress and anxiety (Lengacher et al, 2012). Other 
suggestions for improving the management of FOR, include treatment for anxiety, the 
provision of social support, and better patient education (Liu et al, 2011). The use of the PCI 
as a tool for the identification of FOR conforms well with recent research supporting the use 
of such measures as well as supporting longitudinal research examining its impact (Simard et 
al, 2013).   
It is increasingly recognised that FOR is an area that patients, carers or clinicians will not 
broach routinely within an outpatient follow-up appointment. The findings presented in this 
study confirm that FOR is a major concern for the majority of patients, and pre-appointment 
interventions such as the PCI may assist by giving tacit permission for these fears to be 
discussed. A possible reason for the low frequency of eliciting these fears by clinicians 
without aids such as the PCI is lack of training. Discussion of FOR in the clinic demands 
members of the clinical team, including senior doctors and nurses, to set aside time for this 
exchange to happen. Time is probably the most strained resource in the running of a 
comprehensive oncology service, therefore, clinician need good communications skills 
[(Samant et al (2010), Epstein et al (2011)] to make the most of these opportunities. These 
skills include: listening carefully to the fears expressed; summarising and checking for 
clarity of understanding; providing clear information; where possible, providing factual 
evidence regarding recurrence; and, discussing the potential treatment options for recurrent 
tumours. This discussion may occur over a number of routine appointments. The balance 
between realism and providing some hope [Olver (2012), Leydon (2008)] needs to be 
carefully balanced. However, the offer of discussing this crucial topic may be the difference 
between a patient developing a stable FOR, an intrusive FOR that is resistant to change, or a 
patient who is able to face the prospect of further disease and not be disabled by FOR.   
Identifying FOR in the routine outpatient clinic may have further clinical implications. The 
relationship between FOR, and it role in steering the treatment preferences of patients, is 
complex. It may be that if a strong patient-centred approach were adopted, it would increase 
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the frequency of bilateral mastectomies. This example has been illustrated in a study by 
Corter et al (2012), where all illness perceptions were associated with FOR. In addition, 
beliefs on the necessity of medication were significantly correlated with FOR, although 
concerns were more often raised over the treatment effectiveness and there were calls for 
extended prescriptions. 
A potential implication of PCI implementation that would require further evaluation, is that 
it is difficult to know when the level of FOR becomes so high that rational intervention and 
risk reduction strategies become near irrelevant. Indeed, if a patient believes that their risk of 
recurrence is near 100%, then any attempt to implement practical risk reduction could be 
ineffective. For example, the benefits of reducing body-weight to lower cancer recurrence 
risk may not be practised because of this FOR, making any attempt to persuade patients to 
reduce calorific intake pointless. Other important aspects to consider once FOR is identified 
in the outpatient clinic, will therefore be an establishment of the level at which FOR should 
be considered suitable for intervention. Further research will be required in order to identify 
the active components of an intervention (such as AFTER for example).  
Many changes to our appearance may occur through life. These may be planned or 
unplanned, desired or not (Newell et al, 2000). There are several definitions of body image 
in the literature based on body size estimation, evaluation of body attractiveness, feelings 
associated with body size and shape (Grogan et al, 1999). The definition we use relates body 
image to a person's perceptions, feelings, and thoughts about his or her body [Grogan et al 
(1999), Muth et al (1997). 
Women treated for breast cancer endure scars and disfigurement of the breast, skin changes 
related to radiotherapy and/or hair loss due to chemotherapy [Hopwood et al (2001), Falk 
Dahl et al (2010)]. These effects from the disease and its treatment are life changing and can 
lead to a significant alteration in body image [Falk Dahl et al (2010), Helms et al (2008)]. In 
turn this effect on body image can result in undesirable Health-Related-Quality-of Life 
(HRQOL) changes that affect the transition from patient to breast cancer survivor [DeFrank 
et al (2007),Holmes et al (2008), Pikler et al (2003), Hopwood P(1993), Frierson et al 
(2006), Collins et al (2011)]. Younger patients may be more susceptible to stress related to 
change in body image and report greater changes in HRQOL scores [Noguchi et al (1993), 
Margolis et al (1990), Kemeny et al (1988), Beckmann et al (1983)]. Brunet et al (2013) 
(Brunet et al, 2013) reported that women with breast cancer experienced various physical 
changes that negatively affected, their perceptions, thoughts, attitudes, feelings, and beliefs 
about their bodies. Based on these findings they highlighted the need to recognise body 
image concerns that could have a long lasting effect on the HRQOL. 
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Przezdziecki et al (2012) have recognised the link between body image disturbance, lower 
self-compassion, and an increase level of distress. Specific treatment options such as 
mastectomy may adversely affect specific aspects of body image such as problems related to 
sexual intimacy (Fallbjork et al, 2012). Mastectomy may alter body image so much that can 
obliterate sexual relationships for a period of time (Boehmke et al, 2005). Support in relation 
to sexuality and body image could improve relationships by modifying perceptions with a 
direct improvement in patient's and spouse's HRQOL (Sheppard et al, 2008). Clinicians do 
not always elicit such concerns from patients. One way of improving recognition of these 
problems is to develop tools to improve clinicians’ communication with patients. Cohen et al 
(2012) suggested that patients want honesty, openness, and directness from their physicians 
during the discussion of breast-related body image issues (Cohen et al, 2012). Breast cancer 
patients rate the information on physical changes, sexual response, and body image as very 
important (Ussher et al, 2013). However, Ussher et al (2013) reported that only 41% of their 
patients obtained such information,   hence only 34% of patients claimed to be satisfied with 
this aspect of their consultation.  
Body image can affect a woman’s treatment decisions with respect to surgical options such 
as mastectomy versus breast conserving surgery (Fadaei et al, 2011). A multidisciplinary 
approach to address the impact of body image, with specific medical and psychosocial 
interventions has been analysed (Bifulco et al, 2012). Younger patients take longer to make 
treatment decisions and require enhanced levels of support compared to older adults. The 
availability of breast reconstruction only partially ameliorates this effect (Metcalfe et al, 
2012). 
Body image changes associated with mastectomy, chemotherapy, and radiotherapy are well-
recognised [Esmaili et al (2012), McGaughey A (2006), Hopwood et al (2010)]. Up to a 
third of women report moderate or marked breast, arm, and shoulder symptoms over 5 years 
of follow-up after radiotherapy, and skin changes related to radiotherapy are well document 
in the literature (Schnur et al, 2011). However, these appear to have little impact on body 
image. As expected, adjuvant treatments (chemotherapy and radiotherapy) are associated 
with decrease in overall HRQOL, an increase in physical problems and adverse effects on 
the body image [Browall et al (2008), Boehmke et al (2005)].  
Tools exist to evaluate changes in body image following breast cancer, and are useful in both 
research and clinical settings (Hopwood et al, 2001). A number of HRQOL instruments in 
use in breast oncology have incorporated body image questions [Hopwood et al (2001), 
Sprangers et al (1996), Kanatas et al (2012), Baxter et al (2006), Polivy J (1977), Stanton et 
al (2005), Brady et al (1997), Pusic et al (2009)] (Table 16, Appendix 1) . HRQOL 
questionnaires are designed as outcome measures to compare groups of patients. Although 
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some studies have described their use in clinical practice, they are not specifically designed 
for this context. While it is tempting to use the scores derived from such tools to screen 
patients from problems relating to body image, thresholds to trigger specific interventions 
are not currently defined in breast cancer care. Furthermore, these tools are time-consuming 
to use and hence may not be practical in a busy clinical environment. 
In other types of cancer, HRQOL tools have been used as a trigger for discussion of patients’ 
problems of appearance (Flexen et al, 2012). HRQOL tools can help focus the consultation 
and are a suitable means of screening for appearance issues (Katre et al, 2008). In head and 
neck cancer, the PCI has been used with HRQOL tool and its role has been defined (Flexen 
et al, 2012). The PCI enables holistic evaluation of body image concerns in the breast-cancer 
outpatient clinic (Kanatas et al, 2013).  
This is the first study in which the BR23 questionnaire and the PCI have been used in 
combination to screen for body image problems in patients with breast cancer. Although 
several important points have been raised, we must recognise that there are limitations to this 
study. The study involved a relatively small sample of patients from one area in the United 
Kingdom, thus the results may reflect the beliefs and practice of this group, and caution is 
necessary before extrapolating our findings to other settings. Future longitudinal studies need 
to focus on body image and could to examine whether body image state eventually returns to 
values similar to those before the breast cancer diagnosis. Body image should not be seen in 
isolation. There is a need to examine any possible associations with sexual function and 
quality of life. In this study there were weak correlations between the number of PCI body 
image items and the EORTC tool. Another limitation of this study is that a specific body 
image scale would have been appropriate (Hopwood et al, 2001). Items such as change in 
self-consciousness with appearance, less sexually attractive, less feminine, dissatisfaction 
with appearance when dressed, and body feeling less whole that are present in the QOL 
BR23 were not assessed in our study. The absence of these items may be seen as a weakness 
of the breast specific PCI, but these were items that there were not selected during the 
development of the PCI. This may be due to characteristics of the cohort of patients that 
were used for the development of the PCI. 
The body can be viewed as a symbol of social expression (Cohen et al, 1998). Breast cancer 
diagnosis and treatment can result in a sustained disturbance of that view at 12 months post-
diagnosis and beyond (Falk-Dahl et al, 2010). This is reflected in our study since 54% of 
patients were diagnosed at least two years prior to enrolment. Body image is clearly an 
important issue since 68% of patients selected an item from the body-image domain. In this 
study, the number of body image related items was significantly associated with 
chemotherapy and mastectomy, and reconstructive surgery. Some previous studies showed 
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that chemotherapy, hormonal therapy and radiotherapy do not have a negative effect on body 
image (Fehlauer et al, 2005). In contrast, the findings from this study are consistent with, 
Schover et al. (Schover et al, 1995) who concluded that chemotherapy do have a negative 
impact on body image, while hormonal and radiation therapy do not. Breast appearance was 
the item most frequently selected followed by weight and mastectomy appearance. This is 
not unexpected since the physical effects of breast cancer treatment on the body serve not 
only as a personal reminder of the disease but also as an 'announcement' to others 
(Rasmussen et al, 2010). Yurek et al (2000) (Yurek et al, 2000) reported that those patients 
who underwent a lumpectomy faced less body-change stress than women undergoing a 
modified radical mastectomy with or without breast reconstruction. 
 In this work only 14% of patients selected hair loss. This low incidence may be explained 
because most participants completed the PCI several months after their chemotherapy by 
which point hair-loss had recovered for the majority.   
As it can be seen in table 18 (appendix 1), those patients selecting body image related items 
selected a median of 17 other items. The effect of breast cancer on body image should not be 
under-estimated, and this is widely reflected in the literature. Fallowfield et al. (Fallowfield 
et al, 1986) found that the incidence of anxiety and/or depression was as high as 38% in 
patients with a surgical intervention. Age was negatively correlated with the items detected.  
We found that older patients tended to select fewer items and this is consistent with Al-
Ghazal et al (2000) (Al-Ghazal et al, 2000) who compared the psychological outcome and 
satisfaction of patients undergoing wide local excision, mastectomy alone or mastectomy 
with breast reconstruction. This study reported that while women of all age groups face body 
image issues after breast cancer surgery, women between 40 and 59 years of age report more 
body image issues after breast cancer surgery. 
The head and neck PCI has been used before as a tool to identify appearance-related 
concerns (Flexen et al, 2012). Appearance was highlighted as a problem on the PCI at 9% 
(42/454) of questionnaires, and was indicated as a serious problem on 10% (47/454) of UW-
QoL questionnaires. Concerns about appearance were raised on the inventory or were shown 
to be a serious problem on the UW-QoL in 14% (64/454) of patients. One must be cautious 
comparing our findings with that work since appearance was related to the face, and the 
participants included male patients and patients with different socioeconomic characteristics. 
The methodological weaknesses of this study include the small sample size, specific patient 
groups, and specific cancer-related aspects such as positive adjustment following breast 
cancer. In addition, patients completed the breast cancer specific PCI after their clinical 
consultation and there was no clear link between the PCI and subsequent consultations, as 
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the study took place over two institutions. These factors may have influenced the responses, 
and a degree of caution is required in the interpretation of the results.  
The extent to which all questions contribute positively toward measuring the same concept is 
known as internal consistency (Staquet et al, 1988; Tavakol, 2011) and can be assessed using 
Cronbach's alpha. In general, the acceptable range is between 0.70–0.95, although levels 
above 0.85 are optimal (Staquet et al, 1988). In the context of the PCI items generated, 
interpreting the coefficient values (Figure 5) is not an easy task, as the list is composed of 
diverse items measuring diverse issues. Similarly, the PCI domains were created for the 
convenience of grouping loosely related items, rather than for a parsimonious set of closely 
related items. Indeed, we know that a low alpha value can result from too few questions, 
poor interrelatedness between items, or heterogeneous constructs (Staquet et al, 1988; 
Tavakol, 2011). Additionally, alpha is affected by test length and dimensionality, with longer 
tests having greater reliability, regardless of homogeneity. This may have occurred in the 
case of the breast cancer specific PCI, which had an overall acceptable alpha value. 
However, at times the analysis by domain (that is, the percentage selecting at least one item 
from the domain) seems appropriate. 
Care was required when contemplating the removal of items at this stage of the PCI 
development. The balance for the PCI checklist was towards having inclusive 'content' rather 
than ansuring an economical set of items with psychometric methods applied to remove 
items that correlated poorly with other items within the domains.  
The Cronbach’s alpha values are difficult to interpret, with generally low domain values, and 
the highest being those with the greatest number of items. The alpha for the whole PCI check 
list (56 items) was the highest at 0.897, which at first inspection seems at odds with the clear 
multi-dimensionality of the items. However, this probably reflects the large number of items 
as stated above. Thus, acceptable alpha values are possible even when using items with poor 
internal consistency, provided a scale has sufficient items. The sample size of 200 gives a 
reasonable denominator, while the rarity of many of the items (the numerators) inevitably 
detracts from assessing their usefulness as domain items. 
An equally important consideration is the reliability and validity of what is being asked of 
patients; they are being asked to highlight concerns that they want to discuss. Reliability is 
therefore implied if respondents provided consistent responses (as to which issues they 
wished to discuss) over a specified time-period. Validity, which refers to a tool measuring 
what it is supposed to measure, is determined by whether someone who says they want to 
discuss an item of concern really does want to discuss it. Future study including more 
clinicians with a longitudinal design would be required to address this issue. 
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A key message from this phase was that the alpha value was heavily dependent on the 
number of items withing the scale/domain/dimension. Since PCI items should highlight 
slightly different aspects of the same construct, our aim was not to achive a perfect 
association between items, but to avoid redundancy. Internal consistency should then be 
assessed for each sub-construct separately. However, we do not know which items relate to 
which domains, or how many psychometric domains actually exist. To evaluate 
dimensionality further would require a factor analysis to determine whether specific items 
are related to particular domains, and whether all domains are sufficiently covered by the 
specified number of items. This would ideally require numerous items, using a Likert-type 
scale, and many hundreds of patients (Staquet et al, 1988). However, the sample size of 200, 
the less informative binary Yes/No options, and the infrequent responses to many items 
imply a lack of power for factor analysis in the present study.  
 
Conclusions 
 
The PCI may empower patients to raise issues that otherwise could be missed. This could 
improve self-efficacy within the patient–physician encounter. In addition, there is the 
opportunity for multi-professional engagement across a range of issues specific to breast 
cancer thus allowing for additional support, which might result in a higher rate of symptom 
resolution, and improved HRQOL. Finally the breast cancer specific PCI is a practical tool 
that may be able to assist in the holistic needs assessment of patients during the cancer 
journey. 
Potentially the PCI may be employed in the outpatient clinic to assess the relationship 
between the levels of FOR and when any new information, such as the results of 
mammograms, is presented. For example, it has been shown that the results of imaging and 
their description by clinical members have an influence on the images held by patients of 
their tumour (Harrow et al, 2008). Some images that are memorised by patients have been 
shown to possess ‘active’ elements described by patients as ‘tentacles’ or ‘pincers’. Do the 
impressions gained by patients during clinical procedures or appointments produce 
conditions in which FOR is magnified? Do they lead to a quality that prevents dismissal 
from consciousness to the point that the fears and thoughts generated become uncomfortably 
intrusive? Such processes fit Leventhal’s model (Leventhal et al, 1997) of illness 
representations and demonstrates the fertile landscape of patient imagination, management 
challenges in the presentation of images, and associated stimuli (e.g., the drawing of 
diagrams by the clinician) associated with the cancer diagnosis and personal response to 
cancer threat and post-treatment coping including FOR development.  
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The routine use of the PCI in breast cancer patients facilitates a holistic approach to 
management. It identifies the need for interventions; this can have a bearing on resource 
allocation and should provide a direction for future research. The role of interventions such 
as body beauty treatments to body image (Quintard et al, 2008) and exercise need (Adamsen 
et al, 2009) in breast cancer patients needs to be evaluated further. 
The breast cancer specific PCI may help women to engage in an honest conversation about 
their cancer related body image issues. It can be used as a screening tool for body image in 
order to identify a subgroup of patients that would benefit from focused interventions. 
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CHAPTER 8. Further Development of a Breast Cancer Specific Patients 
Concerns Inventory (PCI):  A Pilot Before-and-After Study (Phase 3) 
 
Introduction 
 
This section of the thesis focuses on phase 3 of the development of the Patient Concerns 
Inventory (PCI), from the introduction and pilot use of the PCI in a before-after study of the 
breast cancer specific PCI in a single breast consultant-led outpatient clinic. This part of the 
research involves the collection and analysis of qualitative data and was designed to provide 
an early indication of the effectiveness of the instrument in a clinical setting. 
Qualitative Research 
A qualitative research is defined as an inquiry process conducted in a natural setting for 
understanding a social or human problem, based on building holistic pictures formed with 
words, and reporting the detailed views of informants (Creswell JW, 1998). Kenny et al 
(1980) suggested the following three conditions to help decide on the appropriateness of 
using a qualitative approach:  
1. Consider a case study when the focus is on humanistic outcomes or cultural 
differences, as opposed to behavioural outcomes or individual differences. 
2. The uniqueness of the situation.  
3. Consider case study data when collection is not subject to truth or falsity but 'can 
be subject to scrutiny on the grounds of credibility. 
We employed a qualitative approach since it is exploratory by definition, and it is suitable 
when we do not know what to expect. This approach allows both the definition of specific 
issues resulting from breast cancer, and for the development of mechanisms for their 
resolution. There is general agreement in the literature (Miles et al, 1994) that qualitative 
researchers need to ensure study validity; this can be achieved through peer reviews, member 
checking and external audits to ensure the validity of the methodology. In this study, we used 
the coding process in order to control any investigation bias. 
Thematic coding and analysis of the qualitative data after rolling out the PCI in a consultant 
outpatient clinic 
Thematic coding refers to any method of categorising segments of qualitative data into 
meaningful themes (Krippendorff K, 2004). Content analysis is a rigorous form of thematic 
coding with a good inter-rater reliability; codes can then be used as basis for quantitative 
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analysis (Krippendorff K, 2004). Content analysis involves counting instances of particular 
occurrences that can be anything of interest such as a specific word or phrase, a semantic 
category or a type of utterance for e.g. adjective, verb, laughter, silence. In 1952, Bernard 
Berelson published Content analysis in Communication Research, which was regarded as a 
versatile tool for social science and media researchers (Berelson, B, 1952) considered to be 
an unobtrusive, non-reactive method of social research (  Loy, 1979). One of the uses of 
content analysis is to study the changing trends in theoretical content and methodological 
approaches. As a known unobtrusive method, content analysis is often used with sensitive 
topics, to corroborate the findings of other methods (Hansen A., 1998). Studies using content 
analysis usually involve the following six steps (Stempel GH, 1989): 
1. Formulation of the research question or objectives 
2. Selection of communication content and sample 
3. Developing content categories 
4. Finalising units of analysis 
5. Preparing a coding schedule, pilot testing, and checking inter coder reliabilities 
6. Analysing the collected data 
Analytical frameworks including the framework approach (Ritchie J, 2003) and thematic 
networks (Attride-Stirling J, 2001) are gaining in popularity because they systematically and 
explicitly apply the principles of undertaking qualitative analysis to a series of 
interconnected stages that guide the process. A framework approach was employed in this 
work in order to describe and interpret the views of participants. 
This section of the thesis attempts to answer to the hypothesis: 'Using a specifically 
developed Breast Cancer PCI in clinical practice, will help to identify patient concerns, 
improve consultations between professionals and patients, and help inform pathways for 
patients to follow so that their concerns are addressed.' The Specific objective was to pilot 
the use of PCI in breast cancer, in a before-after study.  
The outcomes that were recorded included: 
1. Duration of consultation 
2. Items discussed in the consultation 
3. Any onward referrals made 
4. Patient satisfaction Questionnaire score  
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Materials and methods 
                                  
Inclusion Criteria  
Adult patients (over 18-years) with a history of either diagnosis or treatment for breast 
cancer were included. For non-English speakers interpreters were provided in the clinic as 
per current NHS practice. 
Design and research subjects 
We proposed the introduction of the breast PCI (Appendix 2-N) into a clinic, with the aim of 
evaluating items raised in the consultation before and after its implementation with a specific 
clinician. The patient population was limited to 50 for several reasons. Primarily, it was a 
pragmatic choice, given that the interviews were to be recorded and analysed. Additionally, a 
literature review confirmed that this was a suitable number, and it was consistent with our 
experiences in the development of the Head and Neck PCI. Consecutive patients were 
recruited from the clinic.  
The study was designed to compare the outcome measures between two different cohorts:  
1) Patients attending clinic prior to the introduction of the PCI labelled cohort 1 (the ‘no PCI 
cohort’; n=25) 
2) Patients attending clinic after the introduction of the PCI labelled cohort 2 (the ‘PCI 
cohort’; n=25) 
An 9-item patient satisfaction questionnaire has been used in this study (Stewart el al, 1999 
and 2001) (Appendix 2-R).This 9-item questionnaire was developed for education purposes, 
to provide feedback to physicians on their own perceptions on a series of patient encounters 
compared to their patients’ perceptions of those same encounters. When examining this 9-
point scale for validity and reliability the Cronbach’s alpha reliability of the 9-item patient 
questionnaire is 0.80, n=85. Validity of the 9-item questionnaire is based on the origin of the 
items. This measure was chosen for practical purposes -easy to complete, brief- in addition 
to the fact that has been validated in breast cancer patients. This questionnaire has been used 
before in the breast oncology department of Leeds Teaching Hospitals. 
 
Phase 3: The introduction of the breast PCI in to clinic 
 
The treating consultant (KH) and the Clinical Nurse (CPN) identified suitable patients. 
During routine clinic appointments, patients were asked if they wanted to participate in the 
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study, starting at their next appointment (at least 4 weeks in advance). Those that they 
wished to participate were given an information pack by the clinical team. This included the 
study details (Appendix 2-P) and a consent form (Appendix 2-Q). On their next appointment, 
the patients that agreed to take part in the study attended their consultation.  
The ‘no PCI cohort’ attended for their clinic appointment as normal and the principal 
investigator recorded their consultations. After the consultation, they were asked to fill in a 
brief questionnaire about their satisfaction with the consultation (Appendix 2-R) (Stewart el 
al, 1999 and 2001). The 'PCI cohort' was asked to complete the PCI in the waiting room 
prior to their appointment. The PCI used is presented in Appendix 2-O; this contained 
identical items to those in the PCI shown in Appendix 2-N, with the exception that the 
format was changed to bring it in line with the style used in the Head and Neck PCI. The 
consultation was recorded. After the consultation, they were asked to fill in a questionnaire 
about their satisfaction with the consultation (Appendix 2-R).  
Data analysis of qualitative data 
The audio tapes were transcribed and the transcripts were checked against each audio 
recording to verify their accuracy. The transcripts were then analysed using a thematic 
framework analysis. The framework presented (Appendix 2-T) is based on the themes 
derived from previous knowledge acquired during the development of the head and neck PCI 
[Rogers et al (2009), Ghazali et al (2013)]. 
Evaluation of the consultation involved: the identification of both the number and type of 
concerns; involvement by healthcare or supportive professionals; and, the clinical actions 
that resulted from the consultation. The framework approach (Ritchie J, 1994) (Appendix 2-
S) was used to analyse the transcribed recordings.  
The themes were then coded into discrete categories: the items of concern, healthcare 
professionals, and the type of clinical action or decision made during the consultation. For 
example, words or phrases such as “lethargy,” “exhausted,” or “run down” were categorised 
under the theme of “Fatigue or tiredness.” Outcomes were classified as medical or non-
medical. Medical actions included: being placed on operative waiting lists, symptomatic or 
supportive medical treatment, investigation, and referral. Non-medical actions included: 
information provision, lifestyle advice, coping strategies, and reassurance. The system was 
developed to standardise the classification of spoken phrases or terms used by patients and 
clinicians for evaluation purposes. 
To improve the reliability of the qualitative data analysis, a second independent and skilled 
qualitative researcher (BR), assessed the transcripts and compared their conclusions. Both 
assessors randomly evaluated one out of every four transcripts. Concordance was 78% to 
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100%. This enabled formation of the thematic framework, which was used to evaluate the 
remaining transcripts. When an item was identified by one assessor but not by the other, it 
was discussed until resolved, which involved building a holistic picture of either the patient, 
the clinician, or both. On this basis, both assessors ultimately agreed key ideas and themes. 
This was particularly relevant when items were missed because they were not in the 
framework, as they were carefully considered for potential new coding. However, for the 
purpose of this thesis, they were considered under “Others.” The overall level of agreement 
for each consultation assessed was derived as a percentage using the simple formula: number 
of items agreed divided by the total number of items identified. 
Audio-recording equipment 
To ensure uniformity, audio-recordings were only conducted in consultations that involved a 
breast cancer surgeon, as other clinicians were not familiar with the PCI. A Tascam DR-40 
(TEAC UK Ltd., Watford, UK) recorder was used to record whole consultations, which were 
saved in MP3 format. All identifiable information was removed to maintain confidentiality. 
Only recordings of complete consultations were transcribed for use (Appendix 2-U). 
Study Measures and statistical analysis 
1. Consultation questionnaire (Stewart el al, 1999 and 2001) asked patients to consider the 
consultation that day. Nine questions were asked, each with four response options.  
2. The PCI. 
SPSS version 19 was used for the statistical analysis. The Mann-Whitney test was used to 
compare Cohort 1 (no PCI) and Cohort 2 (with PCI) for distribution of responses to ordinal 
questions from the consultation questionnaire, and in the distribution of tumour staging and 
year of most recent diagnosis. Age was compared between cohorts using the two-sample t-
test, whilst Fisher’s exact test compared other characteristics. The chi-squared test compared 
responses to question 5 of the consultation questionnaire, which was non-ordinal.   
 
Results 
 
Cohort 1 had 24 female patients, and cohort 2 had 29. The personal, clinical and treatment 
characteristics of patients in both cohorts were similar (Table 23, Appendix 1).  
Answers to the consultation questionnaire were generally positive irrespective of cohort 
(Table 24, Appendix 1). However, Cohort 1 gave better responses for seven of the nine 
questions (i.e. before the introduction of the PCI). The exceptions were questions 3 and 9, 
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asking about how much the doctor listened to what the patient said, and how much the doctor 
discussed personal or family issues that might affect their health, respectively. The onward 
referral made can be seen in Figure 9. The PCI items and health professionals selected by the 
29 patients in cohort 2 are shown in ranked order of frequency in Figures 10, 11, and 12 
(below) and are summarised in table 25 (appendix 1).  
Patient 
number 
Outcome of 
consultation 
Patient 
number 
Outcome of consultation 
Cohort 1  Cohort 2  
1 General Practitioner 
(GP) letter 
25 GP letter 
2 Plastic surgeon , GP 
letter 
26 GP letter 
3 GP letter 27 GP letter 
4 GP letter 28  
5 GP letter 29 GP letter 
6 Medical Oncologist, 
GP letter 
30 GP letter 
7 GP letter 31 GP letter 
8 GP letter 32 GP letter, Complementary therapies 
9 GP letter, referred 
for mammogram 
33 GP letter 
10 GP letter 34 GP letter 
11 GP letter 35 GP letter 
12 GP letter 36 Geneticist, GP letter 
13 GP letter 37 GP letter 
14 GP letter 38 Breast care nurse, GP letter 
15 GP letter 39 Plastic surgeon, Specialist nurse, GP 
letter 
16 GP letter 40 Complementary therapies, GP letter 
17 GP letter 41 GP letter 
18 GP letter 42 GP letter 
19 GP letter 43 Breast care nurse, GP letter 
20 Plastic surgeon, GP 
letter 
44 GP letter, referral for mammogram 
21 Dietician, GP letter 45 GP letter 
22 GP letter 46 GP letter 
23 GP letter 47 Lymphoedema clinic, Breast care 
nurse, GP letter, Complementary 
therapies 
24 GP letter 48 Clinical Psychologist, GP letter, 
referral for body scan 
  49 GP letter 
  50 GP letter, complementary therapies 
  51 Plastic surgeon, GP letter, Breast 
care nurse 
  52 Complementary therapies, clinical 
psychologist, GP letter 
  53 Breast care nurse, Complementary , 
Dietician 
Figure 9 Referrals made at the end of the consultation in the before and after study 
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The most frequent items were: fear about the future (48%, 14), anxiety (38%, 11), fear of 
cancer coming back (28%, 8), breast appearance (21%, 6), fear of cancer spreading (14%, 4), 
pain in the breast (14%, 4), pain elsewhere (14%, 4) and nausea/vomiting (14%, 4). The 
members of the MDT that were the most frequently selected were the breast surgeon (100%, 
29) and the plastic surgeon (10%, 3). The number of items selected is shown in Table 26 
(Appendix 1), both overall, and by domain. The items selected and discussed in the clinical 
consultations are shown in Table 27 (Appendix 1), and are compared in Figure 12 (see 
below). The duration of the consultation in minutes is shown in Table 28 (Appendix 1).   
 
Figure 10 Health professionals selected by the 29 patients in Cohort 2 of the study. 
 
 128 
 
P
ag
e1
2
8
 
 
 
Figure 11 PCI items selected by the 29 patients in Cohort 2 of the study. 
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Figure 12 Items selected by all patients in the study 
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Discussion 
 
Breast cancer patients have issues that may make them reluctant to volunteer in a busy 
outpatient review clinic especially when they do not see the same member of the treating 
team. If, as clinicians, we are to claim that we can respond to the issues of breast cancer 
patients, first we must ask the right questions. In this work the breast cancer specific PCI 
may provide the right questions. It can be used as an aid to the clinician-patient interaction, 
as a communication tool, or as a needs assessment tool in everyday clinical practice. 
However, using the breast cancer specific PCI as a holistic needs assessment tool makes 
clinical sense. During this work, the PCI was developed to identify patients’ issues during 
the post-treatment phases. While this pilot study provides a vital initial assessment of a new 
tool, the results should be interpreted with caution. In the qualitative assessment, both the 
primary investigator and the second researcher (BR) reviewed the consultation recordings to 
ensure item agreement and to improve the reliability of the qualitative data analysis. 
However, neither were breast clinicians, which may have resulted in certain points being 
misunderstood and incorrectly marked. That said, this will have reduced the investigator bias 
somewhat, providing a trade-off of unclear weighting.  
The research also involved only one consultant clinic. This may represent a disadvantage 
with the validation of the PCI. At this stage in the formation of the PCI tool, it arguably 
represents an advantages as it ensures that any changes observed in the before and after study 
were not attributable to differences between consultants. Neverthe less, the fact that patients 
were mainly recruited during the post-treatment phase in a surgical clinic, probably 
represents a limitations of the before and after study. This apprioach was chosen due to time 
constraints and practical reasons; including taking into account the availability of supportive 
stuff in a busy National Health Service clinic.  
The study involved a limited number of patients and health professionals from one area in 
the United Kingdom, and the results may reflect the beliefs and practice of this group. 
Despite the diversity of the sample, common features were identified in consultations and 
they were incorporated in the development of the breast cancer specific PCI. Setting the 
above limitations aside there are several aspects worthy of further evaluation. Looking at the 
patient satisfaction from the consultation, the results obtained from this small subgroup of 
patients suggest that most were satisfied with their consultations (Appendix 1, Table 24). 
Other generic questionnaires have been considered but this 9-item scale has been employed 
for practical purposes and has been used before in breast cancer patients in Leeds Teaching 
Hospitals. The results from this scale is in agreement with other studies (Epstein et al, 2005) 
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and not unexpected as patients may still feel that the expression of any dis-satisfaction may 
adversely affect their clinical care. In addition, the clinical team may have introduced bias as 
this study did not include a blinded methodology. The clinician knew that he was recorded, 
and they may have made more of an effort to include all the possible points than under 
normal situations. It would be interesting to explore the outcomes of PCI use in a blinded 
setting as well as with more clinicians and other health care professionals. Due to the nature 
of the PCI, any attempts at blinding would be very difficult to ensure. Nevertheless, this 
should be investigated further but is beyond the scope of this thesis. When we interpret the 
result from this study we must keep in mind that while surveys on the satisfaction of patients 
are thought to favour the clinician, scales that are specific to a visit are thought to measure 
different aspects than those that cover the duration of the relationship between the patient 
and physician (Epstein et al, 2005). When the results of this section of this thesis are 
examined, the PCI items selected by the patients favourably supported the psychological and 
body image categories. In addition, pain appeared to be a common issue that needed 
addressing in the clinic. This may be because an issue such as fear of cancer recurrence is a 
frequently cited and unmet need of cancer survivors (Lebel et al, 2012). It may also be 
because the PCI gives a platform in order to express this particular concern to their clinical 
team. The answer to those questions will need addressing with a larger scale clinical study 
involving the PCI. 
Another somewhat unexpected observation has been that 54% of patients from the first phase 
and 34% from the second had their more recent diagnosis in 2008/2009. In the clinical 
setting, that this research took place patients will be normally reviewed for three years. The 
identification of such patients, that as it appeared still had issues, may indicate that they 
represent a subgroup that may benefit from more targeted supportive care. It is unclear from 
this work if the PCI played a role in the identification of long term unmet needs in this 
patient group. A larger scale study should be in a position to clarify this point.  
Looking at the results from table 25 (appendix 1) they appeared to be in agreement with the 
narrations seen in the appendix 2-U. When we compare these results with the literature, it 
may appear that there are obvious variations. For example in the second phase only 7% of 
patients reported depression as an issue. Yet in the literature (Heins et al, 2013) primary 
health care use of breast cancer patients because of depression was as high as 64%, even 
years after active treatment. In other studies, depression is recognised in 15% of breast 
cancer patients [Ganz et al (2011), Bailey et al (2005)]. This may be due to the group or 
indeed the population characteristics but depression is nevertheless an issue that is present in 
the breast cancer specific PCI that may encourage a reluctant patient group to express such 
an unmet need. On the other hand, it may be that in our population depression among breast 
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cancer patients is recognised and treated in primary care rather than remain an unmet need to 
be recognised and treated in an outpatient breast-cancer clinic. 
Pain in the breast (14%), pain in the arm and shoulder (10%) and pain elsewhere (14%) are 
all items selected in the PCI cohort of this section of the study. Pain is often a concern partly 
due to its effect on HRQOL but partly due to its association with cancer recurrence. The 
treatment trajectory for these patients is unclear and beyond the scope of this study. 
However, it serves to highlight a current quality of survivorship for breast as well as the 
fundamental obligation of clinicians that must extend beyond the survival of disease and 
include symptom-related concerns such as the persistent pain. We must exercise caution if 
we aim to provide some blanket comments for breast cancer patients. We must remember 
that the incidence of breast cancer is higher in older adults (Deimling et al, 2007). This group 
of cancer survivors are particularly vulnerable to the effects of chronic pain due to high 
incidence of multiple co-morbidities related to aging (Deimling et al, 2007). Clinicians must 
prioritise pain as a chronic concern in cancer survivors, and should support clinical guidance 
and resources. The PCI cohort of this study may have unravelled a common issue in breast 
cancer. We know that surgery-related chronic pain is common in breast cancer survivors. 
Chronic pain has been reported to be as high as 50% of mastectomy patients (Jung et al, 
2003). In breast-conserving surgery patients, pain is reported to be around 39%   [Jung et al 
(2003), Tasmuth et al (1995), and Perkins et al (2000)]. It is also reported in the literature 
that chronic pain is one of the most distressing symptoms of cancer patients and an area that 
has been ignored clinically (Sun et al, 2008). 
Pain, anxiety, and depression often occur together (Asmundson et al, 2009). Findings from 
the Galloway  et al (2012) study suggested that anxiety and depression may be common 
among newly diagnosed breast cancer patients, and that these patients may be experiencing 
an appreciable amount of pain even before oncologic treatment starts (Galloway et al, 2012). 
In this before and after study, 34% of patients had their diagnosis in 2008/09 hence allowing 
more than three years after their treatment. One would expect that depressive symptoms 
were by now recognised and treated. Interestingly anxiety remain an issue even after all 
these years, but we must take into account that anxiety and depression can develop at 
different points on the treatment continuum from the point of abnormal finding to diagnosis,  
completion of treatment and survivorship, and throughout palliative care (Pirl WF, 2004). 
Clinicians may promptly treat depression during survivorship but may be more reluctant or 
effective in treating anxiety related to disease or its treatment. The breast cancer specific PCI 
provides a comprehensive list of issues that relate to anxiety, depression, and pain, and can 
be employed as part of a multidisciplinary approach to holistic patient care. Smith et al 
(2011) that breast cancer patients have persistent issues with fatigue , pain sleep, distress, 
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fear of recurrence (FOR), concerns about employment and uncertainty over the future (Smith 
et al, 2011). Most of these results are reflected in this before and after study with the 
exception of the concerns about employment. In cohort 2 of this study, 48% of patients 
expressed a fear about the future (Figure 7). The difference of the PCI when compared with 
other tools is that contains a continuum of domains and can identify issues as diverse as fear 
of the future , anxiety family and financial issues relatively quickly in a busy routine 
outpatient clinic. The PCI can identify issues relating to FOR, fear of cancer spreading and 
fear about the future. Indeed, FOR has often been identified in studies as a common response 
and a prevalent unmet need [Kim et al (2008), Hodgkinson et al (2007), Deshields et al 
(2005), Cowley et al (2000)]. In this somewhat limited pilot study, ethnic backgrounds were 
not adequately represented. A larger study should be able to assess the needs of patients of 
varying cultural backgrounds. 
In cohort 2, 21% of patients selected breast appearance as an issue that they would like to 
discuss in the outpatient clinic. We must remember that the impact of issues related to 
treatment such as surgery, chemotherapy, and radiotherapy may result is significant levels of 
psychological symptoms. This is reflected in this before and after study and has been 
presented before by others. Fallowfield et al. (Fallowfield et al, 1986) found that the 
incidence of anxiety and/or depression was 33% in mastectomized patients and 38% in 
breast-conserved patients. 
Coping is an important determinant of adaptation to cancer and may be defined as the 
adaptation to a demanding situation (Tunks et al, 1988). Other definitions have been 
presented in the literature (Heim E, 1991). In our study 10% of patients selected coping as an 
issue. The PCI can identify coping as a concern but it there is no consensus of how best to 
deal with that group of patients. Several proposed coping strategies have been proposed and 
may be employed by the patients [Endler et al (1990), Singh et al (1985)]. The clinician may 
not be equipped to deal with that issue and the involvement of another expert from the MDT 
may be required. A coping strategy that often employed by cancer patients is talking to 
others, family and friends (18%). As seen in various studies, women approach their partners, 
close relatives, and friends as their informal helpers (Pistrang et al, 1992). This was not seen 
in this study and may explain the larger proportion of patients selecting this issue. It is can be 
concluded from table 25 (Appendix 1) that the PCI can identify a range of psychological 
issues that may be beyond the expertise of the breast cancer surgeon. 
The breast cancer specific PCI includes sexual functioning items and these are intimacy, 
relationships, and sex. It is of note that none of the patients in this part of the study selected 
any of these items as issues Table 25 (Appendix 1). The literature is clear in that sexual 
problems occur with significant frequency, and are present in women who do not undergo 
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mastectomy, as well as to those who have subsequent breast reconstruction [Ganz et al 
(1992), Broeckel et al (2002), Burwell et al (2006), Meyerowitz et al (1999), Rowland et al 
(2000), Taylor et al (2002), Yurek et al (2000)]. 
The lack of selected items as well as the lack of discussions in the clinic about sexual 
function issues may be due to several factors. From the clinician point of view despite the 
prevalence of sexuality and intimacy problems among large numbers of breast cancer 
survivors, few interventions have been developed specifically to address these issues 
[Newell et al (2002), Shell JA (2002)]. That may be one reason that clinician seem to be 
reluctant to explore that issue in clinic. Another reason may be that multidisciplinary teams 
may not have the expertise to deal with sexual functioning issues. This lack of selected items 
in that domain is reflected in the literature. Sbitti et al (2011) reported that 100% of patients 
in their study have never spoken with their doctor about sexual dysfunction issues following 
breast cancer (Sbitti et al, 2011). Clearly more research in the management of such issues 
may be of benefit and programs involving psycho-educational interventions should be 
supported (Rowland et al, 2009). 
The above discussion is based on the results obtained from a small number of 
patients.Unfortunately some of the predicted effects did not materialise. The most important 
outcome from this before and after study was derived from the analysis of the patient 
satisfaction questionnaire (Appendix 1, table 24). It appeared that the satisfaction was 
reduced after the introduction of the PCI. At present, this is difficult to explain; it may be 
that the PCI raised patient expectations of what their clinician could deal with. Of course, 
this may have not been possible because of lack of time in a busy NHS outpatient clinic, lack 
of expertise / training of the clinical team members. This has to be evaluated further is a 
study of bigger size. 
The evaluation of consultation duration, and any onward referrals made, revealed that 100% 
of patients wanted to see a breast surgeon. Currently, there is a supportive network of 
specialist breast-cancer nurses to deal with transient and less distressing issues in the current 
clinical setting. However, whenever an issue requires clinical intervention, an appointment is 
made with the breast surgeon. It is possible that this has introduced bias in this part of the 
study with the inclusion of patients that were told that they needed to see a breast surgeon. It 
is also well documented (Shell JA, 2002) that patients with an appointment in a consultant-
led breast clinic expect to see the consultant. A larger scale study may provide results that 
are more comprehensive. In addition, it appears that less items were discussed in cohort 2 of 
this study, and that the consultation duration did not increase compared to the non-PCI 
group. We must exercise caution in the interpretation of these results due to a possible 
selection bias and the limitations on internal validity that were imposed by compromises in 
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the study design. Nevertheless, the PCI appeared to result in a more focus consultation, with 
a better utilisation of the available time. 
A typical breast cancer follow-up clinic for surveillance provides an opportunity for patients 
and their doctors to address items of concern. In this clinic, a proportion of the appointment 
time involves patient–doctor discussions, where the range of issues discussed will vary 
according to individual patients. Usually the first part of the consultation involves the 
discussion of specific surveillance results from a mammogram or an ultrasound. Then 
specific issues may be elicited and discussed. All clinical appointments involve a patient 
physical examination that is taking place in different consultation room. This change in the 
set up involves time that sometimes in a busy clinic can at the expense of patient issues. 
Two out of the twenty-nine patients in the consultation talked about family bereavement and 
the effect on the psychological state. It appeared that the loss of a spouse in the one patient 
and the loss of a mother had a marked effect on the overall patient well-being. This can be 
correlated with published data. In two studies of breast cancer patients, less social support, 
greater precancer trauma history, and more stressful life events directly predicted higher 
levels of posttraumatic stress disorder symptoms and general distress [Andrykowski et al 
(1998), Green et al (2000)]. A range of mediating factors may further exacerbate or 
ameliorate the stress of cancer treatment, including social support, concurrent stressful life 
events, and comorbid conditions, lack of economic resources, and individual characteristics. 
Because of that, family bereavement is an item that should be consider for inclusion in the 
breast cancer specific PCI. The statuses of separated, divorced, or widowed also significantly 
increased the likelihood of patients becoming severely distressed. Previous studies that used 
community samples have established that being widowed, not married, or socially isolated 
were related significantly to shorter survival [Schaefer et al (1995), Goodwin et al (1987), 
Kornblith et al (2001)].The identification of these group of patients can benefit from simple 
interventions such as social support. Social support can directly influence adjustment 
through reassurance – i.e., by making patients feel greater control, and by knowing that 
others would be able to help them (Friedman et al, 2000). 
Another item that needs to be included in the breast cancer specific PCI is 'Skin changes '. 
4/29 patients attended the consultation and required further support with respect to erythema 
or what they described as a 'rash' on the skin around the skin area. The breast cancer specific 
PCI accounts for 'wound healing'. However, the skin changes were a frequent issue and seem 
to be related with the effects of radiotherapy. In a study by Hill-Kayser et al (Hill-Kayser et 
al, 2012) changes in texture and colour of irradiated skin were reported in 48% of women 
following treatment for breast cancer. Schnur et al (Schnur JB et al, 2011) concluded that 
skin toxicity affects numerous dimensions of QOL, and assessment approaches and 
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psychosocial interventions should address this. Inclusion of this item in the PCI would allow 
the development of specific approaches that may include education approaches participants' 
own creativity and problem solving. 
There are items on the PCI that were selected by the patients but were not discussed in the 
consultation, including 'Unable to go out and enjoy my family', memory /concentration, 
indigestion and mastectomy appearance. The first three are parameters often associated with 
chemotherapy and radiotherapy rather than surgery and hence the consultant surgeon 
considered appropriate to focus the consultation at aspects traditionally discussed in surgery. 
Mastectomy appearance may have been included under the umbrella of breast appearance 
and this may have been the reason of not including it in the discussion. 
Homeopathic medicine is an item that was brought up in the consultation but not marked by 
the patients. These may be an indication that clinicians try to incorporate all available 
options for patient care. From the patient point of view, this may be an indication that more 
information needs to be available to patients about options that are available in community 
rather than those limited in a tertiary service. 
It is of interest to note that items such as anxiety, breast appearance, fear about the future and 
fear of cancer coming back, scored highly in the items selected by the patients in the PCI. 
Some such as anxiety and breast appearance were adequately discussed in the consultation 
whilst items about fear of cancer coming back and coping with the disease or its treatment, 
were addressed significantly less. 
A significant variation is seen in the PCI items selected by the patients in the cross-sectional 
study (Figure 6) when compared to those selected by Cohort 2 (PCI cohort) in the before and 
after study (Figure 11). There may be several reasons for that variation. One may be that 
patients selected the PCI items at home in the cross-sectional study, where they are probably 
in a more comfortable and non-threatening environment, without the same time pressures 
experienced in a busy surgical clinic. Also, these patients did not come into contact with the 
clinician immediately afterwards. Thus, they y were less likely to feel embarrassed by the 
items selected. Additionally, variation may be related to the wording of the opening 
statement of the PCI, which prompted patients to choose the issues present at that moment in 
time only. The cross-sectional study included patients from more than one hospital that had 
treatment from more than one consultant. The before and after study included patients from 
one hospital that had treatment from a specific senior consultant. Thus, these results do not 
compare like with like, as several potential confounders changed between assessments. This 
specific result must therefore be interpreted with particular caution. 
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Conclusions 
 
This part of the study provided an insight in the use of the PCI in practice. It appears that 
introducing the PCI in a busy routine outpatient clinic is possible with no adverse practical 
difficulties. In addition, it provided relevant information that contributed to the further 
development of the PCI. New items such as bereavement, skins changes, and appearance 
were raised during the consultations and incorporated in the PCI. Appendix 2-V shows the 
final PCI. Future research needs to identify the specific question content, as well as how such 
content might be associated with satisfaction. 
Adequate assessment of needs and HRQOL may identify subgroups of breast cancer patients 
requiring better supportive care targeting. Modern clinical care is beginning to recognise the 
importance of the perspective of the patient in health care and more investigations are 
needed to understand the importance of the inter-relationships among health needs and 
patient satisfaction. 
Offering the breast cancer specific PCI online with high accessibility may result in patient 
motivation, and may provide skills that could promote self-management of specific issues. 
The breast cancer specific PCI may contribute to a generation of 'expert' patients with a 
favourable effect on their satisfaction and on National Health Service resources. 
The identification of pain as an unmet need in the PCI can stimulate research into its 
assessment and management, and hence could provide valuable knowledge of this neglected 
issue in cancer survivorship. 
With items related to pain, anxiety and depression the PCI may be the optimal strategy in 
order to identify and to tailor interventions targeting anxiety, depression, and pain among 
breast cancer patients. 
Coping with the disease or its treatment is an issue that it can be identified in the 
psychological state and emotional wellbeing domain of the PCI and includes a range of 
psychological issues that may be beyond the expertise of the breast cancer surgeon. 
The lack of selected items on the PCI as well as the lack of discussions in the clinic about 
sexual function issues may highlight inadequacies in the clinical team as well as the lack of 
effective interventions. Clinicians may use the PCI as a means to overcome established taboo 
subjects such as sexual functioning following breast cancer treatment. Specialist oncology 
nurses are best suited to offer support and guidance with respect to intimacy issues and can 
use the PCI as an icebreaker in order to overcome an embarrassing direct approach that may 
have a negative effect on the professional-clinician relationship. 
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This study evaluated the early experiences and impact of introducing the PCI into clinical 
practice in a cohort of one consultant’s clinic, where both doctor and patients were 
unfamiliar with the tool and this novel approach. This should be taken into account in the 
interpretation of the results. Further evaluation in the clinical setting would be essential in 
order to ensure that this evolving tool reaches stability. At present, it appears that the PCI is 
best utilized as an adjunctive tool that can be incorporated into consultations.  It has the very 
real potential to change the current clinical setting, with direct benefits to patient care. 
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CHAPTER 9. Further Development of a Breast Cancer Specific Patients 
Concerns Inventory with Input from the clinicians that used the PCI in the 
before and after study (phase 4) 
 
This chapter covers phase 4 of the study. This was the final part of the thesis, and involved 
gaining feedback from the consultant surgeon and the two specialist breast cancer nurses that 
used the breast cancer specific PCI in the before and after study (phase 3), in order to 
evaluate the Patient Concerns Inventory’s (PCI) practical usefulness in patient care. 
 
Aims 
 
To gain feedback from the consultant surgeon and the two specialist breast care nurses that 
used the PCI (phase 3) as to their experiences of using the PCI and its potential merit of use 
in the breast cancer setting. 
 
Materials and methods 
 
Qualitative semi-structured interviews took place in a breast cancer clinical setting and 
recorded the perceived advantages and disadvantages of the PCI and experiences of its use. 
One clinician and two specialist nurses who used the PCI were included in phase 4. They 
were a pragmatic convenience sample. Lines of questioning were based on the literature 
review and experience from the development of the Head and Neck PCI. The interviews 
were audio-recorded, and stored in keeping with General Medical Council guidance (GMC, 
2011). A professional medical transcription company transcribed the interviews and the 
transcripts were checked for accuracy against each recording.  
Ethical considerations 
Permission from the Leeds Central Research Ethics Committee was given to record the 
clinicians (12/YH/0215). 
Data analysis 
Content analysis of the interviews was performed using the questions as themes and involved 
the identification of the perceived advantages and disadvantages of the PCI based on their 
experiences (Miles et al, 1994). 
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Reliability  
To improve the reliability of the qualitative data analysis, a second skilled qualitative 
researcher, also assessed the transcripts. Themes and responses were then compared and 
discussed with agreement reached by consensus. 
 
Results 
 
This was a qualitative assessment, and relevant direct quotes are tabulated below that 
identify the advantages and perceived disadvantages of the PCI in breast cancer from the 
perspectives of the surgeon and clinical nurse specialists. Some concerns of using the PCI in 
breast cancer were identified but in the main, its use was seen as advantageous as reported 
below. 
 
Role of the PCI as perceived by the clinician: Interview with the breast cancer surgeon 
 
Question 1: What was your experience of the PCI use in the clinic? 
Response from clinician:  
“It is a very helpful way of trying to break down areas that patients often want to 
discuss. It has all the different complaints commonly seen in a breast cancer clinic. 
One issue that will need to be addressed is that it will need somebody to be available 
for help to complete the PCI especially ethnic minorities or for example people with 
dyslexia. Several language translations will be required in order for the PCI to be 
adapted in the area of Leeds” 
Question 2: Do you feel that the PCI affected your clinics for example in terms of 
duration?  
Response from clinician: 
“It is helpful for patients to have a chance to sit down and work out ahead of time 
what they would want to discuss. The hardest consultations as a clinician are the 
ones that it seems as though the patient has no concerns and as you wrapping up the 
consultation they bring out something else they would want to discuss and this can 
mean that the clinic does not run as smoothly as it might... I think what is useful with 
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this tool is that it gives the patient a chance to reflect on the journey and focus to 
what they would want to discuss with the clinician that immediate time. 
Having a written outline of issues is helpful to patients. Inevitably, it may make 
patients to select things that they would not otherwise going to discuss. Also, the 
referral pattern is helpful. For example cosmetic aspects... a consultation with a 
plastic surgeon may be more appropriate.” 
Questions 3: How about aspects of care, or issues that we as surgeons have difficulty 
talking about (for example intimacy and sexuality)?  
Response from clinician:  
“Of course the same applies to religious concerns. This is the area least documented 
in the clinical notes. The spiritual aspect of been a cancer patient is very rarely 
discussed. Unless somebody is active in faith themselves is very difficult to engage in 
the consultation. The PCI is another way that can be used to approach taboo aspects 
of the human nature. Some patients are hesitant to discuss sexual matters in the 
clinic. The primary function of the breast is for breast feeding and that has been 
overlooked in a way because of the sexualisation of the breast in the media. This tool 
helps to normalise talking about issues that perhaps as British people we are having 
difficulties to discuss, although how often the people would tick the box remains to 
be seen.” 
 
Role of the PCI as perceived by the breast care nurses 
 
Question: This is a tool designed for a holistic approach to patient management. Do 
you think that a tool like this will help your practice? 
 
Response from specialist nurse 1: 
“At present not enough funding is available for more breast cancer nurses. I think 
traditionally we rely very heavily on breast care nurse giving holistic support to 
patients as they go through the different stages of the journey. A tool like this is very 
helpful, it can be used in the same way as the Distress thermometer for example is a 
patient has concerns in multiple areas, clearly this patient needs more input not only 
from medical professionals of one form or another but from their designated breast 
cancer care. There are some patients that they are very good in expressing when 
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they need care, whereas there are others with issues that they do not tend to contact 
us and are living with a considerable level of anxiety...yet they go unnoticed. 
Clearly, any tool that can identify these patients will be very useful especially in the 
outpatient clinic where help is readily available. 
I have some concerns as to how this will work in clinic. A lot of our patients are 
elderly and they may not be in a position to fill the forms...they may feel upset ... they 
may feel that they will not get the right treatment ... and disadvantage. We have to be 
careful of how to use this in clinic. Completing this with a nurse can be an option 
but it is time consuming...there are not many of us, sometimes is difficult. This will 
add time to fill and time to deal with the issues ...especially if they have many” 
 
Response from specialist nurse 2: 
“This checklist can be useful to help patients remember any problems that may have. 
I have some concerns…one concern is that patients may become anxious if they see 
this list at the beginning of their treatment…they may worry… they may think that 
all these problems will come…may become unnecessary distressed. This list needs to 
be completed with support ... not alone at home. 
 
Another problem is that this list may raise the patients expectations…they may think 
that if their problem is there I could do something about it ... well I may be not … 
that if for different reasons, resources, busy clinic, staff away, lack of expertise, all 
these may be a problem rather than trying to help by identifying the issues… 
 
Other than that … sorry … I think this list will be helpful and it may result in 
extending the team with further experts such as a clinical psychologist, or can help 
us acquire further skills through further training … can result in a comprehensive 
package of care.” 
 
Discussion 
 
The consultant surgeon confirmed that the issues that have been included in the PCI are 
commonly seen in a breast cancer clinic, which supports and validates the phases 1 and 2 of 
its development and adaptation from the head and neck PCI (Rogers et al, 2009). The 
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description of the PCI as a tool that can help patients to reflect on the cancer journey and 
identify concerns that they would not otherwise discuss, may be a valid one but further 
research is required in order to verify it. The use of  different language translations will be of 
benefit and needs to be addressed in the further development of the breast cancer specific 
PCI.  
 The PCI may be used partly as 'written proof' in the clinical notes that items that 
traditionally are difficult to approach, such as religion, have been included in the 
consultation. Apart from that, the PCI may be an aid to communication as it may help to 
normalise talking about issues that patients may have difficulty to discuss. Further evaluation 
of this suggestion would be necessary in a larger scale clinical study.  
In the current financial climate, resources might be a limitation in the use of the PCI. The 
practical aspects of the PCI need to be taken into account and their perceived benefits need 
to be evaluated further against the cost of its introduction in a busy NHS clinic. 
It was expected that introducing a new intervention in a busy clinic would be difficult. This 
was partly due to the attitudes of clinic staff that the research may affect the timing of 
appointments, and hence patient care. Because of the nature of this before and after clinic 
and the fact that the PCI was completed whilst patients were waiting to see the clinician, 
there was no notable effect on the practicalities of running the clinic. In addition, clinicians 
appeared to be reluctant to have their consultations recorded. This has been the case in other 
studies using audio recordings of consultations (Tattersall et al, 2002). These issues were 
surpassed with organisation and gradual 'desensitisation' of the clinicians. At the start of the 
before and after study, only one patient was recorded, but that number was gradually 
increased, and the PCI was accepted into the clinic. 
The consultant involved ultimately accepted the PCI as a tool that could promote, co-
ordinate and provide high quality clinical care. Practitioners in a busy NHS practice would 
like their daily work to be easier, safer, and faster. Comments from the consultant and 
specialist nurses included that the PCI could make their work more efficient and accurate. 
Furthermore, the PCI could help them to anticipate, prevent, and solve clinical problems. 
In a resource driven environment, the co-ordination of clinical teams may not be an easy 
task. Some concerns were raised with the use of the PCI in an NHS clinic. In particular, it is 
a reality that clinicians may not be trained to deal with specific issues selected by a patient. 
This of course can be accommodated by referring patients to other members of the MDT, 
primary care, or voluntary organisations who have the necessary expertise. Factors such as 
this may have implications on funding as well as on teaching and training. The broader 
feasibility would need to be tested in studies that rolled out the Breast PCI across a number 
 144 
 
P
ag
e1
4
4
 
of organisations and clinics. By identifying patient concerns and managing them, could 
ultimately help with their condition, their experiences of services and satisfaction with care. 
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CHAPTER 10. Concluding remarks: the future scope and potential use of the 
Patient Concerns Inventory (PCI) and similar tools. 
 
Some practical difficulties were encountered during this study. The principal investigator 
was not part of the breast cancer surgical team. That created recruitment difficulties that 
were imposed by the Research Ethics Committee (REC).  
Following four meetings and presentation of the research protocols to the local REC, it was 
agreed that the clinical team should approach the patients initially for this study. This 
allowed a period of four weeks for every patient to decide whether they wished to participate 
in one of the four phases of this study. It is difficult to know the precise impact of this 
decision on this research. It may have affected the participation rate. On the other hand, it 
may have reduced potential investigator bias by not allowing an initial contact with the 
principal investigator.  
The methods section is an accurate reflection of the initial protocol. An aspect that was 
different was step 2 of phase 1. This had to be modified because of time constraints in 
consultant led National Health Service clinics. The impact of this was likely to be minimal, 
taking into account the interaction with clinicians during the third and fourth phase of this 
study. 
The development of the breast specific PCI was based on information generated by patients 
following diagnosis and treatment or during their treatment. For the PCI to be used during 
the pre-treatment phase it will need further development. 
Evaluation in the clinical setting will be required for the validation process of the PCI. The 
longitudinal effect needs to be assessed. It is possible that patients will stop pointing out 
issues in the PCI if these are consistently ignored or not resolved. This is a classical method 
of generating a persisting unmet need. 
During this work, several points with a direct effect on patient care were recognised. As 
clinical standards of care increase, expectations on the clinical team also increase. As an 
inevitable consequence, there is a clear need to develop a new set of skills for the proper 
provision of modern care. In addition, the National Health Service as an  organisation, is 
currently undergoing significant scrutiny in terms of cost effectiveness, with services in the 
secondary care sector being rationalised, and where possible being relocated to primary care 
settings. The breast cancer specific PCI has the potential to provide the multidisciplinary 
team (MDT) with a tool that could form part of the clinical framework that ensures 
appropriate, optimal, and accessible care. For example, it may be possible to provide a 
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username and password to all newly diagnosed patients with breast cancer; with minimal 
guidance these patients could use the PCI in their home environment, thereby ensuring 
continuous care and a ‘point of contact’ with the clinical team. The results from the PCI 
could then be directed electronically to a designated member of the extended team with the 
responsibility to triage and direct the patients to an appropriate member of the clinical team. 
The PCI may be of benefit if used by the clinician as an aid memoire in a busy outpatient 
clinic. This would ensure that the clinician includes all relevant or most common patient 
generated (and therefore of significance to the patient) issues in their consultations. 
The use of the PCI in a community setting could divert clinical services away from hospitals 
for transient and less significant symptoms that do not require specialist intervention. 
Properly trained in the use of the PCI, specialist primary care services could offer significant 
cost-savings compared with an approach that is based on the delivery of those same 
procedures being carried out in a consultant-led service. This would be of even greater 
significance in the putative consultant (or specialist based service). In order to ensure 
optimal clinical care provision, it is essential that consistency should also be assessed for 
quality assurance, and this may be incorporated into a PCI training programme. Equally, the 
PCI may be used in the primary care setting where the General Practitioner or community 
nurse could utilise the tool to identify issues, before communication with the relevant clinical 
team.  
The PCI may be the start of a model of care that has the ‘expert patient’ as the central figure. 
This would ensure that all key aspects of care are examined, and that those aspects are those 
that matter most to the individual patient. Only in this situation will any Health Service be 
able to deliver a truly tailored (patient centric) service that ensures patient satisfaction over 
their complex and uniquely individual cancer journey. This journey may be completely 
different to that which textbooks, training, and peer pressure lead clinicians to believe in. A 
patient centric evidence base may describe multiple diverse journeys, which intersect with 
the clinician and pathology led journey only at specific “hard” points. 
The overriding purpose of modern medical training is to create a competent clinician at 
specialist level who can provide core medical or surgical treatments, which meet the needs of 
their patient population. Sometimes there is an over-emphasis on clinical rather than 
communication or personal skills. A balance must be found between the anatomical, 
physiological, and pathological based cognitive and psychomotor skills and those based in 
the interpersonal and attitudinal domains. The PCI can be used as both a communication-
skills tool and a tool that focuses the consultation, thereby bridging this gap.   
 147 
 
P
ag
e1
4
7
 
The use of the PCI could aid the clinician in the identification and management of 
traditionally difficult issues, such as those related to social or sexual function. Some patients 
find the clinical setting intimidating and may not feel able to express their concerns to 
clinical staff regardless of attempts by those staff to appear open to enquiry despite attending 
regularly as part of their cancer surveillance program. Indeed, it may be because they are 
appearing in a “cancer clinic” where they are “glad to be alive” that they feel unable to 
engage. The PCI can help patients in this group to vocalise their concerns in multiple and 
varied environments with consistency, therefore ensuring that some concerns are not missed 
completely. 
The PCI encourages the interaction and use of the expertise of multiple teams that can 
collaboratively accommodate and resolve difficult clinical problems. Integrated care 
pathways describe, for a specific clinical condition, the tasks to be carried out together with 
the timing and sequence of these tasks and the discipline involved in completing the task 
(Baker J, 1996). Further research is needed to provide evidence that the incorporation of the 
breast cancer specific PCI in integrated care pathways can make a real clinical difference. 
There is a need to assess the presence of a relationship between PCI use, and a variety of 
measurable outcomes including patient recovery, physical function, and emotional health. 
Screening interventions are designed to identify disease in a community early, thus enabling 
earlier intervention. A screening tool for the identification of psycho-oncological treatment 
need in breast cancer patients has been developed (Meraner et al, 2009). However, this is 
only applicable to the psycho-oncological treatment need rather than to the range of issues 
that may be present in breast cancer patients. The breast cancer PCI includes a range of items 
that are part of validated health-related quality of life tools and has the potential to be used 
on its own. Further work will be essential in order to verify the ability of the PCI to be used 
as a screening tool on its own, or together with a health-related quality of life measure.  
Drawn from the experience of the breast cancer patients participating it appears that there are 
several issues that breast cancer patients would like to discuss. As clinicians, it seems we 
have a tendency to discuss the cancer and its treatment but these may not be what our 
patients want to discuss in an outpatient clinic. During this work, the principal investigator 
published papers related to the head and neck PCI and the details of these have been given in 
chapter 11. A direct comparison of the issues that patients would like to discuss in the head 
and neck and breast cancer clinics has been made (Kanatas et al, 2013). For 447 HNC 
patients, 8% (37) wanted to discuss ‘mood’, 13% (57) ‘anxiety’, 9% (41) ‘depression’, with 
one or more of these 20% (91). HNC patients wanted most (39%, 174) to discuss fear of 
recurrence. For 200 BC patients, 15% (30) wanted to discuss ‘mood’, 21% (41) ‘anxiety’, 
17% (33) ‘depression’, with one or more of these 35% (70). Also, 62% (124), wanted to 
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discuss fear of recurrence, 39% (78) fear of cancer spreading and 32% (63) fear about the 
future, with 72% (143) one or more of these. These are presented in detail, in Figures 13 and 
14 below.  
 
Figure 13 A typical PCI profile of issues patients wish to talk about in their consultation with their 
head and neck cancer consultant / doctor 
 (N=447 patients) H&N domains-Physical and functional well-being (GOLD), Treatment related 
(BLUE), Social care and well being (Yellow), Psychological, emotional, spiritual (GREEN), Others 
(GREY) 
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Figure 14 A typical PCI profile of issues patients wish to talk about in their consultation with their 
Breast cancer consultant / doctor   
 (N=200 patients) Breast Cancer domains-General Information (YELLOW), Body image (BLUE), 
Physical Functioning and health (GOLD), Psychological, emotional (GREEN), Sexual Functioning 
(GREY), Social functioning /Family related (PURPLE) 
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There is a range of items and there is variation between the two different types of cancers. 
Considering these variations there is scope for the development of the PCI for other cancer 
types as well as for chronic diseases such as diabetes and osteoarthritis. 
Finally, the PCI allows patients to tell us what they want to discuss, and facilitates 
collaborative care. Through the PCI, patients can communicate their concerns and needs as 
adults in partnership with the clinical team managing their illness, allowing for improved 
assistance in managing their cancer and its consequences. This is very much in keeping with 
the move away from paternalism within modern clinical practice and embracing the issues 
around survivorship in cancer. 
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CHAPTER 11. Research Dissemination  
 
This thesis provided the author with the opportunity to be involved in the preparation of a 
number of papers. Some of these papers were related to the use of the patient concerns  
inventory (PCI) as a tool in oncology in general, and some were directly related to the breast 
cancer specific PCI. Some of these papers have been published, or are in the process of 
publication in peer-reviewed journals. Details of these manuscripts are presented in 
Appendix 3.  
The papers related to the head and neck PCI in particular, gave the author the opportunity to 
gain valuable experience in the preparation of manuscripts, as well as in understanding the 
various research methods required. In addition, results were disseminated by other means, 
with parts of this research forming the basis for both oral and poster presentations at National 
and International meetings. This research also gave the opportunity for the author to gain a 
range of skills from interacting within diverse teams, to establishing valuable research 
networks.  
 
The literature review for the breast cancer specific PCI has been published and cited as 
follows: 
Kanatas A, Velikova G, Roe B, Horgan K, Ghazali N, Shaw RJ, Rogers SN. Patient-
reported outcomes in breast oncology: a review of validated outcome instruments. 
Tumori. 2012 Nov;98(6):678-88. 
 
The head and neck PCI related papers that have been published alongside this work include: 
Ghazali N, Kanatas A, Langley DJ, Scott B, Lowe D, Rogers SN. Treatment referral 
before and after the introduction of the Liverpool Patients Concerns Inventory (PCI) 
into routine head and neck oncology outpatient clinics. Support Care Cancer. 2011 
Nov;19(11):1879-86. 
Kanatas A, Ghazali N, Lowe D, Rogers SN. The identification of mood and anxiety 
concerns using the patients concerns inventory following head and neck cancer. Int J 
Oral Maxillofac Surg. 2012 Jan 18. [Epub ahead of print] 
Kanatas A, Ghazali N, Lowe D, Udberg M, Heseltine J, O'Mahony E, Rogers 
SN.Issues patients would like to discuss at their review consultation: variation by 
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early and late stage oral, oropharyngeal and laryngeal subsites. Eur Arch 
Otorhinolaryngol. 2013 Mar;270(3):1067-74. 
Ghazali N, Kanatas A, Scott B, Lowe D, Zuydam A, Rogers SN. Use of the Patient 
Concerns Inventory to identify speech and swallowing concerns following treatment 
for oral and oropharyngeal cancer. J Laryngol Otol. 2012 Aug;126(8):800-8. 
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Table 1 (Chapter 4): Appraisal of the psychometric and operational performance of the 
instruments: inclusion criteria [Fitzpatrick et al (1998), Fitzpatrick et al (2006)  
 
 
 Validity  
 Reliability (includes internal consistency and test-re-test reliability 
 Responsiveness 
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Table 2 (Chapter 4): Psychometric Qualities of the instruments included in this study  
 
 
 BC
Q 
EORT
C 
QOL-
BR23 
EORT
C 
QOL 
C30 
FACT
-B 
FACT
-ES 
BIBCQ Polivy 
BIS 
Hopwoo
d BIS 
Validity + + + BR23 
module 
+ + +  + 
Reliability 
(includes 
internal 
consistency 
and test-re-
test reliability 
+ + + + + + - + 
Responsivenes
s to change 
+ No 
evidenc
e in 
favour 
+ + + No 
evidenc
e in 
favour 
No 
evidenc
e in 
favour 
No 
evidence 
in favour 
 
 BCTO
S 
MAS BREAS
T-Q 
MBRO
S-S 
MBRO
S-BI 
SLDS-
BC 
BCPT 
Validity +  +  +   
Reliability 
(includes 
internal 
consistency 
and test-re-
test 
reliability 
+  + + + + + 
Responsivene
ss to change 
No 
evidenc
e in 
favour 
No 
evidenc
e in 
favour 
+ No 
evidence 
in 
favour 
+ No 
evidenc
e in 
favour 
No 
evidenc
e in 
favour 
 
(The ‘+’ sign indicates that there are evidence that the specific property has been assessed)  
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Table 3 (chapter 4):  Breast cancer-specific quality of life instruments. All these 
instruments satisfied the inclusion criteria. 
 
Measure 
and 
authors 
Purpose Domains Scale 
 
No. 
of 
item
s 
Reliability 
 
Validity 
 
 
1 
 
 
Breast 
Cancer 
Chemother
apy 
Questionna
ire 
(BCQ)  
 
Levine et 
al (1988) 
 
Developed 
to measure 
outcomes of 
women with 
stage II 
breast cancer 
receiving 
adjuvant 
chemotherap
y 
 
Seven 
domains: 
Consequences 
of hair loss; 
emotional 
dysfunction; 
physical 
symptoms; 
trouble and 
inconvenience 
associated 
with 
treatment; 
fatigue; 
nausea; 
positive well-
being 
 
Seven 
point 
Likert 
scale 
ranging in 
responses 
 
30 
 
Internal 
consistency 
ranging from 
.89 to .91 
 
Correlation 
coefficients 
between 
BCQ and 
Spitzer QL-
Index was 
.62 
 
2 
 
European 
Organizati
on for 
Research 
and 
Treatment 
of Cancer 
QOL 
Breast 
Cancer 
Specific 
Version  
(EORTC 
QLQ-
BR23) 
Sprangers                     
et al 
(1996) 
 
Designed to 
measure 
QOL in the 
breast cancer 
population at 
various 
stages and 
with patients 
with 
differing 
modalities 
 
Five domains: 
Therapy side 
effects; arm 
symptoms; 
breast 
symptoms; 
body image; 
sexual 
functioning 
 
Four point 
Likert 
scale 
ranging 
from 1 
(Not at all) 
to 4 (Very 
much) 
 
23 
 
Reliabilities 
ranged from 
.70 to .91  
 
Discriminant 
validity of 
mutually 
exclusive 
groups based 
on their 
initial 
performance 
status scores 
produced 
medium to 
large effect 
sizes ranging 
from .43 to 
1.1 
 
3 
 
European 
Organizati
on for 
Research 
and 
Treatment 
of Cancer 
QOL 
Cancer 
Specific 
Version 
(EORTC 
QLQ-C30)  
Aaronson 
et al 
(1993) 
 
Cancer 
specific 
questionnair
e designed to 
measure 
QOL in the 
cancer 
population 
 
Nine domains: 
Physical; role, 
cognitive; 
emotional; 
social; fatigue; 
pain; nausea 
and vomiting; 
global health 
status and 
quality of life 
 
Four point 
Likert 
scale 
ranging 
from 1 
(Not at all) 
to 4 (Very 
much); 1 
(Very 
poor) to 7 
(Excellent) 
 
30 
 
Reliabilities 
ranged from 
.69 to .90.[14]  
Test-retest 
reliabilities 
ranged from 
.63 to .87  
 
 
Correlation 
coefficient 
between the 
QLQ-C30 
and the 
Profile of 
Mood States 
(POMS) was 
.56 [16].  
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4 
 
Functional 
Assessmen
t of Cancer 
Therapy – 
Breast 
Symptom 
Index 
(FACT-B) 
[19] 
Brady et 
al (1997) 
 
Specific to 
breast cancer 
patients 
 
Six domains:  
Physical well-
being; 
social/family 
well-being; 
emotional 
well-being; 
functional 
well-being; 
relationship 
with doctor; 
additional 
concerns 
 
Five point 
Likert 
scale 
ranging 
from 0 
(Not at all) 
to 4 (Very 
much) 
 
37 
 
Internal 
consistency 
was .90 
 
Spearman 
correlations 
between 
FBSI and 
FACT 
ranged from 
.34 to .84 
 
5 
 
Functional 
Assessmen
t of Cancer 
Therapy – 
Endocrine 
System  
(FACT-
ES) [20] 
Fallowfiel
d et al 
(1999) 
 
Focus on 
endocrine 
concerns 
experienced 
during breast 
cancer 
treatment 
 
One domain: 
Endocrine 
concerns 
 
Five point 
Likert 
scale 
ranging 
from 0 
(Not at all) 
to 4 (Very 
much) and 
comprises 
a total 
score 
 
18 
 
Internal 
consistency 
was .79 
Test-retest 
reliability was 
.93 
 
Discriminant 
validity of 
known 
groups 
comparing 
adjuvant 
chemotherap
y and those 
without any 
endocrine 
therapy 
produced a 
significant t 
score with 
the adjuvant 
chemotherap
y group 
experiencing 
more 
endocrine 
symptoms 
than the non-
endocrine 
therapy 
group 
6 BIBCQ 
(Body 
Image after 
Breast 
Cancer 
Questionna
ire) 
Baxter et 
al (2006) 
Designed to 
assesses 
the long-
term impact 
of breast 
cancer on 
body 
image. 
There are six 
domains: 
vulnerability, 
body 
stigma, 
limitations, 
body 
concerns, 
transparency, 
and 
arm concerns 
 53 Good 
reliability was 
found for the 
six scales 
(ranging from 
0.77 to 0.87). 
The BIBCQ 
distinguished 
between 
women 
treated with 
lumpectomy 
and 
mastectomy, 
and between 
women with 
breast cancer 
and a control 
group, 
supporting 
the validity 
of the 
BIBCQ 
7 Polivy BIS 
(Body 
Image 
Scale) 
Polivy 
(1977) 
Design to 
measure an 
individual's 
satisfaction 
with various 
body parts. 
Measures 
the 
psychologica
l effects of 
It covers three 
domains: body 
image, self-
concept, and 
feelings of 
satisfaction 
with 
intimate 
relationships 
6-point 
Likert-type 
scale 
ranging 
from (1) 
very 
dissatisfied 
to (6) very 
satisfied 
13-
item 
Psychometric 
analysis 
showed 
adequate  
reliability 
The scale 
demonstrated 
criterion-
related, 
convergent, 
and construct 
validity as 
indicated by 
its 
correlation 
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mastectomy 
on 
breast cancer 
patients 
with the 
Body Image 
Visual 
Analogue 
Scale (r = 
.78, p < .001) 
8 Hopwood 
BIS (Body 
Image 
Scale) 
Hopwood 
et al 
(2001) 
Designed for 
assessing 
body image 
changes in 
patients with 
cancer, 
suitable for 
use in 
clinical 
trials. 
  10-
item 
The scale 
showed high 
reliability 
(Cronbach's 
alpha 0.93) 
Good 
clinical 
validity 
based on 
response 
prevalence, 
discriminant 
validity 
(P<0.0001, 
Mann–
Whitney 
test) 
9 BCTOS 
(Breast 
Cancer 
Treatment 
Outcome 
Scale) 
Stanton et 
al (2001) 
The BCTOS 
was 
designed to 
assess 
women’s 
subjective 
evaluation of 
the aesthetic 
and 
functional 
outcome 
after breast 
cancer 
treatment. 
Three domains 
included 
functional 
status, 
cosmetic 
status and 
breast-specfiic 
pain 
The 22 
items lead 
to the 
subscales. 
The 
Aesthetic 
Status 
subscale 
consists of 
7 items. 
The patient 
rates these 
items 
according 
to 
symmetry 
between 
treated and 
untreated 
breast on a 
4-point 
Likert 
scale  
22 
item
s 
Developed 
from literature 
review and 
expert opinion 
alone, the 
BCTOS also 
underwent 
psychometric 
analyses that 
showed 
adequate 
internal 
consistency 
(Cronbach’s 
alpha 0.81–
0.91) 
There was no 
comparison 
with other 
patient 
reported 
outcome 
measures 
10 MAS 
(Mastecto
my 
Attitude 
Scale) 
Feather et 
al (1988) 
Designed to 
assess 
the attitudes 
and 
expectations 
of post-
mastectomy 
breast cancer 
patients 
regarding 
adjustment 
to 
mastectomy 
 4-point 
Likert 
scale 
33-
item 
Reliability of 
the knowledge 
assessment 
tool was 
analyzed by 
calculating the 
coefficient 
alpha for those 
who 
responded to 
all 36 
questions (N = 
326). The 
coefficient 
alpha 
was 0.61 
 
11 Breast-Q 
Pusic et al 
(2009) 
Measures 
satisfaction 
and surgery-
related 
quality of 
life in 
patients 
undergoing 
mastectomy 
with and 
A conceptual 
model for the 
impact of 
breast surgery 
was developed 
with scales 
that examine: 
(1) 
psychosocial 
well-being, (2) 
Summary 
scores 
ranging 
from 0 
(very 
dissatisfied
) to 100 
(very 
satisfied) 
7 Test-retest 
reliability, as 
measured by 
intraclass 
correlation 
coefficients, 
ranged from 
0.85 to 0.98. 
Validation 
studies 
examining 
convergent 
and 
discriminant 
validity of 
the new 
measure 
relative to 
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without 
reconstructio
n 
physical 
wellbeing, 
(3) sexual 
well-being, (4) 
satisfaction 
with 
breasts, (5) 
satisfaction 
with overall 
outcome and 
(6) 
satisfaction 
with care. 
for each 
scale 
multiple 
existing 
measures 
have recently 
been 
completed  
12 MBROS-S 
(Michigan 
Breast 
Reconstruc
tion 
Outcomes 
study-
Satisfactio
n 
questionnai
re) 
Alderman 
et al 
(2000) 
Designed to 
assesses 
patient 
satisfaction 
after 
breast 
reconstructio
n 
Factor 
analysis was 
used to group 
the 7 items 
into 2 domains 
measuring 
General 
Satisfaction (5 
items) and 
Aesthetic 
Satisfaction 
(2 items) 
 7 Cronbach’s 
alpha was not 
calculated. 
 
13 MBROS-
BI 
(Michigan 
Breast 
Reconstruc
tion 
Outcomes 
study-
Body 
Image 
questionnai
re) 
Wilkins et 
al (2000) 
Designed to 
evaluate 
patient 
perceptions 
of physical 
appearance 
after 
breast 
reconstructio
n 
  9 Cronbach’s 
alpha 
was found to 
be 0.89, 
indicating 
adequate 
internal 
consistency 
for the single 
construct of 
body image 
 
14 SLDS-BC 
(The 
Satisfactio
n with Life 
Domains 
Scale for 
Breast 
Cancer) 
Spagnola 
et al 
(2003) 
Developed 
to measure 
satifaction 
with life 
among 
breast cancer 
patients 
Five domains: 
Social 
functioning; 
appearance; 
physical 
functioning; 
communicatio
n with medical 
providers; 
spirituality 
Seven 
point 
Likert-type 
scale 
ranging 
from 1 (A 
“delighted
” face) to 7 
(A “very 
unhappy” 
face 
32 Reliabilities 
ranged from 
.90 to .93 
Correlation 
coefficient 
between 
SLDS-BC 
and FACT-B 
was .59 
  15                          
(BCPT) 
Breast 
Cancer 
Prevention 
Trial 
Symptom 
Checklist 
Questionnair
e designed to 
examine the 
physical and 
psychologica
l symptoms 
associated 
with 
menopause 
and 
Tamoxifen 
usage 
8 symptoms 
(Hot flashes, 
nausea, 
bladder 
control, 
vaginal 
problems, 
musculoskelet
al pain, 
cognitive 
problems, 
weight 
problems, and 
arm 
problems). 
  
 
43  
Hot flashes = 
0.83, nausea = 
0.65, bladder 
control = 0.73, 
vaginal problems 
= 0.79, 
musculoskeletal 
pain = 0.82, 
cognitive 
problems = 0.85, 
weight problems = 
0.59, arm 
problems = 0.72. 
 
 
 Content & 
Face 
Validity – 
Formulated 
by adapting 
items from 
existing 
questionnaire
s of 
menopausal 
symptoms 
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Table 4 (Chapter 5): Domain groups obtained from the literature 
8. Global Quality of Life domains 
9. Body Image-related domains 
10. Physical Functioning and health-related domains 
11. Psychological state and emotional well being-related domains 
12. Sexual Functioning 
       6.    Social Functioning/ Family-related domains 
 
 
 
Table 5 (Chapter 5): Number of specific items obtained from the literature review 
1. Global Quality of Life domains-10 
2. Body Image-related domains-54 
3. Physical Functioning and health-related domains-49 
4. Psychological state and emotional well being-related domains-25 
5. Sexual Functioning-8 
       6.    Social Functioning/ Family-related domains-18 
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Table 6 (Chapter 5): Breast Cancer Specific Patients Concern Inventory-Version 1 
Following reduction process from Literature Review - grouped alphabetically 
 
If you were to attend a clinical consultation today which of the following concerns would 
you wish to discuss with your Breast specialist / Consultant doctor 
 Activity 
 Angry 
 Anxiety 
 Appearance  
 Appetite 
 Arm swelling 
 Bowel Habit (Diarrhoea or constipation) 
 Breathing 
 Breast texture 
 Breast appearance 
 Breast sensitivity /Breast pain 
 Breast Prosthesis / Padding 
 Cancer Treatment 
 Carer 
 Coping 
 Dependants /Children 
 Depression 
 Dry mouth 
 Energy Levels 
 Fatigue / Tiredness 
 Fear of Cancer coming back 
 Fear of Cancer spreading 
 Financial issues 
 Hair loss 
 Hair replacement 
 Home care / district nurse support 
 Indigestion 
 Information about Breast Cancer  
 Information about personal hygiene 
 Intimacy 
 Lifestyle (smoking/ alcohol) 
 Memory/ Concentration 
 Mobility 
 Mood 
 Nausea 
 Pain in the Breast 
 Pain in the arm or shoulder 
 Pain elsewhere 
 Relationships 
 Self esteem 
 Sex 
 Sleeping 
 Speech 
 Spiritual / Religious aspects 
 Support for my family 
 Swallowing 
 Taste 
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 Temperament and personality 
 Vomiting / Sickness 
 Weight 
 Wound healing / Mastectomy appearance 
 Other 
 
If  you were to attend a clinical consultation today which of the following members of staff 
would you like to see or be referred on to: 
 Oncoplastic Breast surgeon 
 Breast Care Nurse 
 Clinical Oncologist 
 Chaplain 
 Clinical Psychologist 
 Dietician 
 Family doctor 
 Lymphoedema specialist 
 Medical Geneticist 
 Medical Oncologist 
 Medical Prosthetic 
 Nurse Practitioner 
 Occupational Therapist 
 Palliative Care Team 
 Research Nurse 
 Social worker 
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Table 7 (Chapter 6): The PCI type tool following the input from the focus groups 
 
If you were to attend a clinical consultation today which of the following concerns would 
you wish to discuss with your Breast specialist:  
 
 Activity (Information about exercise; returning to my daily routine) 
 Angry (why me?, why this treatment) 
 Anxiety 
 Appearance (overall physical appearance; breast appearance) 
 Appetite 
 Arm swelling 
 Bowel Habit (Diarrhoea or constipation) 
 Breast texture 
 Breast sensitivity /Breast pain 
 Breast Prosthesis / Padding 
 Cancer Treatment 
 Coping (coping with the disease, the treatment or the side effects of treatment) 
 Depression 
 Sore mouth 
 Fatigue / Tiredness (Low energy levels overall) 
 Fear of Cancer coming back 
 Fear of Cancer spreading 
 Financial issues 
 Hair loss 
 Hair replacement 
 Home care / district nurse support  
 Indigestion 
 Information about Breast Cancer  
 Information about personal hygiene 
 Intimacy 
 Lifestyle (smoking/ alcohol) 
 Memory/ Concentration 
 Mobility 
 Mood 
 Nausea 
 Pain in the Breast 
 Pain in the arm or shoulder 
 Pain elsewhere 
 Self esteem 
 Sex 
 Sleeping 
 Spiritual / Religious aspects 
 Support for my family 
 Swallowing 
 Taste 
 Temperament and personality 
 Vomiting / Sickness 
 Weight 
 Wound healing / Mastectomy appearance 
 Other, please state 
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If  you were to attend a clinical consultation today which of the following members of staff 
would you like to see or be referred on to: 
 
 Breast surgeon (He or she will perform the biopsy of the breast tumour and the   
 lumpectomy or mastectomy) 
 Plastic surgeon ( This doctor performs your breast reconstruction) 
 Medical oncologist ( This specialist administers anticancer drugs or chemotherapy) 
 Radiation oncologist ( He or she administers radiation therapy) 
 Breast Care Nurse  
 Chaplain 
 Psychologist (He or she may help with anxiety /depression) 
 Dietician 
 Lymphoedema specialist /clinic 
 Hair prosthesis / Breast prosthesis expert 
 Nurse Practitioner (Person that removed fluid from my operation site) 
 Pain specialist 
 District Nurse 
 My own doctor (General Practitioner) 
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Table 8 (Chapter 6): PCI items following consultation with National breast cancer 
bodies and clinicians 
 
 
Patients who have had breast cancer usually report issues in the following areas. If you 
were to attend a clinical consultation today which of the following issues would you wish 
to discuss with your Breast specialist  
1. General Information 
□ Activity (Conflicting information about exercise; unable to do exercise or 
problems returning to my daily routine) 
□ Information about Breast Cancer (Unable to get or unable to understand) 
□ Information about personal hygiene (May be related to breast prosthesis 
or wig) 
□ Lifestyle (Smoking/ alcohol-started or unable to stop) 
□ Complementary /Homeopathic Medicines (Problems with or unable to get        
information about) 
□ Fertility issues following treatment (Problems with or unable to get 
information about) 
2. Body Image-related  
□ Appearance (Overall physical appearance) 
□ Arm appearance  
□ Breast appearance 
□ Breast Prosthesis / Padding 
□ Hair loss 
□ Hair replacement (wig) 
□ Weight (Unable to control my weight) 
□ Wound healing (Scar appearance)  
□  Mastectomy appearance 
3. Physical Functioning and health-related  
□ Appetite 
□ Arm swelling (Lymphoedema) 
□ Diarrhoea  
□          Constipation 
□ Breast texture 
□ Breast sensitivity /Breast pain 
□ Cancer Treatment 
□ Sore mouth / Dry Mouth 
□ Fatigue / Tiredness (Low energy levels overall) 
□ Indigestion 
□ Memory/ Concentration 
□ Nausea 
□ Pain in the Breast 
□ Pain in the arm or shoulder 
□ Pain elsewhere 
□ Sleeping 
□ Swallowing 
□ Taste 
□ Vomiting / Sickness 
□ Hot Flushes 
4. Psychological state and emotional well being-related  
□ Angry (why me?, why this treatment) 
□ Anxiety (Related to the diagnosis or treatment) 
□ Coping (coping with the disease, the treatment or the side effects of 
treatment) 
Breast Cancer Specific Patients Concern Inventory-56 items 
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□ Depression 
□ Fear of Cancer coming back 
□ Fear of Cancer spreading 
□ Mood 
□ Self esteem 
□ Temperament and personality 
□ Fear about the future 
5. Sexual Functioning 
□ Intimacy 
□ Relationships 
□ Sex 
6. Social Functioning/ Family-related 
□ Financial issues 
□ Home care / district nurse support  
□ Mobility 
□ Spiritual / Religious aspects 
□ Support for my family 
□ Worried about the future of my children 
□ Unable to go out and enjoy my family 
□ Unable to go to go to work 
7. □        Other, please state 
.................................................................................................................. 
 
 
If you were to attend a clinical consultation today which of the following members of staff 
would you like to see or be referred on to: 
□ Breast surgeon (He or she will perform the biopsy of the breast tumour and the 
lumpectomy or mastectomy) 
□          Plastic surgeon (This doctor performs your breast reconstruction) 
□          Medical oncologist (This specialist administers anticancer drugs or chemotherapy) 
□          Radiation oncologist (He or she administers radiation therapy) 
□ Breast Care Nurse  
□ Chaplain 
□ Psychologist (He or she may help with anxiety /depression) 
□ Dietician 
□ Lymphoedema specialist /clinic 
□ Hair prosthesis (wig advisor) / Breast prosthesis expert 
□ Nurse Practitioner (Person that removed fluid from my operation site) 
□          Pain specialist 
□          District Nurse 
□          My own doctor (General Practitioner) 
□ Complementary therapies 
 
 
 
Referral Options at consultation: 
 203 
 
P
ag
e2
0
3
 
Table 9 (Chapter 7): Clinical/personal characteristics and survey response 
 
     
  % 
Response 
Patients 
P value* 
Age <50 79 38/48 
0.02 
 50-9 86 64/74 
 60-9 85 63/74 
 70+ 65 34/52 
Gender Female 80 198/247 
Na 
 Male 100 2/2 
IMD deprivation: living in 
area that 
No 80 148/186 
0.40 excl NK 
 is one of the  20% most 
deprived  
Yes 73 30/41 
 Not known 100 22/22  
Year of most recent diagnosis 2009/2010 83 108/130 
0.04 excl NK 
 2011/2012 71 61/86 
 Not known 94 31/33  
Location Leeds 77 113/146  
 Wakefield 82 64/78 0.21 
 Other 92 23/25  
Extent of disease: Primary  
Local 
No 91 99/109 
<0.001 
 Yes 72 101/140 
Extent of disease: Local 
recurrent 
No 80 197/245 
0.59 
 Yes 75 ¾ 
Extent of disease: Metastatic No 81 191/237 
0.71 
 Yes 75 9/12 
Extent of disease: Living with 
cancer 
No 81 192/237 
0.26 
 Yes 67 8/12 
Treatment (known for 
242/249) 
    
Chemotherapy  No 81 100/123 
0.63 
 Yes 78 93/119 
Radiotherapy  No 70 67/96 
0.003 
 Yes 86 126/146 
Wide local excision 
/lumpectomy 
No 78 100/128 
0.53 
 Yes 82 93/114 
Mastectomy No 79 105/133 
0.75 
 Yes 81 88/109 
Reconstructive surgery No 78 168/216 
0.04 
 Yes 96 25/26 
Anti-oestrogen therapy** No/NK 87 111/128 
0.006 
 Yes 72 82/114 
Other treatment: ** No/NK 79 176/224 
0.13 
 Yes 94 17/18 
*Fishers exact test or chi-squared test as appropriate  
** Anti-oestrogen therapy included: tamoxifen, letrozole, anastrozole, aromasin, arimidex, 
exemestane;  
Other treatment included :Herceptin, lepatinib, trastuzumab, neratinib. 
 204 
 
Table 10 (Chapter 7-A): Clinical/personal characteristics and number of PCI ite 
 
   
% of 200 patients selecting one or more items within domain 
Median (IQR) of 
total number of 
PCI items 
selected 
Median (IQR) of total 
number of health 
professional staff 
selected 
  
Number 
of patients 
General 
information 
Body 
image 
related 
Physical 
functioning and 
health-related 
Psychological state 
and emotional 
wellbeing 
Sexual 
functioning 
Social 
functioning / 
family related 
  
All patients Total 200 51% (102) 68% 
(136) 
87% (173) 83% (167) 24% (49) 35% (70) 8 (5-13) 2 (1-4) 
Age <50 38 66% (25) 71% (27) 82% (31) 92% (35) 45% (17) 45% (17) 12 (5-17) 2 (1-4) 
 50-9 64 45% (29) 73% (47) 88% (56) 89% (57) 27% (17) 39% (25) 7 (5-12) 2 (1-3) 
 60-9 63 57% (36) 63% (40) 90% (57) 81% (51) 21% (13) 37% (23) 8 (4-12) 2 (1-4) 
 70+ 34 35% (12) 62% (21) 82% (28) 68% (23) 6% (2) 15% (5) 6 (2-10) 1 (1-3) 
IMD deprivation: living 
in area that 
No 148 52% (77) 72% 
(106) 
90% (133) 82% (122) 29% (43) 34% (50) 8 (5-14) 2 (1-4) 
 is one of the  20% most 
deprived  
Yes 30 50% (15) 63% (19) 80% (24) 83% (25) 10% (3) 47% (14) 6 (4-11) 2 (1-3) 
 Not 
known 
22 45% (10) 50% (11) 73% (16) 91% (20) 14% (3) 27% (6) 6 (1-12) 2 (1-3) 
Year of most recent 
diagnosis 
2009/2010 108 58% (63) 66% (71) 87% (94) 85% (92) 26% (28) 35% (38) 8 (5-15) 2 (1-4) 
 2011/2012 61 39% (24) 70% (43) 89% (54) 84% (51) 25% (15) 36% (22) 8 (4-12) 2 (1-3) 
 Not 
known 
31 48% (15) 71% (22) 81% (25) 77% (24) 19% (6) 32% (10) 6 (4-12) 2 (1-3) 
Location Leeds 113 58% (66) 71% (80) 87% (98) 82% (93) 23% (26) 36% (41) 8 (5-15) 2 (1-4) 
 Wakefield 64 39% (25) 67% (43) 88% (56) 86% (55) 28% (18) 36% (23) 7 (3-12) 2 (1-3) 
 Other 23 48% (11) 57% (13) 83% (19) 83% (19) 22% (5) 26% (6) 6 (3-12) 1 (1-3) 
Extent of disease: 
Primary  Local 
Yes 101 45% (45) 67% (68) 86% (87) 78% (79) 23% (23) 34% (34) 7 (3-12) 2 (1-3) 
 No 99 58% (57) 69% (68) 87% (86) 89% (88) 26% (26) 36% (36) 8 (6-15) 2 (1-4) 
Extent of disease: Local 
recurrent 
Yes 3 67% (2) 100% (3) 67% (2) 100% (3) 67% (2) 100% (3) 15 (-) 2 (-) 
 No 197 51% (100) 68% 
(133) 
87% (171) 83% (164) 24% (47) 34% (67) 7 (5-13) 2 (1-4) 
Extent of disease: 
Metastatic 
Yes 9 56% (5) 67% (6) 100% (9) 100% (9) 33% (3) 44% (4) 8 (-) 2 (-) 
 No 191 51% (97) 68% 
(130) 
86% (164) 83% (158) 24% (46) 35% (66) 7 (4-13) 2 (1-4) 
Extent of disease: Living 
with cancer 
Yes 8 50% (4) 63% (5) 100% (8) 88% (7) 13% (1) 38% (3) 6 (-) 2 (-) 
 No 192 51 (98) 68 (131) 86% (165) 83% (160) 25% (48) 35% (67) 8 (4-13) 2 (1-4) 
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Chemotherapy Yes 93 51% (47) 77% (72) 88% (82) 88% (82) 31% (29) 37% (34) 8 (5-16) 2 (1-4) 
 No 100  51% (51) 60% (60) 85% (85) 79% (79) 19% (19) 33% (33) 7 (4-11) 2 (1-3) 
Radiotherapy Yes 126 55% (69) 66% (83) 88% (111) 83% (104) 26% (33) 35% (44) 8 (5-13) 2 (1-4) 
 No 67 43% (29) 73% (49) 84% (56) 85% (57) 22% (15) 34% (23) 6 (3-13) 2 (1-3) 
Wide local 
excision/Lumpectomy 
Yes 93 53% (49) 59% (55) 86% (80) 83% (77) 22% (20) 37% (34) 8 (4-13) 2 (1-3) 
 No 100 49% (49) 77% (77) 87% (87) 84% (84) 28% (28) 33% (33) 7 (5-14) 2 (1-4) 
Mastectomy Yes 88 52% (46) 83% (73) 86% (76) 86% (76) 32% (28) 40% (35) 9 (6-17) 2 (1-4) 
 No 105 50% (52) 56% (59) 87% (91) 81% (85) 19% (20) 30% (32) 7 (4-12) 2 (1-3) 
Reconstructive surgery Yes 25 72% (18) 84% (21) 88% (22) 96% (24) 40% (10) 48% (12) 11 (7-17) 3 (2-5) 
 No 168 48% (80) 66% 
(111) 
86% (145) 82% (137) 23% (38) 33% (55) 7 (4-13) 2 (1-3) 
Anti-oestrogen 
therapy** 
Yes 82 38% (31) 68% (56) 87% (71) 83% (68) 24% (20) 33% (27) 7 (3-11) 2 (1-3) 
 No 111 60% (67) 68% (76) 86% (96) 84% (93) 25% (28) 36% (40) 8 (5-16) 2 (1-4) 
Other therapy** Yes 17 59% (10) 59% (10) 71% (12) 82% (14) 41% (7) 35% (6) 8 (2-18) 2 (1-5) 
 No 176 50% (88) 69% 
(122) 
88% (155) 84% (147) 23% (41) 35% (61) 7 (5-12) 2 (1-4) 
*Mann-Whitney (2 group comparison) or Kruskall-Wallis test (>2 group comparison) as appropriate using the full distribution of number of items selected, apart from age for which Spearman 
correlation methods were used. Missing data categories were excluded from the significance tests. Tests for extent of disease and treatment were tested against the absence of each, results of 
which are not shown. Results were displayed within domains as % with one or more item selected for convenience of presentation - the use of Fishers Exact test or chi-squared test as appropriate 
with these statistics did not add any further statistically significant results at P<0.01.  P values: P <0.001 (yellow highlight), 0.001≤P<0.01 (blue highlight), 0.01≤P<0.05 (grey highlight) 
** see footnote to Table 1  
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Table 11 (chapter 7-A):  Correlations (at P<0.001) between number of PCI items / staff 
selected and summary scores from the EORTC QLQ-C30 and EORTC breast cancer 
module QLQ-BR23 
 
PCI items / staff EORTC 
Correlation 
coefficient* 
General information C30 Cognitive functioning -0.25 
Body image-related BR23 Body image -0.34 
Body image-related BR23 Systemic therapy side 
effects 
0.32 
Body image-related C30 Fatigue 0.29 
Body image-related C30 Insomnia 0.26 
Body image-related BR23 Arm symptoms 0.26 
Body image-related C30 Cognitive functioning -0.25 
Body image-related C30 Social functioning -0.25 
Physical functioning and health-related BR23 Systemic therapy side 
effects 
0.53 
Physical functioning and health-related C30 Fatigue 0.45 
Physical functioning and health-related C30 Insomnia 0.39 
Physical functioning and health-related BR23 Arm symptoms 0.37 
Physical functioning and health-related C30 Cognitive functioning -0.37 
Physical functioning and health-related C30 Physical functioning -0.35 
Physical functioning and health-related C30 Pain 0.34 
Physical functioning and health-related C30 Role functioning -0.33 
Physical functioning and health-related C30 Social functioning -0.33 
Physical functioning and health-related C30 Constipation 0.32 
Physical functioning and health-related BR23 Breast symptoms 0.32 
Physical functioning and health-related C30 Nausea and vomiting 0.27 
Physical functioning and health-related C30 Dyspnoea 0.25 
Psychological state and emotional well-
being 
C30 Emotional functioning -0.35 
Psychological state and emotional well-
being 
BR23 Future perspective 0.33 
Psychological state and emotional well-
being 
C30 Cognitive functioning -0.33 
Psychological state and emotional well-
being 
BR23 Body image -0.27 
Psychological state and emotional well-
being 
C30 Fatigue 0.26 
Social functioning / family related C30 financial difficulties 0.43 
Social functioning / family related C30 Fatigue 0.31 
Social functioning / family related C30 Social functioning -0.30 
Social functioning / family related BR23 Systemic therapy side 
effects 
0.29 
Social functioning / family related C30 Role functioning -0.28 
Social functioning / family related C30 Nausea and vomiting 0.27 
Social functioning / family related C30 Physical functioning -0.26 
Social functioning / family related C30 Cognitive functioning -0.26 
Social functioning / family related C30 Appetite 0.25 
Total PCI items BR23 Systemic therapy side 
effects 
0.48 
Total PCI items C30 Fatigue 0.45 
Total PCI items BR23 Upset by hair loss 0.44 
Total PCI items C30 Cognitive functioning -0.42 
Total PCI items C30 Insomnia 0.40 
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Total PCI items C30 Social functioning -0.36 
Total PCI items BR23 Arm symptoms 0.33 
Total PCI items C30 Role functioning -0.31 
Total PCI items C30 Pain 0.30 
Total PCI items C30 Physical functioning -0.30 
Total PCI items BR23 Body image -0.29 
Total PCI items C30 Emotional functioning -0.28 
Total PCI items C30 financial difficulties 0.28 
Total PCI items BR23 Breast symptoms 0.28 
Total PCI items C30 Nausea and vomiting 0.26 
Total PCI items C30 Diarrhoea 0.26 
Staff: Psychological state and emotional 
well-being 
C30 Emotional functioning -0.31 
Staff: Psychological state and emotional 
well-being 
C30 Cognitive functioning -0.30 
Staff: Psychological state and emotional 
well-being 
BR23 Arm symptoms 0.29 
Staff: Psychological state and emotional 
well-being 
C30 financial difficulties 0.28 
Staff: Total number C30 Fatigue 0.26 
*Spearman, for which P<0.001 
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Table 12 (chapter 7-B):  Number of PCI domain items selected by number of  Fears (of 
cancer coming back, of spread, about the future) selected 
 
   Number of items selected from PCI 
Domain 
 
PCI Domain 
description  
Number 
of Fears  
selected 
on PCI 
Number 
of 
Patients 
 
Median 
IQR 
≥ 1 
item 
≥ 3 
items 
Total 
Items 
Spearman 
correlation* 
General 
information  (6 
items) 
3 Fears 36 1 1-2 81% 
(29) 
8% 
(3) 
47 
0.26 
P<0.001 
 2 Fears 50 1 0-1 52% 
(26) 
6% 
(3) 
37 
 1 Fear 57 0 0-1 37% 
(21) 
2% 
(1) 
24 
 0 Fears 57 0 0-1 46% 
(26) 
2% 
(1) 
34 
Body image 
related  (9 
items) 
3 Fears 36 3 1-5 86% 
(31) 
53% 
(19) 
108 
0.34 
P<0.001 
 2 Fears 50 2 1-2 76% 
(38) 
18% 
(9) 
86 
 1 Fear 57 1 0-2 56% 
(32) 
14% 
(8) 
59 
 0 Fears 57 1 0-2 61% 
(35) 
12% 
(7) 
60 
Physical 
functioning 
and health-
related (20 
items) 
3 Fears 36 7 4-9 94% 
(34) 
92% 
(33) 
261 
0.34 
P<0.001 
2 Fears 50 4 2-6 90% 
(45) 
68% 
(34) 
198 
1 Fear 57 3 1-4 81% 
(46) 
54% 
(31) 
173 
0 Fears 57 3 1-5 84% 
(48) 
54% 
(31) 
184 
Psychological 
state and 
emotional 
wellbeing  
excluding Fear 
items (10-3=7 
items) 
3 Fears 36 2 1-3 81% 
(29) 
44% 
(16) 
86 
0.25 
P<0.001 
2 Fears 50 0 0-1 46% 
(23) 
4% 
(2) 
38 
1 Fear 57 0 0-1 30% 
(17) 
4% 
(2) 
30 
 0 Fears 57 0 0-2 42% 
(24) 
18% 
(10) 
53 
Sexual 
functioning  (3 
items) 
3 Fears 36 0 0-1 47% 
(17) 
11% 
(4) 
25 
0.31 
P<0.001 
 2 Fears 50 0 0-1 32% 
(16) 
6% 
(3) 
25 
 1 Fear 57 0 0-0 19% 
(11) 
- 14 
 0 Fears 57 0 0-0 9% 
(5) 
- 7 
Social 
functioning / 
3 Fears 36 1 0-3 72% 
(26) 
25% 
(9) 
59 0.30 
P<0.001 
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family related  
(8 items) 
 2 Fears 50 0 0-1 28% 
(14) 
6% 
(3) 
29 
 1 Fear 57 0 0-1 30% 
(17) 
5% 
(3) 
27 
 0 Fears 57 0 0-0 23% 
(13) 
4% 
(2) 
23 
  
Patients Median IQR 
≥ 3 
item 
≥ 5 
items 
Total 
Items 
 
Total: PCI 
excluding Fear 
items 
 (56-3=53 
items) 
3 Fears 36 16 9-
21 
97% 
(35) 
92% 
(33) 
586 
0.38 
P<0.001 
2 Fears 50 7 4-
11 
88% 
(44) 
72% 
(36) 
413 
1 Fear 57 5 2-7 68% 
(39) 
51% 
(29) 
327 
 0 Fears 57 6 3-9 75% 
(43) 
63% 
(36) 
361 
Total: Health 
professional 
staff  (15 
items) 
3 Fears 36 5 3-6 78% 
(28) 
40% 
(18) 
177 
0.41 
P<0.001 
 2 Fears 50 2 1-4 34% 
(17) 
16% 
(8) 
128 
 1 Fear 57 1 1-2 21% 
(12) 
4% 
(2) 
98 
 0 Fears 57 1 1-3 25% 
(14) 
9% 
(5) 
105 
*between number of items selected and number of fears.  
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Table 13 (chapter 7-B):  Percentage of patients selecting specific PCI items and health 
professionals, by number of PCI Fear items selected 
Body table gives % of column 
totals 
Number of PCI Fear items 
selected  
   
 
0 1 2 3 
P 
value* 
   
N=57 N=57 N=50 N=36  
FoR 
N=124 
FOS 
N=78 
FFF 
N=63 
GENERAL INFORMATION         
B11 Activity (Conflicting 
information about exercise; 
unable to do exercise or 
problems returning to my daily 
routine) 
21 18 22 56 0.002 30 36 43 
B12 Information about Breast 
Cancer (Unable to get or unable 
to understand) 
12 9 18 31 0.02 19 18 29 
B13 Information about personal 
hygiene (May be related to 
breast prosthesis or wig) 
2 2 2 6 0.34 3 4 3 
B14 Lifestyle (Smoking/ 
alcohol-started or unable to 
stop) 
14 4 12 8 0.54 10 9 10 
B15 Complementary 
/Homeopathic Medicines 
(Problems with or unable to get        
information about) 
9 4 18 28 0.006 17 19 25 
B16 Fertility issues following 
treatment (Problems with or 
unable to get information 
about) 
2 0 2 3 0.61 2 3 2 
BODY IMAGE RELATED         
B21 Appearance (Overall 
physical appearance) 
12 11 16 36 0.008 19 26 29 
B22 Arm appearance  11 5 16 22 0.06 15 19 16 
B23 Breast appearance 26 25 26 47 0.08 31 37 37 
B24 Breast Prosthesis / Padding 9 4 18 33 0.001 19 26 24 
B25 Hair loss 0 11 20 31 <0.001 18 26 27 
B26 Hair replacement (wig) 0 4 8 14 0.003 8 10 11 
B27 Weight (Unable to control 
my weight) 
21 19 34 44 0.007 33 37 37 
B28 Wound healing (Scar 
appearance)  
12 9 16 36 0.006 21 26 22 
B29 Mastectomy appearance 14 14 18 36 0.02 21 28 27 
PHYSICAL FUNCTIONING 
AND HEALTH RELATED 
        
B31 Appetite 16 16 10 33 0.18 17 23 25 
B32 Arm swelling 
(Lymphoedema) 
14 4 12 33 0.04 16 22 24 
B33 Diarrhoea  9 4 8 17 0.32 9 14 13 
B34 Constipation 12 9 18 22 0.12 15 19 21 
B35 Breast texture 14 11 10 17 0.92 13 14 11 
B36 Breast sensitivity /Breast 
pain 
33 39 54 64 0.001 52 58 56 
B37 Cancer Treatment 11 9 24 33 0.002 19 26 35 
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B38 Sore mouth / Dry Mouth 18 11 14 36 0.08 17 26 29 
B39 Fatigue / Tiredness (Low 
energy levels overall) 
42 30 48 72 0.005 50 56 59 
B310 Indigestion 5 11 4 28 0.01 12 18 17 
B311 Memory/ Concentration 23 19 26 50 0.01 31 35 40 
B312 Nausea 2 4 8 28 <0.001 12 18 17 
B313 Pain in the Breast 19 23 34 44 0.005 35 37 37 
B314 Pain in the arm or 
shoulder 
23 21 20 42 0.13 24 35 32 
B315 Pain elsewhere 14 16 12 33 0.09 19 21 27 
B316 Sleeping 26 16 44 58 <0.001 39 50 46 
B317 Swallowing 2 2 2 6 0.34 2 3 6 
B318 Taste 2 11 2 25 0.005 10 13 19 
B319 Vomiting / Sickness 4 5 4 19 0.02 7 12 16 
B320 Hot Flushes 35 40 42 64 0.02 48 51 54 
PSYCHOLOGICAL STATE 
AND EMOTIONAL 
WELLBEING 
        
B41 Angry (why me?, why this 
treatment) 
2 5 4 22 0.002 10 10 17 
B42 Anxiety (Related to the 
diagnosis or treatment) 
4 4 22 67 <0.001 29 38 48 
B43 Coping (coping with the 
disease, the treatment or the 
side effects of treatment) 
19 11 18 42 0.03 22 28 32 
B44 Depression 14 14 12 31 0.13 16 23 24 
B45 Fear of cancer coming 
back 
0 70 96 100 NA NA 85 86 
B46 Fear of cancer spreading 0 18 64 100 NA 53 NA 60 
B47 Mood 23 9 4 28 0.71 11 17 19 
B48 Self esteem 12 4 12 33 0.01 15 19 25 
B49 Temperament and 
personality 
16 4 4 17 0.59 9 9 13 
B410 Fear about the future 0 12 40 100 NA 44 49 NA 
SEXUAL FUNCTIONING         
B51 Intimacy 5 12 12 22 0.03 16 17 16 
B52 Relationships 4 2 12 28 <0.001 14 17 21 
B53 Sex 4 11 26 19 0..002 21 18 21 
SOCIAL FUNCTIONING / 
FAMILY RELATED 
        
B61 Financial issues 12 21 14 36 0.03 24 22 29 
B62 Home care / district nurse 
support  
0 4 10 14 0.002 9 12 11 
B63 Mobility 9 2 6 22 0.07 9 13 16 
B64 Spiritual / Religious 
aspects 
4 0 0 8 0.40 2 4 5 
B65 Support for my family 4 5 8 28 0.008 12 17 21 
B66 Worried about the future 
of my children 
2 4 10 25 0.001 15 12 22 
B67 Unable to go out and enjoy 
my family 
4 4 4 17 0.07 7 9 16 
B68 Unable to go to go to work 4 2 6 14 0.04 7 8 11 
HEALTH PROFESSIONALS         
R1 Breast surgeon (He or she 
will perform the biopsy of the 
42 49 34 64 0.28 49 50 49 
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breast tumour and the 
lumpectomy or mastectomy) 
R2 Plastic surgeon (This doctor 
performs your breast 
reconstruction) 
11 9 8 25 0.13 13 17 17 
R3 Medical oncologist (This 
specialist administers 
anticancer drugs or 
chemotherapy) 
18 16 34 53 <0.001 31 37 52 
R4 Radiation oncologist (He or 
she administers radiation 
therapy) 
12 2 10 31 0.02 14 21 17 
R5 Breast Care Nurse  39 33 48 81 <0.001 52 63 65 
R6 Chaplain 2 2 0 6 0.48 2 3 3 
R7 Psychologist (He or she 
may help with anxiety 
/depression) 
12 14 14 50 <0.001 24 26 41 
R8 Dietician 16 4 22 25 0.08 18 21 21 
R9 Lymphoedema specialist 
/clinic 
4 5 12 19 0.04 11 17 14 
R10 Hair prosthesis (wig 
advisor) / Breast prosthesis 
expert 
4 5 6 25 0.002 10 17 16 
R11 Nurse Practitioner (Person 
that removed fluid from my 
operation site) 
2 0 4 14 0.007 6 9 8 
R12 Pain specialist 5 12 12 22 0.03 15 15 19 
R13 District Nurse 2 0 4 6 0.17 3 5 3 
R14 My own doctor (General 
Practitioner) 
9 11 16 22 0.06 16 15 22 
R15 Complementary therapies 5 11 20 50 <0.001 26 32 37 
*Mann-Whitney test comparing 0,1,2,3 Fears count distribution for specific PCI 
items being selected Vs. not selected. NA not applicable as these items make up the 
Fears count. FoR: Fear of cancer coming back, FoS: Fear of spread of cancer, FFF: 
Fear about the future. The percentages given in the last three columns are for 
descriptive purposes only – specific tests of significance for each cell result in 
relation to absence of that specific fear have not been summarised.  
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Table 14 (chapter 7-B):  Clinical/personal characteristics and selection of Fear items on 
the PCI 
 
Body table gives % (n) of row 
totals 
 
Number of Fear items selected  
% (n) 
with 
FoR 
%(n) 
With 
FoS 
% 
(n) 
with 
FFF 
  Pati
ents 
0 1 2 3 P 
value* 
 ALL 200 29  
(57) 
29 
(57) 
25 
(50) 
18 
(36) 
- 
Age <55 69 23  
(16) 
26  
(18) 
29 
(20)) 
22 
(15 
0.04 
74  
(51) 
38 
(26) 
38 
(26) 
 55-64 59 20  
(12) 
34  
(20) 
25 
(15) 
20 
(12) 
68  
(40) 
41 
(24) 
37 
(22) 
 65-74 52 37  
(19) 
29  
(15) 
19 
(10) 
15 
(8) 
50  
(26) 
38 
(20) 
25 
(13) 
 75+ 19 53  
(10) 
16  
(3) 
26 
(5) 
5 
(1) 
32  
(6) 
42 
(8) 
11 
(2) 
Gender Female 198 28  
(56) 
28  
(56) 
25 
(50) 
18 
(36) 
- 
63  
(124) 
39 
(77) 
32 
(63) 
 Male 2 50  
(1) 
50  
(1) 
- - 0  
(0) 
50 
(1) 
0 
(0) 
IMD 
deprivation: 
living in area 
that is one of 
the  20% most 
deprived  
No 148 32  
(47) 
24  
(35) 
25 
(37) 
20 
(29) 
0.90 
excl 
NK 
61  
(90) 
41 
(60) 
31 
(46) 
Yes 30 23 
(7) 
37  
(11) 
23 
(7) 
17 
(5) 
63  
(19) 
37 
(11) 
33 
(10) 
 Not 
known 
22 14  
(3) 
50  
(11) 
27 
(6) 
9 
(2) 
 
68  
(15) 
32 
(7) 
32 
(7) 
Year of most 
recent diagnosis 
2009/2010 108 23  
(25) 
28  
(30) 
29 
(31) 
20 
(22) 
0.07 
excl 
NK 
69  
(74) 
44 
(47) 
34 
(37) 
 2011/2012 61 31  
(19) 
36  
(22) 
18 
(11) 
15 
(9) 
56  
(34) 
31 
(19) 
30 
(18) 
 Not 
known 
31 42  
(13) 
16  
(5) 
26 
(8) 
16 
(5) 
 
52  
(16) 
39 
(12) 
26 
(8) 
Location Leeds 113 27  
(31) 
20  
(23) 
32 
(36) 
20 
(23) 
 
63  
(71) 
48 
(54) 
35 
(39) 
 Wakefield 64 27  
(17) 
39  
(25) 
17 
(11) 
17 
(11) 
0.07 
67  
(43) 
33 
(21) 
25 
(16) 
 Other 23 39  
(9) 
39  
(9) 
13 
(3) 
9 
(2) 
 
43  
(10) 
13 
(3) 
35 
(8) 
Extent of 
disease: Primary  
Local 
No 99 23  
(23) 
27  
(27) 
32 
(32) 
17 
(17) 
0.13 
63  
(62) 
47 
(47) 
33 
(33) 
Yes 101 34  
(34) 
30  
(30) 
18 
(18) 
19 
(19) 
61  
(62) 
31 
(31) 
30 
(30) 
Extent of 
disease: Local 
recurrent 
No 197 29  
(57) 
28  
(56) 
25 
(50) 
17 
(34) 
- 
62  
(122) 
39 
(76) 
30 
(60) 
Yes 3 0  
(0) 
33  
(1) 
0 (0) 67 
(2) 
67  
(2) 
67 
(2) 
100 
(3) 
Extent of 
disease: 
Metastatic 
No 191 29  
(56) 
28  
(54) 
25 
(47) 
18 
(34) 
0.31 
62  
(119) 
39 
(75) 
29 
(56) 
 Yes 9 11  
(1) 
33  
(3) 
33 
(3) 
22 
(2) 
57  
(5) 
33 
(3) 
78 
(7) 
Extent of 
disease: Living 
with cancer 
No 192 29  
(55) 
28  
(53) 
26 
(49) 
18 
(35) 
0.61 
64  
(122) 
39 
(75) 
31 
(59) 
Yes 8 25  
(2) 
50  
(4) 
13 
(1) 
13 
(1) 
25  
(2) 
38 
(3) 
50 
(4) 
Treatment (known for 193/200) 
Chemotherapy  No 100 32  
(32) 
28  
(28) 
22 
(22) 
18 
(18) 
0.41 
57  
(57) 
36 
(36) 
33 
(33) 
 Yes 93 25  
(23) 
30 
(28) 
28 
(26) 
17 
(16) 
68  
(63) 
40 
(37) 
30 
(28) 
Radiotherapy  No 67 27  
(18) 
30 
(20) 
25 
(17) 
18 
(12) 
0.79 
61  
(41) 
40 
(27) 
33 
(22) 
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 Yes 126 29  
(37) 
29 
(36) 
25 
(31) 
17  
(22) 
63 
(79) 
37 
(46) 
31 
(39) 
Wide local 
excision 
/lumpectomy 
No 100 29  
(29) 
27 
(27) 
26 
(26) 
18  
(18) 
0.86 
60 
(60) 
43 
(43) 
30 
(30) 
Yes 93 28  
(26) 
31 
(29) 
24 
(22) 
17  
(16) 
65 
(60) 
32 
(30) 
33 
(31) 
Mastectomy No 105 30 (32) 34 
(36) 
24 
(25) 
11  
(12) 
0.04 
58 
(61) 
28 
(29) 
30 
(32) 
 Yes 88 26 (23) 23 
(30) 
26 
(23) 
25  
(22) 
67 
(59) 
50 
(44) 
33 
(29) 
Reconstructive 
surgery 
No 168 31 (52) 30 
(50) 
25 
(42) 
14  
(24) 
0.003 
59 
(99) 
35 
(58) 
29 
(49) 
 Yes 25 12 (3) 24 
(6) 
24 
(6) 
40  
(10) 
84 
(21) 
60 
(15) 
48 
(12) 
Anti-oestrogen 
therapy** 
No/NK 111 27 (30) 23 
(26) 
27 
(30) 
23  
(25) 
0.05 
66 
(73) 
44 
(49) 
35 
(39) 
 Yes 82 30 (25) 37 
(30) 
22 
(18) 
11  
(9) 
57 
(47) 
29 
(24) 
27 
(22) 
Other treatment: 
** 
No/NK 176 29 (51) 31 
(54) 
24 
(42) 
16  
(29) 
0.13 
61 
(107) 
37 
(65) 
30 
(53) 
 Yes 17 24 (4) 12 
(2) 
35 
(6) 
29  
(5) 
76 
(13) 
47 
(8) 
47 
(8) 
Mastectomy 
with 
chemotherapy 
Yes 59 24 (14) 25 
(15) 
27 
(16) 
24  
(14) 
0.10 
Yes 
Vs Not 
both 
73 
(43) 
49 
(29) 
29 
(17) 
* Mann-Whitney (2 group comparison) or Kruskall-Wallis test (>2 group comparison) as 
appropriate using the number of Fear items selected; ** Anti-oestrogen therapy included: 
tamoxifen, letrozole, anastrozole, aromasin, arimidex, exemestane. Other treatment included 
:Herceptin, lepatinib, trastuzumab, neratinib. FoR: Fear of cancer coming back, FoS: Fear of 
spread of cancer, FFF: Fear about the future:-   Grey shading: P<0.01 Fishers exact test 
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Table 15 (chapter 7-B):  Association between PCI Fear items and summary scores from 
the EORTC QLQ-C30 and EORTC breast cancer module QLQ-BR23 
 
 Spearman correlation* Mann-Whitney Test** 
EORTC 
Correlation 
coefficient1 
P 
value 
Patients 
FoR 
P value 
FoS 
P value 
FFF 
P value 
C30 Physical 
functioning 
0.14 
0.05 
199 
0.002 0.06 0.34 
C30 Role functioning 0.05 0.52 200 0.10 0.09 0.03 
C30 Emotional 
functioning 
-0.10 
0.15 
195 
0.61 0.78 0.001 
C30 Cognitive 
functioning 
-0.08 
0.26 
196 
0.99 0.55 0.02 
C30 Social functioning -0.04 0.57 195 0.47 0.84 0.06 
C30 Fatigue 0.02 0.74 200 0.45 0.41 0.01 
C30 Nausea and 
vomiting 
0.02 
0.74 
200 
0.62 0.99 0.20 
C30 Pain -0.02 0.74 199 0.23 0.60 0.27 
C30 Global health status 
/ QOL 
0.04 
0.56 
196 
0.19 0.18 0.14 
C30 Dyspnoea -0.06 0.39 200 0.72 0.29 0.67 
C30 Insomnia 0.06 0.38 200 0.86 0.86 0.09 
C30 Appetite loss -0.04 0.57 200 0.29 0.34 0.43 
C30 Constipation -0.06 0.41 200 0.28 0.91 0.61 
C30 Diarrhoea 0.06 0.44 193 0.74 0.14 0.87 
C30 Financial 
difficulties 
0.02 
0.74 
196 
0.41 0.25 0.23 
BR23 Body image -0.12 0.08 195 0.06 0.96 0.04 
BR23 Sexual 
functioning 
0.07 
0.36 
177 
0.12 0.87 0.63 
BR23 Sexual enjoyment -0.14 0.25 68 0.24 0.16 0.93 
BR23 Future 
perspective 
-0.33 
<0.001 
195 
<0.001 0.28 <0.001 
BR23 Systemic therapy 
side effects 
0.06 
0.39 
197 
0.68 0.57 0.06 
BR23 Breast symptoms 0.01 0.92 197 0.57 0.99 0.77 
BR23 Arm symptoms 0.01 0.93 197 0.48 0.38 0.83 
BR23 Upset by hair loss 0.23 0.08 62 0.51 0.95 0.002 
 
* Spearman correlation coefficient between number of PCI Fear items selected 
(range 0-3) and the EORTC scores 
**Mann-Whitney test comparing distribution of EORTC scores in relation to 
FoR (Fear of cancer coming back), FoS (Fear of spread) or FFF (Fears about the 
future).  
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Table 16 (chapter 7-C): Body image –related domain 
 
During the past week have you lost any hair (Sprangers et al, 1996)  
During the past week have you felt physically less attractive as a result of your disease or 
treatment (Sprangers et al,1996)  
During the past week have you been feeling less feminine as a result of your disease or 
treatment (Sprangers et al, 1996)  
During the past week did you find it difficult to look at yourself naked (Sprangers et al,1996)  
During the past week have you been dissatisfied with your body (Sprangers et al,1996)  
I avoid looking at my scars from breast surgery (Baxter et al, 2006)  
I am satisfied with the shape of my body (Baxter et al, 2006)  
I feel less feminine since cancer (Baxter et al,2006)  
I Like my body (Baxter et al, 2006)  
I feel comfortable about the way I look when exercise (Baxter et al, 2006)  
I would feel comfortable changing in a public change-room (Baxter et al, 2006)  
I feel my body has been invaded (Baxter et al, 2006) 
I am satisfied with the appearance of my arm (Baxter et al, 2006)  
I am satisfied with the appearance of my hips (Baxter et al, 2006)  
I am satisfied with the shape of my  buttocks (Baxter et al, 2006)  
I feel comfortable looking at my mastectomy (Baxter et al, 2006)  
I am happy with the position of my nipple (Baxter et al, 2006)  
I feel satisfied with the size of my breast (Baxter et al, 2006)  
I feel comfortable when other see my breasts (Baxter et al, 2006)  
The appearance of my breasts could disturb others (Baxter et al, 2006)  
I feel that people are looking at my breasts (Baxter et al, 2006)  
How satisfied are you with the way your breast looks (Polivy J, 1977)  
Have you been feeling self-conscious about your appearance (Hopwood et al, 2001)  
Have you felt less physically attractive as a result of your disease or treatment (Hopwood et 
al, 2001)  
Have you been dissatisfied with your appearance when dressed (Hopwood et al, 2001)  
Did you find it difficult to look at your self naked (Hopwood et al, 2001)  
Did you avoid people because of the way you felt about your appearance (Hopwood et al, 
2001)  
Have you been feeling the treatment has left your body less whole (Hopwood et al, 2001)  
Have you been dissatisfied with your body (Hopwood et al,2001) 
Have you been dissatisfied with the appearance of your scar (Hopewood et al, 2001)  
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Is there a difference between the treated and untreated areas in terms of Breast size (Stanton 
et al,2005)  
Is there a difference between the treated and untreated areas in terms of breast texture 
(hardening) (Stanton et al, 2005) 
Is there a difference between the treated and untreated areas in terms of nipple appearance 
(Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of breast shape (Stanton 
et al, 2005)  
Is there a difference between the treated and untreated areas in terms of breast elevation 
(Stanton et al, 2005)  
Is there a difference between the treated and untreated areas in terms of scar tissue (Stanton 
et al, 2005)  
I am self-conscious about the way I dress (Brady et al, 1997)  
I am bothered by hair loss (Brady et al, 1997)  
How satisfied or dissatisfied have you been with how you look in the mirror clothed (Pusic 
et al, 2009)  
How satisfied or dissatisfied have you been with the shape of your reconstructed breasts 
when you are wearing a bra (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how normal you feel in your clothes (Pusic 
et al, 2009) 
How satisfied or dissatisfied have you been with the size of your reconstructed breasts (Pusic 
et al, 2009) 
How satisfied or dissatisfied have you been with being able to wear clothing that is more 
fitted (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how your breasts are lined up in relation to 
each other (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how comfortably your bras fit (Pusic et al, 
2009)  
How satisfied or dissatisfied have you been with the softness of your reconstructed breasts 
(Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how equal in size your breasts are to each 
other (Pusic et al, 2009) 
How satisfied or dissatisfied have you been with how natural your reconstructed breast looks 
(Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how natural your reconstructed breast 
sits/hangs (Pusic et al, 2009)  
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How satisfied or dissatisfied have you been with how your reconstructed breast feels to 
touch (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how much your reconstructed breast feels 
like a natural part of your body (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how closely matched your breasts are to 
each other (Pusic et al, 2009) 
How satisfied or dissatisfied have you been with how your reconstructed breast look now 
compared to before you had any surgery (Pusic et al, 2009)  
How satisfied or dissatisfied have you been with how you look in the mirror unclothed 
(Pusic et al, 2009)  
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Table 17 (chapter 7-C):  Body image related items selected on the PCI 
 
Body table gives % (n) of column 
totals Number of body Image related items 
 
 
0 1 2 3 4-8 ALL 
N=64 N=56 N=37 N=17 N=26 N=200 
BODY IMAGE RELATED items:       
B21 Appearance (Overall physical 
appearance) 
0 4 (2) 22 (8) 47 (8) 62 (16) 17 (34) 
B22 Arm appearance 0 5 (3) 22 (8) 29 (5) 35 (9) 13 (25) 
B23 Breast appearance 0 18 (10) 43 (16) 59 (10) 88 (23) 30 (59) 
B24 Breast Prosthesis / Padding 0 4 (2) 22 (8) 18 (3) 65 (17) 15 (30) 
B25 Hair loss 0 7 (4) 19 (7) 24 (4) 46 (12) 14 (27) 
B26 Hair replacement (wig) 0 0 3 (1) 12 (2) 31 (8) 6 (11) 
B27 Weight (Unable to control my 
weight) 
0 46 (26) 30 (11) 24 (4) 58 (15) 28 (56) 
B28 Wound healing (Scar 
appearance) 
0 9 (5) 16 (6) 47 (8) 54 (14) 17 (33) 
B29 Mastectomy appearance 0 7 (4) 24 (9) 41 (7) 69 (18) 19 (38) 
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Table 18 (chapter 7-C):  Median (IQR) and total number of items selected on the PCI, 
by number of body image related items selected.  
 
Body table gives median (IQR), 
total number of  items in other 
domains 
N of body Image related items* 
0 1 2-3 4-8 
N=64 N=56 N=54 N=26 
General information  (6 items) 0 (0-0), 19 1 (0-1), 37 1 (0-1), 48 1 (1-2), 38 
Physical functioning and 
health-related (20 items) 
2 (0-4), 155 3 (2-4), 166 5 (3-7), 279 7 (5-11), 216 
Psychological state and 
emotional wellbeing  (10 items) 
1 (1-2), 101 1 (1-2), 88 3 (2-4), 159 5 (3-6), 124 
Sexual functioning  (3 items) 0 (0-0), 10 0 (0-0), 11 0 (0-1), 28 1 (0-1), 22 
Social functioning / family 
related  (8 items) 
0 (0-0), 16 0 (0-1), 21 0 (0-2), 52 2 (1-3), 49 
Total number of other PCI 
items (range 0-47 after 
excluding the 9 body image 
related items) 
4 (2-6), 301 6 (4-7), 323 
10 (5-14), 
566 
17 (10-23), 
449 
Health professionals (15 staff) 1 (1-2), 92 2 (1-3), 110 3 (2-4), 174 5 (3-6), 132 
*Spearman correlation was significant at P<0.001 between the number of body image 
related items (range 0-9) and the number of items in each other domain, and also with 
total number of other items and with the number of health professionals selected. 
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Table 19 (chapter 7-C):  Percentage selecting other specific PCI items and health 
professionals, by number of PCI body image related items selected 
 
Body table gives % of column totals 
N of body Image related 
items P 
Value* 0 1 2-3 4-8 
N=64 N=56 N=54 N=26 
GENERAL INFORMATION      
B11 Activity  9 29 31 54 <0.001 
B12 Information about Breast Cancer (Unable to get 
or unable to understand) 
9 14 15 38 0.005 
B13 Information about personal hygiene (Maybe 
related to breast prosthesis/wig) 
0 2 0 15 0.007 
B14 Lifestyle (Smoking/ alcohol-started or unable to 
stop) 
6 11 13 15 0.10 
B15 Complementary /Homeopathic Medicines 
(information about) 
3 11 26 23 0.001 
B16 Fertility issues following treatment (information 
about) 
2 0 4 0 0.93 
PHYSICAL FUNCTIONING AND HEALTH RELATED 
B31 Appetite 8 16 19 42 0.001 
B32 Arm swelling (Lymphoedema) 6 5 24 38 <0.001 
B33 Diarrhoea  6 7 11 19 0.06 
B34 Constipation 9 5 20 35 0.002 
B35 Breast texture 0 12 20 27 <0.001 
B36 Breast sensitivity /Breast pain 28 39 61 69 <0.001 
B37 Cancer Treatment 16 4 22 42 0.004 
B38 Sore mouth / Dry Mouth 13 13 19 42 0.004 
B39 Fatigue / Tiredness (Low energy levels overall) 33 43 50 73 0.001 
B310 Indigestion 3 4 20 23 <0.001 
B311 Memory/ Concentration 16 23 35 50 <0.001 
B312 Nausea 2 4 11 31 <0.001 
B313 Pain in the Breast 17 25 37 46 0.001 
B314 Pain in the arm or shoulder 17 11 35 54 <0.001 
B315 Pain elsewhere 19 13 15 31 0.36 
B316 Sleeping 17 21 52 62 <0.001 
B317 Swallowing 0 2 4 8 0.03 
B318 Taste 2 2 9 38 <0.001 
B319 Vomiting / Sickness 3 2 6 31 <0.001 
B320 Hot Flushes 28 46 46 69 0.001 
PSYCHOLOGICAL STATE AND EMOTIONAL WELLBEING 
B41 Angry (why me?, why this treatment) 2 4 7 27 <0.001 
B42 Anxiety (Related to the diagnosis or treatment) 8 13 30 50 <0.001 
B43 Coping (coping with the disease, the treatment or 
the side effects of treatment) 
16 9 28 42 0.005 
B44 Depression 11 11 19 38 0.006 
B45 Fear of Cancer coming back 55 57 67 81 0.02 
B46 Fear of Cancer spreading 25 27 52 73 <0.001 
B47 Mood 8 7 20 38 <0.001 
B48 Self esteem 8 4 17 42 <0.001 
B49 Temperament and personality 6 5 13 27 0.004 
B410 Fear about the future 20 21 43 58 <0.001 
SEXUAL FUNCTIONING      
B51 Intimacy 5 5 19 31 <0.001 
B52 Relationships 3 2 17 27 <0.001 
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B53 Sex 8 12 17 27 0.01 
SOCIAL FUNCTIONING / FAMILY RELATED      
B61 Financial issues 8 16 30 35 <0.001 
B62 Home care / district nurse support  0 0 11 23 <0.001 
B63 Mobility 5 2 15 19 0.008 
B64 Spiritual / Religious aspects 2 2 4 4 0.38 
B65 Support for my family 0 5 11 46 <0.001 
B66 Worried about the future of my children 5 5 15 19 0.01 
B67 Unable to go out and enjoy my family 5 4 7 19 0.04 
B68 Unable to go to go to work 2 4 4 23 0.002 
HEALTH PROFESSIONALS      
R1 Breast surgeon  50 41 41 58 0.99 
R2 Plastic surgeon  0 2 24 38 <0.001 
R3 Medical oncologist  14 23 35 54 <0.001 
R4 Radiation oncologist  5 7 17 31 <0.001 
R5 Breast Care Nurse  30 39 65 69 <0.001 
R6 Chaplain 0 2 2 8 0.04 
R7 Psychologist  13 13 26 42 0.002 
R8 Dietician 9 18 15 27 0.08 
R9 Lymphoedema specialist /clinic 0 9 17 23 <0.001 
R10 Hair prosthesis (wig advisor) / Breast prosthesis 
expert 
0 4 9 38 <0.001 
R11 Nurse Practitioner  0 0 8 15 <0.001 
R12 Pain specialist 5 7 17 31 0.001 
R13 District Nurse 0 0 7 4 0.03 
R14 My own doctor (General Practitioner) 11 16 15 12 0.70 
R15 Complementary therapies 8 16 26 35 0.001 
*Mann-Whitney test comparing the full distribution (range 0-9) of body image related items 
for specific PCI items being selected Vs. not selected.  
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Table 20 (chapter 7-C):  Clinical/personal characteristics and selection of PCI body 
image related items  
 
Body table gives % (n) of row totals  Number of Body image related items 
selected 
 
  Patients 0 1 2-3 4-8 P value* 
 ALL 200 32 (64) 28 (56) 27 (54) 13 (26) - 
Age <55 69 28 (19) 23 (16) 36 (25) 13 (9) 
0.04** 
 55-64 59 25 (15) 34 (20) 24 (14) 17 (10) 
 65-74 52 42 (22) 31 (16) 15 (8) 12 (6) 
 75+ 19 42 (8) 16 (3) 37 (7) 5 (1) 
Gender Female 198 32 (64) 28 (56) 27 (53) 13 (25) 
- 
 Male 2 0 0 50 (1) 50 (1) 
IMD deprivation: living in 
area that is one of the  
20% most deprived  
No 148 28 (42) 30 (44) 28 (41) 14 (21) 
0.38 
excl NK 
Yes 30 37 (11) 27 (8) 23 (7) 13 (4) 
 Not 
known 
22 50 (11) 18 (4) 27 (6) 5 (1) 
 
Year of most recent 
diagnosis 
2009/2010 108 34 (37) 26 (28) 26 (28) 14 (15) 
0.84 
excl NK 
 2011/2012 61 30 (18) 31 (19) 28 (17) 11 (7) 
 Not 
known 
31 29 (9) 29 (9) 29 (9) 13 (4) 
 
Location Leeds 113 29 (33) 26 (29) 31 (35) 14 (16)  
 Wakefield 64 33 (21) 34 (22) 17 (11) 16 (10) 0.21 
 Other 23 43 (10) 22 (5) 35 (8) 0  
Extent of disease: Primary  
Local 
No 99 31 (31) 24 (24) 30 (30) 14 (14) 
0.48 
Yes 101 33 (33) 32 (32) 24 (24) 12 (12) 
Extent of disease: Local 
recurrent 
No 197 32 (64) 28 (55) 27 (53) 13 (25) 
- 
Yes 3 0 33 (1) 33 (1) 33 (1) 
Extent of disease: 
Metastatic 
No 191 32 (61) 28 (54) 27 (52) 13 (24) 
0.84 
 Yes 9 33 (3) 22 (2) 22 (2) 22 (2) 
Extent of disease: Living 
with cancer 
No 192 32 (61) 28 (53) 28 (53) 13 (25) 
0.55 
Yes 8 38 (3) 38 (3) 13 (1) 13 (1) 
Treatment (known for 193/200)   
   
 
Chemotherapy  No 100 40 (40) 30 (30) 21 (21) 9 (9) 
0.002 
 Yes 93 23 (21) 28 (26) 31 (29) 18 (17) 
Radiotherapy  No 67 27 (18) 28 (19) 28 (19) 16 (11) 
0.24 
 Yes 126 34 (43) 29 (37) 25 (31) 12 (15) 
Wide local excision 
/lumpectomy 
No 100 23 (23) 30 (30) 30 (30) 17 (17) 
0.005 
Yes 93 41 (38) 28 (26) 22 (20) 10 (9) 
Mastectomy No 105 44 (46) 30 (31) 22 (23) 5 (5) 
<0.001 
 Yes 88 17 (15) 28 (25) 31 (27) 24 (21) 
Reconstructive surgery No 168 34 (57) 31 (52) 23 (38) 13 (21) 
0.006 
 Yes 25 16 (4) 16 (4) 48 (12) 20 (5) 
Anti-oestrogen therapy*** No/NK 111 32 (35) 23 (25) 28 (31) 18 (20) 
0.08 
 Yes 82 32 (26) 38 (31) 23 (19) 7 (6) 
Other treatment: *** No/NK 176 31 (54) 30 (53) 27 (47) 13 (22) 
0.92 
 Yes 17 41 (7) 18 (3) 18 (3) 24 (4) 
 
* Mann-Whitney (2 group comparison) or Kruskall-Wallis test (>2 group comparison) as 
appropriate using the number of body image related items selected (range 0-9) 
** Spearman correlation  between age in years and number of body image related items 
(range 0-9) 
*** Anti-oestrogen therapy included: tamoxifen, letrozole, anastrozole, aromasin, arimidex, 
exemestane;  
Other treatment included :Herceptin, lepatinib, trastuzumab, neratinib. 
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Table 21 (chapter 7-C):  Number of body image related items by treatment  
 
Wide local 
excision or 
lumpectomy  
surgery 
Reconstructive 
surgery 
Chemotherapy Mastectomy 
 
Total 
Number of  Body image-
related items 
0 1 2-3 4-8 
No No No No 8 2 3 - 13 
No No No Yes 1 6 7 4 18 
No No Yes No 1 4 3 - 8 
No No Yes Yes 10 14 7 10 41 
No Yes No Yes - 2 4 - 6 
No Yes Yes Yes 3 2 6 3 14 
Yes No No No 31 19 6 2 58 
Yes No No Yes - 1 1 2 4 
Yes No Yes No 6 6 10 3 25 
Yes No Yes Yes - - 1 - 1 
Yes Yes No Yes - - - 1 1 
Yes Yes Yes No - - 1 - 1 
Yes Yes Yes Yes 1 - 1 1 3 
Treatment not known 3 - 4 - 7 
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Table 22 (chapter 7-C):  Number of PCI Body image related items and summary scores 
from the EORTC QLQ-C30 and EORTC breast cancer module QLQ-BR23 
 
 
Spearman correlation* 
Number of PCI body image related 
items 
EORTC 
Correlation 
coefficient1 
P value Patients 
0 1 2-3 4-8 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
Mean 
(SE) 
C30 Physical 
functioning 
-0.23 
0.001 
199 
85.3 
(2.4) 
81.3 
(2.7) 
77.5 
(3.2) 
76.8 
(3.5) 
C30 Role 
functioning 
-0.18 
0.01 
200 
82.6 
(3.0) 
77.1 
(3.9) 
70.7 
(4.2) 
69.9 
(6.0) 
C30 Emotional 
functioning 
-0.13 
0.08 
195 
73.8 
(2.8) 
75.3 
(2.7) 
66.2 
(3.5) 
62.7 
(6.0) 
C30 Cognitive 
functioning 
-0.25 
<0.001 
196 
84.1 
(2.5) 
77.8 
(3.2) 
65.4 
(3.8) 
69.2 
(6.2) 
C30 Social 
functioning 
-0.25 
<0.001 
195 
86.6 
(2.9) 
76.2 
(3.7) 
70.1 
(3.9) 
70.5 
(6.2) 
C30 Fatigue 
0.29 
<0.001 
200 
22.6 
(3.1) 
32.1 
(2.7) 
38.5 
(3.3) 
41.0 
(5.5) 
C30 Nausea and 
vomiting 
0.18 
0.01 
200 
3.4 
(1.0) 
5.4 
(2.1) 
10.2 
(2.4) 
11.5 
(4.4) 
C30 Pain 
0.17 
0.02 
199 
19.3 
(2.6) 
23.3 
(3.4) 
34.3 
(4.4) 
30.8 
(6.0) 
C30 Global health 
status / QOL 
     -0.06 
0.39 
196 
67.2 
(2.6) 
66.2 
(2.5) 
61.7 
(3.1) 
63.5 
(4.6) 
C30 Dyspnoea 
0.22 
0.002 
200 
9.4 
(2.6) 
16.7 
(3.3) 
14.2 
(3.2) 
26.9 
(5.2) 
C30 Insomnia 
0.26 
<0.001 
200 
22.9 
(3.3) 
37.5 
(4.7) 
54.3 
(4.9) 
37.2 
(7.0) 
C30 Appetite loss 
0.09 
0.23 
200 
8.9 
(2.7) 
8.9 
(2.8) 
18.5 
(4.3) 
10.3 
(4.8) 
C30 Constipation 
0.11 
0.13 
200 
14.6 
(3.4) 
13.1 
(2.9) 
17.9 
(3.7) 
19.2 
(5.0) 
C30 Diarrhoea 
0.22 
0.002 
193 
2.8 
(1.4) 
8.6 
(3.2) 
10.7 
(2.8) 
14.1 
(5.3) 
C30 Financial 
difficulties 
0.15 
0.03 
196 
12.0 
(3.0) 
15.8 
(3.4) 
25.3 
(4.4) 
21.8 
(7.1) 
BR23 Body image 
-0.34 
<0.001 
195 
78.8 
(3.3) 
74.4 
(3.3) 
53.8 
(4.4) 
60.3 
(5.5) 
BR23 Sexual 
functioning 
-0.01 
0.87 
177 
21.5 
(3.2) 
15.4 
(2.4) 
18.8 
(3.2) 
24.3 
(5.9) 
BR23 Sexual 
enjoyment 
-0.05 
0.69 
68 
57.3 
(5.3) 
47.1 
(5.8) 
47.1 
(7.6) 
59.3 
(10.8) 
BR23 Future 
perspective 
0.01 
0.95 
195 
41.9 
(4.1) 
51.2 
(4.5) 
43.4 
(4.7) 
42.3 
(6.6) 
BR23 Systemic therapy 
side effects 
  0.32 
<0.001 
197 
14.0 
(1.6) 
18.7 
(1.7) 
23.8 
(2.2) 
30.8 
(4.8) 
BR23 Breast 
symptoms 
0.19 
0.007 
197 
15.8 
(1.9) 
20.9 
(2.4) 
29.6 
(3.2) 
21.5 
(3.8) 
BR23 Arm 
symptoms 
0.26 
<0.001 
197 
13.1 
(2.0) 
16.9 
(2.4) 
23.5 
(3.8) 
32.9 
(5.5) 
BR23 Upset by hair 
loss 
0.41 
0.001 
62 
15.8 
(5.3) 
64.4 
(10.0) 
62.2 
(9.1) 
56.4 
(8.8) 
* Spearman correlation coefficient between the number of PCI Body image related items 
selected (range 0-9) and the EORTC scores 
SE: Standard Error of mean 
 
 226 
 
P
ag
e2
2
6
 
Table 23 (Chapter 8): Clinical/personal characteristics of patients in the two cohorts of 
the study 
 
  Cohort 1 Cohort 2 P value* 
  N=24 N=29  
Age Mean (SD) Age 59 (17) 62 (15) 0.58  
 Age ≥75 years 33% (8) 45% (13) 0.41  
IMD 
deprivation: 
living in area 
that 
Living in area 
described as one of 
IMD most 20% 
deprived 
33% (8) 24% (7) 
0.55 
Year of most 
recent diagnosis 
2008/2009 54% (13) 34% (10)  
2010 21% (5) 24% (7) 0.25 
 2011 
13% (3) 34% (10) 
using 
actual 
 2012/2013 13% (3) 7% (2) Year 
Overall tumour 
staging 
Tis (0) 
13% (3) 14% (4) 
 
 1 38% (9) 38% (11) 0.96  
 2 46% (11) 41% (12)  
 3 4% (1) 7% (2)  
     
Treatment Chemotherapy 25% (6) 18% (5/28) 0.74 
 Radiotherapy 58% (14) 50% (14/28) 0.59 
 Wide local excision 46% (11) 36% (10/28) 0.57 
 Mastectomy 33% (8) 29% (8/28) 0.77 
 Reconstructive 
surgery 
8% (2) 4% (1/28) 
0.59 
 Anti-oestrogen 
therapy** 
58% (14) 79% (22/28) 
0.14 
 Other treatment: ** 17% (4) 0% (0/28) 0.04 
*Fishers exact test apart from two-sample t test (to compare ages) and Mann-Whitney test 
(year of diagnosis and tumour staging) 
** Anti-oestrogen therapy included: tamoxifen, letrozole, anastrozole (ARIMIDEX), 
aromasin, arimidex, exemestane;  
Other treatment included :Herceptin, lepatinib, trastuzumab, neratinib. 
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Table 24 (Chapter 8):  Results of the consultation questionnaire, by study cohort 
 
1 To what extent was 
your main 
problem(s) discussed 
today? 
 
Completel
y 
Mostly A little Not at all 
P 
value 
Cohort 1 67% (16) 29% (7) 4% (1) - 
0.02 Cohort 2 34% (10) 55% (16) 7% (2) 3% (1) 
2 How satisfied were 
you with the 
discussion of your 
problem(s)? 
 
Very 
satisfied 
Satisfied 
Somewhat 
satisfied 
Not 
satisfied  
Cohort 1 54% (13) 42% (10) - 4% (1) 
0.08 Cohort 2 34% (10) 45% (13) 21% (6) - 
3 To what extent did 
the doctor listen to 
what you had to say? 
 
Completel
y 
Mostly A little Not at all 
 
Cohort 1 58% (14) 38% (9) 4% (1) - 
0.70 Cohort 2 62% (18) 38% (11) - - 
4 To what extent did 
the doctor explain 
your problem(s) to 
you? 
 
Completel
y 
Mostly A little Not at all 
 
Cohort 1 58% (14) 38% (9) 4% (1) - 
0.09 Cohort 2 38% (11) 45% (13) 14% (4) 3% (1) 
5 To what extent did 
you and the doctor 
discuss your 
respective roles? 
(Who is responsible 
for making decisions 
and who is 
responsible for what 
aspects of your 
care?) 
 
Completel
y 
Mostly A little 
Not 
discussed  
Cohort 1 38% (9) 17% (4) 4% (1) 42% (10) 
0.40 
Cohort 2 18% (5) 18% (5) 11% (3) 54% (15) 
6 To what extent did 
the doctor explain 
treatment? 
 Very well Well Somewhat Not at all  
Cohort 1 46% (11) 50% (12) 4% (1) - 
0.09 Cohort 2 28% (8) 55% (16) 17% (5) - 
7 To what extent did 
the doctor explore 
how manageable this 
(treatment) would be 
for you? 
 He/she 
explored this… 
 
Completel
y 
Mostly A little Not at all 
 
Cohort 1 58% (14) 33% (8) 8% (2) - 
0.02 
Cohort 2 24% (7) 59% (17) 10% (3) 7% (2) 
8 How well do you 
think your doctor 
understood you 
today? 
 Very well Well Somewhat Not at all  
Cohort 1 50% (12) 50% (12) - - 
0.38 
Cohort 2 38% (11) 62% (18) - - 
9 To what extent did 
the doctor discuss 
personal or family 
issues that might 
affect your health? 
 
Completel
y 
Mostly A little Not at all 
 
Cohort 1 25% (6) 29% (7) 13% (3) 33% (8) 
0.16 
Cohort 2 34% (10) 41% (12) 7% (2) 17% (5) 
P Value from Mann-Whitney test comparing Cohort 1 (no PCI) and Cohort 2 (with PCI) 
patients in distribution of responses to ordinal questions, except for the chi-squared test 
for question 5.  
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Table 25 (Chapter 8): PCI items / health professionals selected by the 29 patients in 
Cohort 2 of the study 
 % Patients 
GENERAL INFORMATION   
B11 Activity (Conflicting information about exercise; unable to do 
exercise or problems returning to my daily routine) 
3 1 
B12 Information about Breast Cancer  10 3 
B13 Information about personal hygiene  - - 
B14 Lifestyle (Smoking/ alcohol-started or unable to stop) - - 
B15 Complementary /Homeopathic Medicines (Problems with or 
unable to get  information about) 
- - 
B16 Fertility issues following treatment (Problems with or unable to 
get information about) 
- - 
BODY IMAGE RELATED   
B21 Appearance (Overall physical appearance) - - 
B22 Arm appearance  - - 
B23 Breast appearance 21 6 
B24 Breast Prosthesis / Padding 3 1 
B25 Hair loss 7 2 
B26 Hair replacement (wig) - - 
B27 Weight (Unable to control my weight) 7 2 
B28 Wound healing (Scar appearance)  - - 
B29 Mastectomy appearance 3 1 
PHYSICAL FUNCTIONING AND HEALTH RELATED   
B31 Appetite 7 2 
B32 Arm swelling (Lymphoedema) 7 2 
B33 Diarrhoea  - - 
B34 Constipation - - 
B35 Breast texture 10 3 
B36 Breast sensitivity /Breast pain 3 1 
B37 Cancer Treatment 7 2 
B38 Sore mouth / Dry Mouth - - 
B39 Fatigue / Tiredness (Low energy levels) 7 2 
B310 Indigestion 3 1 
B311 Memory/ Concentration 3 1 
B312 Nausea/ Vomiting / Sickness 14 4 
B313 Pain in the Breast 14 4 
B314 Pain in the arm or shoulder 10 3 
B315 Pain elsewhere 14 4 
B316 Sleeping 10 3 
B317 Swallowing - - 
B318 Taste - - 
B320 Hot Flushes 10 3 
PSYCHOLOGICAL STATE AND EMOTIONAL WELLBEING   
B41 Angry (why me? Why this treatment) - - 
B42 Anxiety (Related to the diagnosis or treatment) 38 11 
B43 Coping (coping with the disease, the treatment, the side effects of 
treatment) 
10 3 
B44 Depression 7 2 
B45 Fear of Cancer coming back 28 8 
B46 Fear of Cancer spreading 14 4 
B47 Mood 7 2 
B48 Self esteem - - 
B49 Temperament and personality 3 1 
B410 Fear about the future 48 14 
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SEXUAL FUNCTIONING   
B51 Intimacy - - 
B52 Relationships - - 
B53 Sex - - 
SOCIAL FUNCTIONING / FAMILY RELATED   
B61 Financial issues - - 
B62 Home care / district nurse support  - - 
B63 Mobility - - 
B64 Spiritual / Religious aspects - - 
B65 Support for my family - - 
B66 Worried about the future of my children - - 
B67 Unable to go out and enjoy my family 3 1 
B68 Unable to go to go to work - - 
HEALTH PROFESSIONALS   
R1 Breast surgeon (He or she will perform the biopsy of the breast 
tumour and the lumpectomy or mastectomy) 
100 29 
R2 Plastic surgeon (This doctor performs your breast reconstruction) 10 3 
R3 Medical oncologist (This specialist administers anticancer drugs or 
chemotherapy) 
- - 
R4 Radiation oncologist (He or she administers radiation therapy) - - 
R5 Breast Care Nurse  3 1 
R6 Chaplain - - 
R7 Clinical psychologist (He or she may help with anxiety /depression) 3 1 
R8 Dietician 3 1 
R9 Lymphoedema specialist /clinic 3 1 
R10 Hair prosthesis (wig advisor) / Breast prosthesis expert - - 
R11 Nurse Practitioner (Person that removed fluid from my operation 
site) 
- - 
R12 Pain specialist - - 
R13 District Nurse - - 
R14 General Practitioner 3 1 
R15 Complementary therapies 3 1 
R16 Physiotherapist - - 
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Table 26 (Chapter 8): Number of items selected from PCI domains by the 29 patients in 
cohort 2 of the study 
 
 Median IQR Range ≥ 1 
item 
≥ 3 
items 
Total 
items 
General information  (6 items) 0 0-0 0-2 10% 
(3) 
- 4 
Body image related  (9 items) 0 0-1 0-2 31% 
(9) 
- 12 
Physical functioning and health-
related (19 items) 
1 0-2 0-6 62% 
(18) 
14% 
(4) 
35 
Psychological state and emotional 
wellbeing  (10 items) 
1 0-3 0-6 59% 
(17) 
24% 
(7) 
45 
Sexual functioning  (3 items) 0 0-0 0-0 - - 0 
Social functioning / family related  
(8 items) 
0 0-0 0-1 3% (1) - 1 
Total: PCI (55 items) 2 2-4 1-17 100% 
(29) 
41% 
(12) 
97 
Total: Health professional staff  (16 
items) 
1 1-2 1-2 100% 
(29) 
- 38 
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Table 27 (Chapter 8): Items selected in detail in cohorts 1 and 2 and during 
consultation 
 
 
Cohort 1: 
during 
consultation 
(N=24)  
Cohort 2: 
during 
consultation 
(N=29)  
Cohort 2: 
PCI (N=29)  
 % % % 
B11 Activity (Conflicting information about 
exercise; unable to do exercise or problems 
returning to my daily routine) 
17 14 3 
B12 Information about Breast Cancer  25 3 10 
B13 Information about personal hygiene  0 0 0 
B14 Lifestyle (Smoking/ alcohol-started or 
unable to stop) 
4 0 0 
B15 Complementary /Homeopathic Medicines 
(Problems with or unable to get  information 
about) 
17 17 0 
B16 Fertility issues following treatment 
(Problems with or unable to get information 
about) 
0 0 0 
B21 Appearance (Overall physical appearance) 0 0 0 
B22 Arm appearance  0 0 0 
B23 Breast appearance 50 31 21 
B24 Breast Prosthesis / Padding 13 10 3 
B25 Hair loss 0 3 7 
B26 Hair replacement (wig) 0 0 0 
B27 Weight (Unable to control my weight) 13 3 7 
B28 Wound healing (Scar appearance)  29 24 0 
B29 Mastectomy appearance 0 0 3 
B31 Appetite 4 0 7 
B32 Arm swelling (Lymphoedema) 8 3 7 
B33 Diarrhoea  0 0 0 
B34 Constipation 0 0 0 
B35 Breast texture 21 10 10 
B36 Breast sensitivity /Breast pain 13 10 3 
B37 Cancer Treatment 8 0 7 
B38 Sore mouth / Dry Mouth 4 0 0 
B39 Fatigue / Tiredness (Low energy levels) 29 3 7 
B310 Indigestion 0 0 3 
B311 Memory/ Concentration 0 0 3 
B312 Nausea/ Vomiting / Sickness 13 3 14 
B313 Pain in the Breast 8 10 14 
B314 Pain in the arm or shoulder 0 0 10 
B315 Pain elsewhere 25 21 14 
B316 Sleeping 17 7 10 
B317 Swallowing 0 0 0 
B318 Taste 0 0 0 
B320 Hot Flushes 29 14 10 
B41 Angry (why me? Why this treatment) 4 21 0 
B42 Anxiety (Related to the diagnosis or 
treatment) 
46 48 38 
B43 Coping (coping with the disease, the 
treatment, the side effects of treatment) 
21 0 10 
B44 Depression 17 7 7 
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B45 Fear of Cancer coming back 8 7 28 
B46 Fear of Cancer spreading 8 3 14 
B47 Mood 4 3 7 
B48 Self esteem 8 0 0 
B49 Temperament and personality 8 0 3 
B410 Fear about the future 4 21 48 
B51 Intimacy 0 0 0 
B52 Relationships 0 0 0 
B53 Sex 0 0 0 
B61 Financial issues 0 0 0 
B62 Home care / district nurse support  0 0 0 
B63 Mobility 0 0 0 
B64 Spiritual / Religious aspects 4 0 0 
B65 Support for my family 0 0 0 
B66 Worried about the future of my children 4 0 0 
B67 Unable to go out and enjoy my family 0 0 3 
B68 Unable to go to go to work 4 0 0 
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Table 28 (Chapter 8): Consultation duration in minutes. The first 24 patients are 
before the introduction of the PCI, and just the use of the consultation satisfaction 
scale. The rest involve the use of the PCI with the consultation satisfaction scale. 
 
Patient number Duration (mins) 
Cohort 1  
1 7.36 
2 19.99 
3 7.87 
4 5.18 
5 8.88 
6 22.89 
7 26.65 
8 28.19 
9 11.88 
10 7.58 
11 9.27 
12 7.31 
13 8.16 
14 20.83 
15 11.16 
16 11.76 
17 4.45 
18 7.66 
19 19.99 
20 20.59 
21 19.52 
22 14.24 
23 11.18 
24 11.32 
Mean 13.50 minutes 
Cohort 2  
25 10.0 
26 4.3 
27 4.0 
28 8.8 
29 9.85 
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30 5.21 
31 6.95 
32 7.32 
33 7.54 
34 5.38 
35 8.3 
36 6.15 
37 10.55 
38 18.3 
39 17.2 
40 8.85 
41 28.01 
42 14.7 
43 14.55 
44 10.1 
45 12.01 
46 6.15 
47 7.59 
48 28.87 
49 6.05 
50 7.61 
51 22.83 
52 19.2 
53 21.33 
Mean 11.6 minutes 
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Table 29 (Chapter 8): Mean , median and interquartile range of the cconsultation 
duration (based on the data from Table 28).  
 
 Number of 
patients 
Median Interquartile 
range (IQR) 
Mean Standard 
Deviation 
(SD) 
Cohort 1 24 11.3 7.7-20.0 13.5 7.0 
Cohort 2 29 8.9 6.6-16.9 11.6 6.9 
 Mean-Whitney test P=0.21 
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APPENDIX SECTION 2: SUPPLEMENTAL STUDY 
MATERIAL (LETTERS, FORMS AND OTHER 
DOCUMENTS) 
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Appendix 2-A -Clinical staff Consent Form for audio recording of semi structured 
interviews 
Study Title: Development of a breast cancer specific Patients Concerns Inventory (PCI) 
This is an observational study involving 
· Audio-recordings of consultations 
................................................................................................................................. 
          
· I agree to participate in this study                                                                                      
· I give my permission for the researchers to audio-tape the consultation              
· I have read the Information Sheet and this consent form and have had the 
opportunity to ask questions about them                                   
· I understand that the information collected during the study will be treated strictly 
confidentially. None of the data collected during the study will ever be given to a 
third party or used for any other purposes except the analysis of this project. 
· I am happy for the contribution I have already made to be used in the analysis if I 
choose to withdraw from the study 
 
Name of Clinician..................................................................................................... 
Signature of Clinician:............................................................................................... 
Signature of Researcher:....................................................................................... 
Date:..................................................................... 
If you would like any further information, want to see the full protocol or have any 
comments, please contact Mr A Kanatas  
Tel:07769946105 e-mail:a.kanatas@doctors.org.uk 
Galina Velikova, Professor of Psychosocial and Medical Oncology 
/Consultant Medical Oncology, Level 4, Bexley Wing, St James's Institute of Oncology, St 
James's Hospital, Beckett street, Leeds LS9 7TF, UK. Tel: +44 113 2067917 Fax: +44 113 
2068512 e-mail: g.velikova@leeds.ac.uk   
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Appendix 2-B-Questions to clinicians 
The following questions will be asked to the clinicians: 
1. What are the common problems that patients needs advice/support one year post diagnosis 
3. What are the common problems that patients need advice /support with after the first year 
and up to three years post diagnosis? 
4. What concerns do you think may be missed during a consultation? 
5. What specialists are available to provide support in the MDT? 
6. What is their role? 
7. What specialist clinics are there for breast cancer patients? 
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Appendix 2-C -Study information Phase 1             
 
Institute of Oncology 
We would like to invite you to take part in a RESEARCH study that will involve the 
formation of a group of 8-10 people. Once a group is formed it would involve a meeting at a 
convenient time for all the members of the group. During the meeting we would ask you 
questions about problems you experienced after your diagnosis and treatment. The meeting 
would involve non-identifiable audio recordings.Before you decide whether to take part, 
please read this information sheet to find out why the research is being done and what it 
involves. Please take time to read the following information carefully. Talk to others about 
the study if you wish, and ask the researcher if you have any questions at all. 
Purpose of the study 
The aim of the study is to gain an understanding of standard practice in oncology with 
respect to how patients discuss problems with their doctor and how decisions are being 
made. This is needed for the following reason: 
 In the near future we will aim to introduce a new approach to detecting patient 
problems, by asking patients to respond to brief questionnaires on touch-screen 
computers and giving this to their doctors. This initial period of assessment will 
provide the research team with information that will be used for the development of 
the brief questionnaire. 
Why have I been chosen? 
We are inviting patients who had treatment for breast cancer and are between one year and 
three years post diagnosis. We are hoping to recruit about 40 patients for this study. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given this 
information sheet to keep. Then you will be asked to sign a consent form. Even after signing 
the consent form, you are free to decide not to take part and you do not have to give us a 
reason for doing so. A decision not to take part will not affect the standard of medical care 
you receive. 
If you prefer not to take part in the study, we would like to ask for your permission to keep a 
record of your initials, age, gender and diagnosis for the purposes of the study, so that we 
know who we have approached. 
What is involved? 
Once 8-10 people agree to participate, on your next clinic appointment we will approach you 
again and give you details about a meeting. During this meeting all the patients invited 
would be in a room together. We would start by introducing out first names only. This 
meeting would be audio recorded in order for us to be able to process the information. Then 
we would ask you to tell us about specific problems that you experienced after your 
diagnosis and treatment. Then we would give you a list of problems that people may 
experience and we would appreciate your opinion about the frequency of these problems.  
Will my taking part in this study be kept confidential? 
All information is confidential. The recordings will be kept securely and will only be 
available to the research team. It will not be shared with the clinical team looking after you. 
Any analysis or publication of results will not name or identify individual patients.  
What are the possible benefits of taking part? 
Leeds Institute of Molecular MedicineLeeds Institute of olecular edicine
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We hope the information you provide will contribute to improving the support we can offer 
patients in the future and been able to identify specific problems at every consultation. 
Thank you for taking the time to read this information sheet and consider this study. 
Would you inform my Family Doctor? 
Once we have your consent to participate in the study we will send a letter to your doctor. 
We would do this to ensure that at all times there would be support for you if you need it. 
 
If at any point you have questions or concerns regarding this study, please contact 
the researchers below: 
1. Mr A Kanatas  Tel:07769946105 
Specialist Registrar 
e-mail:a.kanatas@doctors.org.uk 
2. Galina Velikova BMBS(MD) PhD 
FRCP  
Professor of Psychosocial and Medical 
Oncology 
/Consultant Medical Oncology 
Level 4, Bexley Wing; St James's Institute of Oncology; St James's Hospital; Beckett 
street; Leeds LS9 7TF, UK; Tel: +44 113 2067917; Fax: +44 113 2068512; e-mail: 
g.velikova@leeds.ac.uk  
 242 
 
P
ag
e2
4
2
 
Appendix 2-D – Patient Consent Form for the Focus Groups.                    
Centre Number: 
Patient Identification Number for this trial: 
Patient Initials: 
Title of Project: Further Development of The Patients Concerns Inventory (PCI) to help 
reveal patients concerns in Head and Neck and Breast Oncology clinics 
Name of Researcher: A Kanatas 
 Please tick to confirm  
  
 I confirm that I have read and understand the information sheet 
dated .....................................) for the above study.  
•  □ 
  
 I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.  
•  □ 
  
 I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical  
or legal rights being affected.  
•  □ 
  
 I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by responsible individuals 
from the NHS, from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research. I give permission 
for these individuals to have access to my records.  
•  □ 
   I agree to my GP being informed of my participation in the study.       □• 
  
 I agree to take part in the above research study, and I agree for the 
interview to be recorded  
      • 
         □ 
  
 I give permission for anonymised direct quotes to be included in a 
written report and publications   
 I give permission to the research team to contact me with relation to 
the study 
   □• 
       □  
 
__________________________ 
Name of Patient  
______________ 
Date 
__________________________ 
Signature 
__________________________ 
Researcher 
______________ 
Date 
__________________________ 
Signature 
When complete, 1 copy for patient: 1 (original) to be kept in medical notes. 
 
Leeds Institute of Molecular MedicineLeeds Institute of olecular edicine
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Appendix 2-E: Study reply slip             
 
Title of project: Development of a breast cancer specific Patients Concerns Inventory 
(PCI)  
 
Please read the statements below and tick the one that applies to you: 
 
 
I do not wish to take part in this study                                                                 □ 
 
I am interested in taking part in this study and would be happy to speak to 
researchers again at my next clinic appointment                                                □ 
 
 
Name 
 
 
Date 
 
Which clinic are you currently attending? 
 
 
Breast clinic 
 
 
(Monday morning)                                                                                                  □ 
Please use the freepost envelope provided to return completed forms to: 
 
Anastasios Kanatas 
Psychosocial Oncology and Clinical Practice Research Group 
St James’s Institute of Oncology 
Level 3, Bexley Wing 
Beckett StreetLeeds, LS9 7TF If you have any queries please contact Anastasios Kanatas 
Tel:07769946105      e-mail:a.kanatas@doctors.org.uk 
Leeds Institute of Molecular MedicineLeeds Institute of olecular edicine
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Appendix 2-F: EORTC 30 and - BR23 module 
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Appendix 2- G: Patient Information Sheet              
 
 
Institute of Oncology 
We would like to invite you to take part in a RESEARCH study that will involve the 
completion of two questionnaires. We will also ask you to complete two questionnaires and 
return them in the SAE provided. Before you decide whether to take part, please read this 
information sheet to find out why the research is being done and what it involves. Please take 
time to read the following information carefully. Talk to others about the study if you wish, 
and ask the researcher if you have any questions at all. 
Purpose of the study 
The aim of the study is to gain an understanding of standard practice in oncology with 
respect to how patients discuss problems with their doctor and how decisions are being 
made. This is needed for several reasons: 
 1) In the near future we will aim to introduce a new approach to detecting patient problems, 
by asking patients to respond to brief questionnaires on touch-screen computers and giving 
this to their doctors. This initial period of assessment will provide the research team with 
information that will be used for the development of the brief questionnaire. 
3) The information from the consultations and the questionnaires will help to develop and 
individualise the consultation to the specific patient needs. 
Why have I been chosen? 
We are inviting patients who had treatment for breast cancer and are between one year and 
three years post diagnosis. We are hoping to recruit about 200 patients for this study. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given this 
information sheet to keep. Then you will be asked to sign a consent form. Even after signing 
the consent form, you are free to decide not to take part and you do not have to give us a 
reason for doing so. A decision not to take part will not affect the standard of medical care 
you receive. 
If you prefer not to take part in the study, we would like to ask for your permission to keep a 
record of your initials, age, gender and diagnosis for the purposes of the study, so that we 
know who we have approached. 
What is involved? 
If you agree to take part in the study, please complete the two questionnaires provided.The 
questionnaires cover issues relating to doctor-patient communication, and those such as 
symptoms, emotions, coping, and family life. You are not obliged to answer any question 
that you are not comfortable with. Questionnaires should take no longer than 20 minutes to 
complete in total, and you can either complete them before you leave the clinic or take them 
home to complete and return in a pre-paid addressed envelope. 
When would I take part? 
Please take the time to read all the information provided and if you wish discuss with the 
researchers, clinic staff and your carer(s). 
If you decide you would like to take part in this study, please inform the researcher present 
in clinic. You will be asked to read and sign the consent form (a copy is shown overleaf). 
Leeds Institute of Molecular MedicineLeeds Institute of olecular edicine
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You can keep this information sheet and a copy of the signed consent form. 
Will my taking part in this study be kept confidential? 
All information from the questionnaires is confidential. The questionnaire data will be kept 
securely and will only be available to the research team. It will not be shared with the 
clinical team looking after you. Any analysis or publication of results will not name or 
identify individual patients. We will ask for your permission to look at your medical records 
for information about the treatment you are receiving and for details of your disease 
condition. All information that we collect during the study will be kept anonymous and 
confidential. 
What are the possible benefits of taking part? 
We hope the information you provide will contribute to improving the support we can offer 
patients in the future and been able to identify specific problems at every consultation. 
Would you inform my Family Doctor? 
Once we have your consent to participate in the study we will send a letter to your doctor. 
We would do this to ensure that at all times there would be support for you if you need it. 
Thank you for taking the time to read this information sheet and consider this study. 
If at any point you have questions or concerns regarding this study, please contact 
the researchers below: 
 
1).Mr A Kanatas  Tel:07769946105 
e-mail:a.kanatas@doctors.org.uk 
 
2).Galina Velikova, Professor of Psychosocial and Medical Oncology 
/Consultant Medical Oncology, Level 4, Bexley Wing, St James's Institute of Oncology, St 
James's Hospital, Beckett street, Leeds LS9 7TF, UK. Tel: +44 113 2067917 Fax: +44 113 
2068512 e-mail: g.velikova@leeds.ac.uk 
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Appendix 2- H: Patient Consent Form for the Cross-Sectional Study                
 
 
Centre Number: 
Patient Identification Number for this trial: 
Title of Project: Further Development of The Patients Concerns Inventory (PCI) to help 
reveal patients concerns in Head and Neck and Breast Oncology clinics 
Name of Researcher: A Kanatas 
 Please tick to confirm  
  
 I confirm that I have read and understand the information sheet 
dated ......................... (version ............) for the above study.  
  □• 
  
 I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.  
  □• 
  
 I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical  
or legal rights being affected.  
  □• 
  
 I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by responsible individuals 
from the NHS, from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research. I give permission 
for these individuals to have access to my records.  
  □• 
   I agree to my GP being informed of my participation in the study.   □• 
   I agree to take part in the above research study  
       □ • 
 
  
 I give permission for anonymised direct quotes to be included in a 
written report and publications   
 I give permission to the research team to contact me with relation to 
the study 
     □ • 
        □ 
 
__________________________ 
Name of Patient  
______________ 
Date 
__________________________ 
Signature 
__________________________ 
Researcher 
______________ 
Date 
__________________________ 
Signature 
When complete, 1 copy for patient: 1 (original) to be kept in medical notes. 
Leeds Institute of Molecular MedicineLeeds Institute of olecular edicine
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Appendix 2- I: Study reply slip                       
 
Title of project: Development of a breast cancer specific Patients Concerns Inventory 
(PCI)  
 
Please read the statements below and tick the one that applies to you: 
 
I do not wish to take part in this study                                                                 □ 
 
I am interested in taking part in this study and would be happy to speak to 
researchers again at my next clinic appointment                                                □ 
 
 
Name 
 
 
Date 
 
Which clinic are you currently attending? 
 
Breast clinic 
 
(Monday morning)                                                                                                  □ 
Please use the freepost envelope provided to return completed forms to: 
 
Anastasios Kanatas 
Psychosocial Oncology and Clinical Practice Research Group 
St James’s Institute of Oncology 
Level 3, Bexley Wing 
Beckett StreetLeeds, LS9 7TF 
 
 If you have any queries please contact Anastasios Kanatas 
Tel:07769946105             e-mail:a.kanatas@doctors.org.uk  
Leeds Institute of Molecular MedicineLeeds Institute of olecular edicine
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Appendix 2-J : -Letter to GP                          
                                                                                                                                                                           
AAnastasios 
Kanatas, BSc 
(Hons), BDS, 
MBChB (Hons), 
MFDSRCS, 
MRCSRCS, PhD, 
PGC. Specialty 
Registrar, Leeds 
Teaching Hospitals 
and St James 
Institute of 
Oncology 
a.kanatas@doctors.
org.uk 
Tel: 07769946105 
 
Dear Mr.... 
 
RE:NAME OF PATIENT  
      Date of Birth 
      Address 
This is to inform you that the above patient has agreed to participate in the Questionnaire 
study with a title: Development of a breast cancer specific Patients Concerns Inventory 
(PCI). 
 
This study is carried out by Mr A Kanatas   (Specialist Registrar) under the supervision of 
Prof Galina Velikova and Mr Kieran Horgan in Leeds General Infirmary. 
For further information please do not hesitate to contact us. 
Yours sincerely 
 
A Kanatas 
Leeds Institute of Molecular MedicineLeeds Institute of olecular edicine
 253 
 
P
ag
e2
5
3
 
Appendix 2- K:  Form Collecting Socio-demographic data 
 
Date of birth: 
Post-code: 
Hospital: 
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Appendix 2-L: Clinical Background information 
 
 
 A. Background 
  
 AGE: 
 
 POSTCODE: 
 
 
              B. Clinical information 
 
 
  Diagnosis: 
 
  Stage (TNM or cancer site-specific staging): 
 
  Extent of disease: 
 
  1. Primary local         □ 
  
  2.Local recurrent      □ 
 
 3.Metastatic               □ 
  
 4.Disease free             □ 
 
 
  Treatment : 
  
  Chemotherapy            □ 
 
  Radiotherapy              □ 
 
  Surgery                        □ 
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Appendix 2-M: Information leaflet that was included in the information pack  
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Appendix 2-N: Breast specific Patient Concerns Inventory  
 
 
Patients who have had breast cancer usually report issues in the following areas. If you 
were to attend a clinical consultation today which of the following issues would you wish 
to discuss with your Breast specialist  
1. General Information 
 
□ Activity (Conflicting information about exercise; unable to do exercise or 
problems returning to my daily routine) 
□ Information about Breast Cancer (Unable to get or unable to understand) 
□ Information about personal hygiene (May be related to breast prosthesis 
or wig) 
□ Lifestyle (Smoking/ alcohol-started or unable to stop) 
□ Complementary /Homeopathic Medicines (Problems with or unable to get        
information about) 
□ Fertility issues following treatment (Problems with or unable to get 
information about) 
2. Body Image-related  
 
□ Appearance (Overall physical appearance) 
□ Arm appearance  
□ Breast appearance 
□ Breast Prosthesis / Padding 
□ Hair loss 
□ Hair replacement (wig) 
□ Weight (Unable to control my weight) 
□ Wound healing (Scar appearance)  
□  Mastectomy appearance 
3. Physical Functioning and health-related  
 
□ Appetite 
□ Arm swelling (Lymphoedema) 
□ Diarrhoea  
□          Constipation 
□ Breast texture 
□ Breast sensitivity /Breast pain 
□ Cancer Treatment 
□ Sore mouth / Dry Mouth 
Breast Cancer Specific Patients Concern Inventory-56 items 
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□ Fatigue / Tiredness (Low energy levels overall) 
□ Indigestion 
□ Memory/ Concentration 
□ Nausea 
□ Pain in the Breast 
□ Pain in the arm or shoulder 
□ Pain elsewhere 
□ Sleeping 
□ Swallowing 
□ Taste 
□ Vomiting / Sickness 
□ Hot Flushes 
4. Psychological state and emotional well being-related  
 
□ Angry (why me?, why this treatment) 
□ Anxiety (Related to the diagnosis or treatment) 
□ Coping (coping with the disease, the treatment or the side effects of 
treatment) 
□ Depression 
□ Fear of Cancer coming back 
□ Fear of Cancer spreading 
□ Mood 
□ Self esteem 
□ Temperament and personality 
□ Fear about the future 
5. Sexual Functioning 
 
□ Intimacy 
□ Relationships 
□ Sex 
6. Social Functioning/ Family-related 
 
□ Financial issues 
□ Home care / district nurse support  
□ Mobility 
□ Spiritual / Religious aspects 
□ Support for my family 
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□ Worried about the future of my children 
□ Unable to go out and enjoy my family 
□ Unable to go to go to work 
7. □        Other, please state 
 
.................................................................................................................. 
 
 
If you were to attend a clinical consultation today which of the following members of staff 
would you like to see or be referred on to: 
□ Breast surgeon (He or she will perform the biopsy of the breast tumour and the 
lumpectomy or mastectomy) 
□          Plastic surgeon (This doctor performs your breast reconstruction) 
□          Medical oncologist (This specialist administers anticancer drugs or chemotherapy) 
□          Radiation oncologist (He or she administers radiation therapy) 
□ Breast Care Nurse  
□ Chaplain 
□ Psychologist (He or she may help with anxiety /depression) 
□ Dietician 
□ Lymphoedema specialist /clinic 
□ Hair prosthesis (wig advisor) / Breast prosthesis expert 
□ Nurse Practitioner (Person that removed fluid from my operation site) 
□          Pain specialist 
□          District Nurse 
□          My own doctor (General Practitioner) 
□ Complementary therapies 
Referral Options at consultation: 
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Appendix 2-O: Breast cancer specific patient concerns inventory following formatting 
to be consistent with the Head and Neck PCI 
 
  
PSYCHOLOGICAL STATE AND EMOTIONAL WELL BEING
GENERAL INFORMATION
PHYSICAL FUNCTIONING AND HEALTH-RELATED
Activity (Conflicting information about exercise; 
unable to do exercise or problems returning to my 
daily routine)
Complementary / Homeopathic Medicines 
(Problems with  or unable to get information about)
Fertility issues following treatment (Problems with 
or unable to get information about)
Lifestyle (Smoking / Alcohol-started or unable to 
stop)
Information about Breast cancer
Information about personal hygiene
Angry (Why me? Why this treatment?)
Anxiety (Related to the diagnosis  or treatment)
Coping (with the disease, the treatment, the side 
effects of treatment)
Depression
Fear about the future
Fear of cancer coming back
Fear  of cancer spreading
Mood
Self esteem
Temperament and personality
Intimacy
Relationships
Sex
SEXUAL FUNCTIONING
Appetite
Arm swelling (Lymphoedema)
Breast texture
Breast sensitivity /Breast pain
Cancer treatment
Constipation
Diarrhoea
Fatigue / Tiredness (Low energy levels)
Hot flushes
Indigestion
Breast Cancer 
Patient Concerns Inventory
Please choose from the list of issues you would specifically like to talk about in your consultation in clinic 
today. You can choose more than one option: (Tick the box )
More next page 
BODY  IMAGE-RELATED
Appearance (Overall  physical appearance)
Arm appearance
Breast appearance
Breast prosthesis / Padding
Hair loss
Hair replacement (wig)
Mastectomy appearance
Weight (Unable to control my weight)
Wound healing (Scar appearance)
Memory / Concentration
Nausea/ Vomiting / Sickness
Pain in the breast
Pain in the arm or shoulder
Pain elsewhere
Sleeping
Sore mouth / Dry mouth
Swallowing
Taste
SOCIAL FUNCTIONING / FAMILY-RELATED
Financial issues
Home care / district nurse support
Mobility
Spiritual / Religious aspects
Support for my family
Unable to go  out and enjoy my family
Unable to go to work
Worried about the future of my family
OTHER
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SOCIAL CARE & SOCIAL WELL-BEING 
PHYSICAL & FUNCTIONAL WELL-BEING TREATMENT-RELATED 
PSYCHOLOGICAL, EMOTIONAL & SPIRITUAL 
WELL-BEING 
OTHERS 
Breast Cancer 
Patient Concerns Inventory 
Please indicate the people you would specifically like to talk with either in clinic or by referral. 
You can indicate more than one person. (Tick the box ) 
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Appendix 2-P: Patient Information Sheet—Revision 1       
                    
 
Anastasios 
Kanatas, BSc 
(Hons), BDS, 
MBChB (Hons), 
MFDSRCS, 
MRCSRCS, PhD, 
PGC. Specialty 
Registrar in 
Surgery, Leeds 
Teaching Hospitals 
and St James 
Institute of 
Oncology 
a.kanatas@doctors.
org.uk 
Tel:07769946105 
Institute of Oncology 
We would like to invite you to take part in a RESEARCH study that will involve the 
completion of a maximum of two questionnaires. Some people will only receive one 
questionnaire after their consultation with the clinical team whilst other patients will receive 
one before and a further questionnaire after their consultation. The patients that will agree to 
take part will be divided into two groups. In the first group patients will complete the 
questionnaire after their appointment with the clinical team. In the second group patients will 
be asked to complete a questionnaire before they see their doctor and one just after. The 
allocation of patients into the two groups will be based on a number randomly generated 
from a computer program. Your consultation will be recorded anonymously. Before you 
decide whether to take part, please read this information sheet to find out why the research is 
being done and what it involves. Please take time to read the following information 
carefully. Talk to others about the study if you wish, and ask the researcher if you have any 
questions at all. 
 
What is the purpose of the study? 
Treating cancer is still based on three options-surgery, radiotherapy, and chemotherapy. 
However, these may simply treat the disease, rather than the person. It is recognised that 
every patient has different issues at different times after a diagnosis of cancer. There can be 
unmet needs that may be difficult to identify in a busy clinic. There are barriers to an 
effective patient with cancer and carer consultation. There is reliance on verbal 
communication but certain patient issues could be considered taboo. The aim of the study is 
to gain an understanding of standard practice in oncology with respect to how patients 
discuss problems with their doctor and how decisions are made. This is needed for several 
reasons: 
 
Leeds Institute of Molecular MedicineLeeds Institute of olecular edicine
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 1) In the near future we will aim to introduce a new approach in detecting patient problems, 
by asking patients to respond to brief questionnaires on touch-screen computers and giving 
them to their doctors. This initial period of assessment will provide the research team with 
information that will be used for the development of the brief questionnaire. 
 
2) The information from the consultations and the questionnaires will help to develop and 
individualise the consultation to the specific patient needs. 
 
Why have I been invited? 
We are inviting patients who have had treatment for breast cancer and are between one year 
and three years post diagnosis. We are hoping to recruit about 100 patients in this study. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given this 
information sheet to keep. Then you will be asked to sign a consent form. Even after signing 
the consent form, you are free to decide not to take part and you do not have to give us a 
reason for doing so. A decision not to take part will not affect the standard of medical care 
you receive. 
 
What will happen to me if I take part? 
All suitable patients will be identified by the treating consultant (Mr Horgan) and the 
Clinical Nurse Specialists. (CPN). During your routine clinic appointment you will be asked 
if you would like to participate in this study, starting at the next appointment. This will be at 
least 4 weeks in advance. If you wish to consider this, you will be given the study 
information pack by the clinical team. This will include the study details and a consent form. 
If you wish to take part, the study will take place at your next appointment. 
 
One group will attend for their clinic appointment as normal. Their consultation will be 
recorded by the principal investigator (Mr Kanatas).  After the consultation, they will be 
asked to fill in a brief questionnaire about their satisfaction with the consultation.  
The second group will be asked to complete a questionnaire whilst in the waiting room prior 
to their clinic appointment. Then they will see their doctor as normal. Their consultation will 
be recorded. After the consultation they will be asked to fill in a brief questionnaire about 
their satisfaction with the consultation. 
 
The questionnaires cover issues relating to doctor-patient communication, symptoms, 
emotions, coping, and family life. You are not obliged to answer any question that you are 
not comfortable with. 
 
Why will my consultation be audio recorded? 
Part of this research will be to develop ways to identify patients with problems when they 
attend in the clinic. This may be difficult due to the busy nature of out-patient clinics. A 
large volume of information may be presented during a consultation and in order to ensure 
accurate collection the most efficient way is to audio record the consultation. Your 
consultation will be recorded but will be anonymised before analysis. Also, if you  feel 
uncomfortable at any point you can ask for the recording to be stopped. 
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When would I take part? 
Please take the time to read all the information provided and if you wish you can discuss 
with the researchers, clinic staff and your carer(s). 
If you decide you would like to take part in this study, please inform the researcher present 
in clinic. You will be asked to read and sign the consent form (a copy is shown overleaf). 
You can keep this information sheet and a copy of the signed consent form. 
 
 
Will my taking part in this study be kept confidential? 
All information from the questionnaires is confidential. The questionnaire data will be kept 
securely and will only be available to the principal investigator (Mr A Kanatas) and to your 
Breast Surgeon (Mr Horgan).  
 
What are the possible disadvantages of taking part? 
The questionnaires may take about 8 minutes of your time to complete. We have looked at 
alternative methods but at present this is the best way to collect the information required for 
this research. Also we will ensure that you will not be disadvantaged with respect to the 
timing of your appointment or any parking arrangements. 
 
What are the possible benefits of taking part? 
We hope the information you provide will contribute to improving the support we can offer 
patients in the future and be able to identify specific problems at every consultation. 
 
 
 
Thank you for taking the time to read this information sheet and consider this study. 
If at any point you have questions or concerns regarding this study, please contact 
the researchers below: 
 
1).Mr A Kanatas  Tel:07769946105 
e-mail:a.kanatas@doctors.org.uk 
 
2).Galina Velikova, Professor of Psychosocial and Medical Oncology 
/Consultant Medical Oncology, Level 4, Bexley Wing, St James's Institute of Oncology, St 
James's Hospital, Beckett street, Leeds LS9 7TF, UK. Tel: +44 113 2067917 Fax: +44 113 
2068512 e-mail: g.velikova@leeds.ac.uk 
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Appendix 2-Q: –Patient Consent Form for focus group-Version 2.1 
  
 
Anastasios 
Kanatas, BSc 
(Hons), BDS, 
MBChB (Hons), 
MFDSRCS, 
MRCSRCS, PhD, 
PGC. Specialty 
Registrar in 
Surgery, Leeds 
Teaching Hospitals 
and St James 
Institute of 
Oncology 
a.kanatas@doctors.
org.uk 
Tel:07769946105 
 
 
Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
CONSENT FORM 
Title of Project: Further Development of The Patients Concerns Inventory (PCI) to help 
reveal patients concerns in Breast Oncology clinics 
Name of Researcher: A Kanatas 
Please initial 
all boxes 
1. I confirm that I have read and understand the information sheet dated 
08/07/2012 (version 2.1-Revision 1) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
   
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected. 
 
Leeds Institute of Molecular MedicineLeeds Institute of olecular edicine
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3. I understand that relevant sections of my medical notes and data collected 
during the study, may be looked at by individuals, from regulatory authorities 
or from the NHS Trust, where it is relevant to my taking part in this research.  I 
give permission for these individuals to have access to my records. 
 
4. I understand that the meeting will be audio recorded.    
 
5. I agree to take part in the above study.    
 
6.          I give permission for anonymised direct quotes to be included in a written report  
       and publications. 
 
 
            
Name of Participant   Date    Signature 
  
            
Name of Person   Date    Signature  
taking consent.  
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Appendix 2-R: Consultation  satisfaction questionnaire 
 
 
 
 
 
Please think about the consultation you had at the oncology clinic today. Look at 
the questions below and tick a box on each line to indicate your response.  
 
1. To what extent was your main problem(s) discussed today? 
Completely  □ Mostly □ A little □ Not at all □ 
 
2. How satisfied were you with the discussion of your problem(s)? 
 Very satisfied □  Satisfied □ Somewhat satisfied  □ Not 
satisfied □ 
 
3. To what extent did the doctor listen to what you had to say? 
 Completely □ Mostly □ A little □ Not at all □ 
 
4. To what extent did the doctor explain your problem(s) to you? 
 Completely □ Mostly □ A little □ Not at all □ 
 
5. To what extent did you and the doctor discuss your respective roles? (Who is 
responsible for  making decisions and who is responsible for what aspects of your 
care?)  
Completely □ Mostly □ A little □ Not discussed □ 
 
6. To what extent did the doctor explain treatment? 
 Very well □ Well □ Somewhat  □ Not at all □ 
 
7.  To what extent did the doctor explore how manageable this (treatment) would be for 
you?  He/she explored this… 
Completely □ Mostly □ A little □ Not at all □ 
 
8. How well do you think your doctor understood you today?  
Very well □ Well □ Somewhat  □ Not at all □ 
 
9. To what extent did the doctor discuss personal or family issues that might affect 
your health? 
 
Consultation Questionnaire 
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Completely □ Mostly □ A little □ Not at all □ 
 
 
 
 
 
 
 
 
Thank you for completing these questionnaire. 
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Appendix 2-S: Thematic framework used in the identification of issues from the 
consultation recordings 
ITEM CHECKLIST 
Items of concern Phrase/terms used Assessor  
1 
Assessor 
2 
Items 
missed 
Item 
resolved 
GENERAL 
INFORMATION 
     
Activity Information about 
exercise; unable to do 
exercise or problems 
returning to my daily 
routine / 
Job/duties/work/trave
lling/holidays 
    
Complementary / 
Homeopathic 
Medicines 
Problems with  or 
unable to get 
information, 
reflexology, 
Relaxation 
techniques, 
Acupuncture, Bio-oil, 
Primore oil, E45 
    
Fertility issues 
following 
treatment 
(Problems with or 
unable to get 
information about) 
    
Lifestyle Smoking / Alcohol-
started or unable to 
stop, dependence, 
addiction, habit, 
nicotine patches 
    
Information about 
Breast cancer  
 
     
Information about 
personal hygiene  
 
Prosthesis related 
such as wig /padding 
    
BODY IMAGE-
RELATED 
     
Appearance 
(Overall  physical 
appearance 
Ugly, disfigurement, 
'does not look right' 
    
Arm appearance  
 
Ugly, disfigurement, 
'does not look right' 
    
Breast appearance Ugly, disfigurement, 
'does not look right' 
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Breast Prosthesis / 
Padding 
     
Hair Loss      
Hair replacement 
(wig) 
     
Mastectomy 
appearance 
     
Weight Unable to control my 
weight, putting on 
weight, losing 
weight, 'fat', 'thin'. 
    
Wound healing Scar appearance, 
infection, scars, 
dressing 
    
PHYSICAL 
FUNCTIONING 
AND HEALTH-
RELATED 
     
Appetite Fancy food, desire to 
eat, hungry, enjoy 
food 
    
Arm swelling Lymphoedema     
Breast texture Hard, firm, skin feels 
different 
    
Breast sensitivity /  Breast pain     
Cancer treatment      
Constipation Hard stools, 
difficulties passing 
stools 
    
Diarrhoea Runny stools     
Fatigue / Tiredness  Low energy levels, 
lethargic, lacking 
energy, tiredness, 
exhausted, weary 
'creased' 
    
Hot flushes Feeling hot, hot 
sweats 
    
Indigestion Acid reflux, 
heartburn 
    
Memory / 
concentration 
Forgetfulness, poor 
memory, absent-
minded 
    
Nausea / 
Vomiting/ 
Sickness 
Feel ill, poorly, 
nausea, 'being sick', 
'being ill' ,'throw-up'. 
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Pain in the breast      
Pain in the arm or 
shoulder 
Stiff shoulder, Can't 
lift arm 
    
Pain elsewhere Pain, sore, ache, 
discomfort in other 
parts of the body, 
joint stiffness 
    
Sleeping Insomnia, can't get to 
sleep, awake at night 
    
Sore mouth / Dry 
mouth 
Parched mouth     
Swallowing Food stuck, painful 
swallowing 
    
Taste Can't taste food, food 
tastes awful / 
different 
    
PSYCHOLOGIC
AL STATE AND 
EMOTIONAL 
WELL BEING 
     
Angry Annoyed, angry, 
frustrated, furious, 
irritated 
    
Anxiety Worry, nervous, 
concern, fear, scared, 
panic, shock 
    
Coping Dealing with issues, 
putting-up, struggling 
    
Depression Feeling down /low, 
despair, sadness, 
worthlessness 
    
Fear about the 
future 
Worry about the 
future 
    
Fear of cancer 
coming back 
Worry about the 
cancer returning 
    
Fear of cancer 
spreading 
Worry about cancer 
spreading 
    
Mood Mood, loss of 
motivation, feeling 
emotional, tearful 
    
Self-esteem Emotional 
assessment of self-
worth, attitude 
toward self, feel a 
nuisance 
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Temperament and 
personality 
Shy, quite, character, 
pessimistic, feeling 
emotional 
    
SEXUAL 
FUNCTIONING 
     
Intimacy      
Relationships Connected, lonely, 
isolation 
    
Sex Sex drive, libido, 
fertility 
    
SOCIAL 
FUNCTIONING / 
FAMILY 
RELATED 
     
Financial issues Compensation, pay, 
money. 
    
Home care/ district 
nurse support 
Help at home     
Mobility Limp, Hobbling, 
balance issues 
    
Spiritual / 
Religious aspects 
Beliefs / faith, sense 
of peace/ purpose, 
meaning of life, 
prayer, concerns 
about death 
    
Support of my 
family 
Help for my family, 
housing 
    
Unable to go out 
and enjoy my 
family 
     
Unable to go to 
work 
     
Worried about the 
future of my 
family 
Worried about my 
children 
    
TOTAL     
 
 
PROFESSIONALS 
 Phrase/terms used Ass
ess
or  
1 
Ass
ess
or 
2 
It
e
m
s 
mi
Ite
m 
reso
lved 
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ss
ed 
TREATMENT-
RELATED 
     
Surgeon Breast surgeon, Plastic surgeon     
Radiation oncologist Radiotherapy doctor     
Medical Oncologist  Chemotherapy doctor     
Pain specialist      
Breast cancer nurse Macmillan nurse, case worker, diabetic 
nurse, wound care nurse 
    
Complementary 
therapies 
Acupuncture, relaxation     
SOCIAL CARE 
AND WELL-
BEING 
     
General practitioner Family doctor     
District nurse Home nurse support     
PHYSICAL AND 
FUNCTIONAL 
WELL-BEING 
     
Dietician      
Lymphoedema 
specialist /clinic 
     
Hair / Breast 
prosthesis / advisor 
Wig / Breast pudding     
Physiotherapist      
PSYCHOLOGICA
L, EMOTIONAL 
AND SPIRITUAL 
WELL-BEING 
     
Chaplain Priest, ‘somebody from church’, temple, 
imam 
    
(Clinical) 
Psychologist 
Psychologist     
TOTAL     
      
 
 
 
 
  
CLINICAL ACTION/DECISION TAKEN 
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Medical action Phrase/terms used Ass
esso
r  
1 
Ass
ess
or 
2 
It
e
m
s 
mi
ss
ed 
Ite
m 
reso
lved 
Placement on 
waiting list for 
rehabilitative-related 
surgery 
Implant placement, scar excision, Breast 
reconstruction 
    
Placement on 
waiting list for 
cancer-related 
surgery 
Core biopsy     
Symptomatic 
/supportive medical 
treatment 
Analgesia, antibiotics, topical analgesic 
gel, change of anti-oestrogen tablets 
    
Investigations Mammogram, Blood tests, ultrasound, 
CT scan, MRI scan 
    
Referrals Write referral letter, telephone referral, 
Write letter to the GP 
    
Other Discharge from clinic 
 
    
TOTAL     
 
 
 
 
  
Non-medical action  Phrase/terms used Ass
esso
r  
1 
Ass
ess
or 
2 
It
e
m
s 
mi
ss
ed 
Ite
m 
reso
lved 
Provision of 
information 
Explanation regarding concern item, 
information regarding cancer prognosis, 
information regarding progress of 
healing, reconstruction onformation 
Provide leaflet/video 
    
Lifestyle advice Smoking cessation, alcohol cessation, 
exercise, dietary intake 
    
Coping Suggestions for how to handle or 
manage concerns, Suggestion to 
meet/join support group 
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Reassurance Encouragement, comfort, assurance, 
gives hope 
    
Further surveillance New follow up appointment, 
mammogram 
    
Others Provide letter of support for patient, 
provide medical certificate, GP letter 
    
  
 
    
TOTAL     
 
 
  
 276 
 
P
ag
e2
7
6
 
Appendix 2-T: Thematic Framework development  
 
Steps 
 
Definition Process 
 
Familiarisation 
 
The process through which 
the researcher becomes 
familiarised with the data 
Listened to audio-recordings 
Read through transcripts 
Identification of 
thematic 
framework 
 
 
 
 
Identification of issues, 
themes and concepts from 
the data. They can also be 
based on previous 
knowledge 
At this stage the framework 
can be tentative and open to 
further changes for 
refinement based on logical 
and intuitive thinking 
Previous knowledge of the themes was 
gained from the Head and Neck PCI. 
Themes were structured according to a 
collection of words, terms, and 
expressions considered to be of the 
same type. This provided a 
standardised list for reference during 
evaluation 
 
 
Indexing 
Identification of portions or 
sections of data that 
correspond to a particular 
theme 
Transcripts were analysed by two 
assessors using thematic coding 
Portions of data that represented a 
theme were highlighted in the text, and 
the corresponding theme annotated in 
the margin for the purpose of indexing 
 
Charting 
Organisation of indexed 
data into charts  
Both assessors met to agree the codes. 
For each transcript assessed by both, 
the items were considered as “item 
agreed” or “missed”. Those missed 
were discussed and ultimately resolved. 
Some items were missed because they 
had been overlooked, misclassified, or 
the theme was not included on the 
thematic framework. They were 
carefully considered to create new 
themes to refine the existing 
framework  
Mapping and 
interpretation 
Analysis of key 
characteristics as set out in 
the tables 
The indexed themes from the transcript 
were tabled according to type 
This was contrasted against another 
table consisting of the items identified 
by patients on the PCI before 
consultation 
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Appendix 2-U: Thematic framework and consultation interviews 
ITEMS OF CONCERN INTERVIEW PART 
GENERAL 
INFORMATION 
 
Activity  
Complementary / 
Homeopathic Medicines 
Patient 17: ' I have tried massaging with a...bio-oil, its 
like a moisturiser thing..' 
Fertility issues following 
treatment 
 
Lifestyle  
Information about Breast 
cancer  
 
Patient 33: 'My breast cancer...is it dangerous?...what 
type is it? Please let me know more.. 
Information about personal 
hygiene  
 
 
BODY IMAGE-RELATED  
Appearance (Overall  
physical appearance 
 
Arm appearance  
 
Patient 5:...'This side of my arm...I think is getting 
bigger' 
Breast appearance Patient 2: ' I just don’t like it as it is now, obviously 
because there is a massive difference. I don’t expect them 
to be exactly the same size anyway, because they weren’t 
anyway. So its just...' 
 
 
Breast Prosthesis / Padding Patient 19: ' the only thing I don’t like is you can’t wear 
anything low because if you bend forwards, even though 
you’ve got these, it goes forward' 
 
Hair Loss Patient 35: ' doc: Arimidex. How are you managing with 
those? Are they alright for you? 
pat: yeah, yeah. I think I do get, as it says, hair loss... 
erm... you know, but other than... I just take them and 
that's it' 
 
Hair replacement (wig)  
Mastectomy appearance Patient 25: ' ... so obviously after the surgery the breast 
size is different one side compared to the other...' 
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Weight Patient 7: ' Are you having any bother with the tamoxifen 
in terms of... 
Pat: no. I’ve put weight on definitely, I know 
that’s...common yeah...' 
Wound healing Patient 2: ' well I had, I don’t know if he didn’t mention 
that one, twisted the first implant I had in so they had to 
take that out and put another one in. So that one had been 
fine, this one. And obviously then my skin decided to split 
instead...' 
PHYSICAL 
FUNCTIONING AND 
HEALTH-RELATED 
 
Appetite Patient 21: ' I just don’t feel well 
Doc: how is your appetite? 
Pat: I don’t eat much at all 
Doc: are you losing weight? 
Pat: yeah..' 
Arm swelling Patient 5: ' So its a bit better than it was...but it does 
flare up occasionally (lymphoedema), but its one of these 
things that I’ve come to...You have to live with it really, 
there is not a lot you can do about it...' 
Breast texture Patient 2: ' no I don’t...because I can tell what this feels 
like, I don’t mean like firmer, I mean like it never moved. 
So I didn’t know if it was too big compares to...so I 
thought if it was smaller there might be more room in it' 
Breast sensitivity /  Patient 14: ' and there, it feels funny...pulling sensation. 
It sometimes feel like there is something tickling inside...' 
Cancer treatment Patient 2: ' Doc: it takes multiple goes of doing fat 
injections 
Pat: I’d rather have a mastectomy then having one of 
them again 
Doc: yeah 
Pat: its painful' 
 
Constipation  
Diarrhoea  
Fatigue / Tiredness Patient 8: '... its just that my whole body wants to lie 
down... the problem is, will my body will stand all this? 
Quite honestly...because I could just flop quite quickly... 
' if you don’t have the strength you can’t fight really' 
Hot flushes Patient 20: ' ... if you said to be it would stop the flushes, 
then...like a shot I would swap...' 
Indigestion  
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Memory / concentration  
Nausea / Vomiting/ Sickness Patient 39: ' are you managing alright with Letrozole? 
yes,...I feel sick in the morning so I started taking it at 
night.' 
Pain in the breast Patient 7: ' it is actually, I was really lucky it didn’t go so 
hard, but its  still quite tender where the lump was taken 
out...' 
Pain in the arm or shoulder  
Pain elsewhere Patient 11: '  The joint pains..is joint pains and stiffness 
you are getting  as well, isn’t it? 
Pat: its shooting pains in joints and stiffness and my neck 
is very bad, erm, I was diagnosed during the summer with 
that and that’s partly, my skin because of the pain...My 
skin tends to open and then I get a pain...so its a vicious 
circle.' 
Sleeping Patient 9: ' ...so I am not sleeping brilliantly...laying 
awake in the middle of the night...' 
Sore mouth / Dry mouth Patient 6: ' Letrozole  didn’t do me any good at all. In 
fact it gave me a very dry mouth...' 
Swallowing  
Taste  
PSYCHOLOGICAL 
STATE AND 
EMOTIONAL WELL 
BEING 
 
Angry Patient 48: '  I get... I get snappy coming up to medical 
appointments.. 
Doc: due to stress probably 
Pat: yeah probably...but apart from that, I am not snappy, 
am I? 
Husband: no' 
 
 
Anxiety Patient 9: ' I’ve got these, like two heads...you know; 
sensible head which is quite logical most of the time and 
then laying awake in the middle of the night...' 
Coping Patient 8: ' I don’t think I can stand anything. Quite 
honestly I don’t know if I could stand it' 
Depression Patient 7:' I don’t know if you can tell from my notes, its 
been quite a journey I’ve been down with all this. With 
the...initially I had been told to have a double 
mastectomy..' 
Fear about the future Patient 40: ' it's just that I've had the comfort of a 
mammogram every year and all of a sudden nothing. It 
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stops. And I think it's the fear of it stopping that... you 
know...' 
Fear of cancer coming back Patient 9: ' The sensible bit was like, you know, its fine, 
its going to be absolutely nothing, erm, but just a little bit 
at the back of your mind is there all the time, that is like: 
oh it could be again.' 
Fear of cancer spreading Patient 48: ' erm...does this tablet stop cancer forming in 
another part of my body..? 
Mood  
Self-esteem  
Temperament and personality Patient 6: ' this is making me very, very emotional. I was 
never like that..' 
' I can’t go to anybody without a cry..' 
SEXUAL FUNCTIONING  
Intimacy  
Relationships  
Sex  
SOCIAL FUNCTIONING / 
FAMILY RELATED 
 
Financial issues  
Home care/ district nurse 
support 
 
Mobility  
Spiritual / Religious aspects Patient 6: '  I pray for them each morning that I won’t get 
any. But we are not talking just a flush we are talking one 
after the other, after the other...' 
Support of my family  
Unable to go out and enjoy 
my family 
Patient 6: '...you can’t get ready to go anywhere because 
the sweat  (hot sweats) is coming through... 
Unable to go to work  
Worried about the future of 
my family 
Patient 19: ' because the thought of not eing able to pick 
up my grandkids would kill me...' 
TOTAL 
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Appendix 2-V: Breast cancer specific PCI following input from the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PSYCHOLOGICAL STATE AND EMOTIONAL 
WELL BEING 
GENERAL INFORMATION 
PHYSICAL FUNCTIONING AND HEALTH-
RELATED 
SEXUAL FUNCTIONING 
Breast Cancer  
Patient Concerns Inventory 
Please choose from the list of issues you would specifically like to talk about in your 
consultation in clinic today. You can choose more than one option: (Tick the box ) 
More next 
page  
BODY  IMAGE-RELATED 
SOCIAL FUNCTIONING / FAMILY-RELATED 
OTHER 
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SOCIAL CARE & SOCIAL WELL-BEING 
PHYSICAL & FUNCTIONAL WELL-BEING TREATMENT-RELATED  
PSYCHOLOGICAL, EMOTIONAL & SPIRITUAL 
WELL-BEING 
OTHERS 
Breast Cancer 
Patient Concerns Inventory 
Please indicate the people you would specifically like to talk with either in clinic or by referral. 
You can indicate more than one person. (Tick the box ) 
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APPENDIX SECTION 3: Publications in Support of Thesis 
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Appendix 3-A Summary of Publications related to the PCI: 
 
1. A Kanatas, N Ghazali, D Lowe, M Udberg, J Heseltine, E O’Mahony, SN Rogers. 
Issues patients would like to discuss at their review consultation: variation by early 
and late stage oral, oropharyngeal and laryngeal subsites. European Archives of Oto-
Rhino-Laryngology 270 (3), 1067-1074  
2. A Kanatas, N Ghazali, D Lowe, SN Rogers. The identification of mood and anxiety 
concerns using the patients concerns inventory following head and neck cancer. 
International journal of oral and maxillofacial surgery 41 (4), 429-436 
3. Kanatas A, Velikova G, Roe B, Horgan K, Ghazali N, Shaw RJ, Rogers SN. Patient-
reported outcomes in breast oncology: a review of validated outcome instruments. 
Tumori. 2012 Nov;98(6):678-88. 
4. N Ghazali, A Kanatas, B Scott, D Lowe, A Zuydam, SN Rogers. Use of the Patient 
Concerns Inventory to identify speech and swallowing concerns following treatment 
for oral and oropharyngeal cancer. The Journal of Laryngology & Otology 1 (1), 1-9 
5. N Ghazali, A Kanatas, F Bekiroglu, B Scott, D Lowe, SN Rogers. The Patient 
Concerns Inventory: A Tool to Uncover Unmet Needs in a Cancer Outpatient Clinic. 
Bulletin of The Royal College of Surgeons of England 95 (3), 1-6 
 
Appendix 3-B Poster presentations related to the breast cancer specific PCI: 
 
A. Development Of A Breast Cancer Specific PatientsConcerns Inventory (PCI). 
Kanatas A, Velikova G, Roe B, Horgan K, Lowe. Psycho-Oncology 03/2012;21:1-
20 
B. Integrating Quality Of Life And Patient Concerns Into Routine Out-Patients Clinics 
As A Tool To Promote Intervention. Rogers S, Ghazali N, Kanatas A, Roe B.  
Psycho-Oncology 03/2012; 21(Suppl. 2):1–20  
C. Uncovering patients' concerns using the patient concerns inventory (PCI) in routine 
head and neck and breast oncology follow up clinics: a comparative study. Kanatas 
A, Velikova G,  Lowe D, Roe B, Horgan K, Ghazali N,Shaw RJ and Rogers SN 
BAHNO 04/2013. 
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Appendix 3-C: Issues patients would like to discuss at their review consultation in 
Breast Cancer clinics-a cross-sectional survey 
A Kanatas1, D Lowe2, G Velikova3, B Roe4, K Horgan5, RJ Shaw6 and SN Rogers7 
Abstract 
Introduction: 
In breast cancer (BC) there are different therapies available with different side-effects 
affecting the health-related quality of life (HRQOL). The Patient Concerns Inventory (PCI) 
for head and neck cancer patients was used as the basis to develop a PCI instrument for BC 
patients. Here we report the concerns that BC patients would like to discuss  in the outpatient 
clinic and also their choice of  multidisciplinary team (MDT) members they would like to 
see. 
Methods: 
Cross-sectional survey, using the BC specific PCI, of patients who had completed their 
initial treatment and attending a review outpatient clinic. 249 patients were recruited from 
February to July 2012. 
Results: 
Survey responses were obtained from 80% (200/249). The three most frequent items were 
Fear of Cancer coming back (62%, 124), Breast sensitivity/pain (46%, 92), 
Fatigue/tiredness- low energy levels overall (46%, 92). The most frequently selected 
members of the MDT that patients wished to see were the Breast care nurse (46%, 92), 
Medical oncologist (28%, 55) and Psychologist (20%, 40).  
Conclusions: 
The PCI may empower patients to raise issues that otherwise could be missed. It provides the 
opportunity for multiprofessional engagement across a range of issues specific to BC thus 
allowing for additional support which  might help resolve more symptoms and improve 
HRQOL. The BC specific PCI is a practical tool that may assist in the holistic needs 
assessment of patients during the cancer journey. 
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Appendix 3-D: Fear of recurrence (FOR)-a cross sectional study using the breast 
cancer (BC) specific Patient Concerns Inventory (PCI) 
A Kanatas, D Lowe, G Velikova, B Roe, RJ Shaw, G Humphris and SN Rogers 
 
Abstract 
Introduction: 
Fear of recurrence (FOR) is an issue that is present to varying degrees in almost all cancer 
survivors.   Fear of cancer recurrence (FOR) is a well recognised challenge in BC patients 
and is often an unmet need. This study aimed to explore the role of the BC specific PCI in 
the identification of those patients who report the wish to discuss FOR. 
Methods: 
Cross-sectional survey, using the BC specific PCI with an established breast cancer HRQOL 
measure [EORTC C30 (European Organisation for Research and Treatment of Cancer) with 
BR23] , of patients that had completed their initial treatment and attending in a review 
outpatient clinic. 249 patients were recruited. 
 
Results: 
Survey responses were obtained from 80% (200) of the 249 patients.  49% (122), wanted to 
discuss fear of recurrence, 31% (77) fear of cancer spreading and 25% (62) fear about the 
future, with 57% (141) one or more of these. 
 
Conclusions: 
The PCI may empower patients to raise the issue of FOR that otherwise could be missed. BC 
survivors may use the PCI to convey their concerns to their clinicians. FOR is a difficult 
subject to approach in a routine outpatient clinic. The PCI is tool that provides an 
opportunity to broach and to address this issue early, rather than patients dwelling on their 
fear and potentially adopting negative coping. 
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Appendix 3-E: The breast cancer specific Patient Concerns Inventory (PCI) as a means 
to assist the identification of body image concerns in routine follow up clinics 
A Kanatas1, D Lowe2, G Velikova3, B Roe4, J P White5, RJ Shaw6 and SN Rogers7 
 
Introduction 
Many changes to our appearance may occur through life. These may be planned or unplanned, 
desired or not (1). There are several definitions of body image in the literature based on body 
size estimation, evaluation of body attractiveness, feelings associated with body size and shape 
(2). The definition we use relates body image to a person's perceptions, feelings and thoughts 
about his or her body (2,3). 
Women treated for breast cancer endure scars and disfigurement of the breast, skin changes 
related to radiotherapy and/or hair loss due to chemotherapy (4,5). These effects from the 
disease and its treatment are life changing and can lead to a significant alteration in body image 
(5,6). In turn this effect on body image can result in undesirable Health-Related-Quality-of 
Life (HRQOL) changes that affect the transition from patient to breast cancer survivor (7-12). 
Younger patients may be more susceptible to stress related to change in body image and report 
greater changes in HRQOL scores (11-16). Brunet et al (2013) (17) reported that women with 
breast cancer experienced various physical changes that negatively affected, their perceptions, 
thoughts, attitudes, feelings, and beliefs about their bodies. Based on these findings they 
highlighted the need to recognise body image concerns that could have a long lasting effect on 
the HRQOL. 
The link between body image disturbance, lower self-compassion and an increase level of 
distress has been recognised by Przezdziecki et al (2012) (18). Specific treatment options, such 
as mastectomy, may adversely affect specific aspects of body image such as problems related 
to sexual intimacy (19). Mastectomy may alter body image so much that can obliterate sexual 
relationships for a period of time (30). Support in relation to sexuality and body image could 
improve relationships by modifying perceptions with a direct improvement in patients’ and 
spouses’ HRQOL (31). Clinicians do not always elicit such concerns from patients. One way 
of improving recognition of these problems is to develop tools to improve clinicians’ 
communication with patients. Cohen et al (2012) suggested that patients want honesty, 
openness, and directness from their physicians during the discussion of breast-related body 
image issues (20). Breast cancer patients rate the information on physical changes, sexual 
response and body image as very important (21). However, Ussher et al (2013) reported that 
only 41% of their patients obtained such information,  hence only 34% of patients claimed to 
be satisfied with this aspect of their consultation.  
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Body image can affect a woman’s treatment decisions with respect to surgical options such as 
mastectomy versus breast conserving surgery (22). A multidisciplinary approach to address 
the impact of body image, with specific medical and psychosocial interventions has been 
analysed (23). Younger patients take longer to make treatment decisions and require enhanced 
levels of support compared to older adults. The availability of breast reconstruction only 
partially ameliorates this effect (24). 
Body image changes associated with mastectomy, chemotherapy and radiotherapy are well 
recognised (25,26,27). Up to a third of women report moderate or marked breast, arm, and 
shoulder symptoms over 5 years of follow-up after radiotherapy, and skin changes related to 
radiotherapy are well document in the literature (28). However, these appear to have little 
impact on body image. As expected, adjuvant treatments (chemotherapy and radiotherapy) are 
associated with decrease in overall HRQOL, an increase in physical problems and adverse 
effects on the body image (29,30).  
Tools to evaluate changes in body image following breast cancer exist and may be used in 
both research and clinical settings (32). A number of HRQOL instruments in use in breast 
oncology have incorporated body image questions (32-40) (Table 1). HRQOL questionnaires 
are designed as outcome measures to compare groups of patients. Although some studies have 
described their use in clinical practice, they are not specifically designed for this context. 
While it is tempting to use the scores derived from such tools to screen patients from problems 
relating to body image, thresholds to trigger specific interventions are not currently defined in 
breast cancer care. Furthermore, these tools are time-consuming to use and hence may not be 
practical in a busy clinical environment. 
In other types of cancer, HRQOL tools have been used as a trigger for discussion of patients’ 
problems of appearance (41). HRQOL tools can help focus the consultation and are a suitable 
means of screening for appearance issues (42). In head and neck cancer the Patient Concerns 
Inventory (PCI) has been used with HRQOL tool and its role has been defined (43).  
The PCI enables holistic evaluation of body image concerns in the breast cancer outpatient 
clinic (44). The aim of this work is to assess the role of the breast cancer specific PCI in the 
identification of body image concerns in breast cancer patients and compare this against an 
establish HRQOL such as the European Organization for Research and Treatment of Cancer 
breast cancer-specific quality of life questionnaire module (BR23). 
Materials and methods 
We have performed a cross-sectional survey, using the BC specific PCI with an established 
breast cancer HRQOL measure [EORTC C30 (European Organisation for Research and 
Treatment of Cancer) with BR23]. A convenience sample of 249 breast cancer patients was 
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recruited prospectively from February to July 2012. The patients had completed their initial 
treatments and were attending an outpatient clinic for review. Patients were recruited by the 
clinical team at the outpatient clinic but participants completed the questionnaires at home.  
Prospective study participants received a study information pack containing details about the 
study and the BC specific PCI. The BC specific PCI (44) has two parts and includes 55 items 
that are divided into six groups. In the first part the groups include general information, body 
image- related, physical functioning and health-related, psychological state and emotional 
well being, sexual functioning and social functioning  / family-related. In the second part 
there is a list of the members of the breast cancer MDT that the patients are given the option 
to consult, either in the clinic or by referral. The Body image -specific domains include 
overall physical appearance, arm appearance, breast appearance, breast prosthesis / padding, 
hair loss, hair replacement (wig), mastectomy appearance, weight and wound healing (scar 
appearance).   
Also the pack included a consent form and a reply slip. Study participants also gave consent 
for the principal investigator to collect social and treatment-related data from their clinical 
files. Approval for this study was granted by the Leeds Central Ethics Committee.  
Statistical analysis was performed using SPSS version 19. The distribution of PCI body 
image related items (range 0-9) was analysed using the Mann-Whitney test. Patient/clinical 
subgroups was compared by the number of body image related items selected using the 
Kruskal-Wallis or Mann-Whitney test as appropriate. The association of number of PCI 
Body image related items with number of other PCI items selected overall or within domain 
and with number of health professionals selected, and with EORTC scores was assessed 
using Spearman rank correlation methods. In view of the multiple tests performed, statistical 
significance was taken as P<0.01.   
  
Results 
Survey responses were obtained from 80% (200/249) of participants. Response was lowest 
from patients aged ≥75 (63%), with primary local disease (72%), having anti-oestrogen 
therapy (72%), without radiotherapy (70%), and was higher after reconstructive surgery 
(96%). Median (IQR) age of responders was 59 (52-68) years, and the overwhelming 
majority were female (198), only two were male. The most recent breast cancer diagnosis 
was 2009/2010 for 54% (108), 2011/2012 for 31% (61), unknown 16% (31). Patients with all 
stages of disease were represented: 51% (101) primary local, 2% (3) local recurrent, 5% (9) 
metastatic and 4% (8) living with cancer (includes patients with hormonal or biological 
treatment as the only modality). The multimodal nature of breast cancer management was 
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reflected in the range of treatments received by participants: 47% (93) chemotherapy, 63% 
(126) radiotherapy, 47% (93) wide local excision / lumpectomy, 44% (88) mastectomy, 13% 
(25) reconstructive surgery, 41% (82) anti-oestrogen therapy. Responders were mainly from 
Leeds 57% (113), or Wakefield 32% (64), and 17% (30/178) lived in one of the 20% most 
deprived areas as defined by Indices of Multiple Deprivation (IMD).  
Two-thirds (68%, 136) of patients selected one or more of the nine PCI items within the 
Body-image-related domain, with 28% (56) selecting 1 item, 27% (54) selecting 2-3 items 
and 13% (26) selecting 4-8 items (Table 2).  In descending order of frequency the items 
selected were breast appearance 30%, weight- unable to control weight 28%, mastectomy 
appearance 19%, overall physical appearance 17%, wound healing – scar appearance 17%, 
breast prosthesis/padding 15%, hair loss 14%, arm appearance 13% and hair replacement-
wig 6%. Those who selected hair replacement-wig were a subset of those who selected hair-
loss. Nearly half (26/56) of those selecting just one item selected weight.  
There was significant correlation between the number of body image related items selected 
and the number of PCI items selected in other PCI domains, the total number of other PCI 
items selected and the total number of health professionals selected (Table 3).  Those 
selecting four or more body image related items also selected a median (IQR) of 17 (10-23) 
other items and there was a clear gradient in the increase in numbers of other items across 
the PCI and in the number of health professionals selected as the number of body image 
related items increased. This is reflected also in the analysis of specific PCI items (Table 4) 
and there were associations at P<0.01 for 37 of the 46 non-body image related items. There 
were associations at P<0.001 with wanting to discuss activity, arm swelling, breast texture, 
breast sensitivity/pain, indigestion, memory/concentration, nausea, pain in arm or shoulder, 
sleeping, taste, vomiting/sickness, anger, anxiety, fear of cancer spreading, mood, self-
esteem, fear about the future, and with wanting to see the plastic surgeon, medical 
oncologist, radiation oncologist, breast care nurse, lymphoedema specialist, hair prosthesis 
advisor/ breast prosthesis expert and nurse practitioner.  
The number of body image related items was significantly associated with treatment by 
chemotherapy, wide local excision/lumpectomy, mastectomy and reconstructive surgery 
(Table 5), with an increase in items related to chemotherapy and mastectomy and 
reconstructive surgery and the absence of wide local excision/lumpectomy. There was also a 
tendency for fewer items to be selected by older patients aged 65 years and over, but no 
notable differences in regard to the IMD deprivation measure and time of most recent 
diagnosis.  A fuller stratification by treatment combination is shown in Table 6.  
Correlations between the number of PCI body image related items and summary scores from 
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the EORTC QLQ-C30 and the EORTC breast cancer QLQ-BR23 are summarised in Table 7. 
These correlations were generally quite weak, the strongest of these being with the QLQ-
BR23 Body image score and the QLQ BR23 systemic therapy side effects score.  
Discussion 
To our knowledge this is the first study in which the BR23 questionnaire and the PCI have 
been used in combination to screen for body image problems in patients with breast cancer. 
Although several important points have been raised we must recognise that there are 
limitation to this study. The study involved a relatively small sample of patients from one 
area in the United Kingdom, thus the results may reflect the beliefs and practice of this group 
and caution must be applied before extrapolating our findings to other settings. The present 
study is limited by the cross-sectional nature of the data. Future longitudinal studies need to 
focus on body image and could to examine whether body image state eventually returns to 
values similar to those before the breast cancer diagnosis. Body image should not be seen in 
isolation. There is a need to examine any possible associations with sexual function and 
quality of life. In this study there were weak correlations between the number of PCI body 
image items and the EORTC tool. Another limitation of this study is that a specific body 
image scale would have been appropriate (4).  Items such as change in self-consciousness 
with appearance, less sexually attractive, less feminine, dissatisfaction with appearance when 
dressed, and body feeling less whole that are present in the QOL BR23 were not assessed in 
our study. 
The body can be viewed as a symbol of social expression (45).  Breast cancer diagnosis and 
treatment can result in a sustained disturbance of that view at 12 months post-diagnosis and 
beyond (46). This is reflected in our study since 54% of patients were diagnosed at least two 
years prior to enrolment. Body image is clearly an important issue since 68% of patients 
selected an item from the body-image domain. In this study the number of body image 
related items was significantly associated with chemotherapy and mastectomy and 
reconstructive surgery. Some previous studies showed that chemotherapy, hormonal therapy 
and radiotherapy do not have a negative effect on body image (47). In contrast, the findings 
from this study are consistent with, Schover et al. (48) who concluded that chemotherapy do 
have a negative impact on body image, while hormonal and radiation therapy do not. Breast 
appearance was the item most frequently selected followed by weight and mastectomy 
appearance. This is not unexpected since the physical effects of breast cancer treatment on 
the body serve not only as a personal reminder of the disease but also as an 'announcement' 
to others (49). Yurek et al  (2000) (50) reported that those patients who underwent a 
lumpectomy faced less body change stress than women with a modified radical mastectomy 
with breast reconstruction or just a modified radical mastectomy. 
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 In this work only 14% of patients selected hair loss. This low incidence may be explained 
because most participants completed the PCI several months after their chemotherapy by 
which point hair-loss had recovered for the majority.   
As it can be seen on table 3, those patients selecting body image related items selected a 
median of 17 other items. The effect of breast cancer on body image should not be under-
estimated, and this is widely reflected in the literature.  Fallowfield et al. (51) found that the 
incidence of anxiety and/or depression was as high as 38%  in patients with a surgical 
intervention. Age was negatively correlated with the items detected.  
We found that older patients tended to select fewer items and this is consistent with Al-
Ghazal et al (2000)  (52) who compared the psychological outcome and satisfaction of 
patients undergoing wide local excision, mastectomy alone or mastectomy with breast 
reconstruction. This study reported that while women of all age groups face body image 
issues after breast cancer surgery, women between 40 and 59 years of age report more body 
image issues after breast cancer surgery. 
The head and neck PCI has been used before as a tool to identify appearance-related 
concerns (53). Appearance was highlighted as a problem on the PCI at 9% (42/454) of 
questionnaires, and was indicated as a serious problem on 10% (47/454) of UW-QoL 
questionnaires. Concerns about appearance were raised on the inventory or were shown to be 
a serious problem on the UW-QoL in 14% (64/454) of patients. One must be cautious 
comparing our findings  with that work since appearance was related to the face, and the 
participants included male patients and patients with different socioeconomic characteristics. 
The routine use of the PCI in breast cancer patients facilitates a holistic approach to 
management. It identifies the need for interventions; this can have a bearing on resource 
allocation and should provide a direction for future research. The role of interventions such 
as body beauty treatments to body image (54) and exercise need (55) in breast cancer 
patients needs to be evaluated further. 
 
Conclusions 
The breast cancer specific PCI can empower women to engage in an honest conversation about 
their cancer related body image issues. It can be use as a screening tool for body image  in 
order to identify a subgroup of patients that would benefit from focus interventions. 
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Table 1:Body image –related domain 
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During the past week have you lost any hair (Sprangers et al) (35) 
During the past week have you felt physically less attractive as a result of your disease or treatment 
(Sprangers et al) (35) 
During the past week have you been feeling less feminine as a result of your disease or treatment 
(Sprangers et al) (35) 
During the past week did you find it difficult to look at yourself naked (Sprangers et al) (35) 
During the past week have you been dissatisfied with your body (Sprangers et al) (35) 
I avoid looking at my scars from breast surgery (Baxter et al) (36) 
I am satisfied with the shape of my body (Baxter et al) (36) 
I feel less feminine since cancer (Baxter et al) (36) 
I Like my body (Baxter et al) (36) 
I feel comfortable about the way I look when exercise (Baxter et al) (36) 
I would feel comfortable changing in a public change-room (Baxter et al) (36) 
I feel my body has been invaded (Baxter et al) (36) 
I am satisfied with the appearance of my arm (Baxter et al) (36) 
I am satisfied with the appearance of my hips (Baxter et al) (36) 
I am satisfied with the shape of my  buttocks (Baxter et al) (36) 
I feel comfortable looking at my mastectomy (Baxter et al) (36) 
I am happy with the position of my nipple (Baxter et al) (36) 
I feel satisfied with the size of my breast (Baxter et al) (36) 
I feel comfortable when other see my breasts (Baxter et al) (36) 
The appearance of my breasts could disturb others (Baxter et al) (36) 
I feel that people are looking at my breasts (Baxter et al) (36) 
How satisfied are you with the way your breast looks (Polivy J) (37) 
Have you been feeling self-conscious about your appearance (Hopwood et al) (32) 
Have you felt less physically attractive as a result of your disease or treatment (Hopwood et al) (32) 
Have you been dissatisfied with your appearance when dressed (Hopwood et al) (32) 
Did you find it difficult to look at your self naked (Hopwood et al) (32) 
Did you avoid people because of the way you felt about your appearance (Hopwood et al) (32) 
Have you been feeling the treatment has left your body less whole (Hopwood et al) (32) 
Have you been dissatisfied with your body (Hopwood et al) (32) 
Have you been dissatisfied with the appearance of your scar (Hopewood et al) (32) 
Is there a difference between the treated and untreated areas in terms of Breast size (Stanton et al) (38) 
Is there a difference between the treated and untreated areas in terms of breast texture (hardening) 
(Stanton et al) (38) 
Is there a difference between the treated and untreated areas in terms of nipple appearance (Stanton et 
al) (38) 
Is there a difference between the treated and untreated areas in terms of breast shape (Stanton et al) (38) 
Is there a difference between the treated and untreated areas in terms of breast elevation (Stanton et al) 
(38) 
Is there a difference between the treated and untreated areas in terms of scar tissue (Stanton et al) (38) 
I am self-conscious about the way I dress (Brady et al) (39) 
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I am bothered by hair loss (Brady et al) (39) 
How satisfied or dissatisfied have you been with how you look in the mirror clothed (Pusic et al) (40) 
How satisfied or dissatisfied have you been with the shape of your reconstructed breasts when you are 
wearing a bra (Pusic et al) (40) 
How satisfied or dissatisfied have you been with how normal you feel in your clothes (Pusic et al) (40) 
How satisfied or dissatisfied have you been with the size of your reconstructed breasts (Pusic et al) (40) 
How satisfied or dissatisfied have you been with being able to wear clothing that is more fitted (Pusic 
et al) (40) 
How satisfied or dissatisfied have you been with how your breasts are lined up in relation to each other 
(Pusic et al) (40) 
How satisfied or dissatisfied have you been with how comfortably your bras fit (Pusic et al) (40) 
How satisfied or dissatisfied have you been with the softness of your reconstructed breasts (Pusic et al) 
(40) 
How satisfied or dissatisfied have you been with how equal in size your breasts are to each other (Pusic 
et al) (40) 
How satisfied or dissatisfied have you been with how natural your reconstructed breast looks (Pusic et 
al) (40) 
How satisfied or dissatisfied have you been with how natural your reconstructed breast sits/hangs (Pusic 
et al) (40) 
How satisfied or dissatisfied have you been with how your reconstructed breast feels to touch (Pusic et 
al) (40) 
How satisfied or dissatisfied have you been with how much your reconstructed breast feels like a natural 
part of your body (Pusic et al) (40) 
How satisfied or dissatisfied have you been with how closely matched your breasts are to each other 
(Pusic et al) (40) 
How satisfied or dissatisfied have you been with how your reconstructed breast look now compared to 
before you had any surgery (Pusic et al) (40) 
How satisfied or dissatisfied have you been with how you look in the mirror unclothed (Pusic et al) (40) 
 
Table 2 Body image related items selected on the PCI 
 
Body table gives % (n) of column totals Number of body Image related items  
 
0 1 2 3 4-8 ALL 
N=64 N=56 N=37 N=17 N=26 N=200 
BODY IMAGE RELATED items:       
B21 Appearance (Overall physical appearance) 0 4 (2) 22 (8) 47 (8) 62 (16) 17 (34) 
B22 Arm appearance 0 5 (3) 22 (8) 29 (5) 35 (9) 13 (25) 
B23 Breast appearance 0 18 (10) 43 (16) 59 (10) 88 (23) 30 (59) 
B24 Breast Prosthesis / Padding 0 4 (2) 22 (8) 18 (3) 65 (17) 15 (30) 
B25 Hair loss 0 7 (4) 19 (7) 24 (4) 46 (12) 14 (27) 
B26 Hair replacement (wig) 0 0 3 (1) 12 (2) 31 (8) 6 (11) 
B27 Weight (Unable to control my weight) 0 46 (26) 30 (11) 24 (4) 58 (15) 28 (56) 
B28 Wound healing (Scar appearance) 0 9 (5) 16 (6) 47 (8) 54 (14) 17 (33) 
B29 Mastectomy appearance 0 7 (4) 24 (9) 41 (7) 69 (18) 19 (38) 
 
Table 3 Median (IQR) and total number of items selected on the PCI, by number 
of body image related items selected.  
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Body table gives median (IQR), total number of  items in 
other domains 
N of body Image related items* 
0 1 2-3 4-8 
N=64 N=56 N=54 N=26 
General information  (6 items) 0 (0-0), 19 1 (0-1), 37 1 (0-1), 48 1 (1-2), 38 
Physical functioning and health-related (20 items) 2 (0-4), 155 3 (2-4), 166 5 (3-7), 279 7 (5-11), 216 
Psychological state and emotional wellbeing  (10 items) 1 (1-2), 101 1 (1-2), 88 3 (2-4), 159 5 (3-6), 124 
Sexual functioning  (3 items) 0 (0-0), 10 0 (0-0), 11 0 (0-1), 28 1 (0-1), 22 
Social functioning / family related  (8 items) 0 (0-0), 16 0 (0-1), 21 0 (0-2), 52 2 (1-3), 49 
Total number of other PCI items (range 0-47 after 
excluding the 9 body image related items) 
4 (2-6), 301 6 (4-7), 323 10 (5-14), 566 17 (10-23), 449 
Health professionals (15 staff) 1 (1-2), 92 2 (1-3), 110 3 (2-4), 174 5 (3-6), 132 
*Spearman correlation was significant at P<0.001 between the number of body image related items (range 0-9) 
and the number of items in each other domain, and also with total number of other items and with the number of 
health professionals selected. 
 
Table 4. Percentage selecting other specific PCI items and health professionals, by 
number of PCI body image related items selected 
 
Body table gives % of column totals 
N of body Image related items 
P 
Value* 
0 1 2-3 4-8 
N=64 N=56 N=54 N=26 
GENERAL INFORMATION      
B11 Activity  9 29 31 54 <0.001 
B12 Information about Breast Cancer (Unable to get or unable to understand) 9 14 15 38 0.005 
B13 Information about personal hygiene (Maybe related to breast prosthesis/wig) 0 2 0 15 0.007 
B14 Lifestyle (Smoking/ alcohol-started or unable to stop) 6 11 13 15 0.10 
B15 Complementary /Homeopathic Medicines (information about) 3 11 26 23 0.001 
B16 Fertility issues following treatment (information about) 2 0 4 0 0.93 
PHYSICAL FUNCTIONING AND HEALTH RELATED      
B31 Appetite 8 16 19 42 0.001 
B32 Arm swelling (Lymphoedema) 6 5 24 38 <0.001 
B33 Diarrhoea  6 7 11 19 0.06 
B34 Constipation 9 5 20 35 0.002 
B35 Breast texture 0 12 20 27 <0.001 
B36 Breast sensitivity /Breast pain 28 39 61 69 <0.001 
B37 Cancer Treatment 16 4 22 42 0.004 
B38 Sore mouth / Dry Mouth 13 13 19 42 0.004 
B39 Fatigue / Tiredness (Low energy levels overall) 33 43 50 73 0.001 
B310 Indigestion 3 4 20 23 <0.001 
B311 Memory/ Concentration 16 23 35 50 <0.001 
B312 Nausea 2 4 11 31 <0.001 
B313 Pain in the Breast 17 25 37 46 0.001 
B314 Pain in the arm or shoulder 17 11 35 54 <0.001 
B315 Pain elsewhere 19 13 15 31 0.36 
B316 Sleeping 17 21 52 62 <0.001 
B317 Swallowing 0 2 4 8 0.03 
B318 Taste 2 2 9 38 <0.001 
B319 Vomiting / Sickness 3 2 6 31 <0.001 
B320 Hot Flushes 28 46 46 69 0.001 
PSYCHOLOGICAL STATE AND EMOTIONAL WELLBEING      
B41 Angry (why me?, why this treatment) 2 4 7 27 <0.001 
B42 Anxiety (Related to the diagnosis or treatment) 8 13 30 50 <0.001 
B43 Coping (coping with the disease, the treatment or the side effects of treatment) 16 9 28 42 0.005 
B44 Depression 11 11 19 38 0.006 
B45 Fear of Cancer coming back 55 57 67 81 0.02 
B46 Fear of Cancer spreading 25 27 52 73 <0.001 
B47 Mood 8 7 20 38 <0.001 
B48 Self esteem 8 4 17 42 <0.001 
B49 Temperament and personality 6 5 13 27 0.004 
B410 Fear about the future 20 21 43 58 <0.001 
SEXUAL FUNCTIONING      
B51 Intimacy 5 5 19 31 <0.001 
B52 Relationships 3 2 17 27 <0.001 
B53 Sex 8 12 17 27 0.01 
SOCIAL FUNCTIONING / FAMILY RELATED      
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B61 Financial issues 8 16 30 35 <0.001 
B62 Home care / district nurse support  0 0 11 23 <0.001 
B63 Mobility 5 2 15 19 0.008 
B64 Spiritual / Religious aspects 2 2 4 4 0.38 
B65 Support for my family 0 5 11 46 <0.001 
B66 Worried about the future of my children 5 5 15 19 0.01 
B67 Unable to go out and enjoy my family 5 4 7 19 0.04 
B68 Unable to go to go to work 2 4 4 23 0.002 
HEALTH PROFESSIONALS      
R1 Breast surgeon  50 41 41 58 0.99 
R2 Plastic surgeon  0 2 24 38 <0.001 
R3 Medical oncologist  14 23 35 54 <0.001 
R4 Radiation oncologist  5 7 17 31 <0.001 
R5 Breast Care Nurse  30 39 65 69 <0.001 
R6 Chaplain 0 2 2 8 0.04 
R7 Psychologist  13 13 26 42 0.002 
R8 Dietician 9 18 15 27 0.08 
R9 Lymphoedema specialist /clinic 0 9 17 23 <0.001 
R10 Hair prosthesis (wig advisor) / Breast prosthesis expert 0 4 9 38 <0.001 
R11 Nurse Practitioner  0 0 8 15 <0.001 
R12 Pain specialist 5 7 17 31 0.001 
R13 District Nurse 0 0 7 4 0.03 
R14 My own doctor (General Practitioner) 11 16 15 12 0.70 
R15 Complementary therapies 8 16 26 35 0.001 
*Mann-Whitney test comparing the full distribution (range 0-9) of body image related items for specific PCI 
items being selected Vs. not selected.  
 
Table 5: Clinical/personal characteristics and selection of PCI body image 
related items  
 
Body table gives % (n) of row totals  Number of Body image related items selected  
  Patients 0 1 2-3 4-8 P value* 
 ALL 200 32 (64) 28 (56) 27 (54) 13 (26) - 
Age <55 69 28 (19) 23 (16) 36 (25) 13 (9) 
0.04** 
 55-64 59 25 (15) 34 (20) 24 (14) 17 (10) 
 65-74 52 42 (22) 31 (16) 15 (8) 12 (6) 
 75+ 19 42 (8) 16 (3) 37 (7) 5 (1) 
Gender Female 198 32 (64) 28 (56) 27 (53) 13 (25) 
- 
 Male 2 0 0 50 (1) 50 (1) 
IMD deprivation: living in 
area that is one of the  20% 
most deprived  
No 148 28 (42) 30 (44) 28 (41) 14 (21) 
0.38 excl 
NK 
Yes 30 37 (11) 27 (8) 23 (7) 13 (4) 
 Not known 22 50 (11) 18 (4) 27 (6) 5 (1)  
Year of most recent 
diagnosis 
2009/2010 108 34 (37) 26 (28) 26 (28) 14 (15) 
0.84 excl 
NK 
 2011/2012 61 30 (18) 31 (19) 28 (17) 11 (7) 
 Not known 31 29 (9) 29 (9) 29 (9) 13 (4)  
Location Leeds 113 29 (33) 26 (29) 31 (35) 14 (16)  
 Wakefield 64 33 (21) 34 (22) 17 (11) 16 (10) 0.21 
 Other 23 43 (10) 22 (5) 35 (8) 0  
Extent of disease: Primary  
Local 
No 99 31 (31) 24 (24) 30 (30) 14 (14) 
0.48 
Yes 101 33 (33) 32 (32) 24 (24) 12 (12) 
Extent of disease: Local 
recurrent 
No 197 32 (64) 28 (55) 27 (53) 13 (25) 
- 
Yes 3 0 33 (1) 33 (1) 33 (1) 
Extent of disease: Metastatic No 191 32 (61) 28 (54) 27 (52) 13 (24) 
0.84 
 Yes 9 33 (3) 22 (2) 22 (2) 22 (2) 
Extent of disease: Living 
with cancer 
No 192 32 (61) 28 (53) 28 (53) 13 (25) 
0.55 
Yes 8 38 (3) 38 (3) 13 (1) 13 (1) 
Treatment (known for 193/200)   
   
 
Chemotherapy  No 100 40 (40) 30 (30) 21 (21) 9 (9) 
0.002 
 Yes 93 23 (21) 28 (26) 31 (29) 18 (17) 
Radiotherapy  No 67 27 (18) 28 (19) 28 (19) 16 (11) 
0.24 
 Yes 126 34 (43) 29 (37) 25 (31) 12 (15) 
Wide local excision 
/lumpectomy 
No 100 23 (23) 30 (30) 30 (30) 17 (17) 
0.005 
Yes 93 41 (38) 28 (26) 22 (20) 10 (9) 
Mastectomy No 105 44 (46) 30 (31) 22 (23) 5 (5) 
<0.001 
 Yes 88 17 (15) 28 (25) 31 (27) 24 (21) 
Reconstructive surgery No 168 34 (57) 31 (52) 23 (38) 13 (21) 
0.006 
 Yes 25 16 (4) 16 (4) 48 (12) 20 (5) 
Anti-oestrogen therapy*** No/NK 111 32 (35) 23 (25) 28 (31) 18 (20) 0.08 
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 Yes 82 32 (26) 38 (31) 23 (19) 7 (6) 
Other treatment: *** No/NK 176 31 (54) 30 (53) 27 (47) 13 (22) 
0.92 
 Yes 17 41 (7) 18 (3) 18 (3) 24 (4) 
 
* Mann-Whitney (2 group comparison) or Kruskall-Wallis test (>2 group comparison) as appropriate using 
the number of body image related items selected (range 0-9) 
** Spearman correlation  between age in years and number of body image related items (range 0-9) 
*** Anti-oestrogen therapy included: tamoxifen, letrozole, anastrozole, aromasin, arimidex, exemestane;  
Other treatment included :Herceptin, lepatinib, trastuzumab, neratinib. 
 
Table 6. Number of body image related items by treatment  
 
Wide local 
excision or 
lumpectomy  
surgery 
Reconstructive 
surgery 
Chemotherapy Mastectomy 
 
Total 
Number of  Body image-related items 
0 1 2-3 4-8 
No No No No 8 2 3 - 13 
No No No Yes 1 6 7 4 18 
No No Yes No 1 4 3 - 8 
No No Yes Yes 10 14 7 10 41 
No Yes No Yes - 2 4 - 6 
No Yes Yes Yes 3 2 6 3 14 
Yes No No No 31 19 6 2 58 
Yes No No Yes - 1 1 2 4 
Yes No Yes No 6 6 10 3 25 
Yes No Yes Yes - - 1 - 1 
Yes Yes No Yes - - - 1 1 
Yes Yes Yes No - - 1 - 1 
Yes Yes Yes Yes 1 - 1 1 3 
Treatment not known 3 - 4 - 7 
 
 
Table 7.  Number of PCI Body image related items and summary scores 
from the EORTC QLQ-C30 and EORTC breast cancer module QLQ-BR23 
 
 Spearman correlation* Number of PCI body image related items 
EORTC 
Correlation 
coefficient1 
P value Patients 
0 1 2-3 4-8 
Mean (SE) Mean (SE) Mean (SE) Mean (SE) 
C30 Physical functioning -0.23 0.001 199 85.3 (2.4) 81.3 (2.7) 77.5 (3.2) 76.8 (3.5) 
C30 Role functioning -0.18 0.01 200 82.6 (3.0) 77.1 (3.9) 70.7 (4.2) 69.9 (6.0) 
C30 Emotional functioning -0.13 0.08 195 73.8 (2.8) 75.3 (2.7) 66.2 (3.5) 62.7 (6.0) 
C30 Cognitive functioning -0.25 <0.001 196 84.1 (2.5) 77.8 (3.2) 65.4 (3.8) 69.2 (6.2) 
C30 Social functioning -0.25 <0.001 195 86.6 (2.9) 76.2 (3.7) 70.1 (3.9) 70.5 (6.2) 
C30 Fatigue 0.29 <0.001 200 22.6 (3.1) 32.1 (2.7) 38.5 (3.3) 41.0 (5.5) 
C30 Nausea and vomiting 0.18 0.01 200 3.4 (1.0) 5.4 (2.1) 10.2 (2.4) 11.5 (4.4) 
C30 Pain 0.17 0.02 199 19.3 (2.6) 23.3 (3.4) 34.3 (4.4) 30.8 (6.0) 
C30 Global health status / QOL      -0.06 0.39 196 67.2 (2.6) 66.2 (2.5) 61.7 (3.1) 63.5 (4.6) 
C30 Dyspnoea 0.22 0.002 200 9.4 (2.6) 16.7 (3.3) 14.2 (3.2) 26.9 (5.2) 
C30 Insomnia 0.26 <0.001 200 22.9 (3.3) 37.5 (4.7) 54.3 (4.9) 37.2 (7.0) 
C30 Appetite loss 0.09 0.23 200 8.9 (2.7) 8.9 (2.8) 18.5 (4.3) 10.3 (4.8) 
C30 Constipation 0.11 0.13 200 14.6 (3.4) 13.1 (2.9) 17.9 (3.7) 19.2 (5.0) 
C30 Diarrhoea 0.22 0.002 193 2.8 (1.4) 8.6 (3.2) 10.7 (2.8) 14.1 (5.3) 
C30 Financial difficulties 0.15 0.03 196 12.0 (3.0) 15.8 (3.4) 25.3 (4.4) 21.8 (7.1) 
BR23 Body image -0.34 <0.001 195 78.8 (3.3) 74.4 (3.3) 53.8 (4.4) 60.3 (5.5) 
BR23 Sexual functioning -0.01 0.87 177 21.5 (3.2) 15.4 (2.4) 18.8 (3.2) 24.3 (5.9) 
BR23 Sexual enjoyment -0.05 0.69 68 57.3 (5.3) 47.1 (5.8) 47.1 (7.6) 59.3 (10.8) 
BR23 Future perspective 0.01 0.95 195 41.9 (4.1) 51.2 (4.5) 43.4 (4.7) 42.3 (6.6) 
BR23 Systemic therapy side 
effects 
  0.32 
<0.001 
197 
14.0 (1.6) 18.7 (1.7) 23.8 (2.2) 30.8 (4.8) 
BR23 Breast symptoms 0.19 0.007 197 15.8 (1.9) 20.9 (2.4) 29.6 (3.2) 21.5 (3.8) 
BR23 Arm symptoms 0.26 <0.001 197 13.1 (2.0) 16.9 (2.4) 23.5 (3.8) 32.9 (5.5) 
BR23 Upset by hair loss 0.41 0.001 62 15.8 (5.3) 64.4 (10.0) 62.2 (9.1) 56.4 (8.8) 
* Spearman correlation coefficient between the number of PCI Body image related items selected (range 0-
9) and the EORTC scores 
SE: Standard Error of mean 
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APPENDIX SECTION 4: Letters and Approvals from the 
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Appendix 4-C: Permission Letter 1 
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